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Summary 
Glioblastoma (GBM) is a highly malignant brain tumor where no curative treatment is 
available. According to the cancer stem cell (CSC) hypothesis GBMs rely on a small 
subpopulation of cancer cells with stem-like properties responsible for tumor progression 
and recurrence. Recent experimental data from GBM and other cancers however suggest 
that CSCs cannot be defined by a specific marker expression and may in fact not be a 
stable entity but a population of cells adapting to a changing microenvironment. Here we 
examined inter- and intra-tumoral heterogeneity of GBM cells and their adaptation capacity 
based on stem cell-associated marker expression profiles. Tumor cell subpopulations were 
classified based on their expression of four chosen cell membrane markers (CD133, CD15, 
A2B5 and CD44) using multicolor flow cytometry. 16 subpopulations were separated and 
analyzed for their self-renewal capacity and their ability to reform the original heterogeneous 
cell population in different environmental conditions (normoxia, hypoxia, differentiation and 
in vivo). Mathematical modeling was applied to calculate state transitions between 
phenotypes and predict the adaptive response of tumor cells. Similar to GBM biopsies, we 
observed markers to be heterogeneously expressed in glioma stem-like cells and primary 
cultures. All analyzed tumor cell subpopulations were able to proliferate indefinitely and 
carried stem-cell properties including self-renewal potential. Moreover, all subpopulations 
were able to adapt their marker expression profiles to give rise to the original 
subpopulations. Interestingly, mathematical modeling revealed a different propensity in 
reforming the original heterogeneity between subpopulations over time, which was 
independent of their proliferation index. Each environment presented its specific equilibrium 
with defined proportions of the subpopulations. This equilibrium was reversible upon 
environmental change for each tested condition. Single cell RNA-seq analysis revealed no 
transcriptomic differences between subpopulations. Our results suggest that glioma stem-
like cells do not represent a stable entity and that intra-tumoral heterogeneity in GBM at 
least partially results from a high cellular adaptation capacity. This implies that glioma 
treatment approaches should take into account the strong propensity of cancer cells for 
phenotypic state transitions. 
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1. Brain tumors 
Since 2010 cancer is the first cause of death in Luxembourg (Townsend et al., 2016, Santé, 
2014). For many cancers such as breast, prostate or colorectal cancers, early diagnosis 
and improved therapy decreased mortality rates significantly in the Western world. Brain 
cancer, however, remains an exception. In Luxembourg, the mortality due to brain and other 
nervous system cancers is close to its incidence (5.9 deaths vs 7.5 new cases per 100’000 
people), whereas only 1/3 of brain and other nervous system cancers in the United States 
of America (USA) is malignant (Ferlay J, 2012, Quinn T. Ostrom, 2016). Since 2012 
Luxembourg has set up a national cancer register whose data evaluation may indicate 
similar mortality rates observed in the USA. Amongst all ages and sexes in Luxembourg 
and the European Union (EU), cancers of the brain and nervous system are the 16th most 
prominent cancers (Fig. 1) (Ferlay et al., 2013). The 2016 World Health Organization 
(WHO) classification of tumors of the central nervous system (CNS) distinguishes 17 groups 
of tumor types with each consisting of numerous subtypes representing distinct diseases 
(Louis et al., 2016). The most common non-malignant CNS tumor subtype is meningioma 
and the most common malignant tumor subtype is Glioblastoma (GBM). With an incidence 
rate of 5,47 per 100 000 children CNS tumors represent also the most common neoplasm 
under the age of 14 years (Quinn T. Ostrom, 2016). 
 
Figure 1: Incidence and mortality rate of different tumor types in 2012 in Luxembourg. Data 
was derived from the Globocan webtool (Ferlay J, 2012). Bar plot displays a ranking of the incidence 
(‘dark blue’) and mortality (‘light blue’) of the 25th most common cancers in Luxembourg. Number of 
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deaths and of new cancer cases are represented as a crude rate per population of 100’000 people. 
While breast and prostate cancers show highest incidence, less than 25% of these cases result in 
death. In contrary, brain and CNS cancers are less common (16th place), but survival is very low. 
 
1.1.  Diffuse gliomas 
Brain and nervous system cancers are distinguished based on their cell of origin. For 
instance, meningiomas arise from the meninges whereas schwannomas originate from 
Schwann cells. This thesis focuses on diffuse gliomas that are derived from the glial tissue 
present in the brain. In the USA, diffuse gliomas represent the most common CNS cancer 
type and account for 80% of all malignant brain tumors (Quinn T. Ostrom, 2016). 
Traditionally diffuse gliomas were defined based on their histopathological features (Louis 
et al., 2007). Since 2016 the WHO classification of CNS tumors includes in addition 
molecular profiling (Louis et al., 2016). Amongst diffuse gliomas belong grade II and III 
diffuse astrocytic tumors, grade II and III oligodendrogliomas and grade IV GBMs where 
tumor grading scheme was taken over from the previous WHO classification (Louis et al., 
2007, Louis et al., 2016). These diffuse gliomas are distinguished based on the presence 
or absence of a mutation in the isocitrate dehydrogenase gene (IDH) (Fig. 2). Most common 
IDH mutations are the R132 for IDH1 and on the R172 for IDH2 (reviewed extensively by 
(Megova et al., 2014)). IDH mutated diffuse gliomas are further subdivided in diffuse 
gliomas characterized by the TP53 mutation and loss of ATRX (astrocytic lineage) and 
1p/19q codeleted gliomas (oligodendroglial lineage) (Louis et al., 2016). Although presently 
not clear, IDH mutant GBM most likely represent an aggressive version of diffuse 
astrocytoma grade III, as oligodendroglioma grade III normally do not develop into grade IV 
tumors (Yan et al., 2009). IDH wild-type gliomas are mostly primary GBM (99,1%), and only 
rare cases of IDH wild-type lower grade gliomas are described (0.9%). The latter is only a 
provisional WHO category as it is less defined. Although glioma classification has improved 
by the integration of molecular characteristics, some uncertainties, such as IDH wild-type 
lower grade glioma and IDH mutant GBM subtypes, need to be resolved in future. 
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Figure 2: Classification of diffuse gliomas based on genetic characteristics (Louis et al., 2016, 
Paul et al., 2017, Louis et al., 2007). Diffuse gliomas are classified based on IDH mutation status 
into IDH wild-type resulting in grade IV GBM or lower grade glioma (diffuse astrocytoma grade II and 
III or oligodendroglioma grade II and III) and IDH mutated. Presence of 1p/19q codeletion marks 
oligodendroglioma grade II and III whereas ATRX loss combined with TP53 mutation characterizes 
diffuse astrocytoma (grade II and III). IDH mutated GBM most probably develops from diffuse 
astrocytoma grade III. Percentages were described from (Paul et al., 2017) based on the glioma 
TCGA dataset. Tumor samples were categorized based on the 2016 WHO classification (Louis et 
al., 2016) and tumor grades were applied according to 2007 WHO classification (Louis et al., 2007).  
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1.2.  Glioblastoma 
GBM is the most aggressive grade IV brain tumor with a median survival of 14 months and 
a 2-year survival rate of only 26% (Stupp et al., 2005). Primary GBM accounts for 90% of 
all GBM incidences. They develop de novo and are present in more elderly patients, 
whereas secondary GBM arises from lower grade astrocytoma (Ohgaki and Kleihues, 
2013). GBM is regarded as a sporadic cancer, however, it can be associated with Turcat 
syndrome B and Cowden disease (Collins, 2004). To date, no risk factors for GBM are 
known. 
 
1.2.1. Histopathological features of GBM 
Morphologically primary and secondary GBM are undistinguishable (Furnari et al., 2007). 
Both present a necrotic core accompanied with abnormal newly formed blood vessel 
(angiogenesis) (Fig. 3.a). Tumor borders are not clearly delineated due to its highly 
infiltrative behavior towards healthy brain tissue. An invasive front is particularly visible 
through the corpus callosum. Therefore, both hemispheres are commonly affected with 
cancer cells. Another macroscopic feature of GBM comprise squeezed ventricles, which 
results from an increased tumor volume. Furthermore, the blood-brain-barrier and blood 
vessels in the tumor core are disrupted and leaking (Louis et al., 2007, Kleihues et al., 
1993). GBM was shown to develop with no preference in each part of the brain (frontal, 
parietal, temporal, occipital and the cerebellum) (Denicolai et al., 2016) and GBM 
development may be multifocal (Kleihues et al., 1993). 
Histologically, GBM tumor cells are highly mitotic compared to non-tumor cells and 
demonstrate atypical nuclei. Other common features show hypercellularity and cellular 
pleomorphism (Fig. 3.b). As GBM cells are highly proliferative, cells in the tumor core 
experience nutritional shortage, which the tumor attempts to overcome by the formation of 
new vessels. However, these vessels are often immature, enlarged, tortuous and 
hyperpermeable resulting in abnormal blood flow (Fig. 3.c). Nutritional shortage results 
eventually in cell death, which can be observed by the necrotic core surrounded by 
“pseudopallisading” cells (Fig. 3.d) (Kleihues et al., 1993, Furnari et al., 2007, Miller and 
Perry, 2007). GBMs demonstrate these histopathological features at different degrees 
which may vary between patients. 
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Figure 3: Macro and microscopic features of GBM. a. Coronal brain section displays GBM tumor. 
Tumor has a necrotic core with hemorrhages and is highly infiltrative into adjacent tissue. Figure was 
used from (PubCan, 2014). b. Microscopic hematoxylin and eosin (H&E) staining shows cellular 
anaplasia (arrow) and giant cancer cells (arrow head). c. Increased proliferation of blood vessel 
endothelial cells is typical for GBM. d. Necrotic cores are surrounded by ‘pseudopallisading’ 
cells.Figure 5.b,5.c and 5.d was used from (Agamanolis, 2017). 
 
1.2.2. Glioblastoma treatment 
Current treatment of GBM consists of maximal surgical resection, radio and chemotherapy 
with temozolomide (TMZ). This treatment was shown to prolong survival from 12.1 to 14.6 
months (Stupp et al., 2005). Despite these advances, most GBMs reoccur in a more 
aggressive phenotype (Weil, 2006). Therefore, most treatment approaches are palliative 
and intend to increase quality of life by relieving pain and other symptoms. 
Maximal tumor resection is supported by specifically visualizing GBM tumor cells with 5-
Aminolevulinic-based fluorescence during surgical intervention. However, even very 
aggressive surgical removal does not target all infiltrative tumor cells. Therefore, additional 
post-operative irradiation doses of 5000 to 6000 cGy attempt to eliminate residual tumor 
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cells. Methylated promoter regions of the MGMT gene were shown as positive prognostic 
factor for adjuvant TMZ therapy (Esteller et al., 2000, Hegi et al., 2005). 
Drug treatment for GBM encounters a special requirement compared to cancers in other 
body parts. Drugs need to pass the BBB and to be instantly effective as patient survival is 
very short. In the last decade, only few drugs appeared promising before entering clinical 
trials. Anti-angiogenic treatment, which targets new blood vessel formation and stimulates 
its normalization, was intensively tested in clinical trials, but none of the tested 
antiangiogenic agents such as bevacizumab and cediranib, showed improved overall 
survival (Gerstner and Batchelor, 2012). Although clinical phase III trials did not show a 
survival benefit, bevacizumab was shown to prolong disease free survival and was therefore 
approved for recurrent GBM by the Food and Drug Administration (FDA) in the United 
States (US) (Chinot et al., 2014, Fine, 2014). Effective treatment for GBM patients is still 
not in sight. 
 
1.2.3. Molecular characterization of GBM 
GBM has been extensively characterized in the last years at the genetic and transcriptomic 
level. Through projects such as the Cancer Genome Atlas (TCGA), the genetic profile of 
GBMs has been unraveled. 291 GBM patient samples were sequenced and analyzed for 
their genetic aberrations. The majority of dysregulated genes comprised TP53, PTEN, NF1, 
EGFR, RB1, PIK3RI and PIK3CA. Most gene amplifications were detected in EGFR, 
PDGFRA and MET proto-oncogene (RTK signaling) (Cancer Genome Atlas Research, 
2008, Brennan et al., 2013). Similarly, in a study of 55 GBM biopsies, signaling pathways 
involving the proteins involved in RB signaling (p16(INK4A), p15(INK4B), CDK4/6 and pRb), 
TP53 signaling (p14(ARF), MDM2/4 and p53) and RTK signaling (EGFR, VEGFR, 
PDGFRA and PTEN) were dysregulated in 87%, 87% and 71% of the cases, respectively 
(Yin et al., 2009). Comparable results were obtained from other groups (Ohgaki and 
Kleihues, 2013, Parsons et al., 2008, Beroukhim et al., 2007). Collectively these data 
identified 5 signaling pathways mostly affected by genetic aberrations in GBM: RTK (66%), 
PI3K (60%), MAPK (13%), TP53 (86%) and RB1 (79%) signaling (Brennan et al., 2013) 
(Fig. 4.a). 
At the transcriptional level, gene expression data were extensively analyzed for subgroup 
classification according to patient survival. In 2006, Phillips and colleagues subdivided high 
grade gliomas into proneural, proliferative and mesenchymal GBMs based on the signature 
of 35 genes in a cohort of 76 tumor samples (Phillips et al., 2006). Subgroups varied in 
patient survival, where proneural and mesenchymal demonstrated worst prognosis. 
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However, tumor samples in this study were not all GBM, but contained several grade III 
astrocytoma.  
Besides genetic aberrations, the TCGA project in 2008 measured also DNA methylation 
pattern and transcriptomic data of GBM and lower grade glioma samples. The database 
contains clinical and molecular information from 1122 patients (Brennan et al., 2013, 
Ceccarelli et al., 2016). These publicly available data of glioma samples were further 
analyzed and classified into four subgroups: mesenchymal, neural, proneural and classical 
(Verhaak et al., 2010) (Fig. 4.b.) Analysis was performed by consensus average linkage 
hierarchical clustering of 173 GBM patient samples (Monti et al., 2003), where gene 
signature for each subcategory was based on the expression of 210 genes. To date, the 
GBM classification of Verhaak based on gene expression data is most widely used in the 
scientific community although the clinical relevance was only clear in proneural GBM. This 
subgroup contained a higher percentage of secondary GBM than the other GBM 
subgroups. Since IDH mutated GBM show longer survival, overall survival benefit is also 
observed in the proneural subgroup (Ceccarelli et al., 2016). Subgroups correlate to genetic 
aberrations of PDGFRA amplification/IDH and PIK3R1 mutation (proneural), NF1 
mutation/loss (mesenchymal) and EGFR amplification (classical and neural), however the 
genetic aberrations are not exclusive for specific subgroups (Verhaak et al., 2010, Brennan 
et al., 2013, Cancer Genome Atlas Research, 2008). These genetic aberrations lead to the 
activation of core signaling pathways; in proneural cancer cells HIF1α, PI3K and PDGFRA 
signaling is often upregulated, whereas TNF combined with NFκB pathways and Notch with 
SHH pathways are frequently active in mesenchymal and classical subgroups (Verhaak et 
al., 2010, Agnihotri et al., 2013). However, recent work of the Verhaak group based on 
tumor-intrinsic signature demonstrated that the neural subgroup originated from the gene 
signature found in healthy brain tissue (Wang et al., 2017). Therefore, the transcriptomic 
classification in GBM should be adjusted to solely 3 subgroups, similar to the proposal of 
Phillips et al. in 2006. Moreover, a major drawback of subgroup classification comes along 
with cancer cell variety within one tumor samples. Transcriptomic analysis at single cell 
level and of multiple biopsies of one tumor revealed that multiple subgroups coexist within 
one patient sample, showing that classification of one patient tumor based on bulk 
transcriptomic data does not reflect entire intratumoral complexity (Patel et al., 2014, 
Sottoriva et al., 2013).  
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Figure 4: a) Most common genetic aberrations in GBM (adapted from (Brennan et al., 2013, 
Verhaak et al., 2010). Whole-exome sequencing analysis was performed on a cohort of 291 patient 
samples. Copy number variations and mutations were analyzed and revealed five major 
dysregulated pathways in GBM. The overall frequency of genetic aberrations in RTK, PI3K, MAPK, 
TP53 and RB1 pathways are indicated. In red and blue are depicted activating and inactivating 
genetic aberrations, respectively b) GBM subclasses based on transcriptional heterogeneity. 4 
subgroups of primary and secondary GBM were identified based on gene expression data obtained 
from TCGA project.: proneural, mesenchymal, neural and classical. Certain genetic aberrations 
correlated with subclasses, but were not exclusive. Each subclass has its own specific gene 
signature and more frequently characterized by certain transcriptional markers and signaling 
pathway activation (Verhaak et al., 2010).  
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1.3. Models for tumor heterogeneity 
GBM has been described as a heterogeneous tumor mostly due to its high variability in 
histopathologic features and genetic and transcriptomic profiles between patients 
(intertumoral) and within one patient (intratumoral). In the last decade, two major models 
for tumoral heterogeneity have been pointed out: the clonal evolution and the cancer stem 
cell model. 
 
1.3.1. Clonal evolution model and genetical heterogeneity 
The most popular and well characterized model explaining the generation of intratumoral 
heterogeneity is the stochastic and sequential acquirement of genetic aberrations or 
epigenetic changes in time. Genetic alterations might result from external factors such as 
radiation, bacteria, viruses or chemical agents, that affect normal cells in the human body, 
or genetic instability (Burrell et al., 2013). The best studied example of the generation of a 
neoplasm in a sequential multistep process is the adenoma-carcinoma model of human 
colorectal carcinogenesis. Fearon and Vogelstein showed that adenoma develops from 
genetic instability from a normal epithelial cell. The accumulation of further mutations results 
in the generation of an adenocarcinoma with final metastasis (Fearon and Vogelstein, 
1990). 
In 1976, Peter Nowell presented the linear clonal succession model of cancer evolution 
(Nowell, 1976) (Fig. 5). Aberrations arise stochastically in one single cell turning into a 
tumorigenic cell clone. Hence, tumors originate in this model from a single cell. This parental 
clone creates upon subsequent de novo mutations genetically divergent "daughter” cell 
clones. Clonal variability is created following a hierarchical structure by the accumulation of 
genetical aberrations leading to an irreversible evolution. Each clone has its specific genetic 
aberrations that, in analogy to a trait of an organism, are subject to the Darwinian evolution. 
The genetic aberrations within a cell clone can be advantageous, neutral or 
disadvantageous. Subsequent positive or negative selection depends on the 
microenvironment they encompass. Thus, if the aberration represents no environmental 
disadvantage, the cell will survive. Tumor progression results due to selection of most 
aggressive traits/advantageous mutation (Cairns, 1975). Cells with disadvantageous 
mutations are unable to survive and eventually vanish from the tumor cell pool. Most 
interesting are neutral aberrations. Upon environmental change (e.g. upon treatment 
pressure or metastasis), certain changes can become advantageous and a neutral clone in 
the initial environment, now becomes the most prominent (Greaves and Maley, 2012, 
Rubben and Araujo, 2017, Clevers, 2011, Gupta and Somer, 2017). 
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Although initially described for genetic aberrations, the clonal evolution model can be used 
to explain epigenetic heterogeneity as well. Like genetic aberrations, changes to the 
epigenome are heritable and can be transmitted from parental to daughter cells (Easwaran 
et al., 2014). However, epigenetic changes are reversible. 
Following the clonal evolution model, different genetic and epigenetic backgrounds are 
generated in cancer cells of one tumor creating intratumoral heterogeneity which leads to 
distinct functional and phenotypic patterns among cancer cells (Meyer et al., 2015). 
 
Figure 5: Model of clonal evolution in a tumor. A series of mutations in a normal cell turn it into a 
tumorigenic cell. After continuous accumulation of genetic aberrations and aneuploidization, multiple 
tumor clones with distinct genetic backgrounds develop (distinct colors represent genetically different 
cell clones). DNA transformations might be disadvantageous, neutral of advantageous in a given 
microenvironment. This leads to the selection of the fittest ‘trait’ and the most aggressive clones 
contribute to tumor growth. Neutral mutations lead to coexistence of genetic clones in a tumor 
although not contributing to its growth. On the other side, disadvantageous characteristics will lead 
to cell death. Upon therapeutic pressure or environmental change as in metastasize, neural 
mutations might become advantageous and become most prominent clone in a tumor mass whereas 
tumor clones being the fittest in the initial environment become subject of a negative selection.   
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1.3.2. Genetic intratumoral heterogeneity in GBM 
Already in the early 80’s, researchers detected by karyotyping the presence of divergent 
clones within one GBM tumor (Shapiro et al., 1981). Tumors were karyotyped and cultured 
at a clonal level for functional analysis. Clones derived from a single tumor demonstrated 
variability in growth and chemosensitivity, however, a link to specific karyotypes was not 
done. More recently, our lab has shown that GBM patient samples distinguished two 
genetically divergent clones, aneuploid and pseudodiploid by combined measurement of 
DNA content and copy number variations (Stieber et al., 2013). Aneuploidization appeared 
as a late event in GBM evolution, where aneuploid clones were found to coexist with 
pseudodiploid clones in polygenomic tumors. 
Evolutionary dynamics were studied by Sottoriva and colleagues who isolated tumor 
fragments from different parts of GBM patient tumors (Sottoriva et al., 2013). High 
throughput measurement of DNA copy number variations and RNA-sequencing (RNA-seq) 
revealed the presence of multiple genetic clones within one patient. Similar results were 
later confirmed by other multisector studies in GBM patient tumors (Kim et al., 2015, Kumar 
et al., 2014, Lee et al., 2017). Kim et al. analyzed copy number variations and gene 
mutations of paired primary and recurrent GBM patient samples for longitudinal studies on 
genetic aberrations. Two main observations on recurrent GBM were seen: distally recurrent 
GBM displayed strong genetic differences compared to the initial tumor mutations, with 
major variations detected in driver genes. Locally recurrent GBM shared most of genetic 
aberrations with the initial tumor suggesting that clonal selection was more prominent at 
distant recurrences. Although these experiments clearly demonstrated the existence of 
distinct genetically divergent clones in GBM, the total number of clones might be 
underestimated due to bulk tumor sequencing. 
The novel technique of single cell DNA sequencing methods enabled high throughput 
analysis of copy number variations in single cells of patient biopsies (Wang et al., 2014). 
Reports from breast cancer show that copy number variations can be detected using single 
cell DNA sequencing (scDNA-seq) and identified up to three genetically different profiles 
within one breast tumor (Navin et al., 2011). To date, copy number variations in GBM were 
only inferred from single cell RNA-seq data (scRNA-seq) (Patel et al., 2014), scDNA-seq 
technology has not yet been applied to gliomas. Interestingly, not all GBM tumors displayed 
strong genetic heterogeneity. scRNA-seq of 5 GBM patient samples revealed both 
monogenomic and polygenomic tumors. Similarly, oligodendrogliomas were as well shown 
by RNA-seq analysis as genetically homogeneous and heterogeneous tumors (Tirosh et 
al., 2016b). This is in accordance to previous reports from Sottoriva et al. describing GBM 
as multiclonal tumors, however, most genetic aberrations were retained per tumor and only 
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minor changes were observed.  Indeed, Patel et al. and Tirosh et al. inferred the number of 
CNVs from gene expression patterns obtained by scRNA-seq, which may underestimate 
the number of smaller CNVs. With improved single cell analysis techniques, this 
inconsistency might be solved. 
Meyer and colleagues approached analysis of genetic variability by dissociating and 
clonally expanding GBM tumor cells for subsequent combined genomic and functional 
analysis (Meyer et al., 2015). Clones derived from one tumor exhibited distinct functional 
profiles concerning growth, differentiation capacities, tumorigenic ability and drug response 
to TMZ. Unfortunately, no correlation between genomic and functional profiles could be 
established. Furthermore, genetic variability might be underestimated due to clonal 
selection upon primary culture step. 
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1.3.3. Cancer stem cell model 
A largely debated model for intratumoral heterogeneity is the cancer stem cell (CSC) model. 
As many biomedical hypotheses, the concept of a CSC dates back to Rudolf Virchow in the 
19th century. The German pathologist examined, amongst many biological tissues, also 
human tumors. By histology, he was the first to describe morphological heterogeneity within 
tumors and tumor resemblance to embryonic tissues (Virchow, 1855). In 1863, he stated in 
his embryonal rest theory that tumors develop from embryo-like cells that remained in the 
tissue after organ development (Virchow, 1863). Ten years later, in 1874, Cohnheim and 
Durante extended this theory referring to the rest cell theory (Durante, 1874). Excess of 
embryonic rudiments remaining in tissues of fully differentiated organs could develop into 
tumors in adults. Rippert proposed in 1911 that the environment of these rudimental cells 
is the critical factor determining the phenotype of the tumor (Rippert, 1904). Thus, already 
at that time, scientists developed hypotheses about cancer development based on simple 
histological observations that are still partially accepted today. Although, technically 
speaking, these observations describe tumor initiating capacities, they are seen as corner 
stone for CSC research since stemness capacities were linked to cancer cells. With 
emerging technical tools like the development of the fluorescent-activated cell sorting 
(FACS) in 1972 by Herzenberg at Standford, improved cell culture systems and the 
development of xenotransplantation assays, CSC research gained popularity (Bonner, 
1972). 
 
1.3.3.1.  Definition of cancer stem cells 
The term CSC is used very loosely in scientific publications creating a lot of confusion and 
is often confound with the term tumor initiating cell (TIC). TICs should be considered as 
cells responsible for initiating a tumor, therefore referring to the origin of tumor. CSC on the 
other hand refer to subpopulation of tumor cells responsible for maintenance of tumor 
growth and regrow of tumors after resection and treatment. The CSC hypothesis does not 
make a distinction on the origins of a CSC; thus, a CSC does not necessarily derive from a 
normal stem cell (Jordan, 2009). Of note, for many cancers it is not clear whether the TICs 
originate from a healthy stem, progenitor or fully differentiated cell. The confusion in 
terminology arises from two issues: (1) it is often assumed that CSCs have to arise from 
normal stem cells; (2) researchers often apply the TIC terminology to refer to putative CSC 
populations initiating tumors in experimental models. 
It took over 50 years to find a consensus on the definition of a CSCs as the identification of 
these cancer subpopulations is problematic. No universal marker exists, and putative CSCs 
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need to be determined using functional assays. These tests were slowly developed with 
improved culture systems and analysis methods. In 2006 during the AACR (American 
Association for Cancer Research) workshop on CSCs in Lansdowne, Virginia, the scientific 
community proposed the CSC definition: “CSCs are a population of cells in the tumor that 
have self-renewal capacity and can give rise to all the heterogeneous cell population that 
comprise the tumor.” (Clarke et al., 2006). Accordingly, a CSC cannot be identified by 
marker expression alone, but needs to fulfil several functional properties.  
Following the CSC hypothesis, a subpopulation of cells at the apex of a hierarchical 
organization creates intra-tumoral heterogeneity via a one-way differentiation process (Fig. 
6). The CSC produces in analogy to normal stem cells in the body, progenitor cells that in 
their turn generate fully differentiated cancer cells. CSCs are able to divide symmetrically 
giving rise to either two CSCs or two progenitor cells. Asymmetric division results in one 
CSC and one progenitor cell. CSC are able to proliferate indefinitely, self-renew and form 
heterogeneous tumors upon transplantation assays. Properties of progenitor cells on the 
other hand are not that well defined. Two views are discussed in the scientific field, either 
they are fast, or they are slowly proliferating with a limited number of cell divisions. 
Moreover, it is still unclear whether cells defined as progenitors should be able to self-renew 
and produce tumors in vivo with gradually decreasing capacities upon increased 
differentiation status. Finally, at the bottom of the hierarchical structure are the fully 
differentiated cancer cells. They do not have the potential to self-renew, to generate a tumor 
in vivo and do not show stemness properties in functional analysis. Thus, the differentiated 
cancer cell has no multipotent abilities (Meacham and Morrison, 2013, Shackleton et al., 
2009). Most studies performed tests on putative CSCs and non-CSCs, here non-CSCs may 
represent progenitors and/or fully differentiated cells. 
Several CSCs of distinct genetic backgrounds might coexist within one tumor (Visvader and 
Lindeman, 2012, Piccirillo et al., 2015, Stieber et al., 2013). Genetic aberrations might 
influence CSC marker expression. Similarly, the epigenome determines cell fate 
specifications during differentiation process wherein transcriptional profiles vary accordingly 
(Wainwright and Scaffidi, 2017). Applied on the CSC model, epigenetic, transcriptional and 
phenotypical heterogeneity is created by the presence of cancer cells in the tumor bulk at 
different stages of the one-way differentiation process. 
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Figure 6: The cancer stem cell model. A single CSC at the apex of a hierarchical organization is 
able to self-renew, proliferate indefinitely and give rise to heterogeneous tumors upon transplantation 
into experimental models/immunodeficient animals. A CSC generates more differentiated progenitor 
cells which finite proliferating capacities and extensively contribute to tumor mass. Fully differentiated 
cancer cells are at the bottom of the one-way differentiation process and are not able to generate de 
novo tumors in transplantation assays. There are two variations of the CSC model; the first assumes 
that progenitor cells have self-renewal and tumorigenic capacities. The second model clearly states 
that progenitors are not able to self-renew and cannot form tumors in vivo. 
 
1.3.3.2. Functional properties of CSCs 
Although many properties of CSCs are derived from normal stem cells, it is a major 
misunderstanding that CSCs demonstrate the same characteristics as normal stem cells in 
the body. E.g. the frequency of a normal stem cell in the healthy tissue is constant and very 
low, whereas the number of CSCs within a tumor is thought to vary from patient to patient 
and several distinct CSCs might be present within one tumor (Jordan, 2009). It has been 
suggested that the number of CSCs within a tumor increases with malignancy (Jordan, 
2009). Moreover, stem cells in the healthy tissue are comprised in well-defined niches with 
well-regulated external stimuli, whereas the tumor niche is a more dynamic entity that may 
change with tumor progression (Jordan, 2009). 
1.3.3.2.1. Sphere forming ability 
In 1992, Reynolds and Weiss developed culture conditions to maintain and propagate 
neural stem cells (NSCs) in vitro as neurospheres (Reynolds and Weiss, 1992). Growth 
medium deprived from serum and supplemented with defined growth factors, particularly 
basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), were shown to be 
sufficient to derive and maintain NSCs in vitro (Conti et al., 2005). EGF and bFGF are 
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necessary for stem cell self-renewal, proliferation and maintenance (Haley and Kim, 2014, 
Hebert et al., 2009). Similarly, Ignatova and colleagues applied these growth conditions to 
anaplastic astrocytoma and recurrent GBM patient-derived samples. As a result, GBM cells 
formed spherical cellular aggregates similar to neurospheres (Ignatova et al., 2002). These 
conditions are often considered to enrich for CSCs. The ability to form sphere structures is 
seen as a general prerequisite for CSCs due to the similarity to the NSC culture (Reynolds 
and Vescovi, 2009). Sometimes leukemia inhibitory factor (LIF) is added to the culture 
medium, although it is not necessary to maintain GBM CSC cultures (Yuan et al., 2004) 
(Beier et al., 2007). LIF is predominantly used in mouse embryonic stem cell cultures to 
promote self-renewal capacities via the JAK-STAT pathway (Ernst and Jenkins, 2004). 
Plating GBM patient-derived cultures in serum-free medium on laminin or other extracellular 
matrix coatings was shown to maintain the CSC state in long-term adherent culture (Pollard 
et al., 2009). The addition of serum in the medium turns CSCs into a differentiated-like state 
with decreased tumorigenic potential (Reynolds and Vescovi, 2009, Gunther et al., 2008). 
1.3.3.2.2. Unlimited self-renewal and proliferative ability 
Self-renewal ability is the capacity of a cell to remain in an undifferentiated state through 
symmetric or asymmetric cell division whereby at least one daughter cell is equally 
multipotent than the parental cell. By symmetric division a CSC gives rise to a CSC and a 
progenitor cells, whereas a CSC gives rise to two identical daughter cells upon symmetric 
division either producing two new CSCs or differentiated progenitor cells (He et al., 2009). 
By time-lapse microscopy GBM CSCs were analyzed for their symmetric and asymmetric 
division frequency. Non-CSCs were identified by the presence of differentiation markers 
MAP2 or GFAP which are expressed by neurons and astrocytes, respectively (Lathia et al., 
2011b). Interestingly, the rate to which a putative CSC performs symmetric or asymmetric 
division can be affected by culture conditions. In EGF and bFGF enriched medium, more 
than 80% of CSCs exhibited symmetric division producing two stem-like daughter cells. 
12.6 % of CSCs generated by symmetric division two differentiated daughter cells. Only 
3.6% of CSCs underwent asymmetric division. The frequency of asymmetric division was 
enhanced (20%) upon growth factor depletion whereas symmetric division to two CSCs was 
reduced to approximately 70% (Lathia et al., 2011b). This shows that the decision to 
undergo symmetric or asymmetric cell division is influenced by the microenvironment. 
Since the ability to form a sphere in vitro is regarded as self-renewal potential, sphere 
forming assays have been introduced as measurement for self-renewal ability. However, a 
lot of variation exist in the execution of this test with impact on symmetric and asymetric 
division rates as described above; culture medium composition, volume of culture medium, 
cell density, surface area of the culture dish and duration of cell culture (Chaichana et al., 
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2006). Two main assays have been pointed out in the last years; self-renewal test at single 
cell level over several passages or limiting dilution assay (LDA) which is suitable for rare 
CSCs.  
First, self-renewal test at clonal density over several passages is mainly used for a cancer 
population that is enriched for CSCs. Here single cells are cultured until sphere formation 
occurs. Testing sphere forming capacity at the single cell level in independent cultures 
prevents false positives through cell aggregation. At the first passage, the percentage of 
formed spheres represents their clonogenic ability. Surviving cells from the 1st passage are 
collected and seeded as single cells for a second passage to test sphere forming capacities 
and the number of spheres is counted after formation. To test the CSC model where 
progenitor cells have limited self-renewal capacities, serial passages need to be performed 
to dilute eventual progenitor cells. By the consecutive passages, the number of formed 
spheres reduces in case of progenitors. In contrary, CSCs are expected to keep their sphere 
forming ability over time and demonstrate self-renewal ability throughout passages by 
demonstrating a stable number of formed sphere during testing. Differentiated cells do not 
form spheres at all. 
Often sphere size is used as a read out for differentiation status of a cell. However, caution 
must be taken in data interpretation. Here CSCs are thought to form bigger spheres than 
progenitor cells due to their unlimited self-renewal and proliferative capacities. On the other 
hand, a second variation of the CSC model might suggest that CSC are quiescent and only 
form progenitors when needed. The later are fast proliferative and generate the tumor bulk. 
In this case, spheres from CSCs and their differented progenitors have similar sizes. 
For the LDA test, the cancer cell population is seeded at different dilutions (e.g. 100, 500 
and 1000 cells per culture) to increase the chance a CSC is present. Consequently, LDA is 
best suited to determine the frequency of rare CSCs in a cancer cell population. The number 
of formed spheres is counted for each seeding dilution separately and the final frequency 
of self-renewing cells within a cancer cell population can be statistically estimated. Several 
online tools using different estimation strategies (e.g. generalized linear models or 
maximum likelihood) have been made accessible (Hu and Smyth, 2009).  
CSCs exhibit indefinite proliferative ability where both symmetric and asymmetric cell 
divisions are accounted to cell proliferation (Bu et al., 2013, Bose et al., 2014). The 
measurement of indefinite cell proliferation is rather challenging due to its unlimited 
timeframe. Therefore, experimental design needs to define a minimal number of cell 
passages required for unlimited proliferation. The number of passages may strongly depend 
on the cancer type used. Therefore, cell proliferation between a CSC population and a non-
CSC cell population is generally compared for several passages. Following the CSC 
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hypothesis, non-CSCs are regarded not to have proliferative capacities in case of fully 
differentiated cancer cells or to lose their proliferative ability after several cell passages until 
complete cell cycle arrest in case of progenitor cells.  
1.3.3.2.3. Tumorigenic ability 
The main prerequisite of putative CSCs is the ability to generate a tumor with the same 
heterogeneous pattern as the original tumor upon transplantation into mice. In 1937, Furth 
and Kahn were able to show by transplanting cancer cell lines into mice that a single cell is 
able to induce cancer. The frequency of inducing cancer by this approach was however, 
highly variable (Furth, 1937). This implied that only few cancer cells were able to form 
tumors. Pierce and Speers suggested later that tumors were hierarchically structured and 
only the cancer cells atop of the organization could induce tumors (Pierce, 1988). 
Tumorigenic assays are best performed by orthotopic transplantations i.e. that tumor cells 
are implanted at the same location in mice as it developed in the human body. For instance, 
patient GBM tumors are implanted intracranially into the brain of immunodeficient animals. 
This is done to approximate the microenvironment of the original cancer; although human 
cancer cells are generally transplanted into immunodeficient mice which are impaired in 
their immune system. Of note, the tumor resulting from implanted human patient-derived 
cancer tissue or primary cells is considered as a patient-derived xenograft (PDX). 
Therefore, immunocompromised animals are used to ensure the most permissive 
environment for tumor development. 
In transplantation assays, a tumorigenic and non-tumorigenic cancer populations have 
been demonstrated for several tumors: breast cancer (Al-Hajj et al., 2003), colorectal cancer 
(O'Brien et al., 2007), GBM (Singh et al., 2004b), ovarian cancer (Stewart et al., 2011). 
Following the CSC model, the non-tumorigenic cancer population represents fully 
differentiated and/or progenitor cancer cells depending on the model variations. The 
tumorigenic cells are putative CSCs when they show multipotent abilities. E.g., in GBM it 
was shown that CD133- fraction of the cancer was not tumorigenic, but the CD133+ cell 
fraction was (Singh et al., 2003). Even more, CD133+ cancer cells were able to produce 
CD133- cancer cells. Thus, in vivo transplantation assays are a powerful tool to analyze 
CSC capacities, however several considerations must be taken into account. 
Importantly, it was shown that the use of several distinct strains of immunocompromised 
mice with different degrees of immunogenicity affects the frequency of tumorigenic CSCs. 
Quintana et al. showed that melanoma cells engrafted into NOD/SCID interleukin-2 receptor 
gamma chain null mice increased the frequency of tumorigenic cells and tumors grew faster 
compared to cancer cells transplanted into NOD/SCID mice (Quintana et al., 2008). 
Thereby, the real frequency of tumorigenic cells might be underestimated depending on the 
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mouse strain used for transplantation, which might result from the xenogeneic immune 
response. Human cells injected to mice are recognized as foreign and therefore removed 
by cells from the immune system. Another mechanism that results in the underestimation 
of tumorigenic cells are the lack of human specific adhesion molecules or growth factors 
necessary for tumor development. To overcome that engrafted cancer cells do not survive 
transplantation, it has been shown that an admixture of cancer cells with carrier cells or 
extracellular matrix should be used for assays. Cancer cells with different tumorigenic 
capacities were all able to form tumors in mice to similar rates when co-engrafted with 
irradiated cancer cells (Gupta et al., 2011).  
The number of tumorigenic cells is not necessarily rare. In acute myeloid leukemia (AML) 
10% of engrafted cells were generating tumors (Kelly et al., 2007). In contrast, the minimal 
number necessary for successful tumor generation in GBM can be as low as 10-100 cells 
of a CSC-enriched cell population (Singh et al., 2004b). In melanoma, one single cancer 
cell was sufficient for tumor growth in NOD/SCID II2rg-/- mice (Quintana et al., 2008).  
It has been shown that high self-renewal ability in vitro does not necessarily predict tumor 
formation upon transplantation assays (Barrett et al., 2012). In orthotopic transplantation 
assays, the tumorigenicity of high grade glioma cells with limited self-renewal ability was 
compared to high grade glioma cells with high self-renewal capacity. Interestingly, cells with 
low self-renewal ability marked faster and higher penetrance of generated tumors.  
1.3.3.3. Identification of CSCs 
In analogy to NSC research, identification of CSCs by the expression of stemness markers 
has been widely attempted. These CSC markers represent proteins or other molecular 
components (e.g. sugars, lipids) expressed by a cancer cell and are often used to enrich 
for putative CSC subpopulations in GBM patient-derived cultures. Most of these markers 
are not unique to GBM CSCs, but were reported to identify putative CSCs in other cancers 
as well. Examples for intracellular CSC markers in GBM are Sox2 (Stoltz et al., 2015), 
Vimentin (Reifenberger et al., 1989), Nestin (Singh et al., 2004b), Olig2 (Ligon et al., 2004), 
ALDH1 (Charafe-Jauffret et al., 2009, Ginestier et al., 2007) and Oct-4 (Krogh Petersen et 
al., 2016). Traditionally, specific cell surface markers are used for CSC 
enrichment/identification as it allows subsequent functional testing on the FACS-isolated 
subpopulations. In GBM and other cancers a plethora of cell membrane markers were 
described; e.g. CD133 (Singh et al., 2003), CD44 (Anido et al., 2010), A2B5 (Tchoghandjian 
et al., 2010), CD15 (Son et al., 2009), NG2 (Al-Mayhani et al., 2011), CD9 (Podergajs et 
al., 2016), CD151 (Tilghman et al., 2016), integrin-α 6 (CD49f) (Lathia et al., 2010), CD24 
(Vassilopoulos et al., 2008), CD29 (Vermeulen et al., 2008) and CD90 (Yang et al., 2008). 
In this thesis, we will focus on the four cell surface markers CD133, CD44, A2B5 and CD15. 
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1.3.3.3.1. CD133 
CD133 is a type I glycoprotein composed of five transmembrane domains with two 
intracellular and two extracellular loops and one cytoplasmic domain (Corbeil et al., 2010, 
Miraglia et al., 1997, Yin et al., 1997). The human CD133 gene Prominin 1 (PROM1) has 
six distinct tissue specific promoters suggesting cell type specific CD133 regulation 
(Sompallae 2013. Article 209). The coding region of the gene contains 28 exons, whereof 
7 are optionally expressed (Bauer et al., 2008, Yu et al., 2002). PROM1 has 12 known 
splice variants (reviewed (Fargeas et al., 2007)). To date the CD133 has no known ligands. 
The extracellular domain of CD133 contains 8 possible glycosylation sites (Yin et al., 1997).  
CD133 (PROM1) is the most prominent putative CSC marker. In non-tumoral cells, CD133 
is expressed in brain endothelial cells (Golebiewska et al., 2013) and in hematopoietic, 
neural stem and progenitor cells (Corbeil et al., 2010, Bauer et al., 2011, Uchida et al., 2000, 
Corbeil et al., 1998, Tamaki et al., 2002). Positive marker expression is used to isolate 
neural stem cells from human fetal brain (Uchida et al., 2000). CD133 is present in 
membrane protrusions, filopodia and lamellipodia of mouse neuroepithelial stem cells 
(Weigmann et al., 1997). CD133 expression may be linked with poor patient survival. 
However, the prognostic value of CD133 expression in GBM is highly debated in literature 
due to imperfect sample sizes and analysis methods (Pallini et al., 2008, Zhang et al., 2016, 
Wu et al., 2015). Presence of CD133+ cancer subpopulations have been demonstrated in 
many different cancer types: GBM (Singh et al., 2003, Bao et al., 2006a, Galli et al., 2004), 
colon (Ricci-Vitiani et al., 2007, O'Brien et al., 2007) (Todaro et al., 2007), liver (Ma et al., 
2007), prostate (Richardson et al., 2004), melanoma (Monzani et al., 2007), ovarian cancer 
(Curley et al., 2009) and hepatocellular carcinoma (Song et al., 2008).  
Experiments performed in CD133+ GBM patient-derived cultures showed that the C-
terminal tyrosine residue of CD133 interacts with the PI3K regulatory subunit p85 thereby 
activating the PI3K/AKT signaling pathway (Wei et al., 2013, Liu et al., 2017). Supporting 
evidence comes from CD133 overexpression experiments in gastric cancer cells, here 
CD133+ cells had higher activated PI3K/AKT/ribosomal protein S6 than cancer cells with 
silenced CD133 (Zhu et al., 2014). Concordantly, CD133 knockdown in CD133+ GBM 
sphere cultures resulted in reduced activity of PI3K and AKT proteins and was essential for 
self-renewal and tumorigenic ability (Wei et al., 2013). 
CD133+ GBM cells showed higher proliferation, self-renewal and invasion in vitro than 
CD133- GBM cells grown on equal culture conditions (Wang et al., 2016, Singh et al., 
2004b). In these experiments, only CD133 cells were able to generate tumors in vivo. 
shRNA depletion of CD133 resulted in decreased cell growth and clonogenicity combined 
with reduced tumorigenic potential in CD-1 nude mice (Brescia et al., 2013b). However, 
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these data are conflicting with other reports, demonstrating CSC properties as well in 
CS133- GBM subpopulations (see section 1.3.4). The percentage of CD133+ cells vary 
from rare to highly expressed between GBM patient derived-cultures. Moreover, the portion 
of CD133+ cells in CSCs cultures changes with culture conditions; CD133 surface epitope 
expression decreases in serum containing medium supplemented with retinoic acid 
(Campos et al., 2011b). Western blot analysis of total CD133 protein (intra and 
extracellular), however, did not show significant variations between differentiation and 
normal culture conditions. Commonly used antibodies for CD133 antibody target the AC133 
or AC141 glycosylated cell membrane epitopes (Miraglia et al., 1997, Green et al., 2000). 
It is hypothesized that the AC133 epitope on the second loop of CD133 is masked upon 
differentiation and thereby not accessible for antibody binding (Kemper et al., 2010). Thus, 
the lack of AC133 positive cells does not always reflect the absence of CD133 protein. 
In primary GBM cultures Bao and colleagues demonstrated that the percentage of CD133+ 
cells were higher in irradiated cells than in the initial condition without treatment. They 
concluded that CD133+ cells were more resistant to radiation than CD133- cells due to 
higher DNA damage repair efficiency (Bao et al., 2006a). Moreover, CD133 expression is 
increased in hypoxia (Campos et al., 2011b, Griguer et al., 2008). Upon stress conditions, 
the genetic depletion of mitochondrial DNA and the inhibition of electron transporter chain 
(ETC) by compounds suggests that CD133 might be upregulated (Griguer et al., 2008).  
1.3.3.3.2. CD44 
CD44 is a transmembrane glycoprotein receptor expressed in numerous cell types 
(Jaggupilli and Elkord, 2012) ranging from blood cells and hematopoietic stem cells to 
epithelial cells (Basakran, 2015) to keratinocytes, hair follicles, dendritic cells (Yasaka et 
al., 1995). It is therefore not surprising that CD44 positive cells with CSC properties were 
discovered in many cancer types, e.g. in GBM (Anido et al., 2010), bladder (Chan et al., 
2009), breast (Al-Hajj et al., 2003), colorectal (Dalerba et al., 2007), lung (Leung et al., 
2010), ovarian (Zhang et al., 2008), pancreatic (Li et al., 2007) and prostate cancer (Collins 
et al., 2005). CD44 expression is linked to the mesenchymal subgroup and poor survival in 
GBM (Guadagno et al., 2016, Phillips et al., 2006). 
The CD44 gene has 19 exons, whereof the first 16 exons are designated to the extracellular 
domain and its specific splice variants. Exon 17 encodes for the hydrophobic 
transmembrane domain followed by exon 18 and 19 for the intracellular domain common to 
all isoforms. To date, 12 splice variants are known (Screaton et al., 1992, Morath et al., 
2016). The most described isoforms are CD44s (standard), CD33 variant 3 (CD44v3) and 
CD44 variant 6 (CD44v6). The later is preferentially expressed in GBM (Jijiwa et al., 2011). 
All isoforms contain hyaluran (HA), laminin and collagen binding site (Peach et al., 1993). 
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Only CD44s cannot bind osteopontin (OPN) (Ishii et al., 1993, Weber et al., 1996, Katagiri 
et al., 1999). Upon OPN ligand binding, CD44v6 induces AKT signaling resulting in an 
increased sphere forming capacity of mouse tumor cells (Jijiwa et al., 2011). 
Generally, CD44 is implicated in cell-cell interactions and adhesion to extracellular matrix 
(Zoller, 2011). In GBM, CD44 expression is related to tumor invasiveness in vivo (Su et al., 
2003). CD44 is related to several processes in the nervous system as myelination, astrocyte 
migration and Ca2+ clearance (Dzwonek and Wilczynski, 2015). 
OPN binding leads to γ-secretase dependent proteolytic cleavage of CD44 with the 
intracellular domain translocating to the nucleus where it is involved with the expression of 
stemness genes via CBP/p300 increased HIF-2α (Morath et al., 2016). Addition of TGF-β 
induced CD44 epitope expression in GBM cells via Id1 and Id3 activation (Anido et al., 
2010). Inhibition of TGF-β receptor leads to decreased tumor initiation and volume in 
orthotopic transplantation assays. 
1.3.3.3.3. A2B5 
A2B5 is an epitope of the c-series of gangliosides on the surface of cells (Saito et al., 2001). 
Gangliosides are glycosphingolipids composed of hydrophobic ceramide and a hydrophilic 
group containing oligosaccharides, silialic acids and a sugar chain. C-series gangliosides 
are formed by an enzyme cenoded by the gene ST8SIA1. However, a specific pathway with 
complete list and functioning of modulating enzymes is largely unknown (Svennerholm, 
1963, Yu et al., 2008). In the cell membrane, the acidic glycosphingolipids interact with other 
lipids, cholesterol and sphingomyelin and can form lipid rafts, micro domains and caveolae 
(Simons and Ikonen, 1997). Gangliosides are typically found in the brain and are mainly 
implemented in cell-cell signaling, recognition and adhesion. A2B5 recognizes neural stem 
and progenitor cells (Eisenbarth et al., 1979, Abney et al., 1983). However very little is 
known of its function in cancer, except for its putative role as a CSC marker. Several studies 
were performed on GD3 a b-series ganglioside which is a precursor to the c-series 
gangliosides. Here, normal melanocytes have low levels of GD3, but experience a dramatic 
increase of this gangliosides in metastatic melanoma (Carubia et al., 1984, Ravindranath 
et al., 1991), suggesting a role in promotion of tumor metastasis. Addition of GD3 molecules 
to the medium of GBM and anaplastic astrocytic cell lines induced VEGF release 
(Koochekpour et al., 1996) and overexpression in GBM patient derived cultures is 
associated with tumorigenicity (Yeh et al., 2016). Tchoghandjian et al. reported A2B5 as a 
heterogeneously expressed marker in GBM and a putative marker for CSCs 
(Tchoghandjian et al., 2010, Auvergne et al., 2013, Han et al., 2015). Within the CD133 
negative population, A2B5 positive cells were able to generate tumors in 
immunocompromised mice (Ogden et al., 2008). The CD133- A2B5+ GBM subpopulation 
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was shown to have strong migratory capacities in vitro and in vivo (Sun et al., 2015). Self-
renewal and migratory abilities of A2B5 positive CSCs have been negatively associated to 
PAR1 and miR-218-5p, respectively (Auvergne et al., 2016, Wu et al., 2016). 
1.3.3.3.4. CD15 
CD15 also known as stage-specific embryonic antigen 1 (SSEA-1) or Lewis X (LeX), is 
expressed during all embryonic stages of neuronal development and in the adult brain on 
neural stem and progenitor cells (Capela and Temple, 2002, Capela and Temple, 2006). It 
is also expressed in kidney, primordial germ cells and mouse embryonic stem cells 
(Rauvala, 1976, Fox et al., 1981, Marani et al., 1986). CD15 is a glycosphingolipid belonging 
to the neolacto-series and is formed from paragloboside by fucosyltransferase 4 (FUT4) 
(Yanagisawa, 2011, Yu et al., 2008). The sialylated glycan is commonly linked to 
glycoproteins and glycolipids on tumor cell surfaces and regarded as an adhesion molecule 
(Varki, 1997). CD15 was also shown to be heterogeneously expressed within GBM (Son et 
al., 2009) and other brain tumors as medulloblastoma (Ward et al., 2009, Andolfo et al., 
2012, Read et al., 2009) and gliomas (Mao et al., 2009). Expression of CD15 is described 
as well in breast cancer, Hodgkin disease, B-cell chronic lymphocytic leukemias, and AML 
(Brooks and Leathem, 1995, Hall and D'Ardenne, 1987, Ball et al., 1991). In 
medulloblastoma, CD15 positive CSCs demonstrate specific sensitivity to PI3K inhibitors 
but are resistant to common brain chemotherapeutic agents as TMZ and cisplatin.  
Furthermore, CD15 is associated with cell-cell interaction and the compaction and adhesion 
of mouse embryos at the morula stage (Gomperts et al., 1994, Fenderson et al., 1984, 
Eggens et al., 1989).  
 
1.3.4. Critical assessment of CSC marker expression 
Many functional studies validated CSC-marker negative cells as less proliferative, with less 
self-renewal and tumorigenic abilities (Singh et al., 2004a, Singh et al., 2004b, Ogden et 
al., 2008, Tchoghandjian et al., 2010, Son et al., 2009, Anido et al., 2010, Lathia et al., 
2010). These results suggest that a CSC is not quiescent, but more proliferative than 
progenitor cells. Furthermore, these reports indicate that marker negative progenitor cells 
have limited self-renewal and tumorigenic abilities. Thus, stemness abilities may not be 
exclusive for CSCs, but are found at limited degree in more differentiated progenitor cells. 
This raises the question whether CSC markers as well may be expressed to a limited extend 
on progenitor cells. 
Moreover, CSCs markers cannot be generalized and markers validated in one cancer may 
not work for another cancer specimen (Al-Hajj et al., 2003). As example, it has been 
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demonstrated that CD133+ cancer cells have self-renewal properties and are able to 
generate tumors in vivo whereas CD133- cancer subpopulations cannot (Bao et al., 2006a, 
Singh et al., 2004b). Meanwhile several research groups found similar characteristics in 
CD133- GBM cells (Beier et al., 2007, Ogden et al., 2008, Wang et al., 2008). Chen and 
colleagues showed experimental evidence for CD133 positive and negative GBM cells able 
to form tumors in transplantation assays (Chen et al., 2010). Here all marker positive cells 
demonstrated stemness abilities. However, within the CD133- population two 
subpopulations were distinguished, whereof Nestin and FABP7 positive cancer cells carried 
stemness abilities and Nestin and FABP7 negative cancer cells did not demonstrate 
stemness properties. Wang and colleagues demonstrated that tumors generated from 
CD133- GBM cells reacquire CD133 expression. Hence, CD133 is not an ultimate marker 
for CSC. This holds true for other markers as well and it was therefore proposed that a 
combination of several CSC enrichment markers is necessary to illustrate the hierarchical 
organization in a GBM tumor (Beier et al., 2007, Piccirillo et al., 2009, Penuelas et al., 2009, 
Wang et al., 2008). Moreover, CD133 is increased upon hypoxia in CSC cultures. 
Enrichment of CD133 in hypoxia is reversible in subsequent normoxic condition (Griguer et 
al., 2008). This raises the question whether CD133 enrichment or loss happens through 
selection of the best fitting cell clone or through marker changes in expression through 
adaptation. Unfortunately, most reports do not include apoptotic tests to show/exclude a 
selection process. Comparable controversial results were also found for other CSC 
markers. In GBM, CD15 negative cells were shown to produce CD15+ cells in vitro (Kenney-
Herbert et al., 2015). In breast cancer, CD44- were shown as well to be proliferative, self-
renewing and tumorigenic upon transplantation (Lehmann et al., 2012, Mosoyan et al., 
2013). Thus, hierarchical organization of a tumor could not yet be clearly determined based 
on the CSC markers, which questions whether there is a marker combination able to define 
CSCs able to reproduce phenotypic heterogeneity.  
In GBM it was shown that CD133 positive cells from patient-derived cultures were able to 
produce upon symmetric and asymmetric cell division CSCs and differentiated cancer cells 
(Lathia et al., 2011b). Differentiated cells showed expression of either astrocytes (GFAP) 
or neurons (MAP2). Alike NSCs, the CD133 positive cells population showed multilineage 
differentiation and was able to self-renew. Moreover, it was shown that the CD133 positive 
cell is proliferating over a long-time period and produces tumors upon transplantation 
assays. CD133 negative cells did not retain these properties suggesting a higher 
differentiation status in these cells than in CD133 positive cells (Singh et al., 2003, Singh et 
al., 2004b). Thus, during the differentiation process, along the hierarchical organization, 
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cells accumulate or lose lineage specific properties as the expression of extra and 
intracellular markers (Campos et al., 2010). 
 
1.3.5. From CSC towards adaptivity 
The CSC model has increasingly been criticized in recent years due to conflicting results in 
CSC marker validity. Moreover, experiments from breast cancer and melanoma report non-
hierarchical state transitions (Gupta et al., 2011, Quintana et al., 2010, Chaffer et al., 2013). 
Here, cells of distinct phenotypic states were each able to recreate phenotypic 
heterogeneity until each population reached a common equilibrium with fixed proportions of 
phenotypic states. Using mathematical modeling, Gupta et al. showed that in breast cancer 
cell lines state transitions between stem-like (CD44+ CD24- EpCAMlow), basal (CD44+ CD24- 
EpCAM-) and luminal (CD44low CD24+ EpCAM+) cells were stochastic and phenotypical 
states interconverted, although at different rates. These experiments suggested high 
plasticity of cancer cells with no apparent differentiation status. As the CSC model 
implicates fixed phenotypic states and all of the cells represented CSC properties, results 
can be interpreted in two ways. Either the used CSC markers were not CSC specific or the 
CSC hypothesis does not hold true as it cannot explain the generated phenotypic variability. 
To this end, an adaptive model was proposed which is able to explain inconsistencies in 
the CSC hypothesis. According to the adaptive model, the CSCs are not a distinct 
subpopulation of tumor cells but rather a changing entity (Easwaran et al., 2014, Cabrera 
et al., 2015). Hence, a heterogeneous tumor population consists of cancer cells occupying 
different states e.g. a stem cell state or more differentiated states.  
Similar to the CSC model, the adaptive model represents variations in the abilities of 
different cell types (e.g. CSC, progenitor, differentiated cells or simply cancer cells with no 
gradient in differentiation status). Within the adaptive models, we distinguish two extreme 
models: the dedifferentiation model with the limited number of state interconversions (Fig. 
7.a) and the plastic model where each cancer cell may acquire each phenotypic state 
present in a tumor (Fig. 7.b). 
The dedifferentiation model emphasizes the dedifferentiating ability of each cancer cell 
regardless of their grade of differentiation (Fig. 7.a). This process is also referred to as 
bidirectional interconversion and is thought to be dependent on the environment a cancer 
cell is encompassed. This model still distinguishes between CSCs, progenitor cells and fully 
differentiated cells organized in a hierarchical structure, however the differentiation process 
is reversible. In that sense a progenitor cell can turn into a CSC or a fully differentiated cell. 
A fully differentiated cell is able to turn into a progenitor cell, but cannot change into a CSC 
directly. As CSCs, progenitor cells are able to self-renew and form tumors with the same 
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variability present in the initial tumor. Only differentiated cells may not have self-renewal 
and tumorigenic abilities.  
On the other hand, the adaptive model does not distinguish between differentiation status 
of cancer cells as they are all able to directly change into another cell state (Fig. 7.b). Here 
all the cells have unlimited self-renewal and tumorigenic abilities. No organizational 
structure as hierarchy can be identified in this model since the cancer cells have equal 
plastic behavior. 
As the dedifferentiation and plastic models represents the two most extreme interpretations 
of the adaptive model, the degree of hierarchical organization ranges from high to shallow 
to non-existent. The degree of hierarchy may depend on the cancer type and on genetic 
profiles (Meacham and Morrison, 2013). The rate to which a certain state is ‘favored’ 
depends on the environmental cues (extrinsic features) and stochastic cell-autonomous 
mechanisms (intrinsic features) (Marusyk and Polyak, 2010). Extrinsic features are factors 
originating from the tumor microenvironment. Intrinsic features might only depend on 
genetic and epigenetic background. Although, extrinsic features have a major influence on 
tumorigenicity and phenotypic states, the impact of intrinsic features cannot be disregarded. 
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Figure 7: The adaptive models. a. In the dedifferentiation model, the differentiation process is 
reversible, meaning differentiated cancer cells can acquire stem-like properties. Cancer cells are 
distinguished based on their differentiation status thereby arranged in a hierarchical organization b. 
In the plastic model, cell plasticity is very high, and cells are able to convert to all phenotypic states. 
Here, no hierarchical organization is present. State transitions are thought to be mainly influenced 
by environmental factors. The two adaptive models vary in the degree of plasticity which might 
depend on cancer type and intrinsic features.   
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1.3.6. Transcriptomic stem cell associated intratumoral heterogeneity in GBM 
Besides the analysis of genetic intratumoral heterogeneity, Sottoriva et al. examined the 
GBM tumor sections from different tumor regions at the transcriptional level as well. 
Therefore, transcriptional profiles of tumor sections were divided into the four GBM 
subgroups defined by Verhaak et al.(Verhaak et al., 2010). In 6 out of 10 patients, several 
transcriptional distinct subgroups within one tumor were detected, suggesting the 
coexistence of phenotypically divergent clones. This was one of the first studies revealing 
the transcriptomic intratumoral heterogeneity in GBM patients (Sottoriva et al., 2013). 
Transcriptomic data at the single cell level supported the presence of several transcriptomic 
subgroups within one tumor (Patel et al., 2014). Although reports could not infer genetic 
aberrations at the point mutation level, the results may indicate that transcriptional 
heterogeneity does not necessarily arise through chromosomal aberrations and thereby 
may not solely originate from clonal evolution. Subsequently, transcriptomic profiles of 
serum-free GBM sphere cultures and serum-dependent adherent GBM monolayers were 
used for either stemness and differentiated gene signatures. All tested GBM patient 
samples demonstrated a stemness gradient which was inversely related to cell proliferation 
suggesting that the stem-like cells were slower cycling. Since hierarchy from stem-like to 
differentiated cells was not divided into discrete subentities, no clear CSC or progenitor 
states were identified (Patel et al., 2014).  
scRNA-seq in IDHm oligodendrogliomas revealed a hierarchical organization with a stem-
like and two differentiated phenotypes. Gene transcription profiles showed that the highest 
variation was based on gene signature correlated to an astrocyte-like and an 
oligodendrocyte-like state (Tirosh et al., 2016b). Further discrepancies in transcriptomic 
profiles were based on the expression of stemness markers suggesting that stem-like 
phenotype was able to differentiate into two different lineages proving multipotency. 
Moreover, each genetically different clone (differences in copy number variation) contained 
stem-like and differentiated cell phenotypes which shows that the phenotypic states were 
not entirely correlated to genetic aberrations. In contrast to high grade GBMs, stem-like 
cells in low grade IDHmut gliomas displayed high cell cycling expression pattern. In 
contradiction to the authors interpretations, the representated stem-like phenotype did not 
define a distinct entity in oligodendroglioma, but rather a gradient from most stem-like to 
differentiated phenotype similar to GBM. 
A third RNA-seq study at the single cell level on IDH-mutant gliomas, revealed 
transcriptomic similarities between oligodendrocytomas and astrocytomas (Venteicher et 
al., 2017). In both oligodendrogliomas and astrocytomas a stemness transcription profile 
similar to NSCs was identified that was associated with high proliferation. Differences in the 
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expression profile between glioma subtypes were mostly attributed to genetic aberrations 
and tumor microenvironmental composition where astrocytomas displayed a gene 
signature enriched for macrophages/microglia. Of note, transition from stem-like to 
differentiated phenotype in both astrocytomas and oligodendrogliomas appeared rather 
gradually as no descrete subpopulations could be identifyied based on transcritional 
profiles. A major drawback of transcriptomic analysis is the fact that they only give a 
snapshot in time and do not allow to subsequently perform functional studies which renders 
scRNA-seq data inconclusive on model types present in GBM (e.g. CSC or adaptive model). 
Therefore, different transcriptomic profiles can only inform on the presence of possible 
subpopulations or states at a specific moment in time. 
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1.4. Tumor microenvironments 
The importance of the microenvironment on tumor progression and maintenance is 
increasingly recognized as a hallmark of cancer (Hanahan and Weinberg, 2000, Hanahan 
and Weinberg, 2011). As proposed for the adaptive model, the cell state may vary 
depending on extrinsic cues originating from the microenvironment. It is proposed that 
tumor microenvironment assures self-renewal and multipotency in CSCs and prevent 
differentiation by direct cell contact and secreted factors (Calabrese et al., 2007). Many 
studies have shown that exposure to different environmental cues such as low oxygen, 
extracellular metabolites or ECM components, changes the gene expression of the cells 
and may induce a switch in cellular state (Egeblad et al., 2010). E.g. it was shown that 
tumorigenic capacities of cancer cells are increased by the addition of ECM or irradiated 
cancer cells in transplantation assays (Kelly et al., 2007, Quintana et al., 2008, Gupta et al., 
2011). The unresolved question is whether all tumor cells are able to function as a CSC 
under certain microenvironments and adapt to the best fitting phenotype or whether certain 
microenvironments select for survival of specific cell subpopulations. 
In the brain, the tumor microenvironment involves interaction with different cell types as 
endothelial cells, pericytes, glial cells, astrocytes, NSCs, neurons, macrophages and 
microglia; and extracellular matrix components (ECM) such as fibrous proteins, 
proteoglycans and hyaluronic acid (HA) (Egeblad et al., 2010). Furthermore, bone marrow 
derived cells can be recruited to the tumor site (Burrell et al., 2014). Glioblastoma displays 
several tumor microenvironments such as the invasive, perivascular, hypoxic and/or acidic 
niches (Lathia et al., 2011a, Hjelmeland et al., 2011a, Hjelmeland et al., 2011b). These  
niches may coexist within one single tumor. In this thesis, we concentrate on the 
perivascular and hypoxic niches in GBM and do not consider immune cell-tumor 
interactions. 
 
1.4.1. Perivascular niche 
The perivascular niche delineates the areas around blood vessels where CSCs were 
described to be enriched (Calabrese et al., 2007). In several brain cancer samples, i.e. GBM 
and medulloblastoma, nestin+ CD43- tumor cells are located in proximity of blood vessels 
suggesting that the microenvironment in the perivascular area is favorable for the CSC 
state. Similarly, NSCs are reported to reside in this perivascular niche. NSCs (nestin+) 
coculture with endothelial cells was shown to maintain their stem cell state by Notch and 
Hes-1 activation (Shen et al., 2004). Using the same activation process, CSC may also 
keep their stemness abilities in the perivascular niche. 
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Next to endothelial cells, cancer cells residing in the perivascular niche secrete vascular 
endothelial growth factor (VEGF), fibroblast growth factors (FGF) and platelet derived 
growth factor (PDGF) to their environment (Hambardzumyan and Bergers, 2015, Bao et al., 
2006b). VEGF represents to date the most studied cell signaling molecule contributing to 
the perivascular niche of CSC. In PDXs, VEGF-A concentration is elevated in the 
perivascular niche and was shown to be secreted particularly by CSCs (CD133+) (Bao et 
al., 2006b, Skog et al., 2008). These growth factors induce angiogenesis (Olsson et al., 
2006) and thereby maintains the perivascular niche that is important for the stem cell state. 
This was confirmed in vitro where conditioned medium from CSC secreting EVs containing 
VEGF-A induced migration and tube formation of human brain endothelial cells using a 
tubulogenesis and sprouting assay (Treps et al., 2017). Most importantly, VEGF is also 
induced by HIF in hypoxia. Targeted treatment of the perivascular niche with VEGF 
antagonists (e.g. Bevacizumab) decreased self-renewing abilities of these cells (Calabrese 
et al., 2007).  
Nitric oxide (NO) is another molecule secreted by endothelial cells in the tumor bulk that 
could be related to the maintenance of the stemness state of a cell. NO was shown to 
activate Notch pathway in CSCs (Nestin+). Activated Notch signaling induces increased 
sphere forming capacities in vitro and tumorigenic potential in vivo (Charles et al., 2010). 
Increased self-renewal in cancer cells was also achieved by the expression of the Notch 
ligands DLL4 and JAGGED1 by either cancer cells for autocrine activation or endothelial 
cells (Zhu et al., 2011). Other factors produced by endothelial cells that promote the CSC 
niche are angiopoietin (Ang1) or sonic hedgehog (Shh). They stimulate tumor growth and 
self-renewal ability (Liu et al., 2010, Clement et al., 2007). 
 
1.4.2. Hypoxic niche 
GBM is a rapidly growing tumor with leaky and disorganized blood vessels (Fig. 8). Hence, 
nutrient supply to the tumor core is very poor and eventually becoming a necrotic area. 
Oxygen (O2) can diffuse approximately 100µm into the tissue (Heddleston et al., 2011). The 
average physiological oxygen concentration in the brain is around 7% (53mmHg), but 
ranges from 0.4% (3mmHg) in the midbrain to 8% (60mmHg) in the Pia mater (Evans et al., 
2004). O2 pressure (pO2) is measured in millimeter of mercury (mmHg). In tumor tissue 
oxygen levels can decrease to less than 1% (Mohyeldin et al., 2010), where necrotic zones 
are formed in anoxic tumor regions. The definition of hypoxia is not fixed as O2 levels vary 
throughout tumor tissue (Milotti et al., 2017, Bertout et al., 2008). Tumor areas are regarded 
as mildly hypoxic with 0.5-2.5% O2 (4-20mmHg) and severe hypoxic at 0.1-0.5% 
(≤4mmHg). Most GBM tumors present a hypoxic gradient with an average O2 pressure of 
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2.4mmHg (0.25% O2) (Evans et al., 2008, Evans et al., 2004). Similar results were found 
by Colligridge et al in other gliomas (Collingridge et al., 1999). The presence of hypoxic 
areas in GBM are correlated with poor survival (Walsh et al., 2014). 
The hypoxic response in a cell is largely mediated by two transcription factors known as 
hypoxia-inducible factors (HIF1 and HIF 2). In normoxia, the HIF-1α subunit is degraded via 
van Hippel-Lindau (VHL)-mediated proteasome degradation, whereas it is stabilized and 
dimerizes with HIF-1β to a functional transcription factor in hypoxia. In GBM, HIF-1α is 
mainly localized in pseudopalisading cells around necrotic areas and in invasive cells at the 
edge of the tumor (Zagzag et al., 2000). In vitro cultures showed that HIF-1α is activated in 
acute hypoxia, but only temporarily in chronic hypoxia (Holmquist-Mengelbier et al., 2006). 
In hypoxic environment cancer cells upregulate autophagy in a HIF-1α-dependent process 
for cell survival and growth (Mazure and Pouyssegur, 2010, Abdul Rahim et al., 2017, Hu 
et al., 2012).  
HIF-1α is thus shown to regulate the general GBM cell response to hypoxia, whereas HIF-
2α gene regulation is mostly linked to stemness maintenance and promotion of self-renewal 
abilities (Heddleston et al., 2009, Seidel et al., 2010, Li et al., 2009). Interestingly, in 
medulloblastoma HIF-2α expression is continued in chronic hypoxia and even persists after 
reoxygenation (Holmquist-Mengelbier et al., 2006, Holmquist et al., 2005) suggesting an 
oxygen independent role in stemness maintenance. In knock-down experiments of either 
HIF-1α or HIF-2α, Seidel and colleagues demonstrated in GBM sphere cultures that HIF-
2α is mediating the hypoxia-dependent response leading to the CSC phenotype. In this 
case CSC phenotype was defined by the expression of side population genes (ASPHD2, 
MAML3, NFE2L2, ABL2 and NFATc2) (Seidel et al., 2010). McCord and colleagues showed 
that HIF-2α is active at 7% O2 concentration but not HIF-1α (McCord et al., 2009). He 
observed higher clonogenicity of GBM sphere cultures at 7% O2 compared to normoxia. 
These results indicate that sphere formation capacities are regulated in HIF-2α-dependent 
manner. 
Generally, it is observed that CSC markers as CD133, SOX2, OCT4, Nestin and KLF4 are 
increased upon hypoxia and differentiation markers (GFAP and β3 Tubulin) are decreased 
indicating that low oxygen levels supports the induction and maintenance of stemness 
(Soeda et al., 2009, Bar et al., 2010, Heddleston et al., 2009, McCord et al., 2009).  
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Figure 8: The perivascular and hypoxic CSC niche. The perivascular niche is found near the 
blood vessels delineated by endothelial cells and pericytes. The hypoxic niche is located near the 
necrotic zone, which is anoxic. Oxygen levels gradually increase with the proximity to blood vessels. 
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1.5. Therapeutic targeting of CSC-like states 
The ultimate goal of cancer treatment is the complete eradication of cancer cells in a tumor. 
Different treatment approaches must be taken into consideration depending on the 
organization of a tumor. In case of a strict hierarchical structure, where CSCs are 
responsible for tumor growth, conventional therapy targeting bulk tumor mass is believed 
to be ineffective (Fig. 9). It is suggested that CSCs have increased radio- and 
chemoresistant capacities and thereby are not sensitive and tumor eventually relapses (Bao 
et al., 2006a). Hence, cancer treatment must take into account CSCs and target them 
specifically to overcome tumor recurrence. If CSCs are eliminated from a tumor bulk, cancer 
cannot progress since progenitor and fully differentiated cells have no tumorigenic potential. 
Several approaches are considered to eliminate CSCs in patients.  
First therapeutic strategy involves cancer vaccines. They are designed for specific 
elimination of CSC surface marker positive cells. In the phase 1 trial in recurrent GBM, the 
ICT-121 dendritic cells (DCs) isolated from white blood cells of cancer patients are cultured 
and prepared with CD133 peptides for vaccination. This immunotherapy envisages to 
induce the formation of cytotoxic T cells specific for CD133 positive cells including CD133 
expressing CSC in cancer patients (ClinicalTrials.gov identifier: NCT02049489). Therapy 
appears to be generally well tolerated in the ongoing clinical trial. Another DC-vaccine 
involves 6 peptides whose expression is associated with GBM CSCs: MAGE-1, HER-2, 
AIM-2, TRP-2, gp100 and IL-13Rα2 (Wen et al., 2015, Phuphanich et al., 2013). Phase 2 
trial results show the HLA-A2 MGMT arm with increased progression free survival due to a 
higher immunologic activity compared to HLA-A1 patients. A phase 3 trial is envisaged. 
A second approach to specifically target CSCs uses compounds to inhibit signaling 
pathways involved in the regulation and maintenance of stemness. These include TGF-β, 
Hedgehog, WNT, Notch or Ephrin pathways. The compounds can be subdivided into 
antibodies or small molecules with a maximal size of 900 daltons, which enables the latter 
to freely diffuse through cell membranes. Antibodies target cell surface structures, whereas 
small molecules interact with intracellular targets (for a complete list of compounds and 
clinical trial identifiers see (Marcucci et al., 2016)). Disulfiam (DSF) a small molecule for 
chronic alcoholism therapy is used in a phase II trial in newly diagnosed GBM 
(ClinicalTrials.gov identifier: NCT01777919). DSF was shown to inhibit ALDH+ CSCs and 
MGMT activity (Liu et al., 2012, Paranjpe et al., 2014). Furthermore, it easily crosses BBB 
making it all together a promising drug. 
Another alternative is to develop cancer vaccines that the target tumor microenvironment 
to eliminate CSC favorable tumor niches. The FDA approved bevacizumab is currently 
tested in combination with heat shock protein peptide complex-96 in recurrent GBM 
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(ClinicalTrials.gov identifier: NCT01814813) (Silver et al., 2016). Changing the tumor 
microenvironment by treatment pressure, may lead to negative selection of the CSC clone. 
Another treatment strategy for CSC eradication is the differentiation therapy, where a CSCs 
is forced to differentiate and lose their chemoresistant and tumorigenic potential. The best 
studied inducer of differentiation is all-trans-retinoic acid (ATRA) or also called tretinoin. In 
a phase II clinical trial in acute promyelocytic leukemia (APL) over 80% of the patients could 
be cured (ClinicalTrials.gov identifier: NCT02273102). However, in other AML patients, 
tretinoin was ineffective. In GBM, ATRA treatment was shown to inhibit tumor growth in 
PDXs and was shown to have antimigratory and antiagiogenic outcome (Campos et al., 
2010). Another possible differentiation inducer is BMP4. It directs NSCs towards an 
astroglial fate. BMP4 treatment on CSCs in GBM induces in vitro and in vivo the expression 
of astrocytic markers and renders GBM cells sensitive to TMZ (Bonaguidi et al., 2005, Lee 
et al., 2008, Piccirillo et al., 2006). BMP4 treatment combined with bevacizumab reduces 
tumor size and invasive capacities in GBM PDXs (Rahman et al., 2013). One major 
drawback is the difficult BBB passing of BMP4 (Mangraviti et al., 2016). 
In contrast, CSC-specific therapy in a tumor where the differentiation process is reversible 
due to environmental cues results in tumor regrowth. Here, a single differentiated cancer 
cell may acquire stem-like abilities and regenerate tumor mass (Vermeulen et al., 2012). 
Cancers with no hierarchical structure with adaptive phenotypes need to be additionally 
treated by targeting the adaptive processes. Therefore, it is indispensable to know how a 
certain tumor is organized to increase efficacy of cancer therapy.
 
  
  
  
 
 
Scope and aims of the thesis 
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2. Scope and aims of the thesis 
To this date no curative treatment for GBM is available. One major reason for therapy failure 
is tumor heterogeneity. In this thesis, we focus on understanding inter- and intra-tumoral 
phenotypic heterogeneity. It has been proposed that CSCs create phenotypic diversity in 
GBM in an irreversible differentiation-like process. This small subpopulation of cancer cells 
with stem-like characteristics is made responsible for tumor progression and recurrence. 
However, currently none of the proposed CSC markers was able to identify a pure CSC 
population in GBM, neither alone or in combination with other markers. Numerous other 
experimental data indicate however that CSCs cannot be defined by specific marker 
expression and may in fact not be a distinct entity. Following the latter hypothesis, 
phenotypic heterogeneity is formed by adaptive abilities of cells where dynamic reversible 
state transitions may depend on microenvironmental clues (e.g. oxygen level, nutrient 
shortage, growth factors/inhibitors and inflammatory signals).  
 
The identification of a true distinct CSC subpopulation in GBM would guide the treatment 
towards a cell specific targeted therapy. By specifically eliminating the cells at the apex of 
a one-way hierarchical organization, tumor progression could be arrested as tumor growth 
and chemoresistance would be hindered. On the other hand, if tumor heterogeneity is 
created by transitory cell states, CSC-targeted therapies would become unsuccessful since 
all cancer cells in a tumor would be able to generate new cancer cells. 
 
Due to the recent evidence supporting an adaptive model for phenotype transitions in other 
solid tumors as melanoma and breast cancer (Gupta et al., 2011, Quintana et al., 2010, 
Chaffer et al., 2013), we hypothesized that GBM might modulate their phenotype as well by 
transitory cell states. The overall aim of this thesis was to elucidate whether changes in 
phenotype expression upon environmental change occur via one-way hierarchical 
organization or adaptive abilities.  
To this end, we first assess phenotypical heterogeneity in a plethora of GBM patient-derived 
xenografts and GBM cell cultures. Furthermore, we simultaneously analyze four putative 
CSC-markers by multicolor flow cytometry. This analysis leads to a comprehensive study 
on the adaptive capacities of CSC-associated subpopulations in several environmental 
settings. Using mathematical modeling we elucidate the process in which phenotypical 
heterogeneity is created over time. Finally, transcriptomic differences between individual 
cells of CSC-associated subpopulations are assessed by single cell sequencing. 
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The major specific objectives of this thesis were: 
 
• To characterize phenotypic inter- and intra-tumoral heterogeneity in GBM 
using cell membrane-associated CSC markers 
 
• To assess stem cell properties of phenotypically defined CSC 
subpopulations in GBM 
 
• To appraise hierarchical organization versus reversible adaptive phenotype 
as origin of CSC-associated heterogeneity 
 
• To assess the effect of environmental factors on CSC-associated 
heterogeneity 
 
• To analyze CSC-associated transcriptomic heterogeneity at single cell level 
 
  
 
Materials and methods 
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3. Materials and methods 
3.1. Bioinformatical analysis of the TCGA GBM database 
Gene expression across GBM patients was investigated using The Cancer Genome Atlas 
(TCGA) cohort (160 GBM samples, provisional dataset on 25.10.2016) (Cancer Genome 
Atlas Research et al., 2013). TCGA data with appropriate heatmaps were analyzed and 
generated using Gitools software (Perez-Llamas, 2011 #525). The gene expression value 
corresponded to the median-centered RNA-seq data. DNA methylation data originated from 
a merged dataset of 25,978 probes shared by the HM27 and HM450 platforms analysis 
(#syn2486658). Genomic copy number alterations were obtained from PanCan12 Genom 
(for detailed analysis see https://www.synapse.org/). Group comparison was performed in 
Gitools using Mann-Whitney-Wilcoxon and Benjamini-Hochberg procedure was applied for 
multiple test correction. GBM samples were classified following the four GBM expression 
subgroups previously described by Verhaak (Verhaak et al., 2010): neural (n=28), 
mesenchymal (n=51), proneural (n=39) and classical (n=40) group. The analysis was 
performed with the help of Dr. Sabrina Fritah (Norlux Laboratory, LIH). 
 
3.2. GBM research models 
3.2.1. Clinical GBM samples and spheroids derivation 
GBM samples were collected from the Centre Hospitalier in Luxembourg (Neurosurgical 
Department, Luxembourg) from patients that signed an informed consent. A prior approval 
from the National Ethics Committee for Research (CNER) in Luxembourg was given for 
tumor collection. Some tumors (P3, P8 and P13) used in this study have been obtained 
from the Haukeland University Hospital (Bergen, Norway). All collected biopsies were 
diagnosed as grade IV GBM IDH wilde-type. After removal, the tumor tissue was 
immediately kept on ice and proceeded as fast as possible. The tissue was cut with scalpels 
in order to obtain very small tumor pieces. Subsequently, the minced tumor sample was 
grown in medium consisting of DMEM 4.5g/L glucose w/o L-glutamine (Lonza) completed 
with 10% Fetal Bovine Serum (FBS) (ThermoFisher Scientific), 10 000U/ml Penicillin and 
Streptomycin (Pen-Strep) (Sigma-Aldrich), 200mM UltraGlutamine I (Lonza) and 10mM 
Non-Essential Amino Acid Solution (Lonza) in precoated agar-flasks. To coat flasks, BD 
DifcoTM Agar (BD Biosciences) was heated to dissolve in sterile water to the final 
concentration of 0.85%. The agar solution was mixed 1:2.5 with above described medium 
to coat flasks subsequently. The cells were kept at 37°C and the medium was changed 
every 5 days. After 1-2 weeks in culture, first generation spheroids were collected by 
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decantation and stored in liquid nitrogen in DMEM 20% FBS with 10% dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich) until orthotopic transplantation. This work was performed by the 
technical specialists of the laboratories in Luxembourg and Bergen. 
3.2.2. Orthotopic patient-derived xenografts 
To obtain orthotopic patient-derived xenografts (PDXs), spheroids obtained from GBM 
patient samples were implanted in the brain of eGFP expressing Nod/Scid mice (Bougnaud 
et al., 2016, Golebiewska et al., 2013, Niclou et al., 2008). The mice were anesthetized with 
an intra-peritoneal injection of 100mg/kg Ketamine and 10mg/kg Xylazine. The local 
anesthesia Marcain with 0.25% adrenaline was injected subcutaneously at incision site. 
The head of the mouse was subsequently fixed in a stereotactic frame (Narishige SR-5R) 
and the Hamilton syringe prepared with the organotypic GBM spheroids was introduced at 
the coordinate X=2mm, Y=1mm and Z=0mm (when the bregma is representing position 
0,0,0 on a X-Y-Z axis). 4-5 spheroids were slowly injected (coordinate 2,1,2) and the needle 
was retracted after 2 minutes of incubation. The hole in the skull was closed using bone 
wax and the skin was sewed together by separated knots (Ethilon 3-0). The animals were 
placed in a warming chamber until wake up and were later kept in specific-pathogen-free 
(SPF) condition. Once a week the animals were weighted and they were as well controlled 
every day for neurological symptoms, such as uncontrolled movements, locomotor 
problems, lordosis, behavioral abnormalities in nesting and hyperactivity. At the appearance 
of at least one these symptoms the mice were sacrificed. The surgical protocol and handling 
of the mice was performed by Anais Oudin and Virginie Baus (Norlux Laboratory, LIH) in 
agreement to the European Directive on animal experimentation (2010/63/EU) and the local 
ethical committees. 
3.2.3. GBM cell cultures 
3.2.3.1. 3D GBM stem-like cultures 
The GBM stem-like cells NCH644, NCH421k, NCH660h, NCH601 and NCH465 derived 
from primary IDH wild-type GBM samples, were kindly provided by Dr Christel Herold-
Mende (Department of Neurosurgery, University of Heidelberg) (Campos et al., 2010). Non-
adherent sphere cultures NCH421k, NCH660h, NCH601, and NCH465 were kept in 
DMEM-F12 medium (Lonza) containing 1xBIT100 (Provitro), 2mM L-Glutamine, 30U/ml 
Pen-Step, 1U/ml Heparin (Sigma-Aldrich), 20ng/ml bFGF (Miltenyi) and 20ng/ml EGF 
(Provitro). When spheres reached a size of approximately 150 - 200µm, they were 
mechanically dissociated and then passaged 1:3 twice a week. NCH644 cells also grown 
as non-adherent spheres, were cultured in Neurobasal® base medium (Life Technologies) 
supplemented with 1xB-27 (Life Technologies), 2mM L-Glutamine, 30U/ml Pen-Step, 1U/ml 
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Heparin, 20ng/ml bFGF and 20ng/ml EGF. At a size of 200µm the spheres were 
mechanically dissociated. NCH644 were passaged 1:3-4 twice a week. The remaining GBM 
sphere cultures TB101 and TB107 which were kindly provided by Dr. Håkan Hedman, 
(Umeå University, Sweden) were cultured in DMEM-F12 medium with 1xB27 and 1xN2 
supplements (Provitro), 2mM L-Glutamine, 30U/ml Pen-Step, 1U/ml Heparin, 20ng/ml 
bFGF and 20ng/ml EGF. These cell cultures were mechanically dissociated to be split at a 
ratio of 1:3-4 twice a week. All centrifugation steps of cells were performed for 3 minutes at 
1200rpm. 
3.2.3.2. Conventional GBM cell cultures 
The adherent GBM cell lines U87 and U251 were cultured in DMEM medium (Lonza) 
supplemented with 10% FBS, 30U/ml Pen-Step and 2mM L-Glutamine. When cells reached 
sub-confluency of approximately 80%, they were splited 1:8 twice a week. Passaging of 
cells was performed by washing with Versene (Phosphate Buffered Saline (PBS) (Lonza) 
complemented with 10mM EDTA (ThermoFisher Scientific)) followed by trypsinization 
(1xTrypsin (Lonza)). All centrifugation steps of cells were performed for 3 minutes at 
1200rpm. 
3.2.3.3. Normoxic and hypoxic culture systems 
Classical normoxic cultures were kept at 37°C under 5% CO2 and atmospheric oxygen in 
Thermo Scientific® Steri-cycle CO2 incubator (ThermoFisher Scientific). Hypoxic conditions 
of 0.5% O2, were maintained in the hypoxic incubator chamber (Galaxy 48R incubator, New 
Brunswick) at 37°C under 5% CO2. O2 levels were regulated by injecting N2. Every 4 days, 
new medium was added to 3D GBM stem-like cultures kept at 0.5% O2 and big spheres 
were dissociated by pipetting. Medium of conventional adherent cell lines was exchanged 
every 4 days. Phenotypic reversibility to hypoxic environment was measured by culturing 
NCH644 and NCH421k GBM stem-like cultures for 7 days in hypoxia and passing them to 
normoxic conditions.  
3.2.4. Orthotopic cell line-derived xenografts 
NCH660h, NCH601 and NCH465 sphere cultures were mechanically dissociated to single 
cells and concentrated to 300’000 cells/µl in DMEM-F12 with no supplements. For GBM 
stem-like cultures NCH644 and NCH421k 50’000 cells/µl in Neurobasal and DMEM-F12, 
respectively, were used for transplantation. 1µl per GBM stem-like culture were implanted 
orthotopically into NOD/SCID mice as described above (Heading 3.2.2.) (2-3 mice per 
condition). Phenotype reversibility of tumor cells of NCH644 and NCH421k cell culture-
derived xenografts (2 mice of each GBM stem-like culture) to normoxic culture system was 
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performed by dissociating tumors to single cells (Heading 3.3.1.). Tumor cells were kept 
under normal normoxic in vitro culture conditions with their respective culture media.  
3.2.4.1. In vivo limiting dilution assay 
Single NCH644 cells were stained with 1µg/ml LIVE/DEAD® Fixable Near-IR Dead Cell 
Stain solution for 15 minutes in the dark at room temperature, followed by one HBSS 
washing step. Sterile FACS-sorted viable single cells were collected and serial dilutions of 
100, 300, 500, 1000 and 5000 cells/2µl were injected. 3 nude mice per condition were used. 
3.2.4.2. Tumor formation and survival assay 
To analyze the tumor formation capacities of NCH644 CSC-associated subpopulations 2, 
6, 11 and 15 (Heading 3.3.3.), 5000 FACS-sorted viable single cells of each subpopulation 
were engrafted separately into nude mice directly after sort (n=6-7). Viable sorted NCH644 
cells were used as control. Animals were monitored daily and were evaluated for a survival 
study based on the following criteria: (1) loss of more than 10% of body weight, (2) exhibition 
of strong neurological signs (difficulty ambulating or abnormal movement), (3) increased 
lordosis or (4) swollen belly. The criteria were scored as follows: 0 = none, 1 = early, 2 = 
established, 3 = severe signs and animals were sacrificed when 3 criteria with grade 2 or 1 
criterion with grade 3 were reached. Survival curves and corresponding statistics (Gehan-
Breslaw-Wilcoxon Test) were generated by GraphPad Prism 5. 
3.2.4.3. Tumor volume measurement 
Tumor volume was measured by Magnetic Resonance Imaging (MRI) on a 3T preclinical 
scanner MR Solutions (‘Preclinical Scan’ acquisition software), equipped with a mouse 
head volume coil. The Fast Spin Echo T2-weighted 2D sequence protocol was used with 
the following parameters: echo time of 68ms, repetition time of 3000 ms and echo train of 
8. The MRI imaged an area of 25x25 mm with a matrix size of 256x240. 15 slices of 1 mm 
thickness with no gaps between slices in the sequence were captured. The animals were 
placed prone in the cradle and were sedated with gas anesthesia (2% isoflurane mixed in 
medical air). The body temperature was maintained at 37°C and breathing frequency was 
monitored throughout the scan session. The total scanning time for T2 weighted scan took 
6 minutes and 12 seconds. Obtained MR images of one brain were opened as a stack on 
ImageJ. Tumor was delineated using the polygon selection tool and the delineated area 
was measured by analysis tool. The size of the tumor was defined as:  𝑝𝑖𝑥𝑒𝑙 𝑎𝑟𝑒𝑎 =
𝐹𝑂𝑉𝑥 ∗𝐹𝑂𝑉𝑦
𝑀𝐴𝑇𝑥∗𝑀𝐴𝑇𝑦
 , where Field of View (FOV) and Matrix size (MAT) was defined beforehand in 
the MRI acquisition software. When tumor areas of each stack image were calculated, 
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tumor areas were multiplied by slice thickness (1mm) and volumes were added to obtain 
total tumor volume. Statistical differences were calculated using Student t-test. 
 
3.3. Flow cytometry analysis 
3.3.1. Cell dissociation of GBM xenografts and sphere cultures 
To obtain a single cell solution from GBM xenografts generated in the mouse brain, MACS 
Neural Tissue Dissociation Kit (P) (Miltenyi) was used following manufacturer’s protocol. 
The brain was first removed, minced with scalpels and collected into a tube with HBSS w/o 
Ca2+/Mg2+ for washing. Tissue was resuspended in 37°C prewarmed EM1 solution (50µl 
Enzyme P, 1900µl Buffer X and 2,5µl 2-mercaptoethanol) and the mixture was incubated 
for 15 minutes at 37°C by reverting the tube regularly. In the following step EM2 (20µl Buffer 
Y and 10µl Enzyme A) was added and the tissue was mechanically dissociated using glass 
pipettes. The solution was incubated 10 minutes at 37°C by inverting the tube every 5 
minutes. Mechanical dissociation was repeated and cells were washed with HBSS. Cells 
were passed through a 50µm sterile filter and the tumor cell number was counted using a 
hemocytometer. 106 tumor cells were aliquoted per sample.  
Sphere cultures were mechanically dissociated to obtain single cells. Single cell suspension 
was filtered (50µm pore size) and counted to aliquot 106 cells per test. All cells were kept in 
flow buffer (2% FBS, 10mM Hepes (Sigma-Aldrich), HBSS) until further processing. 
3.3.2. Cell membrane staining 
Single cell suspensions were subsequently stained with 1µg/ml LIVE/DEAD® Fixable Near-
IR Dead Cell Stain for dead cell discrimination. Generally, antibody staining for cell surface 
markers was realized in flow buffer at 4°C for 30 minutes to 2 hours followed by one washing 
step (see Table 1 for list of antibodies and concentrations). For tumor cells derived from 
orthotopic transplantations into non-eGFP mice, human specific CD90 antibody was 
additionally added to the panel to distinguish human tumor cells from mouse stroma. Cells 
were subsequently washed once with flow buffer and diluted to 106 cells per 100µl for 
acquisition on flow cytometer (for flow cytometer settings and the antibody panel see Annex 
1). BDTM Compensation Beads Negative Control (FBS) and BDTM Compensation Beads 
Anti-Mouse Ig,κ were used to determine the amount of spillover to enable fluorescence 
compensation. Cell surface marker testing in GBM PDXs and multicolor panel was setup 
with the help of Dr. Anna Golebiewska (Norlux Laboratory, LIH). 
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3.3.3. Identification of CSC-associated subpopulations  
CSC-associated subpopulations of GBM stem-like cultures were distinguished by multicolor 
flow cytometry. Therefore, single cells were simultaneously stained with the four CSC-
associated cell surface markers, CD133/1, CD44, CD15, A2B5 and LIVE/DEAD® Fixable 
Near-IR Dead Cell Stain (1µg/ml). The staining was performed on ice for 30 minutes 
followed by one washing step (see Table 1 for list of antibodies and concentrations). Cells 
were subsequently diluted to 106 cells per 100µl for acquisition on flow cytometer (for flow 
cytometer settings and the antibody panel see Annex 1.a-b). Using DIVA software, the cells 
were divided into 16 subpopulations based on the intensity of fluorescence measured for 
each cell surface marker. 
3.3.4. Intracellular marker phenotyping 
The cells were stained with 1µg/ml LIVE/DEAD® Fixable Near-IR Dead Cell Stain for 15 
minutes in the dark. In case of tumors derived from xenografts, human specific CD90 
antibody staining was performed simultaneously with LIVE/DEAD® Fixable Near-IR Dead 
Cell staining for 30 minutes on ice in the dark. Once washed with HBSS, the cells were fixed 
with the BD Cytofix fixation buffer (BD Bioscience) for 30 minutes at room temperature. 
Cells were subsequently washed twice in 1x Perm/Wash buffer (BD Bioscience) and 
permeabilized for 10 minutes at room temperature. Antibodies and the appropriate isotype 
controls were added to the cells for staining during 1 hour on ice in the dark (Table 1). Cells 
were washed twice with 1x Perm/Wash buffer and were resuspended in the flow buffer. 
Cells were kept on ice until measurement on flow cytometer (for flow cytometer settings and 
antibody panel see Annex 1.a and c). BDTM Compensation Beads Negative Control (FBS) 
and BDTM Compensation Beads Anti-Mouse Ig,κ were used to determine the amount for 
spillover and enable compensation. The experiment was conducted in 3 biological 
replicates with 3 technical replicates each. 
3.3.5. Flow cytometer recording 
3.3.5.1. FACS AriaTM SORP cytometer 
The FACS AriaTM SORP cytometer (BD Biosciences) was fitted with a red, a UV, a violet, a 
blue and a yellow/green laser (for flow cytometer lasers and filters see Annex 1.a). The flow 
cytometer was stabilized for at least 1 hour before laser alignment and data acquisition. The 
Coefficient of Variation of the instrument (%CV) was routinely examined before each 
experiment. A 100µm (routinely) or 85µm (for differentiation experiments and sorting of 
NCH421k and NCH644 subpopulation 2 and 6 for single cell sequencing) nozzle and 
window extension (WE) 3 were used for data acquisition and sorting. PMT voltages were 
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adjusted each time with Cytometer Setup & Tracking Beads (BD Biosciences) to keep 
fluorescent signals comparable between experiments. Cells were collected at a maximum 
rate of 2500 events/s. For data analysis, approximately 30’000 viable single cells (or viable, 
single tumor cells in case of PDXs samples) were recorded per tube. For CSC-associated 
subpopulation distinction, at least 50’000 viable single cells or tumor cells were collected. 
Data acquisition and analysis were performed using DIVA software (BD Bioscience). 
Histograms were prepared with the FlowJo software. 
3.3.5.2. ImageStream imaging cytometer 
Imaging flow cytometry was performed with ImageStream imaging cytometer (Amnis) fitted 
with a near-UV, a blue, a yellow-green, a red and an infrared laser (for flow cytometer lasers 
and filters see Annex 1.b). Pictures were recorded at 60x magnification at low speed high 
sensitivity mode. 50’000 viable single cells were collected at a maximal speed of 1200 
cells/s. Acquisition and analysis was carried out using IDEAS® image analysis software. 
Acquisition was performed at the Paris Cardiovascular Research Center (Inserm U970, 
Flow Cytometry Core Facility) in France by Dr. Coralie Guerin. 
3.3.5.3. FACS Canto II cytometer 
FACS Canto II cytometer (BD Biosciences) was equipped with a red and a blue laser (for 
flow cytometer lasers and filters see Annex 1.c). Performance of the cytometer was 
controlled each time with the Cytometer Setup & Tracking Beads. For data acquisition, a 
window extension (WE) of 7 was used. Cells were collected at a speed of maximal 2500 
events/s and approximately 30’000 viable single (tumor) cells were recorded per tube. Data 
acquisition and analysis were performed using DIVA software (BD Bioscience). Histograms 
were prepared with the FlowJo software and cell cycle histograms were analyzed using the 
ModFit software. 
3.3.6. Sterile FACS-sorting 
Cell membrane staining for sterile sorting was performed as previously described (Heading 
3.3.2.). All reagents were sterile and handling was performed under laminar flow. 
Furthermore, flow buffer was supplemented with 10µg/ml DNAse I and 30U/ml Pen-Step. 
Before cell acquisition, FACS AriaTM SORP cytometer was rinsed for 30 minutes with sterile 
H2O to remove decontaminants. Sorting was performed at 4°C. 
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Table 1: List of antibodies and reagents used for flow cytometry and 
immunohistochemistry 
Epitope Conjugate Clone Supplier Dilution 
A2B5 APC/PE 105-HB29 Miltenyi FC:10µl/test 
A2B5 AF488 MAB312RX Chemicon ICC:1:20 
AnnexinV APC  Immunotools FC:10µl/test 
TUBB3 Alexa Fluor 647 TUJ1 BD Bioscience FC:5µl/test 
CD15/SSEA-1 Alexa Fluor 647 MC-480 Biolegend 
FC:5µl/test 
ICC:1:50 
CD15/SSEA-1 PE MEM-158 Immunotools FC:10µl/test 
CD15/SSEA-1 PERCP-Cy5.5 W6D3 Biolegend FC:5µl/test 
CD24 PE SN3 Immunotools FC:10µl/test 
CD29 APC MEM-101A Immunotools FC:10µl/test 
CD44 FITC MEM-85 Immunotools FC: 10µl/test 
CD44 PE-Cy7 IM7 eBioscience 
FC:1.2µl/test 
ICC:1:50 
CD56 PE-Cy7 N-CAM BD Bioscience FC:5µl/test 
CD90 PE-Cy7/APC 5E 10 BD Bioscience FC:5µl/test 
CD95 APC Fas/APO1 BD Bioscience FC:20µl/test 
CD133-1 PE /APC 293C3/AC133 Miltenyi 
FC:10µl/test 
ICC:1:50 
CD195 PE 2D7/CCR5 BD Bioscience FC:20µl/test 
EGFR PE EGFR.1 BD Bioscience FC:20µl/test 
GFAP AF647 1B4 BD Bioscience FC:5µl/test 
Isotype control 
IgG1 
FITC PPV-06 Immunotools FC:5µl/test 
Isotype control 
IgG1κ 
PerCP-Cy5.5 MOPC-21 BD Bioscience FC:5µl/test 
Isotype control 
IgG2a 
Alexa Fluor 647 eBR2a eBioscience FC:5µl/test 
Isotype control 
IgG2b 
Alexa Fluor 647 eB1491/10H5 eBioscience FC:5µl/test 
NES PercPcy5.5 25/NESTIN BD Bioscience FC:5µl/test 
NG2 PE LHM-2 R&D FC:10µl/test 
VIM FITC V9 Thermo Fischer FC:5µl/test 
FC = Flow cytometry (test 106 cells/100µl); ICC = Immunocytochemistry 
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3.4. GBM in vitro functional assays 
3.4.1. Cell growth assay 
To test cell growth, 50’000 single cells of every GBM cell line were plated for each 
measuring point. For sphere cultures, medium was added every 3-4 days and spheres were 
mechanically dissociated if necessary. Cells were cultured at normoxia or hypoxia (0.5% 
O2). Medium of adherent cell lines was replaced every 3-4 days. After 3, 7, 10 and 14 days, 
cells were collected (adherent cells were trypsinized). A 1:1 dilution of the cell suspension 
with 0.4% Trypan blue (Invitrogen) was used to distinguish dead cells. Total viable cell 
number was recorded with the Countess® cell counter (Invitrogen). The experiment was 
performed in 3 biological replicates with 3 technical replicates each. Statistical differences 
were calculated using Student t-test. 
Similarly, proliferative capacities of CSC-associated NCH644 subpopulations were 
examined in normoxia and hypoxia, except proliferative capacities were measured over an 
extended time period (14 days vs 60/70 days depending on O2 levels). 300 cells of each 
subpopulation were sorted per well of a 48-well plate and cultured for 20, 30 and 70 days 
at normoxia and for 30 and 60 days at 0.5% O2 hypoxia. At each time point cells were 
derived from each subpopulation and total viable cell number was measured as described 
above. To compare proliferation rates of NCH644 subpopulations doubling time was 
calculated as follows:  𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 =
𝑡2−𝑡1
𝑙𝑜𝑔2 
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟2
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟1
 , where 𝑡1 and 𝑡2
 represented time 
points. The experiment was repeated 3-6 and 6-12 biological repeats in normoxia and 0.5% 
O2 hypoxia, respectively. The significance of the differences from doubling times between 
subpopulations were tested with the help of Ms. Sonia Leite, Dr. Nicolas Sauvageot 
(Competence Center for Methodology and Statistics at LIH) and Dr. Petr Nazarov 
(Proteome and Genome Research Unit, LIH) used mixed linear models with subpopulation 
as fixed-effects and considered plate’s effect as random. 
3.4.2. Cell viability assay 
To test viability of GBM cell cultures at different O2 levels, the number of viable, apoptotic 
and necrotic cells was measured. Therefore, cells were cultured at normoxia or hypoxia 
0.5% O2 for 16 hours, 2 and 7 days. 106 cells per sample were resuspended in 100µl of 
binding buffer (HBSS w/o Ca2+/Mg2+ (Sigma-Aldrich), 2% FBS and 0.01M Hepes pH 7,4, 
0.14M NaCl (Sigma-Aldrich) and 2.5mM CaCl2 (Sigma-Aldrich)). Staining with AnnexinV 
(Table 1) was performed in the dark for 30 minutes at room temperature. The cells were 
subsequently washed with binding buffer and kept on ice until analysis on the flow 
cytometer. 50µg/ml propidium iodide (PI) (Invitrogen) was added 5 minutes before data 
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acquisition to minimize its toxicity for cells (for flow cytometer settings and the antibody 
panel see Annex 1.c). The experiment was performed in 3 biological replicates with 3 
technical replicates each. Statistical differences were calculated using Student t-test with 
Bonferroni multiple-significance-test correction for four comparisons. 
3.4.3. Proliferative activity assay 
To measure the percentage of proliferative cells, cell cycle analysis was performed by DNA 
quantification. Cells were cultured in normoxia or hypoxia 0.5% O2 for 16 hours, 2 and 7 
days. 106 single cells were aliquoted per sample, centrifuged and resuspended in HBSS 
containing 1µg/ml LIVE/DEAD® Fixable Near-IR Dead Cell Stain (Invitrogen). After 15 
minutes of incubation in the dark at room temperature, the cells were washed once with 
HBSS. Cells were subsequently fixed in ice cold 80% ethanol and kept at -20°C over night. 
The next day, ethanol was removed and the cells were stained in the dark for 30 minutes 
at room temperature with PI staining buffer (0,1% Triton, 0.2µg/ul RNAse and 1µg/ml PI 
(Invitrogen) in HBSS). The volume was adjusted to 100µl and the samples were measured 
on flow cytometer (for flow cytometer settings and the antibody panel see Annex 1.c). The 
experiment was performed in 3 biological and 3 technical replicates each. Statistical 
differences were calculated using Student t-test with Bonferroni multiple-significance-test 
correction for three comparisons. 
In contrast to the DNA staining of fixed cells, cell cycle analysis of NCH644 CSC-associated 
subpopulations was performed using viable cells. Therefore, single cells were resuspended 
in their growth culture media (106 cells/100µl) provided with 10mM Hepes and 5µg/ml 
Hoechst 33342 (Sigma-Aldrich) and incubated for 2 hours at 37°C on a shaker in the 
incubator (Stieber et al., 2014). Cells were immediately put on ice to avoid efflux of Hoechst 
and resuspended in ice cold flow buffer. The entire subsequent cell membrane staining 
procedure was performed on ice. The experiment was performed in 3 biological replicates 
and statistical differences were calculated using Student t-test with Bonferroni multiple-
significance-test correction for two comparisons. 
3.4.4. Sphere forming assays 
To test the clonogenic abilities of 3D GBM stem-like cultures and conventional GBM cell 
lines, the cell suspensions were prestained with 1µg/ml LIVE/DEAD® Fixable Near-IR Dead 
Cell Stain (Invitrogen) solution. After 15 minutes incubation in the dark at room temperature 
followed with one HBSS washing, single viable cells were FACS-sorted into 96-well plates 
(1 cell per well, 1 plate per cell line) containing 200µl culture medium (for flow cytometry 
sorting settings see Heading 3.3.6.). Plates were kept at normoxia or hypoxia (0.5% O2). 
Every 4-5 days, fresh medium was added. After 4 weeks, the number of formed spheres 
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per plate were counted. Images of the spheres were recorded on Leica® DMI6000 B 
inverted microscope with a Leica® DFC320R2 camera with its concordant Leica Application 
Suite® software. Sphere size was measured using the “Ruler Tool” on Adobe Photoshop. 
The experiment was conducted in 4 biological repeats for sphere number calculation. 
Sphere sizes were measured of 20 spheres from one biological experiment. Statistical 
differences were calculated using Student t-test. 
To test self-renewal ability of CSC-associated subpopulations, the above described protocol 
was applied and continued. The formed spheres of each subpopulation were collected 
(passage 1) and single viable cells were resorted (one 96-well plate/subpopulation, 1 
cell/well). Replating was repeated three times (passages 2-4). Total sphere number and 
average sphere size (n=20 per subpopulation if available) were recorded at each passage 
before cell collection. Each subpopulation at each passage was phenotyped as described 
above (Heading 3.4.2.). FACS-sorted NCH644 viable single cells were used as a control. 
The experiment was repeated independently 4-6 and 2-4 times in normoxia and hypoxia, 
respectively. Significant differences of sphere number across populations and passages 
were tested with the Kruskal-Wallis test. Significant differences of sphere size between 
populations and passages were tested with mixed linear models with either subpopulation 
or passage as fixed-effects and considering plate’s effect as random. The statistical 
analyses for sphere number and sphere size were performed with the help of Ms. Sonia 
Leite and Dr. Nicolas Sauvageot (Competence Center for Methodology and Statistics at 
LIH). Statistical differences of phenotypic states were calculated using Student t-test with 
Bonferroni multiple-significance-test correction for sixteen comparisons. 
3.4.5. Invasion assay  
Invasive abilities were measured by Boyden chamber assay. Chambers of 8µm pore size 
fitting into a well of a 24-well plate (Thincert cell culture inserts, Greiner) were coated with 
0.05mg/ml collagen type I (Sigma-Aldrich), 0.5mg/ml protein of ECM gel (Sigma-Aldrich) in 
1:1 PBS-DMEM-F12 mixture for 2 hours at 37°C. Non-polymerized coating was removed 
before plating 50’000 cells per upper inlay of the Boyden chamber. Medium supplemented 
with 10% FBS was added in the lower well of the 24-well plate. Incubation time varied 
between 2 to 3 days depending on GBM cultures used. Cells in Boyden chambers were 
fixed in 4% PFA for 15 minutes and washed briefly 3 times in PBS. Cells were stained with 
0.05% Crystal Violet Solution (Sigma-Aldrich) for 15 minutes and then washed in dH2O. 
Non-invading cells in the upper part of the chamber were removed using a cotton swab and 
the chamber was air-dried. 5 random pictures of the porous membrane per chamber were 
taken per inlay on a Leica® DMI6000 B inverted microscope equipped with a Leica® 
DFC320R2 camera and the Leica Application Suite® software. The cell number per area 
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was assessed using ImageJ. The percentage of invading cells was calculated as follows: 
 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑖𝑛𝑣𝑎𝑑𝑖𝑛𝑔 𝑐𝑒𝑙𝑙𝑠 =
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑖𝑛𝑣𝑎𝑑𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑎𝑟𝑒𝑎 ∗100
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 , where the total number of 
cells was obtained by multiplying the number of plated cells with the growth rate for the time 
period the experiment was performed. The experiment was conducted in 3 biological 
replicates with the help of Dr. Anne Schuster (Norlux Laboratory, LIH). Statistical differences 
were calculated using Student t-test. 
3.4.6. Immunocytochemistry 
Protocol to obtain frozen sphere sections, NCH644 cells were cultured 7 days until they 
formed big spheres (approximately 300µm of diameter). These were washed carefully twice 
with PBS and collected by gravity with Tissue-Tek® O.C.T.™ Compound (Sakura Finetek). 
Spheres were flash frozen in -80°C precooled iospentane for 5 minutes. Frozen sphere 
blocks were cut to 10µm sections on the LEICA CM 1850 UV cryostat (Leica Biosystems) 
and mounted on glass coverslips. Slides were dried and subsequently fixed in 4% PFA for 
10 minutes. Sections were blocked for 30 minutes in TBS (Tris-buffered saline) supplied 
with 2% FBS and incubated with conjugated primary antibodies (Table 1) and 1µg/ml DAPI 
(4′,6-Diamidin-2-phenylindol) (Invitrogen). Slides were washed consecutively 3 times 5 
minutes in TBS. After a final short rinse in dH2O, they were water-mounted using 
Fluoromount™ Aqueous Mounting Medium (Sigma-Aldrich). One day later, the sections 
were sealed with nail polish. For image acquisition Leica® DMI6000 B inverted microscope 
with a Leica® DFC350FXR2 camera was supported by the Leica Application Suite® 
software. 
3.4.7. Temozolomide treatment 
Temozolomide (TMZ) (Sigma-Aldrich) was added at subleathal doses of 200µmol for 
NCH644 and 50µmol for NCH421k GBM stem-like cells for short-time (12 hours and 2 days) 
and long term (7 days) treatment. In a second culture condition DMSO was added in an 
equal volume than TMZ. These cells were used as a control to TMZ treatment because 
TMZ was dissolved in DMSO. Every 4 days, new TMZ/DMSO containing culture medium 
was added and big spheres were dissociated by pipetting. Cells were subsequently 
collected and stained for flow cytometric analysis. The experiment was performed in 3 
biological replicates with 3 technical replicates each. Statistical differences were calculated 
using Student t-test with Bonferroni multiple-significance-test correction for sixteen 
comparisons. 
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3.4.8. Differentiation assay 
For differentiation assays, flasks were precoated with 1:20 ECM gel (Sigma-Aldrich) in 
Neurobasal for NCH644 or DMEM-F12 for NCH421k cultures. Flasks were incubated for 
1,5h at 37°C and excess liquid was subsequently removed. NCH644 and NCH421k were 
added in their corresponding growth medium. Cells were allowed to attach for 24h then 
medium was replaced with DMEM-F12/Neurobasal medium supplemented with 10% FBS 
and 10µg/ml all-trans retinoic acid (ATRA) (Sigma-Aldrich). The medium was changed 
every second day and flasks were kept in dark. The experiment was conducted in normoxia 
and 0.5% hypoxia. After 14 days of adherent culture, single cells were detached using 
Accutase Solution (Sigma-Aldrich). The cells were divided in two parts: on part was used 
for flow cytometric analysis. The other part was kept as non-adherent 3D cultures in 
normoxia and the cells were again phenotyped after 14 days. Non-treated 3D sphere 
cultures were used as control to evaluate changes upon non-adherent 3D to adherent 2D 
culture system in normoxia and hypoxia, 2D differentiation in normoxia and hypoxia and the 
reversibility of differentiated and non-differentiated 2D cultures upon non-adherent 3D 
reculture in normoxia. Images of cell cultures were taken on EVOS®fl (AMG-Advanced 
Microscopy Group) digital inverted microscope. The experiment was performed in 3 
biological replicates with 3 technical replicates each for NCH644 cultures. 1 biological 
replicate with 3 technical replicates were realized for NCH421k cultures. Statistical 
differences for internal marker expression were calculated using Student t-test. Additional 
Bonferroni multiple-significance-test correction for sixteen comparisons was applied for the 
statistical analysis of phenotypical states. 
3.4.9. Plasticity/multipotency test  
To examine multipotent capacities of NCH644 subpopulations, 300 cells of each 
subpopulation were sorted to a 48-well plate and cultured for 20, 30 and 70 days in the 
culture medium at normoxia or 60 days at 0.5% O2 hypoxia. At each time point cells were 
derived from each subpopulation and were phenotyped as described above. The 
experiment was repeated for each NCH644 subpopulation independently in 9-12 and 6-12 
biological repeats in normoxia and hypoxia, respectively. The proportion of each 
subpopulation was calculated as percentage of the viable single cells. Alluvial plots have 
been generated under R (Team, 2013) using the package alluvial available at 
https://github.com/mbojan/alluvial (R, 2016) with the help of Arnaud Muller (Proteome and 
Genome Research Unit, LIH). Statistical differences of phenotypic states were calculated 
using Student t-test with Bonferroni multiple-significance-test correction for sixteen 
comparisons.  
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3.5. Mathematical modeling 
3.5.1. Principles of discrete Markov chain modeling 
In order to quantify the transitions between the 16 phenotypes Markov chain modeling was 
applied. This part was performed in collaboration with Thomas Buder, Dr. Andreas Deutsch 
and Dr. Anja Voss-Böhme (Zentrum für Informationsdienste und Hochleistungsrechnen 
(ZIH), Technische Universität Dresden, Dresden, Germany and Fakultät Informatik / 
Mathematik, Hochschule für Technik und Wirtschaft Dresden, Dresden, Germany 
Technische Universität Dresden) who implemented the model in the freely available R 
package CellTrans (Buder et al., 2017) (http://github.com/tbuder/CellTrans).  
The model is based on the assumptions that cell state alterations occur due to stochastic 
cell state transitions only depending on the current state of the cell and possibly the 
experimental environment (e.g. hypoxia) and that proliferation rates of the involved 
phenotypes are approximately equal. This approach leads to the estimations of a Markov 
chain with a transition matrix containing the probabilities of state transitions (Annex 2.a for 
matrix construction). This matrix allowed to discriminate frequent and non-frequent state 
transitions and identify hierarchical or non-hierarchical transition behavior. If the underlying 
network is irreducible, each state can transit directly or via intermediate steps into any other 
state. This behavior implies that the stochastic state transitions are non-hierarchical and 
therefore reversible in biological sense. In contrast, if the transition network has a tree 
structure, this corresponds to a perfect hierarchy. In general, intermediate network 
structures are possible as well, which imply some degree of hierarchy between transient 
states at the top of the hierarchy and recurrent states at the bottom of the hierarchy (Annex 
2.b for Krackhardt calculation). Moreover, transition matrixes can be used to investigate 
whether the cell state transitions between positive and low/negative expression of one 
marker in normoxia and hypoxia were dependent on the level of expression of the other 
markers (Annex 2.c for marker dependency calculation). Most importantly, on the basis of 
the estimated transition matrix, it is possible to predict the composition of the population in 
equilibrium by calculating the Markov chain stationary state. In addition, the time from a 
specific initial composition until an approximate equilibrium is reached can be estimated.  
3.5.2. Markov model validation 
To test predictional capacities of the transition probabilities obtained by Markov modeling, 
two cell population compositions were designed to reach initial equilibrium after 39 days in 
normoxic culture system. Mix A contained 53, 38, 57, 19, 53, 0, 0, 0, 0, 0, 0, 0, 0, 21, 34, 
25 cells from subpopulations 1 to 16, respectively (error < 1%). Mix B contained 75, 74, 36, 
115, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 cells from subpopulations 1 to 16, respectively (error < 
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2.5%). Additionally, CSC-associated subpopulations 2, 4, 5, 9 and 11 were predicted to 
reach final heterogenic distribution after 63, 72, 84, 90 and 108 days of normoxic culture, 
respectively. Mixture of cell subpopulations and CSC-associated subpopulations were 
accordingly FACS-sorted to a well of a 48-wells plate (300 cells per well). A third approach 
tested short time predictions. Phenotypic state of subpopulations 2 and 3 were predicted to 
adapt in an ‘irregular’ manner upon initial culture of 100% pure subpopulation 4. 2000 viable 
single cells of subpopulation 4 were FACS-sorted into a well of 6-wells plate and cultured 
for 11 and 18 days. 
Staining and FACS-sort was performed as described in Heading 3.6.1. and 3.4.6.. After 
predicted days of culture, cells were collected for flow cytometric analysis. The experiments 
were performed in 3 technical replicates. 
 
3.6.  Single cell RNA-seq using Drop-seq 
For single cell sequencing, tumor cells from GBM patient-derived xenografts P3, P8 and 
P13 were isolated (Heading 3.4.1) and pre-selected for viable single hCD90-positive tumor 
cells (staining and FACS-sort was performed as described in Heading 3.4.2, 3.4.5 and 
Annex 2). Moreover, viable single cells of NCH421k (600’000 cells), NCH644 (400’000 
cells), and subpopulation P2 (200’000 cells) and P6 (400’000 cells) of NCH644 were sorted 
on FACS as previously described (staining and FACS-sort was performed as described in 
Heading 3.4.5. and 3.6.1.). After sorting cells were centrifuged for 10 minutes at 1200rpm 
and resuspended in cold HBSS with 0.5% Bovine Serum Albumin (BSA) (Sigma-Aldrich). 
The cells were stored on ice until the start of the Drop-seq experiment. Prior to cell loading 
on the Drop-seq chips, cell viability was verified and the concentration was adjusted to ~150 
cells/ml. This was an optimal concentration based on Poissonian statistics to achieve single 
cell encapsulation within each droplet of ~1nm droplet size. All samples analyzed in this 
work had a cell viability above 95%. 
Subsequent procedure and analysis was performed by Dr. Suresh Kumar Poovathingal 
from the Luxembourg Centre for Systems Biomedicine at the University of Luxembourg 
(Alexander Skupin Group), Dr. Petr V. Nazarov and Arnaud Muller from the Proteome and 
Genome Research Unit at the Luxembourg Institute of Health. 
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4. Results 
4.1.  Characterization of CSC-associated marker expression in GBM 
GBM is a highly heterogeneous tumor at the histological, genetic, epigenetic, metabolic and 
transcriptional level. In this work, we focus on phenotypic heterogeneity which is following 
the CSC hypothesis created by a subpopulation of cells with stem-like abilities. In search 
for eligible CSC markers, we tested the expression of a panel of CSC-associated cell 
surface epitopes in GBM. Putative CSC identifiers should exclusively be expressed by this 
subpopulation, whereas progenitor and differentiated cancer cells are marker negative. 
Consequently, a tumor population following the CSC model consists of CSCs, progenitor 
and differentiated cancer cells with distinct phenotypes. Therefore, heterogeneous 
expression profiles are expected in GBM using putative CSC markers. We assessed the 
CSC-associated marker expression in several GBM models in vitro, in vivo and clinical 
samples. By combining data from the TCGA GBM patient database with cell surface marker 
expression in patient-derived xenografts and GBM stem-like cultures we aimed to identify 
the most suitable cell surface epitopes to study the generation of phenotypic heterogeneity 
in GBM. 
 
4.1.1. GBM patient samples display heterogeneous stem cell associated 
transcriptional expression patterns 
In order to identify cell surface epitopes that generate a heterogenous expression profile, 
the gene expression of 11 cell surface markers (CD90, CD15, CD195, CD29, CD44, CD95, 
CD133, CD56, CD24, A2B5 and NG2) was analyzed in GBM patient samples. They 
represent cell membrane epitopes which had previously been described as putative CSC 
markers (He et al., 2012, Son et al., 2009, Al-Hajj et al., 2003, Singh et al., 2003, 
Tchoghandjian et al., 2010, Svendsen et al., 2011, Collins et al., 2005, Singh et al., 2004b, 
Kleber et al., 2008, Long et al., 2012, Vassilopoulos et al., 2008, Shimojima et al., 2003). 
RNA sequencing data of 166 GBM patient samples was obtained from the publicly available 
Cancer Genome Atlas (TCGA) database (Cancer Genome Atlas Research, 2008). RNA 
expression of the cell surface markers was compared to known cancer drivers in GBM (Fig. 
9.a). CDKN2A, EGFR, PTEN, TP53, PDGFRA, BRAF and CDKN2C belong to the genes 
most often dysregulated in GBM (Cancer Genome Atlas Research, 2008). All analyzed 
genes were differentially expressed in GBM patient samples, revealing strong inter-tumoral 
heterogeneity. The RNA expression levels of the CSC marker genes did not significantly 
correlate to the high confidence driver genes (Fig. 9.b and 9.c). This indicates that the 
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heterogeneous expression of putative CSC cell surface markers is not associated with the 
main driver mutations.  
Interestingly, we observed a trend of putative CSC marker-specific expression patterns 
following the Verhaak classification (Verhaak et al., 2010). Indeed, correlation of gene 
expression between four proposed transcriptional subgroups (neural, mesenchymal, 
proneural and classical) showed amongst others that CCR5, ITGB1, CD44, FAS show 
higher expression in the mesenchymal subtype compared to the proneural subtype (Fig. 
9.d), whereas NCAM1 and CD24 revealed a significantly higher expression in proneural 
subtype compared to the mesenchymal and classical subgroups (Fig. 9.e). These data 
confirm the results by Brown and colleagues (Brown et al., 2015) who previously described 
a correlation between CSC markers and GBM subtypes.  
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Figure 9: CSC-associated heterogeneity in GBM patient samples and correlation of CSC 
marker expression to GBM subtypes. a. RNA sequencing data from 160 GBM patients of the 
TCGA cohort were classified following the GBM subtypes proposed by Verhaak (Verhaak et al., 
2010). Heatmap displaying heterogeneous expression pattern of high confidence drivers (‘grey’ box) 
and putative CSC markers (‘red’ box) in GBM (‘red’, high gene expression levels; ‘blue’, low/absent 
gene expression levels). b. Heatmap showing Pearson’s correlation (‘grey’, positive correlation; 
‘green’, negative correlation) and c. statistical significance (‘red’, low standard error; ‘white’, high 
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standard error) of co-expression between genes of CSC-associated markers and main drivers in 
GBM patients. No significant interdependence was detected. d. Heatmap displaying correlation of 
gene expression data between GBM subgroups (p-value log sum; right-tail significance yields a 
positive p-value log sum, left-tail significance yields a negative). One square represents the 
correlation value calculated using gene expression data of all patients classified to one subgroup 
compared to another subgroup. In order to perform all possible comparisons between GBM 
subgroups, two ‘groups’ were designed. ‘Group 1’ containing neural, mesenchymal and proneural 
subgroups was compared to ‘group 2’ with mesenchymal, proneural and classical subgroups 
(‘yellow-red’, higher expression in group 1; ‘blue’, higher expression in group 2). Many significant 
correlations in CSC-associated gene expression and GBM subtypes were detected. e. Heatmap 
displays the statistical significance of correlation data shown in d (Corrected two-tail p-value for each 
comparison; ‘yellow-red’, significant correlation; ‘white’ not significant correlation). Significant 
differences in gene expression of putative CSC-markers were found mostly between the 
mesenchymal subgroup compared to the proneural and the classical subgroup. Figure 18. was 
realized with the help of Dr. Sabrina Fritah (Norlux Laboratory, LIH). 
 
To exclude that variations in gene expression data from CSC-associated genes result from 
mutations and/or chromosomal aberrations, the genes of the putative CSC markers were 
analyzed for genetic aberrations. TCGA data show that high confidence drivers (CDKN2A, 
EGFR, PTEN and TP53) display numerous mutations and/or loss or gain in gene 
sequences (Fig. 10.a). In contrast only 4 out of 11 CSC-associated marker genes (FAS, 
ST8SIA1, NCAM1 and CSPG4) depicted isolated mutations and/or aberrations in their DNA 
sequence, suggesting that heterogeneous gene expression arising from these markers is 
not a result of genetic aberrations.  
Next, we analyzed whether heterogeneous marker expression is originating from epigenetic 
gene regulation. A well-known gene that is often hyper-methylated in GBM is MGMT (Mellai 
et al., 2012), where promoter methylation is associated with better response to chemo 
therapy in patients. DNA methylation analysis revealed that FUT4 is highly methylated at 
the promoter region in 18% of GBM patients (Fig. 10.b). Other CSC-associated and high 
confidence driver genes did not show promoter methylation, except for one patient in CD44. 
The fact that not all patient samples demonstrated FUT4 promoter methylation may at least 
partially explain a heterogeneous expression in RNA between patient tumors. Indeed, FUT4 
mRNA expression and promoter methylation anti-correlated, confirming regulation of FUT4 
gene expression by DNA methylation of its promoter (Fig. 10.c). This is in line with reports 
from Li and colleagues (Li et al., 2012). Comparing methylations of FUT4 with MGMT 
revealed no significant correlation (p-value = 0.086) (Fig. 10.d). 
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Figure 10: Genetic aberrations and promoter methylations in GBM patient samples. a. 
Heatmap displays GBM cases containing mutations, gain and loss of genes and mutations combined 
with gain of copy number in genes of interest. CSC marker genes rarely display mutations and copy 
number aberrations within the different GBM expression subgroups. b. Heatmap shows promoter 
methylation status of selected genes in patient samples. Only MGMT and FUT4 displayed high 
methylation pattern in a subgroup of patients. c. No significant correlation (standard error; p-value 
0.086) in methylation pattern was found between the two genes. d. Correlation between FUT4 mRNA 
expression and FUT4 promoter methylation revealed anti-correlation (Pearson -0.633; Spearman -
0.592) (purple triangle depicts frameshift mutation; blue dots non-mutated FUT4 gene sequence). 
Figure 4.2.2 was realized with the help of Dr. Sabrina Fritah (Norlux Laboratory, LIH). 
 
In summary, the analysis of TCGA patient data revealed that CSC-associated marker 
expression is heterogeneous at the transcriptional level. In most cases, inter-patient 
differences in marker expression do not originate from genetic aberrations or epigenetic 
promoter regulation. An exception is FUT4, where promoter methylation anticorrelated with 
gene transcription. 
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4.1.2. GBM patient-derived xenografts recapitulate inter-patient and intra-
tumoral phenotypic heterogeneity 
We showed high variation in CSC-associated genes expression in GBM patient samples, 
however, data is based on bulk tumor analysis containing tumor and non-tumor cells. 
Therefore, the results may be biased by the presence of stromal cells as all markers were 
described to be expressed by tumor cells and different stromal cell types (Inoue et al., 2016, 
Zozulya et al., 2007, Ransohoff and Engelhardt, 2012, Barraud et al., 2007). For example, 
CD133 has been shown to be present both on tumor and endothelial cells in patient biopsies 
and GBM patient-derived xenografts (PDXs) (Golebiewska et al., 2013). Furthermore, a 
recent publication of Verhaak and colleagues showed that the specification into four GBM 
subclasses based on transcriptional profiling was strongly influenced by stromal cells. The 
mesenchymal subclass was associated with microglia and macrophage gene signatures 
whereas the neural subclass was shown to originate from non-neoplastic cells (Wang et al., 
2017). PDXs are also a very powerful model to mimic GBM occurring in patients. As a 
previous publication from our lab has shown by ploidy measurement, PDXs recapitulate 
genetically divergent clones from primary tumors (Stieber et al., 2014). Therefore, we took 
advantage of GBM PDXs to assess phenotypic expression of CSC-associated markers 
between and within PDX tumors. Here organotypic spheroids derived from patient biopsies 
were implanted intracranially into immunodeficient mice. GBM tumors that develop upon 
xenografting consist of human cancer cells, which can be discriminated from mouse stroma 
using flow cytometry (Fig. 11.a). The gating strategy was based on the following 
parameters: Single cells from dissociated mouse xenografts were distinguished from debris 
based on their size and granularity using forward (FSC) and side scatter (SSC) (1). Cell 
doublets and aggregates were eliminated from the analysis comparing the height (FSC-H) 
vs area (FSC-A) of the voltage pulse in FSC created by a photomultiplier tube when a cell 
passes a laser beam (2). FSC-H measures the intensity of the signal whereas FSC-H 
multiplied by pulse width (FSC-W) equals to FSC-A. Cell doublets were identified due to 
disproportions in pulse height vs area; cell doublets have double the area value of single 
cells, whereas the height is approximately equal in cell doublets vs single cells. To assure 
analysis of viable cells, dead cells were excluded based on a dead cell marker (3). The 
discrimination between stromal and tumor cells was possible using the eGFP-expressing 
NOD/SCID mice with GFP positive mouse cells and GFP negative human tumor cells 
(Niclou et al., 2008). Thus, the selection of single, viable tumor cells was only possible using 
the above-mentioned gating strategy. 
Eleven GBM PDXs (T101, T185, T233, T239, T251, P8, T16, T238, P3 and P13) with 
different genetic backgrounds were analyzed for the epitope expression of CSC-associated 
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markers previously assessed in GBM patients (Fig. 11.b). EGFR was used as control for 
heterogeneity, since it is known to be differentially expressed among GBM tumors. Similarly, 
the expression profiles of CD90, CD56, CD29, NG2, CD95, CD24 and CD195 were highly 
variable between different PDXs (Fig. 11.b). Expression signals of EGFR, NG2, CD56 and 
CD95 ranged each from low (mean fluorescent intensity (MFI) of marker is equal to negative 
control) to high positive (MFI is 100x higher than negative control) (for flow histograms see 
Annex 5). Some markers (CD90 and CD29) were uniformly highly expressed in most 
tumors whereas others (CD24 and CD195) were less detected. The expression profile for 
the 8 markers tested was relatively uniform within PDXs. Only T238 showed internal 
variability in CD195 expression. Similar to the gene expression profiles of CSC-associated 
genes in patient biopsies from TCGA data, does the epitopes expression of these genes 
demonstrate high variability between different GBM PDXs. 
 
Figure 11: Analysis strategy for tumor/stroma discrimination and marker expression profiles 
of EGFR, CD90, CD56, CD29, NG2, CD95, CD24 and CD195 in GBM patient-derived xenografts. 
a. Flow cytometric scatter plots depict gating strategy for the analysis of tumor cells in PDXs. GBM 
cells were distinguished from debris using forward (FSC) and side (SSC) scatters (1), followed by 
cell doublet and aggregate elimination (FSC-A/FSC-H) (2). Dead cells were recognized as positive 
for dead cell marker (3). Single viable cells were discriminated into eGFP positive stromal and eGFP 
negative tumor cells (4). b. Flow cytometric analysis of 8 cell surface markers in 11 GBM PDXs. 
Negative, low, positive and high positive cells were categorized based on their mean fluorescence 
intensity (MFI) (‘-‘, MFI = negative control; ‘low’, MFI < 10x negative control; ‘+', 10x < MFI < 100x 
negative control; ‘++’, MFI > 100x negative control). PDXs show high variability between patient 
samples. 
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Interestingly, the other 4 markers (CD133, CD44, CD15 and A2B5) of the panel showed 
remarkable intra-tumoral heterogeneity for most PDXs (Fig. 12). For CD133, we were able 
to discriminate between negative and positive cells (‘black gating’ - black line on histogram), 
whereas for CD44, A2B5 and CD15 expression additionally between low and high 
expression levels (‘red gating’ – red line on histogram). No link between the different 
histopathological phenotypes of GBM PDXs and their CSC marker epitope expression was 
observed as marker expression profile was not uniform to solely one histopathological 
phenotype. The next experiments focused on the four markers CD133, CD44, A2B5 and 
CD15 as they presented the highest intra-tumoral heterogeneity in PDXs, a premise 
necessary for a putative CSC marker. Marker expression between PDXs of the four markers 
was highly variable as well. For instance, CD15 expression varied from 0.3% in T16 to 75% 
in T239. Similar results were obtained from Brescia et al. who described a highly variable 
CD133 expression in both GBM patient biopsies and their respective sphere cultures 
(Brescia et al., 2013b). 
 
 
Figure 12: Expression profiles of CD133, CD44, A2B5 and CD15 markers in GBM PDXs. Flow 
cytometric analysis in 11 PDXs for CD133, CD44, A2B5 and CD15 epitopes (‘black’, negative vs. 
positive; ‘red’, low vs. high). All PDXs show high variability between PDXs and within the PDXs 
tumors for the expression of the 4 markers. Figure 12 was realized with the help of Dr. Anna 
Golebiewska (Norlux Laboratory, LIH). 
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4.1.3. GBM stem-like cultures display inter- and intra-tumoral phenotypic 
heterogeneity in CSC-associated subpopulations  
To further analyze variability in CSC marker expression we used GBM stem-like cultures. 
These cells were grown as 3D spheres in serum free medium. On genetic and 
transcriptomic level 3D cultures are described as a better model for GBM than adherent 
cultures (Ishiguro et al., 2017, De Witt Hamer et al., 2008, Lee et al., 2006). Unlike adherent 
GBM cultures in serum-containing medium, GBM stem-like culture spheres were able to 
generate complex tumors upon xenografting with similar histopathology than GBM patients 
(Bougnaud et al., 2016). Moreover, this allowed us to work with a genetically more 
homogeneous population and avoid a possible bias of divergent genetic clones (Stieber et 
al., 2014). 
The expression of the CSC-associated markers (CD133, CD44, CD15 and A2B5) were 
tested in 7 GBM stem-like cultures (NCH421k, NCH465, NCH601, NCH644, NCH660h, 
TB101 and TB107). Similar to PDXs, the GBM stem-like cultures displayed strong inter- 
and intra-tumoral heterogeneity (Fig. 13.a). We have been distinguishing between negative 
and positive cells (‘black’ gating - black line on flow histograms) and cells with high and low 
marker expression levels (‘red’ gating - red line on flow histograms). To define intra-tumoral 
heterogeneity for further experiments, discrimination of cells was performed on low vs. high 
expression levels (‘red’ gating), except for cell populations where discrimination could only 
be performed on negative and positive cells (‘black’ gating). Because GBM stem-like 
cultures recapitulate inter- and intra-tumoral heterogeneity, they appear to be a good model 
to study CSC-associated marker expression.  
The analysis was performed on the four markers (CD133, CD44, A2B5 and CD15) 
simultaneously by multicolor flow cytometry enabling combined measurement of the four 
markers on one single cell (Fig. 13.b). This allowed us to discriminate between 16 distinct 
subpopulations (Fig. 13.c). According to the discrimination pattern subpopulation 1 was 
CD133+ CD44- A2B5+ CD15-. Subpopulation 6 was positive/high for all markers (CD133+ 
CD44+ A2B5+ CD15+) whereas expression for the four epitopes (CD133- CD44- A2B5- 
CD15-) was not detected/low in subpopulation 11. 
Simultaneous multicolor phenotyping was performed for the 7 GBM stem-like cultures. Only 
some of the 16 possible subpopulations could be detected in NCH421k, NCH601 and 
TB101 cultures (Fig. 13.d). NCH421k was predominantly composed of subpopulation 2 
(CD133+ CD44- A2B5+ CD15+), TB101 of subpopulation 16 (CD133- CD44+ A2B5- CD15+) 
and NCH601 mainly of subpopulation 11 (CD133- CD44- A2B5- CD15-), being negative for 
all markers. In contrast to these stem-like cultures, NCH644, NCH465, NCH601 and TB107 
contained all 16 phenotypes. From the 7 analyzed GBM stem-like cultures, NCH644 
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appeared most heterogeneous with the most equal distribution of subpopulations. 
Subsequent experiments were based on NCH644 stem-like cultures as they allowed us to 
isolate a reasonable cell number of each subpopulations for further investigation. 
 
Figure 13: Inter- and intra-tumoral heterogeneity in GBM stem-like cultures. a. Flow cytometric 
analysis in 7 GBM cultures for CD133, CD44, A2B5 and CD15 epitopes (‘black line’: negative vs. 
positive; ‘red line’: low vs. high). Marker expression showed high variability between and within each 
GBM stem-like culture (nB=1-3, nT=1-3). b. Flow cytometric density plots of simultaneous multicolor 
staining of single viable NCH644 stem-like cells. NCH644 demonstrated a highly heterogeneous 
expression of the four markers. c. Discrimination of 16 subpopulations based on the expression 
pattern of four markers in NCH644 cells. Bar indicates 10µm. Microscopic images acquired by 
ImageStream show 16 different subpopulations based on different intensities of simultaneous 
CD133, CD44, A2B5 and CD15 epitope staining. The color code for different subpopulations is 
applied on figures throughout this thesis. d. Quantification of multicolor flow cytometry analysis of 4 
markers performed in 7 GBM stem-like cultures. Pie charts show the distribution of 16 subpopulations 
discriminated based on the marker expression profiles. Division in 16 subpopulations demonstrates 
inter- and intra-tumoral heterogeneity in all cultures (mean percentage; n=3). 
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4.1.4. All CSC-associated subpopulations proliferate in spheres 
CSC sphere cultures are described to contain non-cycling cells at the inner core and highly 
proliferative cells at the outer layer of the 3D sphere (Smith et al., 2012). As several research 
groups reported higher proliferation in CD133 positive cells (Jaksch et al., 2008, Barrantes-
Freer et al., 2015), therefore we expected to find CD133 positive staining at the border of 
the spheres. 
Since flow cytometric analysis was based on single cell measurement, the location of the 
four markers was investigated within individual 3D spheres by immunocytochemistry (Fig. 
14.a). As antibodies might not be able to penetrate to the core of a sphere, CSC spheres 
were flash frozen and cut into sections for staining to assure optimal antibody coverage. 
Expression of the four markers showed a strong phenotypic heterogeneity within each 
sphere with no specific localization pattern within sphere compartments. In contrary, the 
proliferation marker Ki67 was mainly expressed at the edges of the spheres confirming 
Smith et al. reporting a highly proliferative outer layer of 3D spheres (Smith et al., 2012). 
Interestingly, Ki67 showed no association with the four markers analyzed.  
We further investigated whether one of the CSC-associated subpopulations was more 
prone to be proliferative. Therefore, cell cycle was measured in the 16 NCH644 
subpopulations. The standard protocol for cell cycle measurement uses ethanol fixation 
which renders cell membranes porous and can change the structure of cell membrane 
epitopes, which may affect CSC-associated marker stainings. Therefore, DNA staining was 
performed in viable cells to assure proper identification of the 16 subpopulations Hoechst 
fluorescent dye. However, this did not allow an accurate discrimination between S, M and 
G2 phases of the cell cycle (Fig. 14.b). Hence, this analysis was limited to distinguish 
between proliferative (S/G2/M phases) and non-proliferative (G0/G1 phases) cells, 
revealing that all 16 subpopulations contained cycling cells (Fig. 14.c). NCH644 sphere 
cultures grown in serum depleted medium were used as control and are referred in this 
thesis as original NCH644 population. Compared to this population significantly fewer 
proliferating cells were detected in subpopulation 9 (CD133- CD44- A2B5+ CD15-), 10 
(CD133- CD44- A2B5+ CD15+), 11 (CD133- CD44- A2B5- CD15-), 12 (CD133- CD44- A2B5- 
CD15+), 13 (CD133- CD44+ A2B5+ CD15-) and 15 (CD133- CD44+ A2B5- CD15-). 
Interestingly these subpopulations were all negative for CD133, suggesting that the CD133+ 
expression is associated with a higher proliferative potential. This data agrees with previous 
cell cycle analysis showing increased CD133 epitope expression in proliferative colon 
epithelial cancer cells (Jaksch et al., 2008) and GBM cell cultures (Brown et al., 2017). 
Brown and colleagues analyzed simultaneous expression of CD133 and CD44 and 
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confirms lower proliferation in CD133- CD44- cells compared to CD133+ CD44- and CD133+ 
CD44+cells. In general, all subpopulations were shown to contain cycling cells. 
 
Figure 14: Spatial distribution of marker expression and cell cycle analysis in GSCs. a. 
Microscopic images show IHC for CD133, CD44, A2B5, CD15 and Ki67 in frozen sections of 
NCH644 spheres. Bar indicates 100µm. Except for Ki67, all markers were expressed throughout the 
spheres at no distinct localization. Figure was realized with the help of Dr. Anna Golebiewska (Norlux 
Laboratory, LIH). b. Histogram depicts DNA staining of either ethanol fixed cells (DNA staining 
performed with PI) or non-fixed cells (DNA staining performed with Hoechst). Clear discrimination of 
the different cell cycle phases G0/G1, S and G2/M is feasible in fixed cells whereas only between 
G0/G1 and S/G2/M phases can be distinguished in viable cells. c. Barplots represent cell cycle 
analysis of NCH644 subpopulations. Cells in S/G2/M cell cycle phases were distinguished from 
G0/G1 phases based on Hoechst flow cytometric profile combined with multicolor phenotyping in 
viable cells. Cell cycle analysis showed that every subpopulation contained proliferative cells (nB=6). 
t-test was used to calculate significance between subpopulations and viable NCH644 control 
population (mean percentage ± SEM; * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001) 
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4.1.5. CSC-associated subpopulations display minor phenotypical changes 
upon treatment pressure 
Previous reports describe CSCs to be responsible for chemotherapy resistance whereas 
non-CSCs were eliminated by adjuvant therapy (Bao et al., 2006a, Reya et al., 2001, Liu et 
al., 2006, Eramo et al., 2006). We tested CSC-associated marker expression upon 
treatment with Temozolomide (TMZ), a chemotherapy compound used in GBM patients. 
We expected that non-CSC subpopulations would be depleted and subpopulations 
representing true CSCs were enriched. We treated NCH644 cells which are resistant to 
TMZ (IC50 of ±227mM) and TMZ-sensitive NCH421k cells (IC50 of ±272µM) with sublethal 
doses. In both cultures, we observed a change towards CD44+, CD15- and A2B5- 
subpopulations upon long-term (7 days) TMZ treatment whereas an enrichment of CD133- 
subpopulations was registered only in TMZ-sensitive GBM cells. At the subpopulation level 
in NCH644 cultures, we were only able to detect a significant reduction in percentage of 
subpopulation 4 (CD133+ CD44- A2B5- CD15+), 9 (CD133- CD44- A2B5+ CD15-) and 12 
(CD133- CD44- A2B5- CD15+) and a gain in subpopulation 5 (CD133+ CD44+ A2B5+ CD15-
) (Fig. 15.a; see Annex 6.a for all statistical comparisons of phenotypical states and single 
marker expression between time points). In TMZ-sensible cultures GBM stem-like cultures 
(NCH421k), short and long-term treatment resulted in enrichment of all CD133- 
subpopulations (P9-P16) and a major decrease in subpopulation 2 (CD133+ CD44- A2B5+ 
CD15+) (Fig. 15.b; see Annex 6.b for all statistical comparisons of phenotypical states and 
single marker expression between time points). Beier et al. showed similarly to our results 
a decrease in CD133+ subpopulations upon treatment of sublethal TMZ doses (Beier et al., 
2008). More interestingly, they showed that TMZ was shown to inhibit proliferation in 
CD133+ CSC lines. Therefore, the observed phenotypic shift from CD133+ to CD133- 
subpopulations might be linked to the higher proliferation rates in CD133+ subpopulations 
(Fig. 14.c). On the other hand, Liu et al treated CD133- and CD133+ subpopulations 
independently with a series of TMZ concentrations for two days and demonstrated higher 
number of viable cells in CD133+ GBM cells. The controversial results may be explained by 
the use of lethal drug doses that may be more effective on proliferating cells. 
Moreover, phenotype changes appear more dramatic upon 7 days TMZ treatment in TMZ-
sensitive NCH421k cells than in TMZ-resistant NCH644 cells suggesting that the cell 
function of TMZ-resistant cells is longer intact than in TMZ-sensitive cells. Of note, the 
changes in percentage of subpopulations upon short and long-term treatment were not 
always gradual in time in both cultures. This suggests that intermediate states were 
enriched and subsequently depleted over time and vice versa. Moreover, changes in 
resistant NCH644 were observed upon short term treatment suggesting fast adaptive 
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capacities. Since sublethal does were applied no excessive cell death was observed in 
cultures. This shows that clonal selection does not eliminate CD133+ cells upon therapeutic 
pressure and the decrease of CD133+ is regulated in a cell death-independent process. 
 
Figure 15: Response of CSC-associated marker expression to TMZ treatment. Bar plots show 
the distribution of the 16 subpopulations in a. NCH644 upon short (16h and 2d) and long-term 
treatment (7d) with 200µmol TMZ (mean percentage, nB=4, nT=3) and in b. NCH421k upon long and 
short-term treatment with 50µmol TMZ (mean percentage, nB=3-4, nT=3). Error bars are not depicted 
for visualization purposes. Statistical significances of phenotypic states between non-treated and 
TMZ-treated conditions are depicted in table below the graph (t-test with Bonferroni multiple-
significance-test correction). 
 
 77 
 
 
4 
 
To summarize, 4 out of 11 CSC-associated markers showed high variability in their 
expression profiles between and within all analyzed PDXs and GBM stem-like cultures. The 
latter were subsequently used as experimental models since they represent sphere cultures 
that are often associated with cancer stem cells and are optimal to perform functional 
assays in vitro to investigate how CSC-associated marker heterogeneity is created.  
Differential marker expression was demonstrated in single cells, but also in 3D sphere 
cultures. No direct association with spatial localization and proliferative marker (Ki67) were 
observed. Chemotherapy pressure suggests that changes in marker expression of stem-
like cultures does not result from selection but rather from adaptive capacities. 
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4.2. Analysis of stem cell properties and phenotype transitions of GBM CSC-
associated subpopulations 
In the last part, CSC-associated inter- and intra-tumoral heterogeneity was assessed at the 
transcriptomic level in GBM patient samples and at the level of epitope expression using 
flow cytometric analysis of patient-derived xenografts and GBM stem-like cultures. To date, 
there are two hypothesis that might explain the observed phenotypic heterogeneity. First, 
the CSC hypothesis postulates that a small subpopulation of cells with stem-like abilities 
creates differentiated progeny in a one-way hierarchical process. The second model 
suggests that phenotypic heterogeneity may arise by adaptive phenotypes where 
differentiation is a reversible process and each cancer cell is able to generate heterogeneity.  
To determine which subpopulations carry stemness properties and whether the intra-
tumoral heterogeneity is created via a hierarchical one-way differentiation or an adaptation 
process, we used GBM stem-like cultures and analyzed their FACS-isolated CSC-
associated subpopulations for stemness characteristics and adaptive abilities. Phenotypical 
changes of CSC-associated subpopulations were further analyzed by mathematical 
modeling to elucidate state transitions.  
 
4.2.1. All GBM CSC-associated subpopulations carry stem cell properties. 
In order to identify putative CSCs, the 16 NCH644 subpopulations defined by their CSC-
associated marker expression profile (CD133, CD44, A2B5 and CD15) were analyzed for 
stemness characteristics. NCH644 GBM stem-like cultures were phenotyped by multicolor 
flow cytometry and divided into the 16 CSC-associated subpopulations (Fig. 16). For sterile 
sorting, we applied a more stringent gating strategy (‘blue’ gates) (Fig. 16.a) as for 
phenotyping (Fig. 13.b). This prevented contamination with neighboring phenotypic 
subpopulations that may have interfered with the results. The 16 subpopulations were 
subsequently tested for self-renewal ability and indefinite proliferation, two main 
characteristics of stemness (Fig. 16.b). 
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Figure 16: Analysis of stemness characteristics. a. NCH644 cultures were divided into 16 
subpopulations by a stringent gating strategy (‘blue’) based on CD133, CD44, A2B5 and CD15 
epitope expression for FACS-sorting experiments. b. After sterile FACS-sorting, the 16 
subpopulations were individually tested for their self-renewal and proliferative capacities. 
 
4.2.1.1. All CSC-associated subpopulations display self-renewal abilities 
Self-renewal ability is classically evaluated by sphere forming capacities. The CSC 
hypothesis states that spheres are formed by CSCs producing progenitors and fully 
differentiated cells or are producing progenitors that give rise to fully differentiated cells. As 
CSCs and progenitor cells cannot be distinguished upon their clonogenic ability in the first 
passage, the cells need to be plated consecutively several times. Since progenitor cells 
only have a limited capacity to form fully differentiated cancer cells and do not carry self-
renewal potential, they will be eliminated upon several passages. This experimental setup 
will eventually deliver self-renewing subpopulations (Pastrana et al., 2011). Hence, we have 
applied a self-renewal test that assessed clonogenic potential of single tumor cells upon 4 
consecutive passages. Furthermore, self-renewal test in our analysis was feasible at clonal 
level since sphere forming ability of NCH644 stem-like cells was high. 
Our results show that all 16 subpopulations were able to produce progeny, and none was 
diluted upon passaging (Fig. 17.a). FACS-sorted cells of the original NCH644 stem-like 
cells were used as control. Significant differences were observed only for subpopulation 11 
(CD133- CD44- A2B5- CD15-), where an increase in clonogenic ability was observed upon 
the second and the third passage compared to passage 1. However, the self-renewal 
potential did not significantly differ between subpopulations at consecutive passages. Next, 
we measured the sphere size as differences in sphere diameter may suggest the presence 
of progenitor cells forming smaller spheres than putative CSCs. The sphere size of each 
subpopulation did not differ significantly (Fig. 17.b). Thus, the same self-renewal ability can 
be attributed to all 16 subpopulations. 
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Figure 17: Sphere number and size of GBM subpopulations upon self-renewal test. a. FACS-
sorted cells of each NCH644 CSC-associated subpopulation and original NCH644 cells (CTR) were 
individually cultured. Sphere number was counted (first passage) and cells were collected to be 
replated for second and subsequent third and fourth passages. All subpopulations were able to form 
new spheres upon 4 consecutive passages, proving self-renewal properties of all subpopulations 
(mean percentage ± SEM; nB=3-6; Kruskal-Wallis test * = p-value < 0.05). b. The sphere diameter 
did not change between GBM subpopulations (mean ± SEM; nB=3-6, nT=20; mixed model F-test). 
The statistical analysis was realized by Sonia Leite and Dr. Nicolas Sauvageot (Centre of 
Competence for Methodology and Statistics, LIH). 
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4.2.1.2.  All CSC-associated subpopulations display proliferative abilities 
Indefinite proliferation is a second stemness characteristic attributed to CSCs. To examine 
this ability, CSC-associated subpopulations were separated by FACS (300 cells per 
replicate) and recultured. After 20 and 30 days the cell number was determined. All 16 
subpopulations had a similar cell count at 20 and 30 days indicating similar proliferation 
capacities. From these data doubling-times were calculated by dividing culture time by the 
logarithmic number of grown cells. Doubling-times were not statistically distinct when 
compared to another and to original NCH644 control cells (Fig. 18). Thus, all CSC-
associated subpopulations showed proliferative capacities which is in line with the previous 
experiment displaying cells in S/G2/M phases in each subpopulation (Fig. 14.c). 
Discrepancies observed between several CD133+ and CD133- subpopulations may result 
from bulk culture compared to individual culture of CSC-associated subpopulations. 
As all subpopulations showed similar stem cell properties (self-renewal and indefinite 
proliferation), it appears that distinct functional subpopulations may not be identified by 
CSC-marker expression. 
 
Figure 18: Proliferation rate of GBM subpopulations. Cell number of each NCH644 subpopulation 
was measured 20 and 30 days after sort. Chart represents calculated doubling times in days. All 
subpopulations proliferated with comparable growth rates compared to original NCH644 control 
(FACS-sorted viable single cells) where no statistical significance was observed (mean ± SEM) 
(nB=3-4, nT=2-3). The mixed model F-test was used as statistical test. Statistical analysis was 
realized by Sonia Leite and Dr. Nicolas Sauvageot (Centre of Competence for Methodology and 
Statistics, LIH) and Dr. Petr Nazarov (Proteome and Genome Research Unit, LIH). 
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4.2.2. CSC-associated subpopulations create phenotypical heterogeneity 
In analogy to normal stem cells, CSCs are proposed to be multipotent by producing 
differentiated progeny with distinct phenotypes. In that scenario, multipotent CSCs should 
give rise to all phenotypes whereby progenitors only should generate partial heterogeneity 
as they would display impaired multipotency. At last, fully differentiated non-CSCs would 
appear unipotent and represent their own phenotype of the parental cell line. To test 
whether the subpopulations have the ability to reform the initial heterogeneity, NCH644 
FACS-sorted subpopulations cultured for different time periods (20, 30 and 70 days) were 
assessed for their phenotypic profile by multicolor phenotyping (Fig. 19.a). Interestingly, 
analysis revealed that none of the subpopulations retained its initial phenotype suggesting 
that all subpopulations were multipotent and that none was representing a truly 
‘differentiated’ phenotype according to the one-way CSC hierarchical organization. 
Furthermore, all subpopulations generated a heterogeneous distribution consisting of all 
initial 16 phenotypic states which attributes to all subpopulations similar multipotent 
capacities (Fig. 19.b). 
We used alluvial plots for data representation to emphasize the phenotypic changes over 
time (Fig. 19.c). Alluvial plots order subpopulations from top to down by highest to lowest 
percentage. The predominant phenotypes in subpopulations 1 to 4 (CD133+ CD44-) 
remained CD133+ and CD44- phenotypic states. Similarly, subpopulations 6 to 8 
(CD133+CD44+) showed at later time points a higher percentage of CD133+ and CD44+ 
phenotypic states compared to other subpopulations. Except for subpopulation 16, all other 
subpopulations created a heterogeneous distribution that was significantly different from 
the original NCH644 population (Annex 7.a). However, at 70 days subpopulations 2, 4 and 
12 showed phenotype distribution similar to the original NCH644 cultures.  
The results strongly indicate that CSC marker-based heterogeneity is not the result of a 
one-way CSC hierarchical organization. This is supported by the lack of differentiated GBM 
subpopulations seen with the self-renewal and proliferation test. 
86 
 
 
 87 
 
 
4 
 
Figure 19: Dynamic plasticity in GBM subpopulations. a. To analyze which subpopulations were 
multipotent and thereby able to recapitulate phenotypic heterogeneity, we analyzed each FACS-
sorted subpopulation after 20, 30 and 70 days in culture. Subpopulations retaining their phenotypic 
state are unipotent whereas subpopulations generating all other phenotypes are multipotent. b. All 
subpopulations were able to reform a heterogeneous expression profile, although the distribution of 
the four markers differed between subpopulations (mean percentages; nB=3-4, nT=1-3). Error bars 
are not depicted for visualization purposes. See Annex 7.a for statistical differences. c. Alluvial plots 
represent the dynamic state transitions in time, where the most abundant subpopulation (highest 
percentage) is at the top and the least abundant or absent phenotype at the bottom. Error bars are 
not depicted for visualization purposes. The Alluvial plots were realized with the help of Arnaud Muller 
(Proteome and Genome Research Unit, LIH). 
 
4.2.2.1.  Phenotypic heterogeneity is reformed by single cells 
The number of plated cells plays an important role as autocrine and paracrine signals from 
neighboring cells may influence the potency of generating the distinct phenotypic states. 
Hence, generated heterogeneity might differ upon the number of initially plated cells. As the 
previous experiment was performed in a bulk sort using 300 cells per population, we tested 
whether single cells of each subpopulation demonstrate the above observed multipotent 
ability. To this aim, single FACS-isolated cells from each of the 16 subpopulations were 
phenotyped at each passage of self-renewal test (Fig. 20). Similar to multipotency test, we 
expected that progenitor and differentiated cells showed reduced capacity of recreating 
original phenotypic heterogeneity. However, after each of the 4 assessed passages, single 
cells were able to produce phenotypic diversity of all 16 subpopulations. This proved that 
single cells were as well able to recapitulate CSC-associated heterogeneity. Similar to the 
previous multipotency test on bulk cells predominant phenotypic states in subpopulations 1 
to 4 (CD133+ CD44-) were CD133+ and CD44-. CD133+ and CD44+ phenotypes were 
exceeding in subpopulations 5 to 8 (CD133+CD44+). Statistical analysis revealed that 
phenotypic states differed between subpopulations and phenotype distribution of the initial 
NCH644 cultures (Annex 5.a). However, hardly any statistical differences were detected 
between passages within each subpopulation (data not shown). This finding suggests that 
generation of heterogeneity is retarded upon single cell plating compared to bulk cell 
growth, but that single cells from each of the 16 subpopulations are able to reconstitute the 
original CSC marker profile.  
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Figure 20: Phenotypic heterogeneity of single GBM cells. Barplots show the distribution of 16 
subpopulations upon self-renewal test in 4 consecutive passages. For re-phenotyping, all single 
spheres of a subpopulation were pooled at each passage (mean percentage; nT=3-6). Error bars are 
not depicted for visualization purposes. 
 
4.2.2.2.  CSC-associated phenotypic heterogeneity is recreated in other GBM 
stem-like cultures 
A second GBM stem-like culture (NCH421k) was tested for its plastic behavior to assure 
that the observed adaptive capacities were not a cell line specific effect. As this culture 
demonstrated a relatively homogenous distribution of the four CSC-associated markers, the 
adaptive capacities in CD133, CD44, A2B5 and CD15 marker expression were tested 
separately. Both positive (‘red’ gating) and negative (‘blue’ gating) populations for the four 
markers were able to reform the initial expression pattern upon 25 days of culture (Fig. 21). 
This suggests that marker associated plasticity is a general phenomenon of GBM stem-like 
cultures. 
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Figure 21: Adaptive capacities of NCH421k stem-like cultures. 500 CD133, CD44, A2B5 or CD15 
positive and negative cells were FACS-sorted. After 25 days in culture cells were phenotyped for 
marker expression. All populations were able to recreate initial heterogeneity. 
 
4.2.3. Markov chain modeling predicts stochastic CSC-associated state 
transitions in time. 
As phenotype state transitions appeared very dynamic over time, we asked whether the 
phenotypic changes are the result of stochastic processes. We took advantage of 
mathematical modeling to predict state transitions in time between the different phenotypes. 
We specifically used Markov modeling as it allowed quantification of state transitions from 
the observed changes in phenotype distribution measured for multipotency test (Fig. 19.b). 
Andrey Andreyevich Markov, a Russian mathematician of the University of St. Petersburg, 
first introduced the Markov chains on stochastic processes in 1913 (Jurafsky, 2008). He 
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used his newly developed model to estimate the probability that the next letter in the text 
sequence of Pushkin’s novel ‘Eugine Onegin’ would be a vowel or a consonant. Previsional, 
today’s main application of the advanced hidden Markov model lies in language processing 
programs. The Markov chain calculates the probability of a sequence of events. In our case, 
the model calculated the probability of one subpopulation forming another phenotypic state 
in time. As time represents the sequence and the event represents the phenotype state 
transitions, the model was defined more specifically as the discrete-time Markov chains 
model. The model was based on several assumptions. First, cell state transitions are only 
dependent on the current phenotype of the cell. Second, state transitions are stochastic. 
Third, the sum of transition probabilities equals to 1. To calculate phenotype transitions 
additional prerequisites were required. Proliferation rates of the subpopulations need to be 
equal and phenotype transitions occur once in a time-step (e.g. one transition per day). As 
no significant differences in proliferation rates were observed between CSC-associated 
subpopulations (Fig. 18), different growth kinetics did not interfere with Markov modeling. 
The application of the mathematical model on the evolving CSC-associated phenotype 
diversity observed during multipotency test (Fig. 19.b) led to an estimated transition network 
(Fig. 22.a). Phenotype transition probabilities are represented by arrows, where the 
thickness of the arrow is related to the increased chance of transition. The calculated 
transition matrix shows the probabilities of a subpopulation at a present state to form a given 
subpopulation in the next future state (Fig. 22.b). E.g., the probability that subpopulation 1 
forms subpopulation 2 equals 0.4% and to form subpopulation 3 was higher (2.37%). This 
shows that certain state transitions are more likely to occur, suggesting that subpopulations 
differ in their ability to change their phenotype. The probability to form itself, thus self-
renewing, was highest for each subpopulation.  
The transition matrix revealed that only 65 of 240 possible direct state transitions did not 
occur. To investigate whether the improbable transitions (zeros in the transition matrix) 
result from progenitor-like cells, the transition network was analyzed for hierarchical 
structures. First the network appeared irreducible, meaning that each state can transit 
directly or via intermediate states into any other state. Moreover, no obvious bottlenecks 
were detected. A graph hierarchy was calculated as a hierarchy measurement in an 
organization structure. This model was proposed by Krackhardt and colleagues to analyze 
the degree of hierarchy in social systems (Krackhardt, 1994). The Krackhardt hierarchy is 
defined by the reciprocity of the state transitions that are asymmetric. To have a pure 
hierarchy, no direct and indirect reciprocal relations should be detected. In that case 
Krackhardt hierarchy equals to 1. In contrary, when all transitions are reciprocated (e.g. in 
a cycle, where each state can be reached via direct or indirect transitions), no hierarchy 
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exists and the Krackhardt value equals 0. Here, in the transition network of the CSC-
associated phenotype transitions the calculated Krackhardt hierarchy equaled 0. These 
observations imply that the stochastic state transitions were non-hierarchical and therefore 
reversible. 
 
Figure 22: State transition probabilities calculated by Markov modeling. a. The network depicts 
the probability of state transitions to occur. The thickness of the arrows increases with the probability 
of state transitions. b. The transition matrix displays in percentage the probability of phenotypic 
changes. Subpopulations demonstrate variations in the probability of changing their phenotype. 
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Figure 31 was realized with the help of Thomas Buder (Zentrum für Informationsdienste und 
Hochleistungsrechnen (ZIH), Technical University of Dresden). 
Using the calculated transition matrix, we were able to predict the final equilibrium, where 
the distribution of subpopulations and transition changes reach a stationary state of the 
Markov chain, one major property of Markovian chains. For this Markov chain, mathematical 
calculations yielded one unique stationary state regardless of the initial phenotypic state. 
Interestingly, the theoretically calculated equilibrium was similar to the initial phenotype 
distribution in the original NCH644 stem-like cultures (Fig. 23). Hence, for statistical 
comparisons we used in the following experiments the phenotype distribution present in 
original NCH644 stem-like cultures as stationary state control (CTR). This was necessary 
as statistical analysis can only be performed between two groups and predicted equilibrium 
of Markov modeling delivered only one single phenotype distribution. Of note, the original 
composition was not used to calculate the transition matrix. The strong similarity between 
predicted equilibrium and original NCH644 population phenotype distribution strongly 
supports the validity of the estimated transition matrix. These data also imply that each 
phenotype composition will reach the same predicted equilibrium at a given time point and 
supports the hypothesis that all subpopulations observed at 70 days (Fig. 19.b) may 
eventually result in one common heterogeneous phenotype if cultured long enough. 
 
 
Figure 23: Final distribution predicted by Markov model. Phenotypic distribution found in original 
NCH644 stem-like cultures (NCH644 CTR) and predicted equilibrium of Markov chains obtained from 
multipotency data were very similar. Data for predicted equilibrium was obtained with the help of 
Thomas Buder (Zentrum für Informationsdienste und Hochleistungsrechnen (ZIH), Technical 
University of Dresden). 
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4.2.4.  Markov model validation 
To further validate the mathematical model, we took advantage of its potential to estimate 
the time an initial cell population needed to reach a second distribution. Markov chains 
allowed to design the phenotype composition of two cell populations (mix A and mix B) that 
reach equilibrium after 39 days of culture (Fig. 24). This was feasible using the estimated 
transition matrix to predict the time to reach final equilibrium. The two subpopulation 
composites were purified by multicolor FACS-sorting and cultured (day 0). At day 39 the 
cell cultures were re-phenotyped and demonstrated a highly similar phenotypic profile to 
the initial equilibrium of the NCH644 stem-like cultures. Only a slight difference between 
phenotypic state 9 from mix A and the control NCH644 was detected. These data 
underscore the prediction ability of the Markov modeling when applied to dynamic state 
transitions of GBM stem-like cells. 
 
 
Figure 24: Test of predictive ability of the Markov model. Two mixes of FACS-sorted 
subpopulations were tested for their ability to recreate predicted distribution. Mathematical model 
predicted a stationary state after 39 days of culture (mean percentage; nT=3). Error bars are not 
depicted for visualization purposes. Statistical significances of phenotypic states between original 
and measured data after 39 days are depicted in table below the graph (t-test with Bonferroni 
multiple-significance-test correction). Predictive data was obtained with the help of Thomas Buder 
(Zentrum für Informationsdienste und Hochleistungsrechnen (ZIH), Technical University of Dresden). 
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4.2.5. Evolution of phenotype distribution 
The evolution of phenotypic transitions starting from single subpopulations revealed several 
interesting observations. For instance, Markov modeling predicted during the generation of 
phenotypic heterogeneity starting with 100% subpopulation 4 a strong increase for both 
subpopulations 2 (black arrow) and 3 (grey arrow). This was accompanied with a decrease 
of subpopulation 2 after only a few days of culture (Fig. 25). Although, time measurements 
were taken only at 20, 30 and 70 days the model is able to predict short-term phenotypic 
changes. To test whether these predicted observations occur as well in reality, 
subpopulation 4 was cultured and phenotyped after 11 and 18 days. Indeed, the strong 
increase in both subpopulations and subsequent decrease of subpopulation 2 was detected 
(Fig. 25). This event represents only an example as these observations are frequent and 
were also described by Sellerio et al. as an overshoot phenomenon (Sellerio et al., 2015). 
A strong enrichment of marker negative cells accompanied with a decrease was observed 
for both CD271- and CXCR6- melanoma cells. These results further strengthen the validity 
of the Markov model and its utility to study early phenotype changes. 
 
Figure 25: Evolution of phenotype distribution in subpopulation 4 (CD133+ CD44- A2B5- 
CD15+). Left panel shows evolution of subpopulation P4 over time as predicted by Markov model. 
Right panel shows FACS-sorted subpopulation 4 that was cultured for 11 and 18 days. The 
percentages of subpopulations 2 and 3 were measured by flow cytometry (mean percentage, nT=3). 
The measured data (dots on graph) correspond to the predicted data (Markov model curve). Figure 
was realized with the help of Thomas Buder (Zentrum für Informationsdienste und 
Hochleistungsrechnen (ZIH), Technical University of Dresden). 
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4.2.6. CSC-associated subpopulations reach phenotypic equilibrium at 
different timepoints 
Transition matrix showed that certain state transitions were more likely to occur than others, 
however, CSC-associated subpopulations were all predicted to create the same phenotype 
diversity suggesting that subpopulations differ in time needed to reach final equilibrium. 
Thus, time to reach steady state was calculated for each subpopulation using Markov 
chains. All subpopulations were predicted to reach equilibrium between 63 to 120 days, but 
at different time points (Fig. 26). Subpopulation 2 (CD133+CD44-A2B5+CD15+), 4 (CD133+ 
CD44- A2B5- CD15+) and 12 (CD133-CD44-A2B5-CD15+) were predicted to reach 
equilibrium already at day 63, 72 and 66 days, respectively. This lead to the assumption 
that subpopulation 2, 4 and 12 might be more adaptive compared to other phenotypes under 
these conditions.  
 
 
Figure 26: Predicted time to reach equilibrium from single subpopulations. Markov model was 
used to estimate the number of days the transition matrix reaches steady state when starting with 
100% pure subpopulation. Subpopulation 2, 4 and 12 appeared the most adaptive. Data for this 
figure was obtained with the help of Thomas Buder (Zentrum für Informationsdienste und 
Hochleistungsrechnen (ZIH), Technical University of Dresden). 
 
To test whether the time to reach equilibrium from single subpopulations as predicted by 
the Markov model were correct, subpopulations 2, 4, 5, 9 and 11 were cultured for 63, 72, 
84, 90 and 108 days, respectively. Subsequently, all cell cultures were measured and their 
phenotypic distribution was compared to the distribution of NCH644 CTR. Indeed 
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subpopulation 9 reached equilibrium at the predicted time point and did not differ statistically 
from NCH644 CTR. Although subpopulations 2, 4, 5 and 11 showed some differences 
compared to NCH644 CTR, the reached phenotypic distribution was relatively close to the 
equilibrium (Fig. 27). The fact that subpopulations needed different times to reach 
equilibrium cannot be explained by differences in proliferation (see Fig. 18), suggesting that 
phenotype changes are not cell cycle dependent. Deviations from Markov model predictions 
might arise from cell culturing or the use of only one biological replication. Also, the model 
itself may demonstrate some weakness in predicting these complex biological phenotypical 
state transitions. Generally, taking into account the results demonstrating the generation of 
phenotypical heterogeneity (Fig. 19.b) and especially the model validation experiments 
(Fig. 24, 25 and partially Fig. 27), strongly suggest that the partial inconsistencies observed 
in Fig. 27 results from technical issues rather than model weaknesses. 
 
 
Figure 27: Time to reach initial distribution of single subpopulations. Predictions of figure 35 
were tested for subpopulation 2, 4, 5, 9, and 11. Redistribution of subpopulations were partially 
similar to the distribution at equilibrium (mean percentage; nT=3). Error bars are not depicted for 
visualization purposes. Statistical significances of phenotypic states between original and measured 
data after 39 days are depicted in table below the graph (t-test with Bonferroni multiple-significance-
test correction). 
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4.2.7. CSC-associated marker expression is independent 
Markov modeling was further used to test independency of the expression of the four 
markers CD133, CD44, A2B5 and CD15 during state transitions. The final equilibrium of 
each individual marker (CD133, CD44, A2B5 and CD15) was calculated under the 
assumption of dependence and independence (see Annex 2.c for details).  
Calculations of the composition of the two obtained equilibria revealed no differences (Fig. 
28), suggesting that CD133, CD44, A2B5 and CD15 expression is independent in GBM 
cells. Thus, the transitions between positive and low/negative expression of one marker are 
independent of the level of expression of the other markers  
 
 
Figure 28: CSC-associated markers are independent from each other. Single marker equilibria 
were calculated either by the assumption of independency by adding probabilities of single marker 
transition matrixes or deviated from the predicted proportions by Markov modeling of 4 markers 
simultaneously. As equilibria did not differ, markers appeared to be independent. Data for figure was 
realized by Thomas Buder (Zentrum für Informationsdienste und Hochleistungsrechnen (ZIH), 
Technical University of Dresden). 
 
In summary, our data shows that all analyzed tumor cell subpopulations were able to 
proliferate and carried stem-cell properties including self-renewal potential. Moreover, all 
subpopulations were multipotent and able to give rise to the original heterogeneous 
cultures. Using mathematical modeling we were able to predict state transitions over time 
for individual subpopulations. Moreover, the Markov model revealed a different propensity 
for reforming the original heterogeneity between subpopulations over time, which was 
independent of their proliferation index. Finally, phenotype state transitions were 
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independent of marker expression. Markov modeling represented an appropriate model to 
calculate state transitions and predictions were proven to correspond to measured data. 
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4.3. Identification of survival mechanisms of GBM cultures to hypoxia 
GBM tumors are heterogeneous tumors comprising several environmental niches, i.e. 
hypoxic, perivascular and invasive niches. One well characterized and major hallmark of 
GBMs is the hypoxic zone surrounding necrotic areas. Cancer cells residing in this sparse 
environment activate survival mechanisms such as decreased proliferation (Hubbi and 
Semenza, 2015, Carmeliet et al., 1998), enhanced invasiveness (Joseph et al., 2015), 
upregulation of anti-apoptotic pathways (Kumar and Choi, 2015, Graeber et al., 1996), 
autophagy (Annex 11, (Abdul Rahim et al., 2017)) or upregulation of anaerobic glycolysis 
(Lin and Yun, 2010)(Annex 10, (Sanzey et al., 2015)). It has been suggested that the CSC 
population within a tumor bulk is more prone to survive and adapt to hypoxia than non-
CSCs (Lathia et al., 2011a). In order to elucidate the survival mechanisms of putative CSCs 
and non-CSCs in hypoxia, we first characterized several bulk GBM cell cultures under 
severe oxygen deprivation. The response to hypoxia was assessed in patient-derived stem-
like cultures and classical serum dependent GBM cells. Cell growth, death and apoptosis, 
proliferation, clonogenic ability and invasive behavior was analyzed in normoxia, short and 
long-term hypoxia.  
 
4.3.1. GBM cultures display reduced cell counts in hypoxia 
To assess the behavior of GBM cells in hypoxia, cell growth of several GBM cell cultures 
was evaluated for up to 7 days under low oxygen condition which were defined at 0.5% O2. 
We interrogated the adherent serum grown U87 and U251 GBM cell cultures and the non-
adherent serum-free NCH644, NCH421k, NCH660, NCH601 and NCH465 stem-like 
cultures.  
All GBM cells regardless of the culture condition significantly decreased in cell number upon 
hypoxia compared to normoxia, albeit to a different extent (Fig. 29). NCH465 displayed the 
least significant reduction in cell number counts in hypoxia compared to the normoxic 
condition. The most extreme behavior was observed for NCH421k cells which resulted in a 
net cell loss of 72% compared to the initial number of plated cells (from 50´000 to 14´000 
cells in hypoxia) indicating that most cells do not survive in hypoxia. However, all other cell 
lines demonstrated an increased cell number after 14 days of culture in normoxia and 
hypoxia showing that cells are able to proliferate in both conditions. Proliferation rates in 
hypoxia and normoxia may be similar or vary. In case cells equally divide in both conditions 
the decreased cell number in hypoxia compared to normoxia may result from an increased 
cell death as suggested for NCH421k cell line. On the other hand, a decreased proliferation 
rate in hypoxia might leads also to a lower cell number count. 
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Figure 29: Cell number counts of GBM cell cultures are lower in hypoxia than in normoxia. 
Graphs represent changes in growth between standard normoxic and hypoxic condition. Cell number 
was counted 3, 7, 10 and 14 days after plating. Data is represented as a mean cell number with 
standard error of the mean (nB=3-4, nT=2-3). Statistical differences between cell number in hypoxia 
and normoxia were calculated using t-test (p<0.05 = *, p<0.01 = ** and p<0.001 = ***). 
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4.3.2. GBM stem-like cells display increased apoptosis and cell death in 
hypoxia 
Reduced cell growth may result from multiple cellular processes, such as increased cell 
death, slower cell cycle or reduced clonogenicity. To assess cell death upon exposure to 
hypoxia, we performed an apoptosis/necrosis test using AnnexinV/PI staining after 16 hours 
and 7 days of culture. By flow cytometry, we were able to exclude debris from cells by 
forward (FSC-A) and side scatter (SSC-A). Single cells were discriminated from doublets 
by area and height forward scatter (FSC-A; FSC-H). In combination with PI staining we 
were able to distinguish between viable (AnnexinV-PI-), early apoptotic (AnnexinV+PI-), late 
apoptotic (AnnexinV+PI+) and necrotic cells (AnnexinV-PI+) (Fig. 30.a). The majority of the 
stem-like GBM cultures (NCH660h, NCH601 and NCH465) marked a high number of late 
apoptotic and necrotic cells already in short-term hypoxia (16h) (Fig. 30.b). Consequently, 
the number of viable cells significantly decreased in these cultures (73.51 to 32.14% in 
NCH660h, 83.22 to 29.2% in NCH601 and 73.56 to 25.85% in NCH465).  
The reduction of viable cells was even more dramatic upon long-term hypoxia (7d) in 
NCH421k (81.1 to 16.2%). Amongst GBM stem-like cultures, NCH644 was most resistant 
to low oxygen levels and displayed a moderate increase of late apoptotic cells (4.44 to 
12.11%) only in long-term hypoxia. The percentage of necrotic cells, however, did not 
significantly increase. These results suggest that a reduced cell growth of NCH421k, 
NCH660h, NCH601 and NCH465 stem-like cultures in hypoxia compared to normoxia may 
result at least partially from increased apoptosis and cell death. Surprisingly, cell viability 
was not significantly impaired in adherent cell cultures in hypoxia although a slight tendency 
towards increased number of necrotic cells for U251 was observed. Neither was a 
significant increase in apoptotic or necrotic cells detected suggesting that a decreased 
proliferation rate or clonogenicity might cause a reduced cell growth in hypoxia. 
Even more, these observations showed that distinct culture systems (e.g. adherent and 
sphere forming cultures) do react differently to low oxygen conditions. Most stem-like 
cultures showed increased apoptosis and/or cell death in hypoxia compared to normoxia 
with only a small percentage of surviving cells whereas in adherent cultures only a few cells 
enter apoptosis or die. These results contrast with the general assumption that serum 
independent stem-like cultures are more opt to survive in deprived environments than 
adherent cell cultures.  
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Figure 30: Apoptosis test of GBM cultures upon short and long-term hypoxia. a. Flow 
cytometric scatter plots depict gating strategy for the analysis of apoptotic cells in GBM cultures. 
GBM cells were distinguished from debris using forward (FSC) and side (SSC) scatters, followed by 
cell doublet and aggregate elimination (FSC-A/FSC-H). Single cells were divided into four categories: 
viable (AnnexinV- PI-), early apoptotic (AnnexinV+ PI-), late apoptotic (AnnexinV+ PI+) and necrotic 
(AnnexinV- PI+). b. Apoptosis and necrosis in GBM cell cultures was analyzed in normoxic, 16h and 
7d hypoxic conditions. Bar plots represent percentage of cells (mean ± SEM, nB=2-3, nT=2-3). t-test 
was performed to test statistical significant differences between categories and conditions 
(Bonferroni multiple-significance-test correction; p<0.05 = *, p<0.01 = ** and p<0.001 = ***).  
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4.3.3. All GBM cell cultures were able to proliferate in severe hypoxia 
Increased cell death accounted partially for the reduced growth rates in all GBM cell cultures 
in hypoxia. We hypothesized that surviving cancer cells might survive severe hypoxia by 
switching to a non-proliferative G1/G0 state. To determine the cell cycle activity, DNA 
content was measured in GBM cell cultures in normoxia, short and long-term hypoxia. By 
flow cytometric analysis, debris were excluded as described for apoptosis test. Cell doublets 
and aggregates were eliminated using area and width of the forward scatter or, alternatively, 
of the PI staining. Using a dead cell marker, we could discriminate between viable and dead 
cells to assure cell cycle analysis on pure single viable cells (Fig. 31.a). Although at distinct 
levels, all GBM cell cultures were able to proliferate in long-term hypoxic conditions (Fig. 
31.b). Interestingly, the number of G2/M/S cells in NCH644 (±40%), U251 (±50%), 
NCH660h (±40%) and NCH465 (±60%) remained constant from normoxic up to severe 
hypoxic conditions. Since a reduced proliferation rate was not a cause for reduced cell 
number count in hypoxia (Fig. 29) we suggested that apoptosis and cell death (Fig. 30.b) 
have been the major reason. In contrast, U87, NCH421k and NCH601 GBM cultures 
experienced a significant reduction in proliferating cells upon severe hypoxia (G2/M/S cells 
from 30.9 to 8.58% in U87, from 39.13 to 21.85% in NCH421k and 33.74 to 18.33% in 
NCH601) (Fig. 31.b). Simultaneously, these cultures displayed an increased number of 
non-cycling cells. We have previously shown that U87 cells have a similar percentage of 
viable cells in normoxia than in hypoxia indicating that the low cell number count observed 
in hypoxia is a result from a decreased proliferation rate. In NCH421k and NCH601 an 
increased cell death/apoptosis and decreased proliferation was observed suggesting that a 
combined effect of these two processes was responsible for a reduced growth in hypoxia. 
Of note, no distinct proliferative behavior between cell culture systems (e.g. adherent or 
sphere forming) was observed. 
In summary, we show that GBM cell cultures significantly decrease cell number upon severe 
hypoxia. The decreased cell number is a consequence of increased cell death and 
decreased proliferation rate. The extent of reduced cell number depends on the proportion 
of proliferating and apoptotic/necrotic cells. It is either solely based on a reduced 
proliferation rate (U87) or solely an increased cell death (NCH644, U251, NCH660h and 
NCH465). A combined influence of reduced proliferation and increased cell death 
(NCH421k and NCH601) was also observed. 
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Figure 31: Cell cycle analysis during short and long-term hypoxia. a. Flow cytometric scatter 
plots depict gating strategy for the cell cycle analysis of GBM cultures. Cells were distinguished from 
debris using forward (FSC) and side (SSC) scatters, followed by cell doublet and aggregate 
elimination (FSC-A/FSC-H or PI-A/PI-H). Dead cells were recognized as positive for dead cell 
marker. Final histogram depicts DNA staining where cells in different cell cycle phases can be 
discriminated: G1/G0, S and G2/M states. b. GBM cell cultures were analyzed for their cell cycle 
activity in normoxia, 16h and 7d hypoxia (0.5% O2). The cells were categorized into 3 groups 
according to the cell cycle phase: G1/G0, S and G2/M. Data is shown as percentage of viable cells 
(mean ± SEM; nB=2-3, nT=2-3). t-test was performed to test statistical significant differences between 
hypoxic to normoxic conditions (Bonferroni multiple-significance-test correction; p<0.05 = *, p<0.01 
= ** and p<0.001 = ***).  
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4.3.4. All GBM cell cultures display clonogenic potential in hypoxia  
A reduced growth rate may originate from an impaired ability to form progeny after exposure 
to hypoxia. We performed a colony formation assay, also referred to as the clonogenic 
assay, to assess the percentage of cells with the potential to form a clone. The experiment 
is performed at the single viable cell level in separate cultures to assure the measurement 
of the colony forming efficiency of one single cell. All GBM cultures regardless their culture 
type (e.g. serum dependent or independent) were able to form colonies in normoxia as well 
as in hypoxia. Surprisingly, only NCH644 (from 25% to 8%) and NCH421k (from 27% to 
22%) showed a significant reduction in clonogenicity in hypoxia compared to normoxic 
condition (Fig. 32.a). For GBM stem-like cultures, the measurement of sphere diameters 
revealed that NCH644, NCH421k and NCH660h cultures recreated significantly smaller 
spheres in hypoxia (Fig. 32.b). Spheres of NCH601 and NCH465 were already relatively 
small at the initial normoxic state. Since we did not observe a decreased proliferation rate 
for NCH644 and NCH660h we suggest that sphere size is not always directly correlated to 
proliferative capacities in contrast to Mori et al (Mori et al., 2006). Here, sphere size of neural 
stem/progenitor cells was shown to gradually increase in a dependent manner with 
proliferation rate. 
Thus, additionally to reduced proliferation and increased cell death, a decreased clonogenic 
ability and a smaller sphere size contribute to the reduced cell number of NCH644, 
NCH421k and NCH660h in hypoxic condition. Furthermore, serum independent cultures, 
considered to be enriched for CSCs, do not demonstrate an increase in clonogenic potential 
compared to adherent cultures.  
 
Figure 32: Clonogenic potential of GBM cells upon normoxia and hypoxia. a. Single viable 
FACS-sorted cells of each GBM culture were individually cultured in either normoxia or hypoxia. 
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Colony forming efficiency was calculated from the number of formed clones (mean percentage ± 
SEM; nB=4). All GBM cultures demonstrated clonogenic potential in normoxia and hypoxia. 
Significant differences between colony forming efficiency between normoxia and hypoxia were 
calculated using t-test where p<0.05 = *, p<0.01 = **, p<0.001 = *** marked significant. b. Sphere 
size is represented as mean percentage ± SEM (nB=1, nT=20). Significance between sphere size in 
normoxia and hypoxia was tested with t-test (p<0.05 = *, p<0.01 = ** and p<0.001 = ***). 
 
4.3.5. Hypoxic environment promotes a switch in invasive potential 
Hypoxic GBM tumors are shown to have increased invasive/migratory behavior. It is 
hypothesized that tumor formation at distal locations in the brain is realized by so called 
tumor initiating cells (TICs) which are often described with stem-like characteristics (Zhou 
et al., 2009). In vitro assays with GBM cancer cells demonstrated an increased invasiveness 
at low oxygen levels as well (Joseph et al., 2015). Antiangiogenic treatment in vivo reduces 
oxygen delivery to the tumor and was shown to increase invasiveness in PDXs (Keunen et 
al., 2011). Furthermore, we hypothesized that concordant to the ‘go or grow’ hypothesis 
migrating cells might not be able to proliferate or produce progenitors at the same time. 
Therefore, an increased migratory ability might reduce cell growth in hypoxia. We therefore 
tested the invasive capacities of the GBM stem-like cultures at low oxygen concentrations 
using the Boyden chamber assay. To obtain a net percentage of invasive cells, the counted 
number of invasive and non-invasive cells was corrected for their cell growth to control for 
differences in cell death and proliferation between normoxia and hypoxia. In standard 
normoxic conditions GBM cultures demonstrated a distinct invasive potential (Fig. 33). 
NCH644 and NCH421k had a very low invasive ability in contrast to NCH660h, NCH601 
and NCH465. These data correlate with their histopathological phenotype upon orthotopic 
transplantation into immunodeficient mice in vivo (Bougnaud et al., 2016). NCH644 
generated tumors display a poorly invasive angiogenic phenotype, NCH421k an 
intermediate and NCH660h, NCH601 and NCH465 a highly invasive phenotype. 
Surprisingly, the change to hypoxia inverted this behavior in vitro. NCH644 showed a 
significant increase (from 5% to 33%) of invasive cells whereas NCH601 and NCH465 
encounter a significant decrease in invasive potential. No significant difference in invasive 
cell number between normoxic and hypoxic condition was observed in NCH421k and 
NCH660h. These results show that not all GBM cells become invasive upon low oxygen 
levels. Of note, NCH465 cultures show a significant reduction in invasive cell number, 
however, growth rate is only minimally affected by low oxygen levels. 
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Figure 33: Invasion ability upon normoxia and hypoxia. Invasiveness of GBM cell cultures were 
measured using Boyden chamber assays. Cells were cultured for 2 or 3 days in normoxia and 
hypoxia. Invasive cell number is presented as mean percentage of total cells (mean ± SEM, nB=3). 
Significance between normoxic and hypoxic conditions was tested with t-test (p<0.05 = *, p<0.01 = 
** and p<0.001 = ***). 
 
To summarize, we showed that all GBM cell cultures displayed a reduced cell number upon 
severe hypoxia. This observation is a combined consequence of increased cell death, 
decreased proliferative index, reduced clonogenicity and/or formation of smaller spheres. 
Nevertheless, all cell cultures were able to survive and continued to grow in hypoxic 
conditions, albeit to a variable extent. Although, GBM cultured underwent a negative 
selection pressure, remaining cells activated survival mechanism (e.g. reduce proliferation, 
clonogenicity) in hypoxia. The remaining cells might have increased adaptive capacities 
and may have higher stemness capacities since this property was described to favor 
survival in hypoxia (Lathia et al., 2011a). 
There was no clear distinction in proliferation or colony forming efficiency between adherent 
and sphere forming GBM cultures, however lower levels of cell death in hypoxia were 
detected in adherent cultures than in sphere cultures. Furthermore, depending on GBM 
culture invasive capacities were either in or decreased from normoxic to hypoxic conditions. 
Although it is not clear why GBM cultures behave to different degrees, a putative 
explanation might result from distinct genetic and/or epigenetic backgrounds. 
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4.4. Analysis of stem cell properties and phenotype transitions of GBM 
CSC-associated subpopulations in hypoxia 
Certainly, the most popular theory in evolutionary biology is Darwin’s survival of the fittest. 
When applied to cancer development, the cancer cell with the most advantageous 
properties survives different environmental pressures. Classically, research on clonal 
evolution of cancer focusses on genomic alterations as selective traits. Neutral mutations 
in a defined environment (e.g. perivascular niche) may be advantageous following an 
environmental change e.g. when the tumor core becomes hypoxic due to massive cell 
proliferation and reduced nutrient supply. However, some reports suggest that clonal 
competition in certain environments does not solely rely on DNA mutations (Vermeulen et 
al., 2013), but also on epigenetic factors and phenotypic heterogeneity (Greaves and Maley, 
2012).  
Cancer adaptability reflects the property of a cell to change its behavior to best fit the 
environment it encompasses. The change from aerobic oxidative phosphorylation to 
anaerobic glycolytic metabolism upon oxygen deprivation represents one of the best 
described adaptational abilities in cancer (Eales et al., 2016). 
In this part, we analyzed to what extend the phenotypic heterogeneity is dependent on the 
hypoxic environment and how the hypoxic niche governs the CSC state. We took advantage 
of our CSC-associated subpopulations to assess phenotypical heterogeneity. We further 
evaluated whether stochastic adaptation can take place in hypoxia or if phenotypical 
changes result from selection of the most fitted phenotype(s). Therefore, subpopulations 
were characterized for their stemness abilities in hypoxia, e.g. self-renewal, indefinite 
proliferation and multipotency. 
 
4.4.1. Hypoxia leads to a change in phenotypic heterogeneity 
First, we assessed the impact of the environmental change from normoxia (21% O2) to 
hypoxia (0.5% O2) on CSC-associated marker expression. CSC marker expression was 
analyzed in GBM stem-like cultures after short and long-term hypoxia. A mild but distinct 
change in marker expression compared to normoxia was already observed after 16 hours 
and 2 days culture in low oxygen environment. This shift in phenotype became more 
prominent upon long term hypoxia (7 to 60 days). In general, hypoxic NCH644 stem-like 
cells expressed higher levels of CD133 (from 80.58% to 95.41%), CD44 (from 37.32% to 
62.76%) and A2B5 (from 40.59% to 53.18%) whereas CD15 expression was decreased 
(from 35.51% to 14.46%) (Fig. 34.a; see Annex 3.c for all statistical comparisons of 
phenotypical states and single marker expression between time points). In particular, 
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subpopulations 5 (CD133+ CD44+ A2B5+ CD15-) and 7 (CD133+ CD44+ A2B5- CD15-) were 
enriched, whereas numerous subpopulations including 2 (CD133+ CD44- A2B5+ CD15+), 10 
(CD133- CD44- A2B5+ CD15+) and 12 (CD133- CD44- A2B5- CD15+) were predominantly 
reduced. The changes were also detected in more homogeneous NCH421k GBM stem-like 
cultures where, contrary to NCH644 stem-like cultures, CD44 (from 12.43% to 3.86%) 
expression was significantly reduced upon long-term hypoxia. Subpopulations 1 (CD133+ 
CD44- A2B5+ CD15-) and 4 (CD133+ CD44- A2B5- CD15+) showed a tendency for 
enrichment upon hypoxia. A significant decrease was observed for subpopulation 2 
(CD133+ CD44- A2B5+ CD15+), 6 (CD133+ CD44+ A2B5+ CD15+) and 11 (CD133- CD44- 
A2B5- CD15-) (Fig. 34.b; see Annex 3.d for all statistical comparisons of phenotypical 
states and single marker expression between time points). Even thought, phenotypic 
changes occurred over the entire measured time period (60 days for NCH644 and 7 days 
for NCH421k), the first alterations were already observed at early stages (12 hours and 2 
days). Then rapid changes in phenotypic heterogeneity suggest an adaptation rather than 
clonal selection as the underlying process. The results are in accordance to McCord et al. 
who demonstrated that CD133 epitope expression in CD133+ GBM populations remains 
high and increases CD133 in CD133- populations in 7% O2 hypoxia (McCord et al., 2009).  
Similarly to TMZ treatment, changes were not always gradual in time, suggesting indirect 
state transitions via other phenotypic states in time before reaching a new hypoxic 
equilibrium. Nevertheless, we cannot exclude selection for a specific CSC-associated 
subpopulation by cell death observed in the previous chapter.  
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Figure 34: Phenotypic adaptation upon exposure to hypoxic environment. a. NCH644 GBM 
stem-like cultures were cultured at 0.5% O2 for short (16 hours, 2 days) and long term (7-60 days). 
CSC-associated marker expression (CD133, CD44, A2B5 and CD15) was measured by 
simultaneous multicolor flow cytometry (mean percentage; nB=3, nT=2-3). After long term hypoxia, 
CD133 and CD44 epitope expression was increased whereas CD15 and A2B5 were decreased. 
Error bars are not depicted for visualization purposes. Statistical analysis of phenotypic changes 
between states in normoxic vs hypoxic conditions is depicted in table below the graph (t-test with 
Bonferroni multiple-significance-test correction; p<0.05 = *, p<0.01 = ** and p<0.001 = ***). b. 
NCH421k GBM stem-like cultures demonstrated lower number of CD44+ cells (mean percentage; 
nB=8). Error bars are not depicted for visualization purposes. Statistical differences of phenotypic 
states between normoxic and hypoxic conditions are depicted in table below the graph (t-test with 
Bonferroni multiple-significance-test correction; p<0.05 = *, p<0.01 = ** and p<0.001 = ***). 
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4.4.2. Hypoxia induces differences in stemness abilities of CSC-associated 
subpopulations 
As the switch from normoxic to hypoxic condition led to a change in phenotypic 
heterogeneity, we further assessed whether this was modulated by differences in stemness 
abilities between CSC-associated subpopulations. The observed enrichment of 
subpopulations 5 and 7 in hypoxia could arise from increased or decreased clonogenicity 
or proliferative index of these subpopulations. To test self-renewal and proliferative 
characteristics in hypoxia, we followed the same experimental strategy used in normoxia. 
 
4.4.2.1. Impaired clonogenic ability of CSC-associated subpopulations in hypoxia 
We first tested self-renewal capacities of CSC-associated subpopulations. Single viable 
cells from each subpopulation were individually FACS-sorted and cultured for four weeks 
in hypoxia. The number and size of spheres derived from each FACS-sorted subpopulation 
were measured. All derived spheres were further collected to replate again single viable 
cells for a second passage. This was followed by third and fourth passaging. Between each 
passage, the cells were cultured for 4 weeks. FACS-sorted viable single cells from bulk 
NCH644 stem-like cultures served as a control.  
Generally, the average sphere size was smaller in hypoxia (±400µm) compared to normoxia 
(±750µm) (Fig 35.a) regardless of the CSC-associated subpopulation which is in 
accordance to results found in the previous chapter 4.3 (Fig. 32.b). No differences in sphere 
size were detected between the passage number and the same subpopulation. Only 
subpopulation 13 (CD133- CD44+ A2B5+ CD15-) demonstrated significant difference in 
sphere size between the consecutive passages (189.64µm vs 256.79µm and 347.05µm, 
respectively), suggesting its adaption to hypoxia over long time. 
However, numerous differences in sphere number were detected between the 
subpopulations with the same passage number (Fig. 35.b-c). The clonogenic ability was 
impaired for few subpopulations during first passage in hypoxia. The percentage of formed 
spheres of subpopulations 10 (CD133- CD44- A2B5+ CD15+) (3.39%), 12 (CD133- CD44- 
A2B5- CD15+) (3.91%) and 14 (CD133- CD44+ A2B5+ CD15+) (16.41%) was significantly 
lower compared to other subpopulations during the first passage (21.61-39.58%). 
Subsequently, their self-renewing ability increased at passage 2 and was maintained at 
passages 3 and 4, where no more statistical differences were observed between clonogenic 
potential of subpopulations.  
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Although the initial clonogenic potential of subpopulation 11 at passage 1 was similar to 
other remaining subpopulations, a significant increase in sphere forming ability during the 
first three passages was observed (from 29.69% to 43.75% and 45.01%). 
At the second passage, subpopulations 3 (CD133+ CD44- A2B5- CD15-) (47.87%), 11 
(CD133- CD44- A2B5- CD15-) (43.75%) and 15 (CD133- CD44+ A2B5- CD15-) (43.49%), all 
low in A2B5 and CD15 expression displayed a significantly higher sphere number compared 
to other subpopulations. Differences between subpopulations in clonogenic potential were 
lost at later passages (3 and 4) which might be explained by an adaptation of all 
subpopulations to hypoxic condition (Fig. 35.b-c).  
The decreased clonogenicity of subpopulations 10, 12 and 14 upon the first passage is in 
accordance with the observed reduction of these subpopulations upon environmental 
change to hypoxia. Reduced clonogenicity may suggest an increased cell death of these 
phenotypes in hypoxia at the initial time point. On the other hand, the increase in self-
renewal ability of subpopulation 3 at the second passage may account for its enrichment. 
Other significant results could not be associated with the redistribution of the phenotypic 
heterogeneity upon change to hypoxia. 
Importantly, none of the subpopulations was eliminated or ‘diluted’ in hypoxia. Variations in 
self-renewal abilities might rather result from an initial partial selective cell death of specific 
subpopulations and adaptive capacities of surviving clones. However, the statistical 
differences were generally lost at passage 3 and 4, suggesting that all the CSC-associated 
subpopulations were able to self-renew and adapt to hypoxia. 
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Figure 35: Sphere number and size of GBM subpopulations in hypoxia upon self-renewal test. 
a. Sphere number and size was measured during 4 passages of viable single cells of each FACS 
sorted subpopulation. The formed spheres did not differ in diameter between GBM subpopulations. 
Only subpopulation 13 showed an increase on second and third passage compared to the first 
passage (mean ± SEM; nB=2-4, nT=6-20; mixed model F-test). b. All subpopulations were able to 
form new spheres upon 4 consecutive passages, proving self-renewal properties of all 
subpopulations (mean percentage ± SEM; nB=2-4). c. Kruskal-Wallis test was used to calculate 
statistical differences in sphere formation between subpopulations within one passage. Interestingly, 
most significant changes in clonogenicity were observed for subpopulations 10, 12 and 14 at 
passage 1 and for subpopulations 3, 11 and 15 at passage 2, (Kruskal-Wallis test * = p-value < 0.05). 
No statistical differences were present at passage 3 and 4. Statistical analysis for figure 18 was 
realized with the help of Sonia Leite and Dr. Nicolas Sauvageot (Centre of Competence for 
Methodology and Statistics, LIH). 
 
4.4.2.2. Differential proliferative potential of CSC-associated subpopulations in 
hypoxia 
We further investigated whether the enrichment in subpopulation 5 and 7 observed after an 
environmental switch from normoxia to hypoxia might result from an increased proliferative 
ability. The doubling time (dt) was calculated from the cell number measured at 30 and 60 
days after FACS sorting in hypoxia of each cultured subpopulation.  
All subpopulations were able to proliferate, although at a lower rate than in normoxia (CTR 
NCH644: 6.8 days ± 0.2 SEM vs 2.85 days ± 0.16 SEM) (Fig. 36). Since all subpopulations 
proliferated at a similar rate, the enrichment and depletion of CSC-associated phenotypes 
in long-term hypoxia only partially resulted from discrepancies in stemness abilities (i.e. 
clonogenicity of subpopulation 10, 12 and 14). Although we found small differences in 
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stemness abilities (i.e. self-renewal), all subpopulations were able to self-renew and 
proliferate indefinitely. Therefore, it is likely that the redistribution of CSC-associated 
heterogeneity upon environmental change to hypoxia arises from phenotypic adaptation. 
 
Figure 36: Doubling time of GBM subpopulations in hypoxia. a. Cell number of each NCH644 
subpopulation was measured at 30 and 60 days after FACS-sort. No difference in dt was observed 
including that all subpopulations were able to proliferate at similar rate (mean ± SEM; nB= 3-4, nT=2-
3). No statistical difference was detected between subpopulations and CTR NCH644 cells. The 
mixed model F-test was used as statistical test. Statistical analysis for this figure was realized with 
the help of Sonia Leite, Dr. Nicolas Sauvageot (Centre of Competence for Methodology and 
Statistics, LIH) and Dr. Petr Nazarov (Proteome and Genome Research Unit, LIH). 
 
4.4.3. Phenotypic heterogeneity is created via adaptive state transitions of 
CSC-associated subpopulations 
Since all subpopulations possessed stemness abilities and none of the subpopulations 
were lost in hypoxia, we hypothesized that changes in phenotypic equilibrium upon 
exposure to hypoxia cannot arise from clonal selection of the best fitted phenotypes. The 
above-mentioned results suggest strong adaptive capacities of surviving cells to a changed 
environment. 
 
4.4.3.1. All CSC-associated subpopulations recapitulate phenotypic heterogeneity in 
hypoxia 
To test whether all CSC-associated subpopulations were able to generate phenotypic 
heterogeneity in hypoxia, we analyzed the expression patterns of CD133, CD44, A2B5 and 
CD15 in FACS-sorted NCH644 subpopulations cultured for 60 days in 0.5% O2. Similar to 
normoxic condition, all subpopulations were able to recreate CSC-associated heterogeneity 
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and none retained its initial phenotype (Fig. 37. None of the subpopulations appeared as a 
fully differentiated unipotent progeny in hypoxia.  
All subpopulations created a phenotypic distribution statistically different from normoxic 
equilibrium but very similar to control cells at day 60 in hypoxia (Annex 4.b), indicating that 
the phenotypic distribution of all subpopulations is more similar to a hypoxia specific 
equilibrium than to a normoxic equilibrium. The predominant phenotypes in subpopulations 
1 to 3 (CD133+ CD44-) and 9 to 11 (CD133- CD44-) remained CD133+ and CD44- 
subpopulations, whereas subpopulations 4 (CD133+ CD44-), 12 (CD133- CD44-), 5 to 8 
(CD133+ CD44+) and 13 to 16 (CD133- CD44+) were mainly CD133 and CD44 positive.  
Even though statistical differences were still observed between a proportion of phenotypic 
states in distinct subpopulations the similarities between phenotype proportions suggest 
that all CSC-associated subpopulations adapt to a similar phenotypic distribution in hypoxia 
and may eventually reach a same phenotypic equilibrium as observed for normoxic 
condition. 
 
Figure 37: Plasticity test of GBM subpopulations in hypoxia. To analyze whether subpopulations 
were able to recapitulate phenotypic heterogeneity, CSC-associated marker expression patterns 
were analyzed in each FACS-sorted subpopulation after 60 days in hypoxia culture (0.5 O2). As 
control, FACS-sorted NCH644 cultures were used. All subpopulations were able to reform a 
heterogeneous expression profile, although the distribution of four markers differed between 
subpopulations (mean percentages; nB=3-4, nT=2-3). Statistical significances of phenotypic states 
between CSC-associated subpopulations at day 60 and NCH644 control at 0 (T0) and 60 days in 
hypoxia (T60) are depicted in the Annex 4.b (t-test with Bonferroni multiple-significance-test 
correction). Error bars are not depicted for visualization purposes. 
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4.4.3.2. Single cells from CSC-associated subpopulations recapitulate phenotypic 
heterogeneity in hypoxia 
We next tested whether a single cell demonstrates the same plasticity as a bulk of 300 cells 
used in the previous experiment (Fig. 37). Therefore, cells from each CSC-associated 
subpopulation were FACS-sorted and cultured as single cells to eliminate cell to cell 
communication. After 4 weeks of hypoxic cultures, formed spheres were collected and 
phenotyped for four consecutive passages. All single cells could produce phenotypic 
diversity during the four passages (Fig. 38). CSC-associated phenotypic heterogeneity 
followed similar preferences for CD133+ CD44- and CD133+ CD44+ populations as found 
in the previous bulk-sorting experiment, except for subpopulations 13-16. These 
discrepancies might originate from different time periods in culture (60 vs. 28 days). The 
result showed that single cells had the full capacity to recapitulate CSC-associated 
heterogeneity. 
 
Figure 38: Phenotypic heterogeneity of single GBM cells in hypoxia. Barplots show the 
distribution of 16 subpopulations upon self-renewal test in 4 consecutive passages. For re-
phenotyping, all single spheres of each subpopulation were pooled at each passage (mean 
percentage; nB=2-4). Statistical significances of phenotypic states between normoxic NCH644 
control (CTR), NCH644 control 60 days in hypoxia and subpopulations at different passage numbers 
in hypoxia are depicted in Annex 5.b (t-test with Bonferroni multiple-significance-test correction). 
Error bars are not depicted for visualization purposes. 
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4.4.4. Adaptive state transitions of CSC-associated subpopulations are 
stochastic in time 
As we proofed that Markov chains successfully address CSC-associated state transitions 
in normoxia, we applied the mathematical model on the observed phenotypic changes in 
hypoxia (Fig. 37). To shed light on the process of phenotypic redistribution observed upon 
environmental change to hypoxia. Furthermore, mathematical modeling should allow to 
predict phenotypic state transitions in time to evaluate adaptive capacities of CSC-
associated subpopulations. 
 
4.4.4.1. Markov modeling predicts state transition probabilities for all CSC-
associated subpopulations 
We applied the Markov model to predict state transitions between the different phenotypes 
in time. Although the doubling times of subpopulations 7 and 13 were slightly different, we 
omitted this discrepancy as proliferative indexes did not correlate with phenotype 
redistribution upon hypoxia. Thus, proliferation rates were assumed to be equal between 
subpopulations and phenotype transitions to occur at equal discrete time steps. The 
predicted state transition network in hypoxia appeared less dense in possible phenotype 
changes (depicted by arrows) than in normoxia (Fig. 39.a). This was confirmed by the 
transition matrix, where only 103 out of 240 possible direct transitions were predicted to be 
possible (Fig. 39.b). Similar to normoxia, the self-renewal ability (probability to form itself) 
was highest for each subpopulation. Interestingly, subpopulation 10 (CD133- CD44- A2B5+ 
CD15+) could not be formed by any other subpopulation but was able to reform other 
phenotypes. Thus subpopulation 10 represented a transient state. Of note, an absorptive 
state is a state which is formed by other phenotypes but itself cannot form other phenotypes. 
States that are neither transient nor absorptive simply represent a recurrent state. The 
depletion of subpopulation 10 upon environmental change to hypoxia may result from its 
low clonogenic potential in hypoxia at passage 1 (Fig. 35.b) combined with its transient 
state predicted by Markov model (self-renewal 83.68%). Furthermore, subpopulations with 
low/absent CD133 expression were predicted to be formed by fewer phenotypes (<6) than 
CD133+ subpopulations. Hence, the enrichment of subpopulations 3, 5 and 7 in hypoxia 
could be explained by a possible generation from numerous phenotypic states (>9). As 
subpopulation 10 represented a transient state, we further investigated the organizational 
hierarchy in the hypoxic network. Indeed, the degree of hierarchy calculated by Krackhardt 
test was equal to 0.125. Although subpopulation 10 could represent a potential CSC-like 
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state in hypoxia, as it cannot be formed by other phenotypic states, its self-renewal capacity 
did not differ from other subpopulations. 
The results suggest that phenotypic heterogeneity in hypoxia results from adaptive 
stochastic state transitions rather than a hierarchical organization and that subpopulation 
10 is not a favorable state in hypoxia. All subpopulations appear to survive by adapting to 
the best fitted phenotypic equilibrium in hypoxia. 
 
Figure 39: State transition probabilities in hypoxia calculated by Markov modeling. a. The 
network depicts the probabilities of state transitions. The thickness of the arrows represents the 
probability of state transitions. b. The transition matrix displays percentages of the exact probabilities 
in phenotype changes for 1 day. Subpopulations demonstrate variations in the probabilities of 
changing their phenotype with subpopulation 10 representing a transient state. Figure 39 was 
realized with the help of Thomas Buder (Zentrum für Informationsdienste und Hochleistungsrechnen 
(ZIH), Technical University of Dresden). 
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4.4.4.2. Differential abilities in recapitulating final phenotypic distribution of CSC-
associated subpopulations in time 
To determine whether all subpopulations were able to reach the same phenotypic 
heterogeneity in hypoxia, we analyzed the hypoxic transition matrix and calculated its 
stationary state to obtain the final equilibrium. Even though the hypoxic transition probability 
matrix was reducible (meaning that not every state can be produced directly or indirectly by 
another state), we found a unique steady state. A matrix was reducible when at least one 
state (phenotypic state 10) could not be directly or indirectly formed. It is possible, that 
reducible transition matrices never reach a steady state or have several ones when the 
outcome is dependent on the initial state. Interestingly, the final predicted equilibrium in 
hypoxia did not exactly correspond to the equilibrium of the original NCH644 cells grown for 
60 days in hypoxia (Fig. 40.a). This may suggest that longer times were needed for final 
equilibrium. However, we used in the following experiments the phenotype distribution of 
NCH644 stem-like cultures grown for 60 days in hypoxia as CTR for comparisons as we did 
not have data for longer hypoxia cultures and phenotype distribution obtained by Markov 
model was not suitable for statistical analysis (i.e. only one data value). To determine how 
long CSC-associated subpopulations need to reach final phenotypic distribution in hypoxia, 
time to equilibrium was calculated for each subpopulation. None of the subpopulations was 
able to recapitulate final phenotypic hypoxic equilibrium after only 60 days (Fig. 40.b). 13 
out of 16 subpopulations were predicted to require over 250 days to reach the phenotypic 
equilibrium. This increased time to reach steady state compared to normoxia may result 
from the strong decrease in proliferation of GBM stem-like subpopulations in low oxygen 
concentrations. Subpopulations 2, 9 and 12 which needed less than 250 days to 
recapitulate final hypoxic phenotypic distribution, appeared most adaptive. Subpopulation 
2 was predicted to reach equilibrium after 80.5 days, confirming its close resemblance to 
the control at day 60. 
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Figure 40: Markov model predictions on final phenotypic distribution in hypoxia in time. a. 
Stationary state was calculated for the hypoxic transition matrix. Phenotypic distribution of NCH644 
after 60 days of hypoxia and predicted equilibrium are not the same. b. Markov model was used to 
estimate the number of days the transition matrix reaches steady state when starting with 100% pure 
subpopulation. Subpopulation 2, 9 and 12 appeared the most adaptive. Figure 40 was realized with 
the help of Thomas Buder (Zentrum für Informationsdienste und Hochleistungsrechnen (ZIH), 
Technical University of Dresden). 
 
4.4.4.3. Independence of marker expression of CD133, A2B5 and CD15 in hypoxia 
We next tested if the expression of the four markers CD133, CD44, A2B5 and CD15 was 
independent. Therefore, the same mathematical methodology was used as in normoxia 
(Annex. 2.c) applying the data from Fig. 46. Comparing the equilibria of each marker 
obtained under the assumption of dependence and independence revealed similar 
distributions of absent/low and high expression of CD133, A2B5 and CD15. Only CD44 
showed a slight discrepancy between the calculated marker distributions (73.2 vs. 55.79% 
CD44+ cells) (Fig. 41). This suggest that CD133, A2B5 and CD15 are inter-independent 
whereas CD44 expression may depend to some extent on the presence of the other 
markers. 
 
Figure 41: Calculation for marker independency. Equilibria for each marker were calculated either 
by the assumption of independency or independency using the data from fig. 46. As equilibria did 
not differ for CD133, A2B5 and CD15, markers appear to be independent. However, CD44 might 
depend on the combination of CD133, A2B5 and CD15 expression profiles. Data for this figure was 
realized with the help of Thomas Buder (Zentrum für Informationsdienste und Hochleistungsrechnen 
(ZIH), Technical University of Dresden). 
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4.4.5. CSC-associated phenotypic adaptation to hypoxia is reversible 
Highly adaptive capacities were observed for all subpopulations in hypoxia (Fig. 37) and 
normoxia (Fig. 19.b). Furthermore, the observed phenotypical change from normoxia to 
hypoxia could be largely explained by adaption and only partially by selection. Therefore, 
we wondered whether the phenotypical change in hypoxia could be reversed upon reculture 
in normoxia. To this aim, NCH644 stem-like cells were cultured in low oxygen environment 
(0.5% O2) for 7 days and subsequently transferred to high O2 (21%) condition for another 7 
and 14 days. 
The expression of the 4 markers generally reversed upon reculture in normoxia. The 
number of CD133+ cells decreased (from 79.27% to 74.6%), A2B5+ cells (from 70.6% to 
61.08%) and CD15+ cells (from 68.97% to 41.5%) decreased whereas CD44+ cells were 
increased after 14 days of normoxia culture (from 36.62% to 45.34%). Despite similar levels 
of CD44+ and A2B5+ cells, percentage of CD133+ and CD15+ cells in 14 days reculture in 
normoxia did not reach original levels yet (Fig. 42; see Annex 3.e for all statistical 
comparisons of phenotypical states and single marker expression between time points). 
Furthermore, the percentage of enriched subpopulations in hypoxia decreased (e.g. 
subpopulation 7 (from 15.46% to 9.84%)). On the other hand, subpopulations 2 (from 1.49% 
to 7.01%) and 12 (from 0.58% to 1.17%), which were reduced upon low oxygen levels, were 
reformed again. This data suggests that the phenotypic adaptation observed upon 
environmental change from normoxia to hypoxia is reversible. Although distinct, the 
phenotypic distribution upon 7 and 14 days re-normoxia resembled the normoxic 
equilibrium. Markov modeling predicted that the phenotypic profile seen at 7 days hypoxia 
needed 37 days to revert to the normoxic equilibrium. Thus, the differences in phenotypic 
distribution after 7 and 14 days re-normoxia are expected to disappear on time. 
Reversibility of CD133 marker expression was also shown for adherent U251MG cells in 
at 1% O2 hypoxia. Also here cells needed longer to regain initial state. Negative at the 
start of the experiment, where they increased to almost 50% positivity at day3 and going 
to nearly 0 after 6 days (Griguer et al., 2008) 
 
We next used Markov modeling to predict the phenotypical distribution after 7 and 14 days 
of renormoxia. The comparison between predicted and measured phenotype distributions 
revealed that measured data were more similar to normoxic equilibrium than the predicted. 
In this context the mathematical predictions might be imprecise as the model does not take 
into account environmental changes. This means that cells may need to adapt fast to new 
environments suggesting 39 days predicted to reach normoxic equilibrium may be not 
required. 
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Figure 42: Reversibility of phenotypic adaptation to hypoxia. NCH644 stem-like cultures were 
kept for 7 days in hypoxia (0.5% O2) and transferred back to high oxygen. CSC-associated 
heterogeneity was measured 7 and 14 days after environmental change (mean percentage; nB=3, 
nT=3). Statistical significances of phenotypic states between normoxic NCH644 control and 
experimental conditions are depicted in in table below graph (t-test with Bonferroni multiple-
significance-test correction). Error bars are not depicted for visualization purposes. 
 
Taken together these results suggest that the phenotypic shift observed during hypoxia 
results through strong adaptation and is a reversible process. Although we cannot exclude 
a partial selection against the least fitted phenotypic states, all CSC-associated states 
survived in hypoxia and recapitulate phenotypic heterogeneity. Similar to normoxia, Markov 
modeling identified subpopulation 2 to be most adaptive. 
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4.5. Analysis of differentiation capacities of the CSC-associated phenotypes 
CSCs are thought to give rise to fast proliferative progenitor cells that generate the tumor 
mass and produce finally differentiated cells based at the bottom of a one-way hierarchical 
organization. Similar to NSCs which give rise to neurons and glial cell, CSCs in GBM are 
proposed to generate differentiated cancer cell with neuronal-like and glial-like 
characteristics. According to the one-way differentiation process terminally differentiated 
cells should not reacquire stemness abilities and therefore would not contribute to tumor 
growth. To eradicate CSCs and their progenitors, differentiation therapy has been proposed 
as a treatment strategy for GBM patients (Park et al., 2017). However, this approach cannot 
be effective should the differentiation process be reversible. In previous chapters, we 
demonstrated profound cellular adaptability, rather than a stem cell hierarchy at the origin 
of CSC-associated phenotypic heterogeneity. In this part, we assessed lineage commitment 
of GBM stem-like cell and analyzed whether a differentiated state can be reversed to a 
stem-like state. Differentiation and dedifferentiation into glial- and neuronal-like lineages 
was assessed using intracellular markers and CSC-associated cell surface epitopes. To 
evaluate whether the differentiation abilities are dependent on environmental factors, 
experiments were performed under normoxic and hypoxic conditions. 
 
4.5.1. GBM cells display impaired differentiation process 
4.5.1.1. Differentiation induces morphological changes in GBM stem-like cultures 
Since GBM stem-like cultures can differentiate into neuronal-like and glial-like cells, 
dramatic morphological changes are expected such as the formation of neurite outgrowth 
as observed in normal neuronal cells. Single cells were attached to an extracellular matrix 
(ECM) layer in order to obtain a 2D culture system. Differentiation of GBM stem-like cultures 
was induced with All-Trans Retinoic acid (ATRA) and FBS added to the culture medium for 
14 days. The influence of oxygen levels on the differentiation process was assessed using 
normoxic (21% O2) and hypoxic (0.5% O2) culture systems.  
When grown as 2D cultures in CSC medium, single cells attached to the ECM layer and 
kept a round-shaped morphology. The cells subsequently formed adherent spheres. In 
contrast, cells in 2D differentiation conditions formed short protrusions which became 
continuously more prominent and reminiscent of neurite outgrowths (Fig. 43). This behavior 
was observed for NCH644 (Fig. 43.a) and to lesser extend in NCH421k (Fig. 43.b) GBM 
stem-like cultures. Morphologically, there was no difference observed between normoxic 
and hypoxic conditions, suggesting no influence of oxygen concentration on cell shape.  
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In order to investigate whether the observed morphological ‘differentiation’ was irreversible, 
cells were recultured for 2 weeks in 3D CSC medium condition (Fig. 43). Regardless of 
oxygen levels, differentiated GBM stem-like cultures (NCH644 and NCH421k) were all able 
to reform spheres in standard 3D culture system in CSC medium. This result shows that 
morphological changes are reversible and are dependent on differentiation cues (e.g. 
ATRA, EGF, bFGF). 
 
Figure 43: Morphological changes of GBM stem-like cells upon differentiation. Differentiation 
test was performed in medium depleted from EGF and bFGF and supplemented with ATRA and 
FBS. In standard condition, GBM stem-like cultures grew in 3D spheres. Since differentiation 
required exposure to ECM layer, 2D adherent cells in CSC medium were used as second control. 
Experiment was performed in normoxic (21% O2) and hypoxic (0.5% O2) condition. Morphologically, 
differentiated GBM cells displayed neurite-like extensions. Pictures (10x magnification) were taken 
upon 7 days of culture for NCH644 (a.) and NCH421k (b.) GBM stem-like cultures. 
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4.5.1.2. Differentiation is aberrant in GBM stem-like cultures 
To assess the differentiation process at the molecular level, we measured several stemness 
and differentiation markers by flow cytometry. In normal neural stem cells, the stemness 
markers vimentin and nestin are downregulated upon differentiation. β-III tubulin is 
exclusively found in neurons, whereas glial fibrillary acidic protein (GFAP) expression is a 
marker for astrocytes. As retinoic acid is favoring the differentiation of GBM stem-like cells 
towards the neuronal lineage, we expected β-III tubulin to be strongly upregulated and 
GFAP showing only a slight increase in expression. Moreover, we expected the 
upregulation of differentiation markers to be impaired under hypoxia, as this environment 
was reported to enrich for the CSC phenotype (Lathia et al., 2011a). 
In normoxic NCH644 differentiated cultures, stemness marker expression (vimentin and 
nestin) was not lost, but the neuronal marker β-III tubulin was increased (from 38.5% to 
78.3% β-III tubulin+ cells) (Fig. 44.a). Similarly, GFAP levels were higher in differentiated 
cultures compared to non-ATRA treated cells (from 1.5% to 30% GFAP+ cells). Upregulation 
of differentiation markers by ATRA treatment was confirmed by Campos et al. (Campos et 
al., 2010). Of note, the change from 3D to 2D culture system did not affect marker 
expression. Results show coexpression of stemness and differentiation markers in cancer 
cells upon ATRA treatment indicating that differentiated NCH644 GBM stem-like cells 
increase lineage specific marker expression, but keep their stemness-associated 
phenotype at the same time. Comparable results were observed for NCH421k GBM stem-
like cultures (Fig. 44.b). Stemness markers did not change expression levels upon 
differentiation cues, but GFAP was upregulated (from 11,6% to 50,2% GFAP+ cells). 
Noteworthy, β-III tubulin expression is already high in the normoxic NCH421k 3D sphere 
cultures, underlining an aberrant differentiation process. Observations suggest that the 
differentiation process in GBM cells is either not fully completed after 14 days of treatment 
or the differentiation process is aberrant with no clear differentiation states.  
The change to hypoxia did not show a distinct stemness marker expression in NCH644 
culture from normoxia (Fig. 44.a). Unexpectedly, hypoxia provoked an increase in β-III 
tubulin (from 38.5% to 72.9% β-III tubulin+ cells) and GFAP expression (from 1.5% to 16.7% 
GFAP+ cells), despite the lack of morphological change. This upregulation of differentiation 
markers was even increased by the addition of differentiation cues to levels similar (± 30% 
GFAP+ cells) or higher (18.3% in normoxia vs. 92.6% β-III tubulin+ cells in hypoxia) to 
normoxic differentiation culture. Similarly, NCH421k cultures demonstrated higher levels of 
GFAP+ cells in differentiation condition in hypoxia than in normoxia (50.2% in normoxia vs. 
84% in hypoxia), although hypoxia alone did not lead to an increased expression of the 
differentiation marker (Fig. 44.b). These results show that hypoxia does not impair the 
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expression of differentiation markers suggesting that hypoxia alone does not promote a 
stem cell state.  
 
In a next step, the reversibility of the upregulation of differentiation markers was analyzed 
by reculturing cells in normoxic 3D sphere culture system ( ) for 14 days. Vimentin and 
Nestin expression for both NCH644 and NCH421k cultures was not affected (Fig. 44). In 
NCH644 cultures, β-III tubulin expression was fully reversed to initial 3D expression levels 
from all tested conditions. Furthermore, marker expression of GFAP was downregulated to 
the original level found in the 3D sphere cultures from NCH644 and NCH421k cells. These 
results suggest that the differentiation program is reversible. 
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Figure 44: Differentiation and dedifferentiation of GBM stem-like cultures. Flow cytometric 
histograms show the expression of two stemness (Vimentin and Nestin), one neuronal (β-III tubulin) 
and one astrocytic (GFAP) marker upon 2 weeks of differentiation in culture medium depleted from 
growth factors and enriched with ATRA and FBS in (a.) NCH644 (mean ± SEM; nB=3, nT=3) and (b.) 
NCH421k GBM stem-like cells (mean ± SEM; nB=1, nT=3). Negative control for antibody staining is 
shown for each marker (Isotype CTR). Black lines discriminate between negative and positive cells. 
Dotted line indicates mode expression in control cells. Differentiated cultures were then 
dedifferentiated using standard normoxic 3D sphere condition for two weeks and reanalyzed. Marker 
136 
 
phenotypes were expressed at similar levels as original expression profiles of 3D sphere GBM stem-
like cultures. Statistical analysis between 3D normoxic condition and 2D conditions was performed 
using t-test (mean percentage ± SEM; t-test: * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 
0.001). 
 
4.5.2. CSC-associated marker expression changed in differentiation condition 
4.5.2.1. CD133 expression was decreased and CD44 expression was enriched upon 
differentiation treatment in normoxia 
As the differentiation environment did not induce a major change on intracellular stemness 
and markers were not affected by differentiation cues, we tested if the CSC-associated 
phenotype was influenced by this environmental change. Therefore, we measured the 
distribution of the 16 subpopulations based on CD133, CD44, A2B5 and CD15 expression 
upon forced differentiation and subsequent dedifferentiation. Identical experimental setup 
was used as described above (Chapter 4.5.1). 
The change from 3D to the 2D culture system led to minor changes in marker distribution 
in normoxic cells. Phenotype changes were small, but statistically significant. NCH644 
stem-like cultures displayed an enrichment in subpopulations 3 (CD133+ CD44- A2B5- 
CD15-) and 7 (CD133+ CD44+ A2B5- CD15-). Many subpopulations, like subpopulation 2 
(CD133+ CD44- A2B5+ CD15+), 6 (CD133+ CD44+ A2B5+ CD15+) and 10 (CD133- CD44- 
A2B5+ CD15+) were decreased (Fig. 45.a.I, see Annex 3.f for all statistical comparisons of 
phenotypical states and single marker expression between time points). In NCH421k, 
numerous subpopulations, such as subpopulation 4 (CD133+ CD44- A2B5- CD15+), 12 
(CD133- CD44- A2B5- CD15+) and 16 (CD133- CD44+ A2B5- CD15+) were increased 
whereas subpopulation 2 (CD133+ CD44- A2B5+ CD15+) was reduced (Fig. 45.b.I see 
Annex 3.g for all statistical comparisons of phenotypical states and single marker 
expression between time points). These results show that cell surface marker expression 
is more sensible to changes in culture system (i.e. sphere vs. adherent) than internal 
stemness and differentiation marker expression. 
ATRA driven differentiation in normoxia lead to a significant phenotypic shift towards 
CD133- (from 80.58% to 4.40%), A2B5- (from 10.59% to 8.11%) and CD15- (from 35.51% 
to 21.84%) subpopulations. Only CD44 marker expression was significantly enriched (from 
37.32% to 69.29%). Consequently, most enriched subpopulations were 11 (CD133- CD44- 
A2B5- CD15-), 15 (CD133- CD44+ A2B5- CD15-) and 16 (CD133- CD44+ A2B5- CD15+) (Fig. 
45.a.II). Although to a less extent, NCH421k stem-like cultures experienced a similar 
change in marker expression. A decrease in CD133 (from 97.54% to 67.27%), CD15 (from 
98.3% to 93.25%) and A2B5 (from 98.18% to 78.5%) was observed. CD44 was enriched 
(from 12.2% to 53.69%). Subpopulations 6 (CD133+ CD44+ A2B5+ CD15+) and 14 (CD133- 
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CD44+ A2B5+ CD15+) were increased upon differentiation (Fig. 45.b.II). Reduced CD133 
expression is in accordance to Campos et al. (Campos et al., 2010). 
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Figure 45: Reversibility of CSC-associated marker expression upon differentiation in 
normoxia and hypoxia in NCH644 and NCH421k GBM cultures. Barplots show the distribution of 
16 CSC-associated subpopulations based on CD133, CD44, A2B5 and CD15 expression. NCH644 
(a) and NCH421k (b) stem-like cells were cultured for 14 days in 2D normoxia non-ATRA treatment 
(2D_N) (I), in 2D normoxia ATRA treatment (Diff_N) (II), in 2D hypoxia non-ATRA treatment (2C_H 
)(III) or in 2D hypoxia ATRA treatment (Diff_H) (IV) conditions. CTR represent GBM stem like cells 
in 3D standard cultures (NCH644: mean percentage; nB=3-4, nT=2-3) (NCH421k: mean percentage; 
nB=1, nT=3). Subsequently, cells of all conditions were dedifferentiated in 3D sphere culture system 
in normoxia for 14 days (depicted by grey flash and condition names were prefixed with ‘De-’). For 
NCH644 stem-like cultures Markov model predictions were performed to obtain phenotypic 
distribution after 14 days of culture and time to equilibrium was calculated. Error bars are not depicted 
for visualization purposes. Statistical significances of phenotypic states between normoxic NCH644 
3D control and other conditions are depicted in in table below graph (t-test with Bonferroni multiple-
significance-test correction). 
 
4.5.2.2. CD44 expression was enriched upon differentiation treatment in hypoxia 
Since we showed previously that hypoxia leads to an increase in CD133 expression, we 
further evaluated the combined effect of hypoxic condition with ATRA treatment to see 
whether the loss of CD133 observed in normoxic differentiation condition was impaired.  
We first tested whether the change from 3D to 2D culture systems impacted CSC-
associated marker expression. Similar to 3D NCH644 stem-like cultures in hypoxia, cells in 
2D culture at low oxygen levels significantly reduced CD15 (from 35.5% to 29.94%) and 
expression and increased CD133 (from 80.58% to 84.02%) and CD44 (from 37.32% to 
61.51%) expression (Fig. 45.a.III). However, contrary to 3D hypoxia, the number of A2B5+ 
(from 40.59% to 26.59%) cells was reduced in 2D hypoxia. In NCH421k stem-like cultures 
A2B5 (from 98.18% to 69.3%) and CD15 (from 98.3% to 89.84%) expression changed 
significantly from 3D culture in normoxia to 2D culture in hypoxia (Fig. 45.b.III). As for 
NCH644 stem-like cultures, NCH421k stem-like culture CSC-profile could only partially be 
explained by hypoxic environment change alone. This suggests that the switch from 3D to 
2D system culture led to additional accumulative change in phenotypic equilibrium. 
Upon 2D culture in hypoxia combined to ATRA treatment, both GBM stem-like cultures 
showed similar reduction of subpopulations (NCH644: subpopulations 2, 6, 10; NCH421k: 
subpopulation 2). Interestingly, this reduction was consistent between normoxia and 
hypoxia ATRA treatment cells. Generally, combined ATRA treatment with hypoxic culture 
conditions, lead to a depletion in CD133+ CD44- subpopulations (from 41.5% to 2.53%) and 
increase of CD133- and CD44+ subpopulations (from 8.56% to 41.41%) (Fig. 45.a.IV). 
CD133 and CD44 marker changes were observed in NCH421k stem-like cultures as well 
(Fig. 45.b.IV). Even though changes in marker distribution appear less affected in hypoxia 
than in normoxia upon differentiation, we found in both cases a decrease in CD133 and 
A2B5 expression and an increase in CD44 levels for the two tested GBM stem-like cultures. 
Of note, CD133 loss observed in normoxic differentiation is compensated in hypoxia, in 
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agreement with previous data showing that CD133 expression is upregulated in low oxygen 
environment (Fig. 34). 
 
4.5.3. Differentiation induced cell surface marker change is reversible 
In the next step, cells of the four 2D culture conditions (e.g. normoxia, hypoxia, ATRA 
treated and non-ATRA treated conditions) were transferred to non-coated flasks containing 
normal CSC medium to generate 3D spheres in normoxia. With that we aimed to reverse 
CSC-associated phenotype changes. Within 14 days all cultures had partially returned 
towards their original profile in both NCH644 and NCH421k cultures (Fig. 45.a and b), 
however, the initial phenotypic distribution was not reached yet. Indeed, Markov modeling 
predicted that NCH644 non-differentiated cells in normoxia and hypoxia in 2D cultures only 
needed 30 and 42 days, respectively, to reach equilibrium of the initial 3D condition. 
Reversibility from differentiated conditions was predicted to take longer, with 75 and 84 days 
in normoxia and hypoxia, respectively to reach final equilibrium confirming that phenotypical 
change upon ATRA treatment was more dramatic than in non-ATRA treated conditions. 
Furthermore, differentiated and non-differentiated 2D cultures in hypoxia, needed longer 
time to reach initial phenotypic heterogeneity than in normoxia which might be explained by 
a slower proliferation status in hypoxia compared to normoxia.  
Although phenotypic change was shown to be partial reversible, mathematical predictions 
appeared closer to the final equilibrium than the measured phenotypic distribution. Similar 
to reversibility of sphere cultures in hypoxia (Fig. 42), the small discrepancies might be 
explained by the complex environmental change from 2D to 3D culture systems combined 
with ATRA treatment and different oxygen levels. Where the adaptation process might need 
longer time. Even though we could only show partial reversibility upon differentiation, 
Markov model predictions support that CSC-associated heterogeneity will eventually reach 
final equilibrium as we found in normoxia and hypoxia. 
 
To conclude, GBM stem-like cultures underwent a morphological differentiation process, 
intracellular marker expression revealed an aberrant differentiation process as stemness 
proteins and lineage specific markers were simultaneously expressed. CSC-associated 
phenotype expression was strongly altered upon differentiation, which was mainly reflected 
by CD133 and A2B5 decrease and enrichment of CD44. Phenotypical changes in hypoxia 
were less dramatic than in differentiation condition. Combined effects of different 
environments were observed (e.g. extracellular matrix (2D) culture combined with 
differentiation factors and/or oxygen levels). Importantly, the differentiation phenotype was 
reversible for all ATRA treated conditions. These results strongly suggest that GBM cells 
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do not underlie a one way-differentiation hierarchy but represent a highly plastic GBM 
phenotype. 
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4.6.  Analysis of the CSC-associated phenotypes in vivo 
Our previous in vitro results have shown that GBM stem-like cultures generate CSC-
associated phenotypic heterogeneity by adaption of existing cells to the most fitted 
phenotype rather than by hierarchical differentiation. This was true for normoxic (Chapter 
4.2), hypoxic (Chapter 4.4) and differentiation-inducing (Chapter 4.5) environments. Each 
environment led to a specific phenotypic profile of subpopulations. As cell culture systems 
are not able to fully recapitulate the cancer microenvironment, orthotopic xenografts are 
best used to simulate complete tumoral environments including hypoxic, perivascular and 
invasive niches allowing for differentiated and non-differentiated cell states, in reciprocal 
contact with stromal cells. Following the CSC hypothesis, one major characteristic of CSCs, 
besides self-renewal and indefinite proliferation, is the capacity to generate a tumor and the 
recapitulation of its original heterogeneity in vivo. Thus, we next analyzed the tumor 
formation potential and the CSC-associated expression patterns of GBM stem-like cultures 
in vivo. We further asked whether individual CSC-associated subpopulations are 
tumorigenic and can give rise to phenotypic heterogeneity in vivo. Finally, we addressed 
whether the redistribution of CSC-associated markers in vivo is reversible. 
 
4.6.1. CSC-associated marker expression was strongly altered in all GBM 
stem-like cultures derived xenografts 
In the last chapters, we analyzed CSC-associated marker expression in vitro. Here we 
performed multicolor phenotyping of tumors derived from several GBM stem-like cultures, 
which had been orthotopically transplanted into the brain of mice. In this experimental setup, 
the use of eGFP-expressing Nod/Scid mice was not feasible as the GFP signal would 
interact with the CSC-associated marker panel for multicolor flow cytometry. Instead, we 
made advantage of the high CD90 expression observed in GBM PDXs (Fig. 11.b). CD90 
antibody is specific for human cells and thereby enables discrimination between tumor 
(CD90 positive) and stromal cells (CD90 negative) (Annex 2). Implanted NCH644, 
NCH421k, NCH660h and NCH601 stem-like cultures were able to give rise to tumors in the 
brain of Nod/Scid mice. Furthermore, they strongly adapted their CSC-associated 
phenotype to the brain environment (Fig. 46). In general, CD133-CD44- phenotype 
(subpopulations 9-12) were strongly enriched, whereas CD133+CD44+ (subpopulations 5-
8) and CD133-CD44+ (subpopulations 13-16) cells were reduced. Interestingly, no 
correlation in the grade of heterogeneity between cell types was observed between in vitro 
and in vivo phenotype. For instance, NCH421k stem-like cultures expressed CSC-
associated markers rather homogeneously in normoxia but strongly increased 
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heterogeneity upon xenotransplantation. In contrast, NCH601 stem-like cultures displayed 
reduced heterogeneity following orthotopic transplantation into mice, with a strong 
enrichment of subpopulations 9 (CD133- CD44- A2B5+ CD44-) and 10 (CD133- CD44- A2B5+ 
CD44+). The expression of cell surface markers in vivo reflected none of the previously 
analyzed environments in vitro, suggesting a key role of additional environmental factors 
present in the brain that affect the phenotype equilibrium in vivo. 
 
Figure 46: CSC-associated heterogeneity in GBM stem-like derived xenografts. Pie charts 
show the distribution of the 16 subpopulations based on CD133, CD44, A2B5 and CD15 marker 
expression in tumors from 4 different GBM stem-like cultures derived xenografts. Nod/Scid mice 
were sacrificed when symptoms became visible: around day 30 for NCH644, day 60 for NCH421k, 
day 130 for NCH601 and day 230 for NCH660h xenograft (average percentage; nB=2-3).  
 
4.6.2. CSC-associated subpopulations were able to generate a phenotypic 
heterogeneous tumor in vivo 
CSCs are reported to reproduce a tumor in vivo with as little as 100 transplanted cells 
demonstrating a high tumorigenicity (Clarke et al., 2006). However, the number of cells 
needed for reconstitution of tumors upon xenografting differs between cell cultures 
(Quintana et al., 2008). To assess the minimal number of cells needed for tumor 
development in a life time of a nude mouse is tested by an in vivo limited dilution assay, 
where a range of cell dilutions between 50 and 50´000 cells per mouse are engrafted to a 
mouse. We tested a series of dilutions (100, 300, 500, 1000 and 5000 single cells) of 
NCH644 stem-like cultures. Viable single cells were FACS-sorted and instantly implanted 
to nude mice. We found that at least 5000 NCH644 FACS-sorted cells were needed to 
generate a tumor in vivo in a reasonable time frame (i.e. 6 weeks) (Fig. 47.b). Using 5000 
cells per brain, tumor evolution could be followed by magnetic resonance imaging (MRI) as 
early as 3 weeks after implantation. Until the endpoint of the mice at 6 weeks, the tumor 
grew constantly (Fig. 47.a). The use of only 5000 cells (Fig. 47.a) retarded tumor 
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development by approximately 2 weeks compared to the standard protocol for xenografting 
with 50 000 cells per brain (Fig. 47). This time delay likely represents the time needed to 
increase the tumor population by 10-fold.  
We next determined whether CSC-associated subpopulations carry equal tumorigenic 
potential and whether they can reconstitute heterogeneity. The tumorigenic potential of 
different phenotypic states was tested by implanting 5000 cells of each individual 
subpopulation directly after FACS-sorting. We expected that all subpopulations were able 
to generate tumors as all demonstrated strong adaptive capacities in previous experiments 
(e.g. normoxic, hypoxic and differentiation environment). We focused on four out of the 
sixteen phenotypic states: subpopulations 2, 6, 11 and 15. Subpopulations 6 (CD133+ 
CD44+ A2B5+ CD44+) and 15 (CD133- CD44+ A2B5- CD44-) were chosen as they were 
strongly depleted in NCH644 derived xenograft tumors in vivo (Fig. 47). Subpopulation 11 
(CD133- CD44- A2B5- CD44-) was strongly enriched in vivo and subpopulation 2 (CD133+ 
CD44- A2B5+ CD44+) represented the most ‘adaptive’ state in normoxia and hypoxia which 
was partially depleted in vivo.  
All four subpopulations were able to form tumors upon xenotransplantation of 5000 cells 
per brain (Fig. 47.c) and all mice per condition developed a tumor indicating a very high 
tumorigenic potential. Only for subpopulation 15 4 of 6 mice did show tumor development. 
This shows as well that all four subpopulations survive in vivo and none was eliminated by 
a selection process. Differences in tumor size evolution between subpopulations were 
observed by MRI imaging (Fig. 47.d). Only mice bearing subpopulation 2 developed tumors 
as fast as the parental NCH644 cultures, whereas subpopulations 6, 11 and 15 grew 
significantly slower. These results were reflected in the survival of the mice, however, 
eventually all mice succumbed to their tumor (Fig. 47.e). Mice bearing tumors from 
subpopulations 6 (77.86 days ± 10.4 SEM), 11 (58.29 days ± 2.7 SEM) and 15 (67.75 days 
± 9 SEM) survived longer without symptoms than mice bearing the NCH644 control 
population (47.14 days ± 1.7 SEM) and subpopulation 2 (44.29 days ± 2.6 SEM). As 
subpopulation 2 demonstrated the fastest tumor growth, this data suggested again that this 
subpopulation is the most adaptive. Multicolor flow cytometric phenotyping of end-stage 
tumors revealed that all four subpopulations were able to give rise to phenotypic 
heterogenic tumors in vivo. The resulting CSC-associated heterogeneity resembled 
strongly the phenotype obtained in original NCH644 stem-like derived tumors in vivo (Fig. 
47.f). Statistical analysis revealed almost no differences in phenotypic distribution between 
in vivo tumors (Fig. 47.g. see Annex 3.h for all statistical comparisons of phenotypical 
states and single marker expression between engrafted tumors). Similarly to experiments 
performed in normoxia and hypoxia in vitro, these results suggest that CSC-associated 
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subpopulations adapt in vivo to the same final phenotypic equilibrium as the distribution 
observed in control NCH644 xenografts. Differences in time of tumor development may be 
due to different probabilities of state transitions.  
 
Figure 47: Tumorigenic potential of CSC-associated subpopulations. a. T2 weighted MRI scans 
show the evolution of a tumor originating from 5000 FACS-sorted NCH644 stem-like cells (tumor 
area circled in red). b. Limiting dilution assay in vivo was performed for 100, 300, 500, 1000 and 
5000 NCH644 stem-like cells implanted per nude mouse. A minimal number of 5000 cells was 
needed to develop a tumor in 42 days (nB=3). c. All implanted NCH644 subpopulations (2, 6, 11 and 
NCH644 control) generated a tumor in vivo. In subpopulation 15 only 4 out of 6 mice developed a 
tumor whereas the other subpopulations demonstrated 100% tumorigenicity (nB=6-7). d. Nude mice 
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were scanned by MRI at day 29, 34 and 37 and tumor volumes were measured. Differences in tumor 
size between control NCH644 and subpopulations was calculated using t-test (average mean ± SEM; 
nB=4-7; * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001). Tumor volumes of mice bearing 
NCH644 control population and subpopulation 2 were significantly larger at the 3 measured time 
points compared to subpopulations 6, 11 and 15. e. Kaplan-Meier plot shows survival of mice bearing 
tumors from the different subpopulations. Subpopulations 6, 11 and 15 demonstrated significant 
longer survival compared to NCH644 control and P2 mice (Gehan-Breslow-Wilcoxon Test: * = p-
value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001). f. Multicolor flow analysis of developed 
tumors at the time of sacrifice. Barplots revealed that each subpopulation was able to generate 
multiple phenotypes with a similar distribution as found in the NCH644 control tumors (mean 
percentage; nB=3-4). Error bars are not depicted for visualization purposes. g. Table summarized 
statistical analysis between phenotypic distribution in xenografts between NCH644 control and other 
implanted subpopulations (t-test with Bonferroni multiple-significance-test correction; * = p-value < 
0.05). 
 
4.6.3. Internal and cell surface CSC-associated marker adaptation in vivo is 
reversible 
Similar to normoxic, hypoxic and differentiation conditions CSC-associated marker 
expression was highly adaptive and generated an environment-specific phenotype in the 
complex environment of the brain. As adaptive capacities were shown to be reversible in in 
vitro conditions (e.g. hypoxia and differentiation), we next tested whether this was also the 
case in vivo. Therefore, 50´000 single cells of NCH644 and NCH421k stem-like cultures 
were implanted into nude mice and sacrificed upon appearance of symptoms (at around 4 
and 8 weeks, respectively). Internal and cell surface CSC-marker expression in dissociated 
mouse brain was analyzed by flow cytometry, where stromal and tumor cells were 
discriminated by human CD90 expression (Annex 4). Subsequently, dissociated cells from 
NCH644 and NCH421k-derived xenografts were recultured for 4 and 8 weeks, respectively, 
in standard 3D normoxic condition in vitro and rephenotyped. 
The cytoplasmic stemness markers vimentin and nestin were strongly decreased in 
NCH644-derived xenografts compared to in vitro cultures (Fig. 48.a). However, contrary to 
differentiation conditions the neuronal differentiation markers were not upregulated; β-III-
tubulin expression was lost, whereas GFAP expression was barely detectable from the 
start. This was in contrast to the differentiation in vitro which drastically increased the 
expression of the differentiation marker β-III-tubulin and to lesser extend GFAP. Reculture 
of tumor cells in vitro for four weeks reversed their marker expression to the original in vitro 
state of NCH644 stem-like cultures. Similarly to NCH644-derived xenografts, NCH421k-
derived xenografts did demonstrate a decrease in the expression of vimentin and nestin 
stemness markers from in vitro to in vivo/ environmental changes (Fig. 48.c). Similar to 
NCH644-derived xenografts, differentiation marker expression of β-III-tubulin was reduced 
in NCH421k generated tumors. Reculture in vitro reversed marker expression changes. 
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Based on intracellular marker expression, tumor cells in vivo did not resemble neither a 
stem-like nor a differentiated phenotype. 
Interestingly, a CSC-associated phenotype distribution was recreated after 4 and 8 weeks 
of NCH644 and NCH421k-derived xenograft tumor reculture in vitro resembling the initial 
normoxic equilibrium (Fig. 48.b and 48.d). The original phenotypic equilibrium in normoxia 
was not yet reached. This is in line with the Markov model that predicted 67 days for 
phenotype reversal in NCH644 cells. These data strongly suggest that similar to hypoxic 
and differentiation conditions, the in vivo phenotype profile eventually may reach normoxic 
equilibrium upon reculture in standard in vitro conditions. Phenotypic reversibility found in 
internal and cell-surface markers are a strong indicator that GBM cells are able to adapt to 
the environment and that phenotypic changes are not a result of a selection process. 
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Figure 48: Reversibility of phenotypic heterogeneity in vivo. To test reversibility of intracellular 
and cell surface markers in vivo, NCH644 and NCH421k stem-like cells (CTR) were implanted into 
nude mice (CTR_X). Upon disease symptoms mice were sacrificed and tumor cells were isolated 
and recultured for 4 weeks (NCH644) or 8 weeks (NCH421k) in standard normoxic condition in vitro 
(De_X) a. (NCH644) and c. (NCH421k) Flow cytometric histograms show the expression of two 
stemness (Vimentin, Nestin), one neuronal (B-III-tub) and one astrocytic (GFAP) marker in CTR, 
CTR_X and De_X conditions (mean ± SEM; nB=2, nT=1-3 for NCH644 and nB=1, nT=3 for NCH421k). 
b. (NCH644) and d. (NCH421k) Barplots depict phenotypic heterogeneity of CTR, CTR_X and re-in 
vitro conditions (mean ± SEM; nB=2, nT=1-3 for NCH644 and nB=1, nT=3 for NCH421k). Error bars 
are not depicted for visualization purposes. Table summarizes statistical analysis between 
phenotypic distribution between CTR and CTR_X and De_X (t-test with Bonferroni multiple-
significance-test correction; * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001). 
 
To summarize, all tested GBM stem-like cultures and NCH644 CSC-associated 
subpopulations were able to generate phenotypically heterogeneous tumors in vivo. The 
ability of CSC-associated subpopulations to reacquire other phenotypic states in vivo 
suggests strong adaptive capacities of GBM cells. In analogy to normoxic and hypoxic 
states, results confirm that subpopulations varied in their potential to adapt to the 
environment (e.g. subpopulation 2) as measured by the time to reach steady state 
equilibrium. Nevertheless, since the change in phenotypic heterogeneity upon 
xenotransplantation is reversible, similar to other conditions (e.g. hypoxia, differentiation) 
which argues against a selection process in vivo. Furthermore, tumor cells in vivo lose their 
stemness markers vimentin and nestin which is not accompanied by gain of differentiation 
markers β-III-tubulin or GFAP. 
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4.7.  Characterization of CSC-associated phenotypes at single cell 
transcriptional level 
We assessed phenotypical heterogeneity in several GBM models (including GBM patient 
TCGA data, patient-derived xenografts and stem-like cultures), and revealed that CSC-
associated heterogeneity was created by stochastic state transitions where certain 
subpopulations (i.e. subpopulation 2) demonstrated faster adaptation than others. We took 
advantage of the novel single cell RNA sequencing technology combined with flow 
cytometry and microfluidics (Drop-seq) (Macosko et al., 2015) which allowed assessment 
of gene expression at the single cell level. Three GBM patient-derived xenografts and two 
GBM stem-like cultures were analyzed for transcriptomic inter- and intra-tumoral 
heterogeneity at the CSC level. CSC-associated subpopulations 2 and 6 of NCH644 stem-
like cultures were analyzed to correlate intratumoral heterogeneity at the phenotypic and 
transcriptomic level. This work was performed in collaboration with Dr. Suresh Poovathingal 
and Dr. Alexander Skupin from Luxembourg Centre for Systems Biomedicine (LCSB) at the 
University of Luxembourg (Luxembourg). Further data analysis was performed by Dr. Petr 
Nazarov and Arnaud Muller from the Proteome and Genome Research Unit at the LIH 
(Luxembourg). 
 
4.7.1. Single cell transcriptomics clusters GBM cells by tumor of origin 
Drop-seq protocol was performed on FACS-isolated single, viable tumor cells of three 
patient-derived xenografts (P3, P8 and P13) (as described in Annex 2) and two GBM stem-
like cultures (NCH644 and NCH421k) to detect transcriptional variety at single cells level. 
By Drop-seq analysis approximately 6000 transcripts corresponding to 2430 gene on 
average was detected per cell. The expression profile analysis revealed GBM sample-
specific clusters upon non-linear dimensionality reduction (t-distributed stochastic neighbor 
embedding tSNE) followed by density clustering (Fig. 49). By tSNE algorithm high 
dimensional data are reduced to 2D or 3D data points. Visualization on a scatterplot locates 
similar data points nearby whereas distinct points are mapped distantly.  
As expected single cells grouped by tumor of origin (Demeure et al., 2016). At this level, 
only limited number of subclusters within different tumor samples were observed within the 
NCH644 and P3 samples. Due to variable number of cells depicted, visualization displays 
a higher heterogeneity within patient-derived samples. However, cell-to-cell variation in 
each GBM sample showed a similar coefficient of variation meaning that intratumoral gene 
expression diversity is similar in all analyzed tumor samples. Furthermore, the closer the 
coefficient of variation is to 1, the higher is cell-to-cell transcriptional diversity suggesting a 
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high variability within each GBM sample. Variation in the number of cells between tumor 
samples (P3 lowest to NCH644 highest) resulted from technical variations and stringent 
pre-processing analysis steps which included filtering of cells with at least 1500 expressed 
genes or genes expressed in at least 20 cells.  
 
 
Figure 49: Single cell sequencing on P13, P3 and P8 GBM PDXs and NCH644 and NCH421 
GBM cell cultures. tSNE plot showing the overall gene expression relationship between single cells 
of FACS-sorted tumor cells of 3 GBM patient-derived xenografts (P3, P8 and P13) and 2 stem-like 
cultures (NCH644 and NCH421k) with more than 1500 genes detected by Drop-seq. Different tumor 
origins are color coded. Single cells cluster by tumor of origin. 
 
4.7.1.1. GBM tumor cells with distinct phenotypic states carry similar transcriptome 
We next analyzed cell-to-cell variation at the single gene level in GBM cells of different 
tumor origins. Therefore, the expression of CSC-associated extracellular marker genes 
(PROM1, CD44, ST8SIA1, FUT4, THY1 and ITGB1), intracellular stemness genes (NES, 
VIM) and differentiation genes (GFAP, TUBB3 and MAP2) were displayed on tSNE plots to 
visualize the expression levels. EGFR was used as a control, since it is known to be 
differentially expressed between P8 (high expression), P3 (low expression) and 
P13/NCH644/NCH421k (negative) (Demeure et al., 2016). 
Generally, gene expression of analyzed markers was highly heterogeneous within different 
GBM tumor cell clusters, however, no subclusters could be identified based on the 
expression of a single gene (Fig. 50). This was in accordance with the FACS-assessed cell 
membrane epitopes, which showed expression gradients, rather than distinct cellular 
subpopulations.  
RNA expression of several genes was not detected, although prior flow cytometric analysis 
measured high protein abundance (Fig. 50.a). In NCH644 cells, CD15 epitope is highly 
expressed in 40% of the cells, however FUT4 (CD15) transcripts were not detected. Similar 
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β-III-tubulin protein is uniformly expressed in NCH421k cells, but not one cell with TUBB3 
transcripts was identified. Furthermore, transcripts of THY1 (CD90) and ITGB1 (CD29) 
genes that were uniformly positive at the protein level in all GBM PDXs, were 
heterogeneously transcribed at the single cell level. Generally, transcripts coding for cell 
membrane epitopes were detected at very low levels indicating that the marker profile by 
flow cytometry cannot be correlated with gene expression data of the markers. The Drop-
seq method is known to capture mainly abundant transcripts which might explain a low 
detection of cell surface marker transcripts. These observations indicate that gene 
expression of cell surface markers as detected at the single cell level does not always 
directly correlate with expression of cell membrane epitopes which is in accordance to 
previous reports showing differences in AC133 epitope presentation and PROM1 gene 
expression (Barrantes-Freer et al., 2015, Campos et al., 2011b). Furthermore, transcripts 
coding for cell membrane, intracellular stemness and differentiation markers were uniformly 
distributed across each tumor sample without forming specific clusters. Therefore, we were 
not able to discriminate phenotypic states based on markers’ RNA expression levels. 
For better visualization purposes of the expression levels of PROM1 (CD133), ST8SIA1 
(A2B5), CD44 and VIM, we concentrated tSNE plots only on NCH644 (Fig. 50.b) and 
NCH421k stem-like cultures (Fig. 50.c). Expression of all four genes varied between not 
detected (cells depicted in yellow) and highly expressed (cells depicted in red). Again, single 
cells expressing these genes were distributed across the entire cell population on the tSNE 
plot with no specific subclustering. These results emphasize once more the transcriptional 
heterogeneity within each tumor. 
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Figure 50: Inter- and intra-tumoral transcriptional heterogeneity. a. tSNE plots showing the 
expression of CSC-associated marker genes (PROM1, CD44, ST8SIA1, FUT4, THY1 and ITGB1), 
stemness genes (NES, VIM), differentiation genes (GFAP, TUBB3 and MAP2) and EGFR in different 
GBM tumor samples (PDXs: P13, P3 and P8; stem-like cultures: NCH644 and NCH421k). The 
expression gradient is color coded (‘yellow’ – not detected or low expression, ‘red’- highly expressed). 
b. tSNE plots showing the expression of CSC-associated marker genes (PROM1, CD44 and 
ST8SIA1) and the stemness genes VIM in NCH644 stem-like cultures. The expression gradient is 
color coded (‘yellow’ – not detected/low expression, ‘red’- highly expressed). c. tSNE plots showing 
the expression of CSC-associated marker genes (PROM1, CD44 and ST8SIA1) and stemness 
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genes VIM in NCH644 stem-like cultures. The expression gradient is color coded (‘yellow’ – not 
detected/low expression, ‘red’- highly expressed). 
 
4.7.1.2. PROM1, ST8SIA1, CD44 and VIM transcripts were present in cells of each 
cell cycle phase 
To verify if variations in gene expression was linked to different cell cycle states, single cells 
of NCH644 stem-like cultures were clustered by G1/S and G2/M specific gene sets (Fig. 
51). Cells with transcripts of genes expressed during G1 to S phase transition were plotted 
horizontally, whereas cells with gene expression correlated to G2/M cell cycle transition 
signature were distributed vertically. Cell cluster located at the bottom left of the plot were 
in G0/G1 phase. The presence of two main cell clusters showed that NCH644 stem-like 
cultures contained cycling cells and the Drop-seq method did not select for cells in a specific 
cell cycle phase. Moreover, expression of four marker genes (PROM1, ST8SIA1, CD44 and 
VIM) were found throughout the analyzed cells without forming a specific cluster which 
indicates that the transcriptional variability previously observed (Fig. 50) is not linked to cell 
proliferation state. 
 
Figure 51: Gene expression in cell cycle phases. Cell cycle state of individual NCH644 cells is 
estimated on the basis of relative expression of G1/S and G2/M gene sets. Plots displayed the 
expression of PROM1, ST8SIA1, CD44 and VIM genes in NCH644 single cells distributed by their 
cell cycle gene expression. The expression gradient of marker genes is color coded. 
 
4.7.2. Single cell sequencing of CSC-associated subpopulations revealed 
minimal transcriptomic differences 
Since we were not able to discriminate CSC-associated phenotypic subpopulations based 
on marker gene expression profiles at the single cell transcriptomic level, FACS-sorting 
combined with Drop-seq was applied to subpopulation 2 and 6 of NCH644 stem-like 
cultures. These subpopulations were chosen for single cell sequencing as subpopulation 2 
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represented the most adaptive phenotypic state in normoxia, hypoxia and in vivo, whereby 
subpopulation 6 was positive for the four-assessed stem cell-associated markers and 
showed a lower level of adaptability. 
scRNA-seq revealed only 6 differentially expressed genes between the two phenotypic 
subpopulations (FDR<0.01, |logFC|>0.5) (Fig 52.a). Compared to subpopulation 2, 
subpopulation 6 had significantly upregulated Macrophage migration inhibitory factor (MIF), 
a known ligand of the CD74/CD44-receptor complex (Shi et al., 2006), S100 calcium binding 
protein A6 (S100A6), Nestin (NES), Galectin 1 (LGALS1) and Histone cluster 1 H1 family 
member e (HIST1H1E). Gene transcripts of Parathymosin (PTMS) were more abundant in 
subpopulation 2 than in subpopulation 6. These results need however caution, even though 
analysis detected significantly differentially expressed genes, their |logFC| values remained 
low, indicating that subpopulations 2 and 6 were only minimally different at the 
transcriptional level.  
Based on the four CSC-associated markers, subpopulations 2 (CD133+ CD44- A2B5+ 
CD15+) and 6 (CD133+ CD44+ A2B5+ CD15+) are only phenotypically distinct by their CD44 
epitope expression. Although, differences in CD44 gene expression were visible on tSNE, 
the two subpopulations were not statistically distinct at the transcriptional level based on 
CD44 as CD44 transcripts were detected for both CD44- and CD44+ subpopulations (Fig. 
52.b). Other CSC-associated genes as PROM1 (CD133), ST8SIA1 (A2B5), THY1 (CD90) 
and stemness marker gene VIM appeared to have the same degree of heterogeneity in 
both analyzed subpopulations. These data indicate that transcriptomic differences between 
the two analyzed CSC-associated subpopulations are very small. The observed functional 
differences in terms of plasticity (e.g. subpopulation 2 is most fast adaptive) are likely to be 
regulated at the post-transcriptional level. 
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Figure 52: Differentially expressed genes between CSC-associated subpopulation 2 and 6. a. 
Volcano plot displays transcriptionally differentially expressed genes between single cells of 
subpopulation 6 versus subpopulation 2. Threshold for differential expression was set at FDR<0.01 
and |logFC|>0.5. Only 6 differentially expressed genes (MIF, S100A6, NES, LGALS1, HIST1H1E 
and PTMS) were detected between the two CSC-associated subpopulations b. tSNE plots showing 
the transcriptional expression of 4 genes in FACS sorted subpopulations 2 and 6. The expression 
gradient is color coded. For visualization purposes cells with no reads were displayed as transparent. 
MIF and CD44 were expressed at higher levels in FACS-sorted P6 subpopulation. PROM1 and 
ST8SIA1 transcripts were detected in similar proportion of cells in the two subpopulations.  
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In summary, as phenotypic states defined by CSC marker expression did not differ at the 
transcriptomic level the regulation of adaptive properties must occur at other molecular 
levels e.g. translational, post-translational or metabolic. Moreover, lack of distinct 
subpopulations at the transcriptomic level further supports the lack of a hierarchical 
organization in GBM. 
  
 
Discussion 
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5. Discussion 
The importance of understanding tumor organization is fundamental for successful 
therapeutic treatment. In case of a hierarchical one-way differentiation structure, treatment 
strategies should target CSCs at the apex of the hierarchy. On the other hand, if the CSC 
state is flexible and can be adopted by all cancer cells, treatment should be targeted against 
the bulk, since all cancer cells may be tumorigenic. Therefore, we aimed to elucidate in this 
thesis whether phenotypic variability in GBM is organized following a hierarchic CSC model 
or following an adaptive model. To this end, we examined CSC-associated expression 
profiles in several GBM models (e.g. patient biopsies, PDXs and GBM stem-like cultures) 
for eligible CSC markers. We found strong inter- and intra-tumoral variability in the 
interrogated models based on the expression profile of four selected cell surface markers: 
CD133, CD15, A2B5 and CD44. Subsequent characterization of tumor cell subpopulations 
distinguished by the expression of these markers was performed in GBM stem-like cultures 
as the sphere culture model is thought to be composed stem, progenitor and differentiated 
cancer cells. All examined subpopulations demonstrated CSC properties (e.g. self-renewal, 
proliferation, multipotency and tumorigenicity), indicating that phenotypic variability does 
not originate from one unique subpopulation of CSCs, but from all cancer cell 
subpopulations. An adaptive model of GBM tumor organization is also supported by 
mathematical modeling that revealed state transitions between different phenotypes. 
Markov modeling predicts that the original heterogeneous phenotype can be created from 
each CSC-associated subpopulation through direct and indirect state transitions, although 
with different timing. The variability in time may result in differences in adaptation behavior 
which could also affect tumorigenic assays in vivo. However, no apparent hierarchical 
structure could be observed suggesting a high plasticity in each CSC-associated 
subpopulation. Interestingly, cancer cells recreate an optimal phenotypic equilibrium which 
seems to be required for growth in each specific environmental condition (normoxia, 
hypoxia, differentiation and in vivo). These changes observed in each microenvironment 
were fully reversible. We also found that differences differences in CSC-associated 
subpopulations do not rely on distinct transcriptional profiles, suggesting that phenotypic 
changes are mediated by subtler molecular processes. 
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5.1. Towards a new model of GBM progression taking into account the 
plasticity of cancer cells 
It has been a debate over the last years whether phenotypic heterogeneity in GBM is 
created by CSCs or a cell state adapting to the environment. Over the last chapters, we 
have accumulated by extensive functional testing and mathematical modeling evidence that 
phenotypic heterogeneity of GBM subpopulations is created by intrinsic cell plasticity 
influenced by the tumor microenvironment. We show to which extent a cancer cell 
population is able to change its phenotype and how this adaptive capability is governed by 
different environments. 
 
5.1.1. Phenotypic adaptivity is intrinsic to cancer cells 
5.1.1.1. Each cancer cell can recreate full phenotypic heterogeneity 
A crucial property of CSCs is the ability to recreate full phenotypic variability in a cancer 
population. Our experiments show that all CSC-associated subpopulations, regardless of 
their initial marker expression profile, are able to recreate positive and negative cell 
fractions. Most interestingly, full heterogeneity of 16 phenotypic states is regained by each 
single subpopulation demonstrating that all subpopulations are multipotent, and no 
hierarchical structure is observed. Several reports using less CSC-associated markers 
show similar results where marker positive cells form marker negative cells and vice versa 
to recreate initial phenotypical heterogeneity (Wang et al., 2008, Brown et al., 2017, Chen 
et al., 2010, Brescia et al., 2013a, Kenney-Herbert et al., 2015). One of the first reports 
showing phenotype interconversion in GBM was published by Wang et al. who show that 
CD133- GBM cells are able to form CD133+ cancer cells upon transplantation into the rat 
brain (Wang et al., 2008). In vitro studies of GBM sphere cultures show that either CD133 
positive or negative cells alone or combined with CD44 marker positive or negative 
expression are all able to regain phenotypical heterogeneity (Brown et al., 2017, Brescia et 
al., 2013b). Kenney-Herbert et al. demonstrate multipotency in CD15 positive and negative 
sorted GBM sphere cultures (Kenney-Herbert et al., 2015). On the other hand, Chen et al 
report a hierarchical structure by clonally expanding CD133- and CD133+ cancer cells in 
vitro. The CD133+ population demonstrated CSC properties, whereas two distinct 
subpopulations with different behavior were detected in the CD133- population: one 
aggressive with multipotent ability and one more differentiated phenotype which was not 
able to reform CD133+ cells (Chen et al., 2010). It should be noted that upon clonal 
expansion two genetically different subpopulations may have developed from the CD133- 
population which might explain the distinct functional phenotypes. Other initial studies that 
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described CSCs in GBM did not test for multipotency in vitro (Singh et al., 2004b, Singh et 
al., 2003). 
 
5.1.1.2. Phenotype changes are stochastic and bidirectional 
We applied mathematical modeling to predict phenotypic changes over time. A common 
mathematical model in economics that predicts the evolution of present states is the Markov 
model. In our study, phenotype transitions can be calculated from phenotypic proportions 
reformed by individual subpopulations measured at different time points. The model fits well 
to our study as it was shown to predict state transitions with similar or even higher precision 
using less detailed information than other described mathematical models (Buder et al., 
2017). Furthermore, the Markov model was successfully applied previously for the 
estimation of state transitions in breast cancer subpopulations (Gupta et al., 2011, Quintana 
et al., 2010, Chaffer et al., 2013, Zapperi and La Porta, 2012). The choice of the Markov 
model is further supported by equal proliferative and self-renewal properties observed in 
our CSC-associated subpopulations which are a prerequisite for this model.  
 
Our data suggest that phenotypic heterogeneity is created via stochastic state transitions 
according to the Markov model. Each phenotypic state may be reached directly or indirectly 
via another state in a transient stochastic manner. As no hierarchy was perceived, the one-
way differentiation model could not be validated. Moreover, not a single analyzed 
phenotypic state was unipotent and irreversible (e.g. transient or absorptive state). Markov 
chains imply that each state transition is stochastic, independent from precedent states 
except from the current one. Non-hierarchical state transitions have been reported 
previously i.e. in breast and melanoma cancer (Gupta et al., 2011, Quintana et al., 2010, 
Chaffer et al., 2013, Zapperi and La Porta, 2012), where different cellular states are able to 
recreate phenotypic heterogeneity until reaching a stable equilibrium consisting of an 
admixture of phenotypic states represented at fixed proportions. Comparably, Markov 
chains on our data reach a steady state similar to the phenotype distribution observed in 
initial stem-like cultures. This equilibrium is identical for all individually cultured CSC-
associated subpopulations indicating that each subpopulation is able to recreate original 
phenotypic heterogeneity by stochastic state transitions.  
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5.1.1.3. Subpopulations show different adaptive capacities that do not result from 
distinct transcriptional profiles 
Although all CSC-associated subpopulations are plastic and change their phenotype by 
state transitions in a non-hierarchical manner, not each state transition is predicted to occur 
(65 of 240 not possible) and state transition probabilities vary across subpopulations and 
the phenotype to be produced. In addition, time to reach the final phenotypic distribution 
differs between CSC-associated subpopulations with subpopulation 2 being the fastest. 
Hence, we show for the first time that despite a lack of a hierarchical organization, certain 
phenotypes are more plastic and can potentially adapt faster to the surrounding 
environment. This is supported by our transplantation studies in mice where subpopulation 
2 is the most fitting phenotype and demonstrates the fastest tumor growth. 
However, it is not clear why some phenotypic states appear more plastic than others. Little 
is known about the functional consequences of the marker expression and how a cell 
population communicates to gain a heterogenic expression profile. Single cell RNA-
sequencing applied to several PDXs and GBM stem-like cultures revealed that each GBM 
sample retained a similar transcriptomic profile although they carry phenotypically distinct 
subpopulations. Within GBM samples, no distinct subclusters were identified which is in 
contrast to studies in breast cancer (Gupta et al., 2011, Chaffer et al., 2013). Stem, basal 
and luminal breast cancer subpopulations could be differentiated at the transcriptional level 
suggesting that these phenotypic states are functionally and/or genetically more distinct in 
breast cancer than in GBM.  
Similarly, two GBM CSC-associated subpopulations (subpopulation 2 vs. 6) with differential 
properties (i.e. subpopulation 2 being the most adaptive phenotype) show only a minimal 
number of differentially expressed genes, suggesting that distinct phenotypes arise most 
probably from translational and post-translational modifications. This is also in agreement 
with the poor correlation of gene expression and epitope presentation of many of the marker 
proteins. Subpopulation 6 shows higher MIF gene expression than subpopulation 2 which 
can be associated to CD44 protein expression that is higher in subpopulation 6 compared 
to subpopulation 2. Indeed, MIF is associated with the activation of the CD74/CD44 receptor 
complex in immune cells (Shi et al., 2006). In glioma, MIF expression is related to immune 
escape and malignancy (Mittelbronn et al., 2011) and is proposed as a therapeutic target 
due to its tumor promoting effect (Kindt et al., 2016). 
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5.1.2.  The cancer cell microenvironment shapes the tumor phenotype 
5.1.2.1. Environment-specific phenotypic distribution 
Similar to normoxia, the Markov model calculates a hypoxia-specific transition matrix and 
predicts a final hypoxia-specific phenotypic equilibrium. GBM stem-like cultures also 
changed their phenotypic distribution upon ATRA driven differentiation in vitro and 
transplantation in vivo. As normoxic and hypoxic environment have their own specific 
phenotypic equilibrium, we suggest that long-term growth of cells in differentiation 
environment in vitro and in the mouse brain in vivo eventually results in an optimal 
phenotypic distribution. The environment specific phenotypes suggest that state transitions 
are tightly regulated by the microenvironment within the boundaries of the intrinsic cancer 
cell phenotypic capacity.  
 
In hypoxia, CD133 and CD44 expression was upregulated whereas differentiation cues lead 
to a downregulation of CD133. When ATRA-driven differentiation was combined with low 
oxygen levels, CD133 reduction upon differentiation was diminished, suggesting that the 
different environmental cues have a combined effect on the final phenotypic equilibrium. 
The phenotypic heterogeneity observed in vivo cannot be considered a simple combination 
of hypoxic and differentiation factors. E.g. CD44 epitope expression was downregulated in 
contrary to all tested environments. The strong decrease of cell surface markers and the 
phenotypic variability upon transplantation assays is likely to be affected by the brain 
microenvironment. Immune cells (Bhat et al., 2013) and an acidic environment (Lathia et 
al., 2010) were shown to influence CSC-associated marker expression and may further 
contribute to the phenotypical heterogeneity observed in vivo. 
 
Although all subpopulations showed CSC properties in hypoxia, mathematical modeling 
revealed a minor hierarchical organization due to subpopulation 10 which could not be 
recreated by other subpopulations. However, this is in contrast with the functional analysis 
showing rather decreased CSC abilities (decreased clonogenicity) compared to other CSC-
associated subpopulations. These results suggest that subpopulation 10 is rather quickly 
changing its phenotype. The disappearance of subpopulation 10 in hypoxia might be linked 
to an unfavorable cell function in hypoxia.  
 
5.1.2.2. Environment specific phenotypes are reversible 
Most importantly we show that phenotypic adaptation upon environmental change was 
reversible in all tested conditions and the initial heterogeneity was recreated. Reversibility 
170 
 
of increased CD133 expression was already previously shown in other reports using 
adherent GBM cell lines and several low oxygen concentrations to mimic hypoxia, which 
suggested that CD133 is involved in a basic survival function under in hypoxia (Griguer et 
al., 2008, McCord et al., 2009). Our data show that phenotype distribution in more complex 
environments, e.g. hypoxia combined with differentiation condition or in vivo environment 
with different stromal cells, is reversible suggesting strong adaptive capacities of CSC-
associated subpopulations. Interestingly, the time needed to reverse the phenotypic 
distribution back to the initial equilibrium was markedly longer than for the primary 
phenotypic change. This delay suggests that despite their high adaptive capacities cancer 
cells may not thrive under constant environmental changes. Future experiments may 
explore whether increased cell death is observed when the culture environment is 
repeatedly changed. 
 
5.1.3. Treatment strategies should target all cancer cells and not only those 
with stemness properties 
5.1.3.1. CSC-targeted therapies 
Many current treatment strategies that are tested in clinical trials target specifically CSCs, 
using cancer vaccines targeting cell surface marker positive cells or compounds interfering 
with stemness regulatory mechanisms. The high cancer cell plasticity described here 
suggests that CSC-targeted therapies will be ineffective since full marker phenotypic 
heterogeneity may be regained once the treatment is discontinued. Although, it is not clear 
yet, how effective CSC targeted therapy in GBM is (Silver et al., 2016), we speculate that 
the outcome will largely depend on cell plasticity. To increase the success of cell surface 
targeting therapies, the ability of a cancer cell to change its phenotype needs to be inhibited.  
To this goal I propose to specifically target proteins that regulate CSC-associated marker 
expression. For instance, Perrot demonstrated that CD44 is internalized in an LRP-1 
dependent manner (Perrot et al., 2012). Inhibition of this protein leads to a permanent 
epitope exposure of CD44, thereby presenting a suitable target for CD44-specific therapy. 
However, it remains questionable to target CSC-associated cell surface markers in GBM 
patients since their functional relevance is not yet fully understood.  
 
5.1.3.2. Bulk treatment 
The CSC hypothesis presumes a better survival of cancer cells with stemness properties 
upon chemo and radiotherapy. In accordance with previous reports we find that sublethal 
doses of TMZ on GBM stem-like cells results in a reduction of CD133+ cells (Beier et al., 
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2008, Lemke et al., 2014). To validate whether TMZ specifically represses the CD133+ 
phenotype, functional assays (e.g. self-renewal, indefinite proliferation and multipotency) 
need to be performed. Moreover, sphere cultures are more resistant to TMZ than adherent 
cultures probably due to a low penetrance of the compound to the sphere cores (data not 
shown). Many reports, addressing CSC chemoresistance determine drug sensitivity in 
sphere cultures for putative CSCs compared to adherent cultures for differentiated cancer 
cells. Data are interpreted as CSCs in sphere cultures to be more resistant to treatment 
than differentiated cells although discrepancies in drug sensitivity relies on the comparison 
of two different culture systems (Ghods et al., 2007, Hsieh et al., 2011). 
Reduced chemosensitivity could be explained by a transient lower proliferation rate of some 
subpopulations, as TMZ requires cell cycle initiation to be effective. Based on 
microenvironmental stimuli, the proliferation rate may however adapt over time. It needs to 
be investigated whether phenotype transitions are cell cycle dependent. Markov modeling 
of our data does not couple phenotype transitions with cell division rates. Phenotype 
interconversions occur within one day which is faster than the cell doubling time (2.6 days 
in normoxia). On the other hand, it was shown that the number of asymmetric cell divisions 
increased with changing culture conditions (i.e. reduction of growth factors) which could 
lead to a faster adaptation of the phenotypic equilibrium (Lathia et al., 2011b). 
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5.2. Critical appraisal of methodologies to identify cancer cells with 
stemness properties  
To identify a cancer cell population with functional stemness characteristics and able to 
recreate phenotypical intratumoral heterogeneity, we applied several functional tests 
including self-renewal, proliferation, multipotency and differentiation abilities in vitro, and 
tumorigenic capacities in immunocompromised mice in vivo. Our tests reveal that each 
CSC-associated subpopulation carries functional CSC properties indicating that stemness 
is not a hallmark of a restricted CSC subpopulation. The importance of applying appropriate 
assays and carefully interpretation of the results is discussed below. 
 
5.2.1. Utility of functional tests to identify cancer cells with CSC properties 
Good tests and models are crucial to determine CSC properties. Often reports are negligent 
by testing short term clonogenicity and not indefinite self-renewal capacities (Suva et al., 
2009). Many reports solely show sphere forming capacity and tumorigenic ability in vivo, 
although on its own this does not prove multipotent ability which is necessary to 
demonstrate phenotypic variability (Singh et al., 2003). To compare properties of different 
subpopulations all subpopulations in question requires to be experimentally tested, which 
is often neglected due to the vast amount of work (e.g. many studies test CD133 positive 
but not negative populations). A clear distinction between CSC and non-CSC can only be 
made if CSC properties of all subpopulations are compared in order to identify CSC (full 
CSC properties), progenitor (no or finite CSC properties) and fully differentiated cancer cells 
(no CSC properties). Taken together, often data is not reliable when tests are incomplete 
and can be interpreted differently. 
 
A major problem in functional testing is the use of different GBM models (e.g. patient 
biopsies, sphere forming GBM cells). Functional analysis of primary patient material is 
hampered by the presence of dying cells, debris and stromal cells. Here, cancer cells cannot 
be accurately separated from stromal cells due to the lack of good markers. Often marker 
positive and negative tumor cells are separated by columns with magnetic beads loaded 
with CSC-specific antibodies. Using this technique, the cell suspension purified in the 
column is enriched with marker positive subpopulations whereas the cell suspension that 
did not bind the column contains dead cells, debris, marker positive and negative cells. In 
this scenario, it can be expected that the flow-through cell suspension is less healthy, less 
viable and hence less tumorigenic than the bound marker positive cells. Using FACS, 
marker positive and negative cell populations can be individually purified from debris and 
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dead cells, however, the “contamination” with stromal cells remains. The problematic 
becomes evident upon functional testing, when marker negative populations are not 
proliferating or/and not tumorigenic due to cell debris. Singh et al. analyzed CD133 positive 
and negative cell fractions from patient biopsies for their stemness properties and found the 
CD133- cell population to have no sphere forming capacities and no in vivo tumorigeneicity 
(Singh et al., 2004b, Singh et al., 2003). The observed discrepancy in stemness properties 
between CD133- and CD133+ cells may result from stromal cells. 
 
5.2.2. Pitfalls of in vivo tumorigenic tests  
One main criteria of a CSC is the ability to generate a tumor in vivo. In our experiments, all 
subpopulations demonstrate tumorigenic abilities, although some subpopulations are able 
to develop a tumor in vivo faster than others. This could be interpreted as such that 
subpopulation 2 represents a CSC whereas the other 3 engrafted subpopulations are 
progenitors due to slower tumor development. However, our previous results on self-
renewal, proliferation and multipotency demonstrate similar stemness abilities between the 
subpopulations, which points to differences in adaptive capacities in vivo. Thus, different 
phenotypes independent of marker expression are able to generate tumors in vivo. This is 
in contrast to the initial CSCs reports in GBM. which suggested that only marker positive 
cells were able to reform GBM tumors in vivo (Singh et al., 2004b, Son et al., 2009, 
Tchoghandjian et al., 2010), However later studies showed that either no difference was 
observed between marker positive and negative fractions (Wang et al., 2008o, Ogden et 
al., 2008, Kenney-Herbert et al., 2015), or both fractions were tumorigenic, but with different 
potency (Chen et al., 2010, Auvergne et al., 2013, Auffinger et al., 2014, Brescia et al., 
2013a).  
Differences in tumorigenicity between these studies can often be clarified by the different 
GBM model used. Other factors that may influence tumorigenicity of implanted cells is the 
use of the mouse strain and the number of cells that be explained by different adaptation 
kinetics (see below). This was impressively shown by Quintana et al. who demonstrated 
that the less mice are immunogenic the higher the frequency of tumorigenic cells in 
melanoma (Quintana et al., 2008). Also the coimplantation of extracellular matrix or 
irradiated stromal cells with together with cancer cells increases tumor forming capacity in 
vivo (Gupta et al., 2011). Kenny-Herbert coinjected CD15 positive and negative GBM cells 
with extracellular matrix, which may have boosted tumor development of less tumorigenic 
subpopulations. Wang et al. and Ogden et al. were both implanting into nude rats 
suggesting that rat brains might be a more permissive environment for tumor formation 
compared to mouse brains. 
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Our data also suggest that different adaptation kinetics in cancer subpopulations might 
result in different experimental outcomes, highlighting the importance of experimental 
endpoints. At a given endpoint subpopulations may not have reached their final tumor 
volume. Indeed, we detect major differences in tumor size at early stages of tumor 
development and differences in survival. Most tumorigenic assays do not show survival 
studies or may not wait long enough for tumor development, thereby partially missing that 
all subpopulations may eventually be lethal. Auvergne et al. sacrificed mice injected with 
either A2B5 positive and negative cells six weeks after operation (Auvergne et al., 2013). 
At this timepoint A2B5 negative cells had not developed tumors, however, using a higher 
cell number led to 100% tumor formation as well in the A2B5 negative cell fraction (5x103 
vs 2.5x104 cells per injection). This indicates that A2B5 negative cells are capable of forming 
a tumor, but with a delay (Auffinger et al., 2014). In our study, some subpopulations needed 
twice as long (i.e. 120 days) to generate a lethal tumor compared to the fastest 
subpopulation (60 days). Thus depending on the interpretation of results opposite 
conclusions can be reported from in vivo xenografting assays, which may explain at least 
some of the controversy in the CSC field. 
 
5.2.3. Identification of cancer cells with CSC properties using cell surface 
markers 
The use of cell surface markers to identify cancer cells with stemness properties is highly 
debated. On the one hand, marker positive cells are often shown to display stemness 
properties, on the other hand no unique marker for cancer cells with stemness properties 
has been identified in GBM. 
 
5.2.3.1. Cell surface markers recapitulate inter- and intra-tumoral heterogeneity in 
GBM 
Next to progenitors and fully-differentiated cancer cells, the CSC hypothesis posits that 
CSCs represent only a subpopulation of a tumor population. Therefore, a CSC-specific cell 
surface marker is expected to display a heterogeneous expression profile. In this thesis, we 
found that most cell surface markers demonstrate a relatively homogeneous expression 
profile within PDX tumors. Only a subset of the tested cell membrane markers (CD133, 
CD44, A2B5 and CD15) fulfilled the CSC criteria and demonstrated strong inter-patient and 
intra-tumoral heterogeneity at the epitope expression level in PDXs and in vitro cultures in 
agreement with previous reports (Brescia et al., 2013b, Auffinger et al., 2014). In several 
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PDXs the percentage of marker positive cells exceeded half of the total cancer cell 
population. It may be that in the first reports identifying a small CD133 positive cancer 
subpopulation as CSCs might simply be explained by inter- and intra-tumoral heterogeneity. 
Intratumoral expression of these cell surface markers was highly variable within cells of the 
same PDX and ranged from undetectable/low to highly positive. Similarly, our single cell 
transcriptional profile analysis on PDXs and stem-like cultures did not identify distinct cell 
subpopulations but rather clear gradients in different GBM samples. This is in accordance 
with the scRNA-seq observations in GBM patient samples which did not reveal distinct 
transcriptional profiles belonging to clear subpopulations, but a gradient in gene expression 
profiles (Patel et al., 2014). The existence of a gradient and the absence of at least two 
distinct subpopulations suggest that putative CSC do not represent a discrete entity. 
 
5.2.3.2. Marker expression cannot be correlated to cell function 
Unfortunately, association between functional properties and CSC-associated 
subpopulations is rather elusive and more investigation is needed to understand the cellular 
function of these markers. Under this aspect it becomes obvious that CD133 expression 
though markedly decreased upon differentiation, cannot be used as a unique marker to 
assess the degree of differentiation (Campos et al., 2010). Following the CSC hypothesis, 
varying expression patterns across patient samples can be explained by the grade of 
differentiation of the tumor. Accordingly, a marker positive tumor would be mainly composed 
of CSCs, whereas marker negative tumors are thought to contain largely differentiated 
cancer cells. This hypothesis suggests that tumors containing CSCs are more aggressive 
and rapidly growing compared to tumors containing less CSCs. However, this cannot be 
confirmed by our data; NCH644 cells (80% CD133+) show shorter mouse survival than 
NCH421k cells (99% CD133+) upon engraftment into nude mice.  
It is however not clear where the strong inter-patient heterogeneity and its distinct 
phenotypic distribution in different GBM are resulting from. Our analysis did not reveal a 
particular link between expression of CSC-associated markers and any analyzed GBM 
drivers nor genetic aberrations. Other intrinsic features as heterogeneous epigenetic 
profiles or uncommon/non-peered genetic mutations or microenvironment may cause inter-
tumoral variability. 
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5.3. Proliferative potential of cells with CSC properties: quiescent or higher 
proliferative? 
It is generally proposed that CSC resistance to therapy results from a quiescent state and 
tumor mass is created by fast proliferating progenitor cells. Although some data is available 
in colon cancer (Kreso et al., 2013) or melanoma (Roesch et al., 2010) where unfrequently 
cycling cells with tumorigenic capacities are described, however, only rare studies in GBM 
have addressed the proliferative state of putative CSCs (Deleyrolle et al., 2011). 
 
5.3.1. Functional tests 
It is reported that cancer cells with dye-retaining properties have tumor initiating capacities. 
Upon cell division, fluorescent dyes are equally distributed to the two daughter cells, thereby 
fast proliferating cells lose the staining faster than slowly proliferating cells. It has been 
shown that both slow cycling cells and bulk cancer cells in in vitro GBM stem-like cultures 
have tumorigenic capacities in immunocompromised mice but to different extent. 
Interestingly, slow cycling cells have higher tumor forming capacities than overall cancer 
cell population (Deleyrolle et al., 2011).  
We showed that self-renewal and proliferative ability for all CSC-associated subpopulations 
is equal and that all subpopulations are able to form spheres of similar size. This indicates 
that subpopulations have a similar degree of stemness/differentiation. This is also 
supported by data showing two forms of division (e.g. symmetric and asymmetric) in CD133 
positive cells with a preferential to symmetric cell division (83% vs. 3,6% of cell 
divisions)(Lathia et al., 2011b). Since the majority of cell divisions in GBM cell cultures are 
thought to be symmetric, CSC-associated subpopulations with self-renewal ability should 
show as well indefinite proliferative ability. Our data show that cancer cells with CSC 
properties are highly proliferative. 
 
5.3.2. Single cell transcriptome analysis 
Recent studies analyzing GBM at the transcriptomic level provide conflicting data on the 
association between stemness and cell cycle (Venteicher et al., 2017, Patel et al., 2014, 
Tirosh et al., 2016b). Patel et al. shows that GBM cells with a transcriptional profile similar 
to GBM sphere cultures are slow cycling whereas GBM cells with a transcriptional profile 
similar to adherent GBM cultures are cycling at a fast rate. In this study stemness and 
differentiated transcription signatures are correlated solely with the transcription profiles of 
sphere forming and adherent GBM cultures, respectively. In contrast Venteicher and 
colleagues report that in lower grade glioma, cells with stem cell properties are faster 
 177 
 
 
5 
 
proliferating than cells with a more differentiated profile. Here the stemness profile of cancer 
cells was defined differently from the Patel study as it was deduced from PCA analysis 
revealing a differentiation gradient from cancer cells with expression of stemness genes to 
astrocytic and oligodendroglial gene expression. Thus, these studies conclude that in lower 
grade glioma CSCs are fast-proliferating whereas CSCs from high grade GBM appear to 
be more quiescent. This data highlights the inconsistency in results with regard to 
proliferative potential of CSCs in glioma. It remains to be seen whether these results are 
dependent on glioma grade or on the different reference stemness gene set applied. 
 
5.3.3. Cell cycle 
I found that when proliferative activity was measured in bulk GBM cancer cells a change in 
cell cycle activity was observed between CD133+ and CD133- cells. All CSC-associated 
subpopulations contained proliferative cells but in 6 out of 8 CD133 low subpopulations cell 
cycle activity was reduced. In previous reports CD133 expression was shown to fluctuate 
across the cell cycle where cells in S, G2 and M phase displayed higher CD133 epitope 
expression (Barrantes-Freer et al., 2015, Griguer et al., 2008, Jaksch et al., 2008, Jordan, 
2009, Soeda et al., 2009). Differences in proliferative capacities in individual CSC-
associated subpopulations and bulk cultures are the culture conditions. Upon cell cycle 
analysis, cells were grown in bulk together with all other subpopulations. By cell-to-cell 
signaling, CD133 positive cells might be favored to enter cell cycle or CD133 might be 
upregulated upon cell division. It is as well suggested that the CD133 epitope is more 
apparent during cell cycle due to conformational change of the cell shape (Campos et al., 
2011b). To resolve this, flowcytometry combined with microscopy (ImageStream) could be 
performed to analyze on a large cell number cell cycle state combined with cell size/shape 
and expression of cell surface markers. Nevertheless, individually cultured CD133 negative 
cells adapt to the environment and are proliferative. In fact, our cell cycle analysis excludes 
that only CD133 positive cells in a cell population are able to proliferate. None of the other 
tested CSC-associated markers (CD44, A2B5 and CD15) was associated with increased 
or reduced cell growth or self-renewal capacities.   
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5.4. Is phenotypic adaptation upon environmental change accompanied by 
selection? 
According to CSC hypothesis specific CSC subpopulations are positively selected upon 
environmental pressure (for instance hypoxia, treatment, …) to regrow a heterogenic tumor. 
Our data shows that the cell number is reduced in hypoxia in several GBM cultures as a 
result of decreased proliferation and/or increased cell death. However, these data could not 
be linked to specific CSC-associated subpopulations. Moreover, all examined CSC-
associated subpopulations proliferate at similar rates and were able to self-renew. This 
shows that different phenotypes are not selected due to differences in the replicative 
potential.  
Moreover, phenotype changes upon hypoxia cannot be explained exclusively by partial 
selection of subpopulations, as each subpopulation was multipotent. Nevertheless, the 
clonogenic test suggested that single cells of subpopulations 10, 12 and 14 were more 
prone for clonal selection than in bulk. To investigate this, dilution of several cell densities 
could be performed for clonogenic testing. Although partial selection cannot be excluded, 
the data strongly favors that phenotypic changes occur by adaptation process and not by 
selection of subpopulations.  
 
5.5. Differentiation therapy ineffective due to aberrant differentiation 
capacities 
Many reports suggest the clinical application of differentiation therapy to inhibit tumor growth 
using ATRA or BMP4 treatment (Campos et al., 2010, Bonaguidi et al., 2005, Lee et al., 
2008, Piccirillo et al., 2006, Rahman et al., 2013). Here we found that NCH644 stem-like 
cultures upregulate the intracellular differentiation markers GFAP and β-III-tubulin upon 
ATRA-driven differentiation. At the same time, cancer cells also kept their stemness marker 
expression (e.g. vimentin and nestin). These results demonstrate that the differentiation is 
incomplete compared to normal neural stem cells where stemness markers are lost upon 
differentiation. Similar data were shown by (Wolanczyk et al., 2010, Lottaz et al., 2010), 
although many other studies claim differentiation of CSCs. However, many studies 
investigating differentiation capacity did not assess stemness markers (Campos et al., 
2010, Forte et al., 2013). A general concept in 3D GBM stem-like cultures is that not all cells 
in the sphere have CSC properties. However our results show that all subpopulations in the 
sphere demonstrate CSC properties. Moreover, no particular expression pattern is 
observed within the sphere indicating that the markers are not bound to sphere organization 
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with quiescent core and proliferative outer layer. Taken together, sphere cultures are not 
composed of cancer cells with distinct differentiation potential. 
In some instances, marker comparison was done in 3D spheres versus 2D cultures, without 
controlling for antibody penetrance to the sphere core through multiple cell layers compared 
to 2D culture (Campos et al., 2010, Forte et al., 2013). Impaired differentiation in GBM is 
often linked to defective retinoic acid signaling, which is associated to resistance towards 
differentiation therapy (Campos et al., 2015, Campos et al., 2011a). Of note, all CSC-
associated subpopulations retained their stemness marker expression upon ATRA-driven 
differentiation in our experiments. Furthermore, the marker expression upon differentiation 
was reversible, indicating that all subpopulations are able to adapt their internal marker 
expression. We propose that GBM cancer cells are able to reverse their phenotypes upon 
differentiation because they retain stemness properties. Similar to the microenvironment-
induced changes, phenotype reversibility from differentiation conditions, further indicates 
that GBM are not organized in a one-way hierarchical process. Similarly to CSC-marker 
targeted therapy, differentiation therapy is likely to be ineffective to target cancer cells with 
stemness properties since tumor cells retain their ability to dedifferentiate once therapy is 
discontinued. 
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6. Outlook 
• Phenotypic heterogeneity in GBM is created by adaptive capacities of cancer 
cells governed by the microenvironment.  
The results of our comprehensive study on CSC-associated subpopulations 
demonstrate that GBM CSCs do not represent a stable entity and that phenotypical 
intra-tumoral heterogeneity in GBM results from a high intrinsic adaptation capacity 
that is modulated by the environment. The adaptive capacities and thereby cellular 
plasticity have major advantages to survive environmental changes such as hypoxia 
or nutrient shortcoming during tumor development and upon treatment. Therefore, 
the underlying molecular mechanisms enabling phenotype transitions need to be 
elucidated as well as the cellular function of CSC-associated markers. Treatment 
approaches should tackle adaptational mechanisms and the tumor 
microenvironment. 
 
• Mathematical modeling as a prospective tool to understand tumor 
development 
To gain a deeper understanding of the interplay of the different levels of 
heterogeneity (e.g. genetic, epigenetic, functional) more performant mathematical 
models need to be developed to unravel cellular plasticity responsible for therapy 
failure. Currently available mathematical models are not able to predict the evolution 
of subpopulations taking into account all parameters involved in tumor development. 
To obtain a comprehensive model of tumor development parameters as migratory 
properties, spatial inhibition, nutritional shortage, age of cells, cell selection, death 
and quiescence. should be incorporated (Enderling et al., 2009). Eventually, 
treatment effects on cancer populations, and genetic and epigenetic backgrounds 
(Abernathy and Burke, 2016, Bozic et al., 2016) need to be unified into a convoluted 
model in order to scope phenotypic heterogeneity. Especially, the dynamic behavior 
of the cellular phenotype is difficult to grasp: indeed, state transitions are difficult to 
demonstrate experimentally since most measures are not continuous and only show 
a snap-shot of an ongoing dynamic process. Therefore, mathematical models will 
be very helpful.  
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Annex 2: Mathematical modeling using discrete Markov Chains 
a. Matrix construction 
The construction of the data matrices was performed as follows. 𝑤𝑖,𝑗
(𝑡)
 denoted the 
experimentally observed mean proportion of phenotype 𝑗, 𝑗 = 1,… ,16, in the experiment 
starting with pure subpopulations of phenotype 𝑖, 𝑖 = 1,… ,16, at time 𝑡. Subsequently, a 
phenotype proportion matrix at time 𝑡 was constructed as follows: 
W(t) = (
w1,1
(t)
⋯ w1,16
(t)
⋮ ⋱ ⋮
w16,1
(t)
⋯ w16,16
(t)
) 
Note that the phenotype proportion matrix describing the initial proportions was the 
16𝑥16 identity matrix, i.e. 
𝑊(0) =
(
 
 
1 0 ⋯ ⋯ 0
0 1 0 ⋯ 0
⋮ ⋱ ⋱ ⋱ ⋮
⋮ ⋱ ⋱ ⋱ 0
0 0 ⋯ 0 1)
 
 
. 
The transitions between the phenotypes were estimated as probabilities per time-step 
length of an underlying Markov chain which was defined here as one day. This lead to three 
phenotype matrices from the obtained data in normoxia: 𝑊(20) after 20 days, 𝑊(30) after 30 
days and 𝑊(70) after 70 days. In hypoxia, one matrix, namely 𝑊(60) for the measurements 
after 60 days was constructed. Markov chain theory allowed to connect the initial phenotype 
proportion matrix with the corresponding matrix after 𝑛 time-steps with the 
equation 𝑊(0)𝑃𝑛 = 𝑊(𝑛). This equation, derived from observations at time 𝑛, was solved for 
the underlying transition matrix 𝑃, i.e. 
?̂?(𝑛) = ((𝑊
(0))
−1
𝑊(𝑛))
1
𝑛
 . 
Hence, three transition matrices ?̂?(20),  ?̂?(30) and ?̂?(70) in normoxia were regularized using 
the QOM-algorithm (Quasi-optimization of the root matrix) in case the root of the matrix was 
not stochastic, i.e. Negative values or row sums not equal to one. The average over the 
three matrices resulted in a final estimate for the transition matrix 𝑃, i.e. ?̂? =
?̂?(20)+ ?̂?(30)+ ?̂?(70)
3
. 
In hypoxia, the transition matrix 𝑃 = ?̂?(60) was used. 
b. Krackhardt hierarchy 
In order to estimate the degree of hierarchy of the estimated transition matrixes from data 
obtained under different environmental conditions, graph hierarchy introduced by 
Krackhardt was calculated (Krackhardt, 1994). The degree of deviation from pure hierarchy, 
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i.e. tree structure, is assessed by counting the number of pairs that have reciprocated ties 
relative to the number of pairs where there is any tie, i.e. the proportion p of all tied pairs 
having reciprocated ties. Krackhardt hierarchy is then defined as 1-p. A perfect hierarchy is 
characterized by no reciprocated ties and exhibits a Krackhardt hierarchy of one. 
Calculations were performed in R using “hierarchy” function with “Krackhardt” measure. The 
analysis was realized with the help of Thomas Buder (Zentrum für Informationsdienste und 
Hochleistungsrechnen (ZIH), Technische Universität Dresden, Dresden, Germany and 
Fakultät Informatik / Mathematik, Hochschule für Technik und Wirtschaft Dresden, Dresden, 
Germany Technische Universität Dresden). 
c. Marker dependency calculation 
We investigated whether the cell state transitions between positive and low/negative 
expression of one marker in normoxia and hypoxia were dependent on the level of 
expression of the other markers. For each marker, we distinguished two phenotypic states 
with respect to positive and low/negative expression of this marker.  
In detail, the multipotency data was modeled in two separate ways (Fig. 54). To calculate 
final equilibrium for marker dependence, the data was processed as shown previously by 
using the Markov model to obtain a 16x16 state transition probability matrix of the 16 CSC-
associated subpopulations. Subsequently, state transition probabilities were summed for 
subpopulation and phenotypic states being positive or negative/low for a specific marker 
expression. For instance, to obtain 2x2 transition matrix for CD133 phenotype changes, 
transition probabilities of subpopulations 1 to 8 to form phenotypic states 1 to 8 were added 
in order to get the transition probability of a CD133+ cell to keep the CD133+ state. To 
calculate the transition probability of CD133+ cells to switch to a CD133- state, probabilities 
of subpopulations 1 to 8 to form phenotypic states 9 to 16 were summed up. This 
quantification was performed for each state transition possibilities for the 4 markers used. 
Finally, Markov model was used to predict the final equilibrium for each individual marker 
transition matrix. 
The second path to model the multipotency data was used to predict final equilibria in case 
marker expression was independent. First, we aimed to calculate 2x2 matrix for each 
individual marker. Using the original data, the percentages of formed phenotypic states of 
each subpopulation were added together for each individual marker as described above for 
state transitions. Subsequently, 2x2 state transition probability matrixes for each marker 
were obtained by Markov modeling. Under the assumption of independence, state transition 
probabilities for all 16 subpopulations were calculated by multiplying state transition 
probabilities of the 4 markers. For example, to calculate the transition probability of 
subpopulation 4 (CD133+ CD44- A2B5- CD15+) to change into phenotypic state of 
190 
 
subpopulation 10 (CD133- CD44- A2B5+ CD15+) we multiplied state transitions of CD133 
2x2 matrix from CD133+ to CD133-, state transition of CD44 2x2 matrix from CD44- to CD44-
, state transition of A2B5 2x2 matrix from A2B5- to A2B5+ and state transition of CD15 2x2 
matrix from CD15+- to CD15+. Thereby we obtained a 16x16 independent state transition 
probability matrix for all CSC-associated subpopulations. Final equilibrium was predicted 
using Markov model. The percentages of equilibria for each individual marker was obtained 
by summing subpopulations for their specific marker expression. Thus, to obtain the final 
equilibrium of CD133 marker, percentages of CD133+ or CD133- subpopulations were 
combined. Finally, we compared the marker equilibria obtained from dependence and 
independence calculations. If the two equilibria were similar, then the markers were 
independent from each other. In contrast, differences in calculated equilibria suggested that 
the markers were dependent on the expression of the other markers.  
The analysis was realized with the help of Thomas Buder (Zentrum für Informationsdienste 
und Hochleistungsrechnen (ZIH), Technische Universität Dresden, Dresden, Germany and 
Fakultät Informatik / Mathematik, Hochschule für Technik und Wirtschaft Dresden, Dresden, 
Germany Technische Universität Dresden). 
 
Figure 53: Calculation scheme for marker dependency. Flowchart displays mathematical 
methodology for marker dependence analysis. Boxes represent obtained data and in blue the 
mathematical calculations. 
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Annex 3: Single cell RNA-seq using Drop-seq 
a. Mircrofluidics Fabrication 
Subsequent procedure and analysis was performed by Dr. Suresh Kumar Poovathingal 
from the Luxembourg Centre for Systems Biomedicine at University of Luxembourg 
(Alexander Skupin Group). Microfluidics devices were fabricated using a previously 
published design (Macosko et al., 2015). Softlithography was performed using SU-8 2050 
photoresist (MicroChem) on 4” silicon substrate to obtain a feature aspect depth of 100mm. 
After overnight silanization (using Chlorotrimethylsilane, Sigma), the wafer masks were 
used for microfluidics fabrication. Drop-seq chips were fabricated using a silicon based 
polymerization chemistry, with the previously published protocol (Mazutis et al., 2013). 
Briefly, Polydimethylsiloxane (PDMS) base and crosslinker (Dow Corning), was mixed at 
the 10:1 ratio, mixed and degassed before pouring the mix onto the Drop-seq master 
template. PDMS was cured on the master template, at 800C for 2h. After the incubation and 
cooling, the PDMS slabs were cut and the inlet/outlet ports were punched with 1.25mm 
biopsy punchers (World Precision Instruments). The PDMS monolith was plasma-bonded 
to a clean microscopic glass slide using Harrick plasma cleaner. Immediately after pairing 
the plasma-treated surfaces of the PDMS monolith and the glass slide, the flow channels 
of the Drop-seq chip was treated for hydrophobicity treatment using 1H,1H,2H,2H-
Perfluorodecyltrichlorosilane (in 2% v/v in FC-40 oil; Alfa Aeser/Sigma). After 5 minutes of 
treatment, excessive silane was blown out through the inlet/outlet ports. The chip was 
further incubated at 80°C for 15 minutes. 
b. Single cell droplet suspension  
The experiments performed align with the original Drop-seq protocol (Macosko et al., 2015). 
Minor changes relevant to this work are described below. Pre-fabricated Drop-seq chip was 
used for the emulsion generation. Specially synthesized barcoded beads (Chemgenes 
corp.) were co-encapsulated with the cells inside the droplet containing optimized lysis 
reagent (for reagents see (Macosko et al., 2015)). The cellular mRNA was captured on 
beads via the barcoded oligo (dT) handles synthesized on the surface. To ensure low 
proportion of two or more beads co-encapsulating within a single droplet, the optimal bead 
concentration of 200 beads/ml was applied. The beads were prepared in the Drop-seq Lysis 
buffer medium. 
2ml of the cell and the bead suspensions were loaded into 3ml syringes (BD Bioscience). 
Due to the stark density difference of the beads, a micro-stirrer was used (VP scientific). 
The QX 200 carrier oil (Bio-rad) was used as a continuous phase in the droplet generation. 
The oil was loaded into a 20ml syringe (BD Bioscience). For the droplet generation, 3.6ml/h 
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and 13ml/h were used for the dispersed and continuous phases, respectively, using KD 
scientific Legato syringe pumps. This generated droplets of the diameter ~115μm (~ 1nl 
volume). After the stabilization of the droplet formation, the droplet suspension was 
collected into a 50ml Falcon tube. The collection of the emulsion was carried out until 1µl 
of the single cell suspension was dispensed. The droplet consistency and stability was 
evaluated in a bright-field inverted microscope using an INCYTO C-Chip Disposable 
Hemacytometer (ThermoFisher Scientific). The bead occupancy within the droplets was 
carefully monitored avoid the multiple bead occupancy. 
The subsequent steps of the droplet breakage, bead harvesting, reverse transcription and 
the exonuclease treatment was carried out in accordance with the earlier work (Macosko et 
al., 2015). The RT buffer contained: 1x Maxima RT buffer, 4% Ficoll PM-400 (Sigma-
Aldrich), 1μM dNTPs (ThermoFisher Scientific), 1U/ml RNase Inhibitor (Lucigen), 2.5μM 
Template Switch Oligo (Macosko et al., 2015), and 10U/ml Maxima H-RT (ThermoFisher 
Scientific). Post Exo-I treatment, the bead counts were estimated using INCYTO C-Chip 
Disposable Hemacytometer, and 10,000 beads were aliquoted in 0.2ml Eppendorf PCR 
tubes. PCR mix was dispensed in a volume of 50l using 1x Hifi HotStart Readymix (Kapa 
Biosystems) and 0.8mM Template-Switch-PCR primer. The thermocycling program for the 
PCR amplification was adapted from the previous work, except for the final PCR cycles: 
1 cycle: 95°C – 3 minutes 
4 cycles:  98°C – 20 seconds 
65°C – 45 seconds 
72°C – 3 minutes 
10 cycles:  98°C – 20 seconds 
67°C – 20 seconds 
72°C – 3 minutes 
1 cycle: 72°C – 5 minutes 
Post PCR amplification, the libraries were purified with 0.6x Agencourt AMPure XP beads 
(Beckman Coulter), in accordance with the manufacturer’s protocol. Finally, the purified 
libraries were eluted in 20μl RNase/DNase-free molecular grade water. Prior to the 
sequencing library preparation, the quality and the concentration of the libraries were 
assessed using BioAnalyzer High Sensitivity Chip (Agilent Technologies). 
c. NGS preparation for Drop-seq libraries 
The 3’ end enriched cDNA libraries were prepared by the tagmentation reaction of 600 pg 
cDNA library using the standard Nextera XT tagementation kit (Illumina). The reactions 
were performed according to the manufacturer’s instruction, except for the 400 nM primer 
sets of: Primer 1 
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(AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTA 
TCAACGCAGAG T*A*C) and Primer 2 (N703: CAAGCAGAAGACGGCATACGAGA 
TTTCTGCCTGTCTCGTGGGCTCGG for the NCH644 subpopulation 6 and N709: 
CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG for NCH644 
subpopulation 2, NCH644 and NCH421k). The PCR amplification cycling program used 
was:  
1 cycle: 95°C – 30 seconds  
14 cycles: 95°C – 10 seconds 
55°C – 30 seconds 
72°C – 30 seconds 
1 cycle: 72°C – 5 minutes 
The libraries were purified twice to reduce the primers and short DNA fragments, with 0.6x 
Agencourt AMPure XP beads (Beckman Coulter) followed by 1x Agencourt AMPure XP 
beads, in accordance with the manufacturer’s protocol. Finally, the purified libraries were 
eluted in 15μl molecular grade water. The quality and quantity of tagmented cDNA library 
was evaluated using BioAnalyzer High Sensitivity DNA Chip. The average size of the 
tagemented libraries prior to sequencing was between 400-700 bases pairs. 
Purified Drop-seq cDNA libraries were sequenced using Illumina NextSeq 500. Sequencing 
protocol recommended by the manufacturer was followed, except for 6pM of custom primer 
(GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC) applied for priming of read 1. 
Paired end sequencing was performed with the read 1 of 20 bases (covering the random 
cell barcode 1-12 bases and the rest 13-20 bases of random unique molecular identifier 
(UMI)) and read 2: 50 bases of the genes. 
d. Bioinformatics processing and data analysis 
The FASTQ files were assembled from the raw BCL files using Illumina’s bcl2fastq 
converter and ran through the FASTQC codes (Babraham bioinformatics; 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to check for the consistency in 
the library qualities. The monitored quality assessment parameters were: a.) quality per 
base sequence (especially for the read 2 of the gene); b.) per base N content; c.) per base 
sequence content and d.) overrepresented sequences. The libraries, which showed 
significant deviation were re-sequenced. The FASTQ files were then merged and converted 
to binaries using PICARD’s fastqtosam algorithm. 
We have applied the Drop-seq bioinformatics pipeline (Macosko et al., 2015). The 
sequencing reads were converted to digital gene expression matrix (DGE). To normalize 
for the transcript loading between the beads, the averaged normalized expression levels 
(log2(TPM+1)) were calculated. To distinguish between the beads exposed to the cell and 
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empty beads, a cumulative function of the total number of transcripts per barcode was 
plotted. Then, a thresholding was applied empirically on the resulting “knee plot” to estimate 
the beads exposed to the cell content. To filter the poor-quality reads and cells reporting 
low transcript content, the following threshold filters were used: only cells that expressed at 
least 1500 genes and, only genes which were expressed in at least 20 cells were 
considered for further analysis. The average number of UMI-collapsed transcripts per cell 
was 5970 corresponding to the 2430 genes detected per cell on average.  
To remove batch effect, we used independent component analysis ICA (R fastICA package) 
decomposing the original expression matrix into a product of statistically independent 
signals and weight matrices:  
Xnm = Snk x Mkm , 
where Xnm is the log-transformed count matrix for n genes and m cells, Snk is a matrix of k 
independent components and Mkm is the weight matrix for each component over m cells. 
Stability of the ICA decomposing was tested by 100 runs of ICA. The log-transformed count 
matrix was decomposed using 8 independent components. The optimal number of the 
components was selected by minimizing the correlation between rows of weight matrix. We 
observed that the weight of component #7 was strongly linked to experimental batch. In 
accordance with (Biton et al., 2014), this component was suppressed by setting its weight 
(M7,i, where i = 1..m) to 0, and the normalized data were recovered by matrix multiplication 
of the components by their weights. 
Estimation of the highly variable genes and principal component reduction and tSNE 
dimensionality reduction was implemented using SEURAT R package 
(http://satijalab.org/seurat/) or the R package Rtsne with an initial PCA, a perplexity 
of 40 and a learning rate of 200 (5000 iterations) (https://github.com/jkrijthe/Rtsne). For 
reproducibility with the original algorithm, the theta value has been set to zero. 
Correlation coefficient has been calculated between each cell after filtering using the 
Pearson method; the mean value is represented for each group/subpopulation/fraction. 
Differential expression analysis was performed using DESeq2 package of R (Love et al., 
2014). Here the raw integer counts were used for consistency with the algorithm 
requirements. Centering of the gene expression value, was performed by obtaining the 
relative expression levels, by subtracting the average expression value (log2(TPM+1)) of 
each gene from all the cells of the gene expression matrix. For cell cycle analysis we have 
applied two prominent gene expression programs of the G1/S (100 genes) and G2/M 
phases (133 genes) (Whitfield et al., 2002), shown to overlap in the two programs (Tirosh 
et al., 2016a, Macosko et al., 2015).  
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Due to the sparsity of the single cell RNAseq data, the expression data for each cell cycle 
phase was refined by evaluating the correlation data between each of the genes in the 
scRNAseq data with the average gene expression values of all the genes involved in the 
respective cell cycle program (G1/S & G2/M), and including all the genes with high 
correlation value (R2 > 0.3; Pval < 0.05). Hierarchical clustering of the data demonstrates 
that some cells are cycling with high relative expression of most of the genes included in 
either of the cell cycle program or both of the programs, while other cells shows basal 
expression for most of these genes (data not shown). The biaxial plot of G1/S and G2/M 
programs is the average score of all the genes involved in the respective cell cycle 
programs. It further represents the expression value of different genes of interest by 
mapping the expression value onto the respective cells.  
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Annex 4: Flow cytometric gating strategy for the analysis of tumor cells in 
PDXs. GBM cells were distinguished from debris using forward (FSC) and side 
(SSC) scatters (1), followed by cell doublet and aggregate elimination (FSC-A/FSC-
H) (2). Dead cells were recognized as positive for dead cell marker (3). Single viable 
cells were discriminated by human CD90 positive cancer and human CD90 negative 
stromal cells (4). 
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Annex 5: Flow cytometric analysis of 8 cell surface markers in 11 GBM PDXs. 
Negative, low, positive and high positive cells were categorized based on their mean 
fluorescence intensity (MFI) (‘-‘, MFI = negative control; ‘low’, MFI < 10x negative 
control; ‘+', 10x < MFI < 100x negative control; ‘++’, MFI > 100x negative control). 
All 8 tested markers demonstrated high variability between PDXs (e.g. green 
square) whereas their expression was uniform within a PDX. Only T238 showed a 
variable expression profile in CD195 (delineated by blue square). 
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Annex 6: Statistical analysis of CSC-associated phenotypic heterogeneity. 
Statistical analysis was performed with the Student t-test with a Bonferroni 
multiple-significance-test correction for 16 phenotypic states. Differences 
between proportion of phenotypic states (PSs) in different conditions, treatments 
and FACS-sorted subpopulations and vs. control cells (CTR = control cells 
cultures in normoxia; CTR_H = control cells cultured 60 days in hypoxia) are 
presented if p-value *<0.05; **<0.01; ***<0.001. 
a. Phenotypic analysis of NCH644 cultures upon TMZ treatment. TMZ 
treatment was performed for 16h, 2 and 7 days (NCH644 TMZ data from 
figure 24.a). 
b. Phenotypic analysis of NCH421k cultures upon TMZ treatment. TMZ 
treatment was performed for 16h, 2 and 7 days (NCH421k TMZ data from 
figure 24.b). 
c. Phenotypic analysis of NCH644 cultures upon hypoxic cultures. Hypoxia (H) 
was applied for 16h, 2, 7 and 60 days (NCH644 Hypoxia data from figure 
43.a). 
d. Phenotypic analysis of NCH421k cultures upon hypoxic cultures. Hypoxia (H) 
was applied for 16h, 2 and 7 days (NCH421k Hypoxia data from figure 43.b). 
e. Phenotypic analysis between NCH644 cultures recultured in normoxia for 7 
(7d renorm) and 14 days (14d renorm) after 7 days (7d h) in hypoxic cultures. 
Additionally, phenotypic proportions of all conditions were compared to 
NCH644 in normoxia (CTR) (NCH644 Reversibility from H to N data from 
figure 51). 
f. Phenotypic analysis of NCH644 cultures upon differentiation (Diff)and de-
differentiation (De-Diff) in normoxic (N) and hypoxic (H) conditions. 2D 
cultures in stem cell medium were used as additional control (2D) (NCH644 
Differentiation data from figure 54.a). 
g. Phenotypic analysis of NCH421k cultures upon differentiation (Diff)and de-
differentiation (De-Diff) in normoxic (N) and hypoxic (H) conditions. 2D 
cultures in stem cell medium were used as additional control (2D) (NCH421k 
Differentiation data from figure 54.b). 
h. Phenotypic analysis of NCH644 cultures upon xenografting (X). Phenotypic 
equilibrium of FACS-sorted subpopulations (P2, P6, P11, P15) was 
compared to control cultures in normoxia in vitro (CTR) and bulk NCH644 
xenografted in vivo (CTR_X) (NCH644 Subpopulation Xenografting data from 
figure 56.f). 
i. Phenotypic analysis of NCH644 cultures upon xenografting (X). Phenotypic 
equilibrium of xenografted NCH644 tumor cells recultured in vitro was 
compared to control cultures in normoxia in vitro (CTR) and bulk NCH644 
xenografted in vivo (CTR_X) (NCH644 Xenografting data from figure 57.b). 
j. Phenotypic analysis of NCH421k cultures upon xenografting (X). Phenotypic 
equilibrium of xenografted NCH421k tumor cells recultured in vitro was 
compared to control cultures in normoxia in vitro (CTR) and bulk NCH644 
xenografted in vivo (CTR_X) (NCH421k Xenografting data from figure 57.d). 
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Annex 7: Statistical analysis of phenotypic state transitions of FACS-sorted 
subpopulation upon time. Statistical analysis was performed with the Student 
t-test with a Bonferroni multiple-significance-test correction for 16 phenotypic 
states. Statistical differences between proportion of phenotypic states (PSs) in 
different FACS-sorted subpopulations vs. control cells (CTR = control cells 
cultures in normoxia; CTR_H = control cells cultured 60 days in hypoxia) at the 
same time point are presented if pvalue *<0.05; **<0.01; ***<0.001. Statistical 
results in a. displays multipotency test in normoxia whereas b. shows 
multipotency test in hypoxia. 
a. Multipotency in normoxia 
 
20d Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs P1 *** ** *** ***
CTR vs P2 *** * ***
CTR vs P3 *** ** ***
CTR vs P4 * *** ** *** ***
CTR vs P5 *** ***
CTR vs P6 *** *** ***
CTR vs P7 ** ***
CTR vs P8 *** *** *** *** ***
CTR vs P9 ** *** ** ***
CTR vs P10 * ** * *
CTR vs P11 *** * *** ** ***
CTR vs P12 **
CTR vs P13 *** *** * ** * *
CTR vs P14 *** *** ** ** ***
CTR vs P15 *** *** *** *
CTR vs P16 ** * *
30d Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs P1 * ** *** ** *
CTR vs P2 *
CTR vs P3 ** ** ** **
CTR vs P4 *
CTR vs P5 ** *** *** ** ** ** **
CTR vs P6 *** *** * *
CTR vs P7 * *** ** *** ** *
CTR vs P8 *** *** ** * *** *** ** *** *
CTR vs P9 *** ***
CTR vs P10
CTR vs P11 *** *** ** *** ** ** * ***
CTR vs P12 *
CTR vs P13 *** *** *** *** *** *** * * ***
CTR vs P14 *** *** *** *** ***
CTR vs P15 *** *** *** ***
CTR vs P16 * ***
70d Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs P1 * *** *** *** *** *** *
CTR vs P2 *** *** *** **
CTR vs P3 *** *** ** *** *** *** **
CTR vs P4 *** *** *** *** * **
CTR vs P5 *** ** *** * *** *** ***
CTR vs P6 *** *** *** *** *** ***
CTR vs P7 *** *** **
CTR vs P8 * *** *** *** *** *** ** ***
CTR vs P9 ** *** *** *** *** **
CTR vs P10 ***
CTR vs P11 * *** *** *** ** *** * **
CTR vs P12 ** ***
CTR vs P13 *** *** ***
CTR vs P14 ***
CTR vs P15 * *** **
CTR vs P16
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b. Multipotency in hypoxia 
 
  
Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs CTR_H *** *** * ** ** *** ** *** *** **
CTR vs P1 *** *** * *** *** *** *** *** *** ** ***
CTR vs P2 *** ** *** *** *** *** *** *** * **
CTR vs P3 *** *** *** ** *** *** *** *** *** *** * **
CTR vs P4 *** *** ** *** *** *** *** *** *** **
CTR vs P5 *** ** *** *** *** *** *** *** ***
CTR vs P6 *** *** ** *** *** *** *** *** *** *
CTR vs P7 ** *** ** *** *** *** *** *** *** *** **
CTR vs P8 *** *** *** *** *** *** *** *** *** **
CTR vs P9 *** *** *** *** *** *** *** *** ** **
CTR vs P10 ** *** ** ** *** ** ** *** ** *** *
CTR vs P11 * *** *** *** *** *** *** *** **
CTR vs P12 *** ** * *** ** *** *** * *** *
CTR vs P13 *** ** *** *** * *** *** *** *** ** *
CTR vs P14 *** *** * *** * * *** *** ***
CTR vs P15 * *** ** *** ** * *** ** *** *** **
CTR vs P16 *** *** *** *** * * *** *** *** ***
CTR_H vs P1
CTR_H vs P2
CTR_H vs P3 ** * **
CTR_H vs P4 *
CTR_H vs P5 *
CTR_H vs P6 **
CTR_H vs P7 * *
CTR_H vs P8 ** *
CTR_H vs P9
CTR_H vs P10 **
CTR_H vs P11 *
CTR_H vs P12
CTR_H vs P13
CTR_H vs P14
CTR_H vs P15
CTR_H vs P16 *
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Annex 8: Statistical analysis of phenotypic state transitions of FACS-sorted 
subpopulation upon 4 consecutive passages in self-renewal analysis. 
Statistical analysis was performed with the Student t-test with a Bonferroni multiple-
significance-test correction for 16 phenotypic states. No statistical differences were 
detected between the same subpopulations at different passages. Statistical 
differences between proportion of phenotypic states (PSs) in different 
subpopulations and control cells (CTR = control cells cultures in normoxia; CTR_H 
= control cells cultured 60 days in hypoxia) at the same passage is presented if 
pvalue < 0.05;*<0.05; **<0.01; ***<0.001. NCH644 exp corresponds to FACS-sorted 
bulk NCH644 cells w/o discrimination of 16 subpopulations. Statistical results in a. 
displays self-renewal test in normoxia whereas b. shows self-renewal test in 
hypoxia.  
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a. Self-renewal in normoxia 
 
Passage 1 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp
CTR vs P1 * *** ** **
CTR vs P2 * ** ** **
CTR vs P3 * *** ** **
CTR vs P4 * *** *
CTR vs P5 *
CTR vs P6 *** *
CTR vs P7 ** * * *
CTR vs P8 ** *** **
CTR vs P9 ** *** ** ** * *
CTR vs P10 * * *
CTR vs P11 ** ** **
CTR vs P12
CTR vs P13 * *** ** ** ** * **
CTR vs P14 *** *** * *
CTR vs P15
CTR vs P16 ** *** ***
Passage 2 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp
CTR vs P1 ** *** **
CTR vs P2
CTR vs P3 ***
CTR vs P4 ** *** *
CTR vs P5 ** * ** *
CTR vs P6 *** *
CTR vs P7 ** ** *** * **
CTR vs P8 ** ** * *** * *
CTR vs P9 ** * *** ** *** *
CTR vs P10 **
CTR vs P11 * * * *** ** *** **
CTR vs P12
CTR vs P13 ** ** * ** ** * *
CTR vs P14 *** * * **
CTR vs P15 ** ** * ** * **
Passage 3 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp *
CTR vs P1 ** ** *
CTR vs P2 *
CTR vs P3 * *
CTR vs P4 *** *
CTR vs P5
CTR vs P6 *** *
CTR vs P7
CTR vs P8 * *** * *
CTR vs P9 ** *** * * *
CTR vs P10 * ** *
CTR vs P11 **
CTR vs P12
CTR vs P13 **
CTR vs P14 *** ** * * **
CTR vs P15 **
CTR vs P16 ** *
Passage 4 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp
CTR vs P1 *** ** * **
CTR vs P2 * ** ** *** * * ** **
CTR vs P3 * * *** * ** **
CTR vs P4 *** **
CTR vs P5 * * *
CTR vs P6 **
CTR vs P7 *** * * *
CTR vs P8 ** ** *** * ** *
CTR vs P9 ** *** *
CTR vs P10 *
CTR vs P11 * *** *
CTR vs P12 ***
CTR vs P13 * * * ** **
CTR vs P14 *** * ** **
CTR vs P15 * * *
CTR vs P16 **
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b. Self-renewal in hypoxia 
 
Passage 1 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp ** * *
CTR vs CTR_H *** *** * ** ** *** ** *** *** **
CTR vs P1 * ** *** ** ** * ** **
CTR vs P2 * *** ** **
CTR vs P3 *** * *** * ** **
CTR vs P4 *** * * ** **
CTR vs P5 ** *** * * *
CTR vs P6 *** * ** ** *
CTR vs P7 *** * ** **
CTR vs P8 * ** *** * ** * ** *
CTR vs P9 ** * *** ** **
CTR vs P10 * *
CTR vs P11 * ** ** ** **
CTR vs P12 *
CTR vs P13 ** * ***
CTR vs P14 ** *** * * *** * ** ** *
CTR vs P15
CTR vs P16 ** *** *
CTR_H vs NCH644 exp * ** *
CTR_H vs P1 * ** **
CTR_H vs P2 * *** * * *
CTR_H vs P3
CTR_H vs P4 ***
CTR_H vs P5
CTR_H vs P6 *
CTR_H vs P7 *
CTR_H vs P8 *
CTR_H vs P9 ** **
CTR_H vs P10 *
CTR_H vs P11 * * * *
CTR_H vs P12 **
CTR_H vs P13 * *** *
CTR_H vs P14 * * *
CTR_H vs P15
CTR_H vs P16 *
Passage 2 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp *** * * * * **
CTR vs P1 ** *** * *** * * ** **
CTR vs P2 *** * * ** ** **
CTR vs P3 * *** * * **
CTR vs P4 * * *
CTR vs P5 * * *** * ** * **
CTR vs P6 * ** * *** * ** ** **
CTR vs P7 *** * * ** **
CTR vs P8 ** *** * *** * ** ** **
CTR vs P9 ** ** ** *
CTR vs P10 ** * *
CTR vs P11 * ** ** ** * * * **
CTR vs P12 ** *
CTR vs P13 * *** * * **
CTR vs P14 *** ** *** * * * **
CTR vs P15 ** * *** ** * **
CTR vs P16 * ** *** ** **
CTR_H vs NCH644 exp *
CTR_H vs P1 ** * *
CTR_H vs P2 *
CTR_H vs P3
CTR_H vs P4 *** *
CTR_H vs P5
CTR_H vs P6
CTR_H vs P7
CTR_H vs P8
CTR_H vs P9 *
CTR_H vs P10 *
CTR_H vs P11 *
CTR_H vs P12
CTR_H vs P13 *
CTR_H vs P14 *
CTR_H vs P15
CTR_H vs P16
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Passage 3 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp ** * * * **
CTR vs P1 ** *** *** ** *** * **
CTR vs P2 * *** * * * **
CTR vs P3 ** * *** * * **
CTR vs P4 ** *** * * * **
CTR vs P5 * *** ** * * **
CTR vs P6 ** * * *** *** * ** **
CTR vs P7 ** * ** ** * * ** **
CTR vs P8 ** * * * *** * ** **
CTR vs P9 ** *
CTR vs P10 ** *
CTR vs P11 * *** ** ** * **
CTR vs P12 **
CTR vs P13 ** ** * *
CTR vs P14 *** ** *** * * **
CTR vs P15 * ** ** * *
CTR vs P16
CTR_H vs NCH644 exp *
CTR_H vs P1 ** ** *
CTR_H vs P2 ** **
CTR_H vs P3
CTR_H vs P4
CTR_H vs P5
CTR_H vs P6
CTR_H vs P7
CTR_H vs P8
CTR_H vs P9
CTR_H vs P10
CTR_H vs P11
CTR_H vs P12
CTR_H vs P13
CTR_H vs P14 *
CTR_H vs P15 * **
CTR_H vs P16
Passage 4 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp ** * ** * *
CTR vs P1 * * *** * ** * * *
CTR vs P2 *** * * *
CTR vs P3 * ** *** * *** * * * *
CTR vs P4 ** * ** *** *** *** * * *
CTR vs P5 * *** * * *
CTR vs P6 * ** * *** * * * *
CTR vs P7 * * *** * * *
CTR vs P8 * ** *** * ** *** * *
CTR vs P9 **
CTR vs P10 **
CTR vs P11 ** * * ** * *** * * * *
CTR vs P12 * * ** * * *
CTR vs P13 * ** * ** * *
CTR vs P14 * ** *
CTR vs P15 * ** * * * ***
CTR vs P16 * *
CTR_H vs NCH644 exp
CTR_H vs P1 * *
CTR_H vs P2
CTR_H vs P3 *
CTR_H vs P4
CTR_H vs P5
CTR_H vs P6
CTR_H vs P7
CTR_H vs P8 *
CTR_H vs P9
CTR_H vs P10
CTR_H vs P11
CTR_H vs P12
CTR_H vs P13
CTR_H vs P14
CTR_H vs P15 **
CTR_H vs P16
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SUMMARY  
Cancer stem cells (CSCs) have been proposed to underlie the hierarchical organization of 
Glioblastoma (GBM) causing resistance to treatment, however the identity of CSCs in solid 
tumors remains largely elusive. Here we show that GBM cells expressing stem cell markers 
do not represent a clonal entity defined by distinct functional properties and transcriptomic 
profiles but rather a changing identity that any cell can adapt. Phenotypic heterogeneity 
arises from reversible cellular state transitions organised in a non-hierarchical manner 
where the final phenotypic equilibrium depends on microenvironmental conditions. While all 
subpopulations survive and adjust their phenotype, their adaptation speed may differ 
resulting in variable tumor growth rates in vivo. Thus stem cell-associated phenotypic 
heterogeneity is a result of a stochastic reversible cellular plasticity which impacts the 
outcome of functional assays. This intrinsic plasticity should be taken into account for future  
treatment strategies targeting cancer stem-like states. 
 
 
KEYWORDS: Glioblastoma, Cancer stem cells, Intra-tumoral heterogeneity, Phenotypic 
plasticity, Markov modeling 
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INTRODUCTION 
Glioblastoma (GBM) shows an extensive cellular heterogeneity which represents a major 
obstacle for effective therapies. Similar to many other cancers, tumor progression has been 
proposed to be maintained by cancer stem cells (CSC), postulated to be responsible for 
tumor recurrence and resistance to therapy. According to the CSC hypothesis 1. tumors 
follow a hierarchical cellular organization via a unidirectional differentiation process, 2. only 
a limited number of cells within the tumor have tumorigenic potential, and 3. CSCs are 
intrinsically different from their differentiated derivatives. Thus CSCs are thought to display 
stem cell properties and to be highly tumorigenic in experimental models in vivo (Vescovi 
et al., 2006)., This hypothesis has however been challenged, with growing evidence 
suggesting that CSCs do not constitute a defined cellular entity, but rather a cellular state 
adapting to microenvironmental cues, a concept which has major implications for treatment 
strategies (Meacham and Morrison, 2013).  
Identification of CSCs is largely based on the expression of cell membrane antigens, which 
are amenable to targeted treatments (Scott et al., 2012). Although many studies in GBM 
rely on cell membrane markers for CSC isolation, such as CD133, CD15/SSEA, CD44, or 
A2B5 (Singh et al., 2004, Ogden et al., 2008, Tchoghandjian et al., 2010, Son et al., 2009, 
Anido et al., 2010), no single marker is able to solely define CSCs (Chen et al., 2010). There 
is controversy whether marker-expressing cells fulfill the functional criteria of bona fide 
CSCs (Beier et al., 2007, Piccirillo et al., 2009, Penuelas et al., 2009, Wang et al., 2008) 
and whether CSCs represent a quiescent or a proliferative subpopulation. These conflicting 
data could be explained by: 1. inter-patient heterogeneity preventing the identification of a 
universal CSC marker, 2. the presence of multiple CSC clones within each tumor, 3. a CSC 
signature based on multiple markers, or 4. strong phenotypic plasticity between cellular 
states. Recent data support the plasticity model over a strict hierarchical organization 
(Easwaran et al., 2014, Cabrera et al., 2015), pointing to a role of the microenvironment in 
shaping the phenotype. Indeed, GBM cells expressing stem cell markers are often 
attributed to specific tumor niches, such as perivascular and hypoxic areas (Lathia et al., 
2011). However, it remains unclear whether the microenvironment selects for survival of 
specific CSCs or whether tumor cells adapt within new microenvironments.  
Recent marker-independent analysis by single cell transcriptomics revealed stem cell-
signatures to be associated with the most proliferative cells in IDH1-mutated gliomas 
(Tirosh et al., 2016) and stemness increasing with tumor grade (Venteicher et al., 2017). 
Such an organization was less clear in GBMs, which displayed a continuum of stemness 
profiles that were anti-correlated with the cell cycle (Patel et al., 2014) and a tendency 
towards an astrocytic program (Venteicher et al., 2017). Importantly, such data describe 
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heterogeneity at a given snapshot in time without considering the dynamic properties of 
tumor cells. Similarly, recent genetic barcoding suggesting an invariant proliferative 
hierarchy in GBM (Lan et al., 2017) did not address the evolution of phenotypic states over 
time. 
Here we asked whether cancer cells with stem cell properties are a defined entity at the 
apex of a hierarchical organization or whether they represent one of many phenotypic 
states that cells can reversibly adapt in response to environmental cues. We find that 
phenotypic heterogeneity arises from intrinsic cancer cell plasticity via bidirectional non-
hierarchical state transitions, tending towards a phenotypic equilibrium within a given 
environment. Therefore therapies targeting primarily a transitory stem cell state may 
ultimately be unsuccessful.  
 
RESULTS 
Strong inter-tumor heterogeneity but limited intra-tumor heterogeneity of putative 
CSC markers. 
To determine CSC-associated marker expression in GBM we analyzed the gene expression 
of putative CSC markers in the GBM patient cohort of TCGA. Analysis of these patients 
indicated highly variable expression levels across tumors (Fig. 1A). CSC marker genes 
were rarely associated with genetic or epigenetic alterations (Fig. S1A-C) and no significant 
correlations were detected between marker genes and main GBM drivers (Fig. 1B). As 
expected (Brown et al., 2015), several markers were enriched in previously defined 
transcriptional subgroups (Table S1).  
Transcriptional profiles of bulk analysis in GBM patients represent mean values of tumor 
and stroma (Wang et al., 2017) and we have previously shown that cell membrane epitopes 
are present in both compartments (Golebiewska et al., 2013). Moreover, it is known that 
gene expression does not always correspond to the epitope presentation of CSC markers 
(Campos and Herold-Mende, 2011). Therefore, we used GBM patient-derived xenografts 
(PDXs) in eGFP-expressing mice (Niclou et al., 2008) to phenotype the tumor compartment 
in an unbiased manner (Fig. S2A-B) by multicolor flow cytometry. Similar to gene 
expression analysis, we observed highly variable epitope presentation of 12 CSC markers 
between tumors from different patients (Fig. 1C, Fig. S3A-B). CD90 and CD29 were 
strongly positive in most GBM, whereas CD24 and CD195 were largely absent. In most 
cases, marker expression was homogeneous within one GBM while only 4/12 markers 
(CD133, CD44, CD15 and A2B5) showed relevant intra-tumoral heterogeneity (Fig. 1C), 
which would be expected from a bona fide CSC marker. 
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Genetically distinct clones adapt marker expression in vivo. 
We have previously shown that genetic intra-tumor heterogeneity in GBM is also seen at 
the ploidy level, with pseudodiploid and aneuploid clones present in the same tumor (Stieber 
et al., 2014). Here, we find that genetically divergent clones can differ in the pattern of CSC-
associated marker expression as shown for CD133 and A2B5 (Fig. 1D). We then FACS-
purified pseudodiploid and aneuploid cells and separately implanted them in the mouse 
brain. Both clones changed marker expression in vivo, i.e., pseudodiploid tumors retained 
a heterogeneous A2B5 profile and increased CD133 (from 12.5 to 80%), while aneuploid 
tumors significantly increased A2B5 epitope presentation (from 4 to 65%) (Fig. 1D). This 
shows that CSC associated marker expression in vivo is adaptable following clonal 
selection, most probably reflecting an adaptation to the new microenvironment.  
 
Heterogeneity in GBM stem-like cultures. 
In order to correlate marker presentation with CSC functional properties, we turned to GBM 
stem-like cultures grown as 3D spheres. This allowed us to work with a genetically more 
homogeneous population (Stieber et al., 2014). Similar to patient biopsies and PDXs, stem-
like cultures displayed remarkable inter-patient heterogeneity of CSC markers (Fig. S3B). 
CD133, CD44, CD15 and A2B5 showed again the strongest heterogeneity within the same 
culture. Focusing on these four markers, we performed multicolor flow cytometry, which led 
to the discrimination of 16 subpopulations (labeled P1-P16; Fig 1E-F, Fig. S2C-D). Some 
cultures contained a limited number of predominant subpopulations, while 4/7 cultures 
contained a substantial amount of all 16 subpopulations. The strong heterogeneity was 
present at the single sphere level without a particular localization pattern, nor a link with 
proliferative cells more prominent at sphere edges (Fig. 1G). All subpopulations were able 
to proliferate, although some CD133-CD44- cells (P9-P12) contained less cells in S/G2/M 
(Fig. S4A). This may reflect the fluctuation of CD133 across the cell cycle (Barrantes-Freer 
et al., 2015). Thus, GBM stem-like cultures recapitulate the intra-tumoral phenotypic 
heterogeneity of CSC marker expression observed in patient biopsies and PDXs.  
 
All GBM subpopulations carry similar stem cell properties. 
To investigate the functional stem cell properties of the cells we performed self-renewal, 
proliferation and multipotency tests on all 16 subpopulations (Fig. 2A). We focused on the 
most heterogeneous culture (NCH644) allowing to obtain a sufficient number of cells of 
each subpopulation. We found that all FACS-sorted subpopulations were able to self-renew 
over multiple passages with no significant differences between each other (Fig. 2B). In 
analogy to normal stem cells, no dilution of differentiated counterparts and progenitors was 
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observed as indicated by similar sphere size. All subpopulations proliferated indefinitely at 
a similar rate (Fig. 2C). This indicated that phenotypically heterogeneous GBM cells have 
similar stem cell properties, suggesting a lack of hierarchical organization in specific 
differentiation states.  
 
GBM subpopulations undergo stochastic state transitions in a non-hierarchical 
pattern. 
We next performed multipotency tests by multicolor phenotyping for each of the FACS-
purified subpopulation over time to reveal which subpopulations were responsible for 
creating the phenotypic heterogeneity. Surprisingly, none of the subpopulations maintained 
its original phenotype (Fig. 2D, Fig. S5A), indicating that none represented a unipotent 
‘differentiated’ phenotype as expected in a one-way hierarchical model. This was also true 
for single cells phenotyped following the self-renewal test (Fig. S5B). Most phenotypic 
states were already reestablished after 20 days (D20), although the adaptation was 
dynamic over time and varied between subpopulations as shown by the alluvial plots (Fig. 
2D). However, at day 70 (D70), all 16 subpopulations were reconstituted in each sample 
suggesting a tendency towards the original phenotypic equilibrium. This was confirmed in 
other GBM cultures (NCH421k) (Fig. S4B).  
To quantify the state transitions in time between the different phenotypes and predict the 
time of equilibrium, we applied CellTrans, a mathematical model based on the Markov chain 
(Thomas Buder et al., 2017). The model estimated the occurrence of 175 of 240 possible 
direct state transitions (Fig. 2E, Fig. S5C). The estimated transition matrix appeared 
irreducible with no bottlenecks, i.e., each phenotype could transit to other states either 
directly or through intermediate steps. No hierarchies or sub-hierarchies were detected 
between the phenotypes (Krackhardt hierarchy score= 0). Moreover, transitions between 
positive and negative states of one marker were independent of the other markers (Table 
S5A). Of note, the theoretical equilibrium was very similar to the original composition (Fig. 
2F).  
We next tested the validity of the model by comparing the predicted values with 
experimental data. We designed two combinations of subpopulations (mix A and B, time=0) 
predicted to reach the equilibrium in 39 days. Indeed, the FACS-sorted admixtures reverted 
to the original equilibrium at the predicted time point (Fig. 2G). Interestingly, although the 
model predicted that all subpopulations would reach the same equilibrium, subpopulations 
varied in the time needed to reach equilibrium (Fig. 2H), with P2 and P12 showing the 
fastest transitions. In conclusion, all subpopulations retain full capacity to generate other 
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phenotypic states in a highly predictable manner. Despite differences in pace, heterogeneity 
is recapitulated in time from each phenotypic state in a non-hierarchical manner.  
 
Hypoxia leads to phenotypic adaptation  
We then asked to what extent the phenotypic heterogeneity is dependent on the 
microenvironment. We first focused on hypoxia, reportedly influencing GBM stem-like 
properties (Heddleston et al., 2009) and potentially selecting for CSCs (Soeda et al., 2009, 
Pistollato et al., 2009).  Exposure to hypoxia led to a clear shift in phenotype. Hypoxic 
NCH644 cells were more positive for CD133, CD44 and A2B5, whereas CD15 was 
decreased (Fig. 3A). In particular, P5 and P7 were enriched, whereas several 
subpopulations (e.g. P2, P10) were reduced.  Changes were not always gradual in time, 
suggesting indirect state transitions before reaching a new hypoxia-specific equilibrium. A 
similar adaptation to hypoxia was detected in NCH421k (Fig. S4C).  
To test whether the changes were a result of selection or phenotypic adaptation we next 
FACS-sorted 16 subpopulations and performed functional assays under hypoxia (Fig. 2A). 
Again, all subpopulations self-renewed (Fig. 3B) and proliferated (Fig. 3C). Certain 
subpopulations differed in self-renewal potential during initial passages (Table S6). P10, 
P12 and P14 showed low clonogenic potential at the first passage, which was in accordance 
with their reduction in long term hypoxia (Fig. 3A), pointing to a possible partial selection at 
early time points. These differences were however lost in later passages, indicating efficient 
adaptation. Although single cells gave rise to smaller spheres compared to normoxia, 
hypoxic spheres did not differ in size between each other (Fig. 3B). The decreased self-
renewal did not correlate with the proliferation index as only two subpopulations statistically 
differed from each other (Fig. 3C). All subpopulations proliferated indefinitely, though at a 
decreased rate. The lack of correlation between phenotypes enriched in hypoxia and their 
proliferation index suggests a strong role of phenotypic adaptation to a changing 
environment. 
 
GBM state transitions in hypoxia 
To model phenotypic adaptation to hypoxia we analyzed FACS-sorted subpopulations after 
60 days in hypoxia. All subpopulations created a phenotypic distribution resembling the 
original hypoxic cultures, rather than the normoxic equilibrium (Fig. 3D). Statistical 
differences were still observed, suggesting that the equilibrium had not been reached yet. 
Nevertheless, all subpopulations recreated a CSC-associated heterogeneity in hypoxia. 
This was also true for single cell clones reformed following the self-renewal test (Fig. S5D).  
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Markov chain modeling revealed that, although direct state transitions were more restricted 
compared to normoxia (103/240; Fig 3E, Fig. S5E), all subpopulations could transit to other 
states except to P10. This was in accordance with the very low proportion of P10 observed 
in hypoxia (Fig. 3A) and its low self-renewal potential at initial passage (Fig. 3B). Notably, 
P10 survived hypoxia and could transform to other states, preferentially to P3. 
Subpopulations enriched in hypoxia (e.g. P5, P7) could be formed from numerous 
phenotypic states (≥9). The transition matrix appeared reducible with one transient state 
(P10, i.e. no phenotype can transit into P10 and P10 is depleted from the hypoxic 
equilibrium), but no absorbing state (i.e. exit from this state is not possible). Most 
populations needed >250 days to reach hypoxic equilibrium (Fig. 3F), compared to 92 days 
for the bulk culture. Of note, the subpopulations enriched in hypoxia (e.g. P5, P7) did not 
carry an advantage to reach equilibrium faster, rather, the subpopulations not enriched in 
hypoxia (P2, P9 and P12) were most adaptive. Interestingly, they also belonged to the 
fastest adapting subpopulations in normoxia (Fig. 2H). Altogether these results suggest that 
the phenotypic shift in low oxygen conditions occurs through adaptation of existing cells. 
Only a very limited hierarchy (Krackhardt hierarchy score=0.125) was observed. Although 
we cannot exclude a partial selection for certain phenotypic states, all subpopulations 
survived hypoxia and readapted to reach a hypoxia-specific equilibrium.  
 
GBM differentiation program is incomplete and reversible 
We further tested the differentiation ability of GBM cultures. Upon differentiation cells 
underwent morphological changes both in normoxia (Fig. 4A) and hypoxia (Fig. S6A). 
Although expression of neuronal (β-III-tubulin) and astrocytic (GFAP) markers increased, 
CSC-associated intracellular markers (e.g. Nestin, Vimentin) remained expressed, 
suggesting an incomplete differentiation process (Fig. 4B; Fig S6B). In normoxia, 
differentiation resulted in a strong shift towards CD133- and CD44+ subpopulations (P13-
P16), although CD133-CD44- cells (P11) were also enriched (Fig. 4C). Although similar 
changes were observed in hypoxia, the phenotypic shift under these condition was clearly 
the result of two environmental pressures, i.e. a decrease of CD133+ cells upon 
differentiation was compensated by increased CD133 in hypoxia (Fig. 4C). Similar data 
were obtained for NCH421k, which lost the predominance of the P2 subpopulation both in 
normoxia and hypoxia (Fig. S6D).  
We next assessed the phenotypic heterogeneity upon returning to normoxic 3D sphere 
conditions. Regardless of the differentiation status and oxygen level, GBM cells regrew 
morphologically as 3D spheres and regained the expression of intracellular stem cell 
markers (Fig. S6C). This was accompanied by a partial regain of the initial membrane 
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marker heterogeneity at day 14 (Fig. 4C, Fig S6D). Markov modeling predicted a longer 
time to revert to normoxic equilibrium from differentiated states in NCH644 cells (75 and 84 
days from Diff_N and Diff_H conditions, respectively). Reversibility of the phenotypic shift 
was also possible from adherent undifferentiated cultures and 3D hypoxic conditions (not 
shown). In summary, GBM cells undergo an incomplete and reversible differentiation 
program, which is independent of oxygen level.  
 
Reversible adaptation of the CSC-associated phenotype in vivo 
We next asked whether the reversible phenotypic adaptation occurs in the mouse brain. All 
implanted GBM cultures adapted their phenotype to the brain environment (Fig. 4D; Fig. 
S6E-F) with a strong tendency towards enrichment of CD133-CD44- cells (P9-P12) and 
depletion of CD133+CD44+ (P5-P8) and CD133-CD44+ (P13-P16) cells.  These changes 
were different from the equilibria observed in hypoxic and differentiation conditions in vitro, 
suggesting the impact of additional factors in the complex in vivo microenvironment. This 
was also true for the intracellular stem cell and differentiation markers (Fig. 4E, Fig. S6G). 
Again, the phenotypic change in vivo was reversible and xenografted tumor cells regained 
the heterogeneous profile when returned to in vitro conditions (Fig. 4D, Fig. S6E). 
Xenografted cells were recultured for a time period equivalent to the tumor development 
time (28 days for NCH644, 56 days for NCH421k), at which point the phenotypic equilibrium 
of the original cultures was not yet reached, in accordance with mathematical modeling 
(estimated at 67 days for NCH644). 
To rule out a negative selection against certain subpopulations, we implanted individual 
subpopulations directly after FACS sorting, focusing on four phenotypic states: P6 and P15 
strongly depleted in vivo; P11 strongly enriched in vivo (Fig. 4D); and P2 the most ‘adaptive’ 
state in normoxia and hypoxia (Fig. 2H, Fig. 3F), partially depleted in vivo. While all 
subpopulations formed tumors, we observed a difference in mouse survival (Fig. 4F). Only 
mice bearing P2 developed tumors as fast as the parental cells, whereas P6, P11 and P15 
grew significantly slower. Interestingly, all subpopulations changed phenotype in vivo 
resembling the original in vivo equilibrium (Fig. 4G). This shows that the subpopulations 
were able to undergo state transitions in vivo, further confirming the strong adaptive 
capacities of GBM cells. In analogy to the hypoxic condition, subpopulations varied in time 
to reach the environment-specific equilibrium, which may explain the differences in mouse 
survival. 
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The phenotypic states display a similar transcriptome 
To correlate intra-tumoral heterogeneity at the phenotypic and transcriptomic level we 
applied single cell sequencing using the Drop-seq method (Macosko et al., 2015) on three 
PDX (P3, P8, P13) and two GBM cultures (NCH644, NCH421k). As expected, cells grouped 
by tumor of origin related to their different genetic background (Fig. 5A). Although a certain 
degree of intra-tumoral heterogeneity was observed within each tumor, we did not detect 
distinct sub-clusters and each tumor showed similar transcriptional cell-to-cell variability 
(cell-to-cell correlation coefficients: 0.72-0.86). If detected, transcripts coding for cell 
membrane markers were uniformly distributed across the tumor (Fig. 5B, Fig. S7A) and 
their expression was not linked to the cell cycle (Fig. 5C). This was also true for intracellular 
stemness (NES, VIM) and differentiation markers (GFAP) (Fig. S7A). 
As transcripts coding for cell membrane markers were generally detected at low levels (Fig. 
S7B), we were not able to discriminate phenotypic states based on mRNA expression. 
Therefore, we performed Drop-seq on two NCH644 subpopulations: P2 (representing the 
most adaptive phenotypic state in normoxia, hypoxia and in vivo) and P6 (representing cells 
positive for all stem cell-associated markers, but being less adaptive). Interestingly, the two 
phenotypic states displayed similar transcriptomic profiles to each other and to the 
heterogeneous parental culture (Fig 5 D, Fig. S7C-D). The lack of distinct cell 
subpopulations at the transcriptomic level further questions a hierarchical organization of 
GBMs.  
 
DISCUSSION  
Functional heterogeneity of cancer cells is determined not only by the genetic makeup but 
also by non-genetic programs such as stemness features and interactions with the 
microenvironment. Although it is widely appreciated that cancer cells with stem cell 
properties exist within solid tumors, increasing controversy surrounds the significance of 
the initial CSC theory. We show that phenotypic heterogeneity in GBM is not a result of a 
one-way hierarchical structure, but a dynamic process of reversible state transitions. All 
GBM subpopulations were able to display stem cell properties and were tumorigenic, 
supporting the notion that cancer cells are highly plastic in response to microenvironmental 
cues. These data argue against the targeting of a small subpopulation of cancer stem cells 
and highlight the importance of considering these dynamic processes during treatment 
design.  
 
Our study confirms previous reports showing strong inter-patient heterogeneity and the 
difficulty to identify bona fide CSC markers. Only a subset of markers fulfilled the CSC 
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criteria of heterogeneous expression within tumors. We show that the expression of CSC 
markers in vivo is not intrinsic to specific genetic clones, but is an adaptation process in 
response to environmental cues. In GBM stem-like cultures the CSC-associated phenotype 
was flexible, all subpopulations carried stemness properties and reconstituted 
heterogeneity. We further show that phenotypic heterogeneity is created via stochastic state 
transitions between phenotypic states, which do not follow a hierarchical organisation. Not 
a single phenotypic state was unipotent and irreversible. GBM cells also reverted from a 
‘differented state’, questioning the effectiveness of differentiation factors as a therapeutic 
strategy (Lee et al., 2008, Natsume et al., 2013). Although differences between solid tumors 
can be expected, our data is in agreement with reports from other cancers such as breast 
and melanoma (Gupta et al., 2011, Quintana et al., 2010, Chaffer et al., 2013). While we 
cannot exclude a partial selection upon environmental pressure, we did not observe the 
complete eradication of subpopulations under any conditions. All populations adapted 
towards the most optimal environment-specific equilibrium, suggesting that state transitions 
are tightly regulated to find the best fitted balance. This is in contrast to previous reports 
suggesting targeted selection of stem-like cells and the loss of differentiation capacities in 
hypoxia (Soeda et al., 2009, Pistollato et al., 2009). Although further studies are needed to 
identify the factors leading to phenotypic adaptation in vivo, stromal cells and the metabolic 
landscape of the brain are likely to play a role. Concordantly, macrophage/microglia (Bhat 
et al., 2013) and an acidic environment (Lathia et al., 2010) were implicated in the 
phenotypic shift.  
 
Although all cell populations carried stem cell properties and were tumorigenic, we observed 
differences in their adaptive capacity to reach to the most fitting equilibrium composition. 
This could explain some of the controversies reported in the CSC literature. Initial reports 
on GBM suggested that only CSC-marker positive cells were multipotent and able to form 
tumors (Singh et al., 2004, Son et al., 2009, Tchoghandjian et al., 2010), while later studies 
reported either no difference in tumorigenic potential (Wang et al., 2008, Ogden et al., 2008, 
Kenney-Herbert et al., 2015), or both fractions being tumorigenic, but with different potency 
(Chen et al., 2010, Auvergne et al., 2013, Auffinger et al., 2014, Brescia et al., 2013). Here 
we show that while all cells were plastic, certain adapted faster to new environments, 
leading to differences in in vitro self-renewal and in vivo transplantation assays. Even cells 
with a similar self-renewal potential in vitro, could differ in tumor development time. In 
agreement with previous reports (Quintana et al., 2008, Barrett et al., 2012) we conclude 
that the outcome of an assay strongly depends on experimental conditions and end-point.  
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Why some states appear more plastic than others is currently not clear. In addition to the 
genomic status, epigenetic flexibility regulating transcriptional networks may play a role in 
adaptive capacities (Easwaran et al., 2014, Wainwright and Scaffidi, 2017). Here we find 
that phenotypically distinct subpopulations retain a largely similar transcriptome, suggesting 
more subtle differences between GBM subpopulations compared to e.g. breast cancer 
(Gupta et al., 2011, Chaffer et al., 2013). This is in line with recent single cell RNA-seq data 
in GBM, revealing a continuous stem cell signature rather than clear subpopulations of 
stem-like versus non-stem-like cells (Patel et al., 2014). 
 
In addition to clonal selection, the importance of cell plasticity in therapy resistance is 
emerging (Sharma et al., 2010). Mathematical simulations of state transitions following 
combinatorial treatment predicted the survival of the most plastic clones (Mathis et al., 2017, 
Leder et al., 2010). In breast cancer, it has been shown that the tumorigenic potential was 
lost by inhibiting the transition from CD44-low towards CD44-high cells (Chaffer et al., 
2013). Caution is warranted towards therapies targeting epitope expressing cells including 
vaccine immunotherapies (Ji et al., 2014). Further elucidating state transition programs and 
mechanisms driving cellular plasticity will be essential to overcome current therapeutic 
limitations.  
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STAR METHODS 
TCGA gene expression analysis 
The gene expression pattern across GBM patients was investigated using The Cancer 
Genome Atlas (TCGA) cohort (160 GBM samples, provisional dataset on 25.10.2016) 
(Cancer Genome Atlas Research et al., 2013). A heatmap was generated using Gitools 
software (Perez-Llamas and Lopez-Bigas, 2011). Expression value corresponds to median-
centered RNA-seq data, DNA methylation data were from a merged dataset on 25,978 
probes shared by the HM27 and HM450 platforms analysis (#syn2486658)), and genomic 
copy number alterations were from PanCan12 Genom (details of the analysis 
https://www.synapse.org/). Group comparison was performed in Gitools using Mann-
Whitney-Wilcoxon, and Benjamini Hochberg multiple test correction was applied (at P = 
0.05, Mann-Whitney-Wilcoxon null hypothesis: correlation = 0). GBM expression subgroups 
were categorized as: Neural (n=28), Mesenchymal (n=51), Proneural (n=39), Classical 
(n=40), NA (n=2)   
 
Clinical glioblastoma samples and patient-derived xenografts 
Glioblastoma samples were collected at Centre Hospitalier in Luxembourg (Neurosurgical 
Department) or Haukeland University Hospital (Bergen, Norway) from patients having given 
informed consent, and with approval from the local ethics committees (National Ethics 
Committee for Research (CNER), Luxembourg; local ethics committee Haukeland 
University Hospital, Bergen). All biopsies were from grade IV glioblastomas. Organotypic 
GBM spheroids from patient samples were implanted in the brain of eGFP expressing 
Nod/Scid mice as previously described (Golebiewska et al., 2013, Niclou et al., 2008). 
Animals were sacrificed at the appearance of neurological symptoms and/or weight loss. 
The handling of the animals and the surgical procedures were performed in accordance 
with the European Directive on animal experimentation (2010/63/EU) and the local ethical 
committees approved the protocol.  
 
Glioblastoma cell cultures 
The glioblastoma stem-like cells NCH421k, NCH660h, NCH465, NCH601 and NCH644, 
were provided by Dr Christel Herold-Mende (Department of Neurosurgery, University of 
Heidelberg) and cultured as described before (Bougnaud et al., 2016). NCH421k, 
NCH660h, NCH465, and NCH601 were cultured as non-adherent spheres in DMEM-F12 
medium (Lonza) containing 1xBIT100 (Provitro), 2mM L-Glutamine, 30U/ml Pen-Step, 
1U/ml Heparin (Sigma), 20ng/ml bFGF (Miltenyi, 130-093-841) and 20ng/ml EGF (Provitro, 
1325950500). NCH644 grew in Neurobasal® base medium (Life Technologies) 
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supplemented with 1xB27 (Life Technologies) 2mM L-Glutamine, 30U/ml Pen-Step, 1U/ml 
Heparin (Sigma), 20ng/ml bFGF (Miltenyi, 130-093-841) and 20ng/ml EGF (Provitro, 
1325950500). The glioblastoma stem-like cells TB101 and TB107, kindly provided by Dr. 
Håkan Hedman, (Umeå University, Sweden) were cultured in DMEM-F12 medium (Lonza) 
containing 1xB27 and 1xN2 supplements (Provitro), 2mM L-Glutamine, 30U/ml Pen-Step, 
1U/ml Heparin (Sigma), 20ng/ml bFGF (Miltenyi, 130-093-841) and 20ng/ml EGF (Provitro, 
1325950500). Classical normoxic cultures were performed at 37°C under 5% CO2 
atmospheric oxygen.  
 
Hypoxia and differentiation conditions 
During hypoxia cells were maintained at 0.5% O2 in a hypoxic incubator (Galaxy 48R 
incubator, New Brunswick) for the indicated time points (16h, 48h, 7 and 60 days). 
Experiments were repeated independently three times (nB=3) with three technical replicates 
per subpopulation (nT=3).  For differentiation, cells were grown as adherent cultures in 10x 
diluted Matrigel in original medium depleted from bFGF and EGF and supplemented with 
10% FBS and 10ng/ml All-Trans Retinoic acid (ATRA, Sigma) for 14 days. Cells were 
readapted to normoxic 3D sphere cultures for an additional 14 days in original culture 
media. Experiments were repeated independently three times (nB=3) with three technical 
replicates per subpopulation (nT=3).   
 
Immunostaining 
After washing, NCH644 spheres were embedded in Tissue-Tek® O.C.T.™ Compound 
(Sakura Finetek) and flashfrozen at -80°C. Immunocytochemistry was performed on 10µm 
sections, subsequently fixed in 4% PFA for 10 minutes. Adherent cultures were fixed in 4% 
PFA for 10 minutes directly in the plates. Fixed samples were blocked for 30 min in TBS 
supplied with 0.1% Triton-X100 and 2% FBS and incubated with primary antibodies (see 
Table S7 for antibodies used) and 1µg/ml DAPI (Invitrogen). Secondary antibody staining 
was performed when needed. For image acquisition a Leica® DMI6000 B inverted 
microscope with a Leica® 350 FX camera was used with its concordant Leica Application 
Suite® software. 
 
Flow cytometry settings 
Data acquisition was performed on a FACS AriaTM SORP cytometer (BD Biosciences) fitted 
with a 640nm (30mW) red laser, a 355nm (60mW) UV laser, a 405nm (50mW) violet laser, 
a 488nm (100mW) blue laser and a 561nm (50mW) yellow/green laser. The Hoechst dye 
was excited by the UV laser and fluorescence was collected in two channels: ‘UV-1’ 450/50 
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band-pass (BP) filter and ‘UV-2’ 660/40 long-pass (LP) filter. An LP635nm dichroic mirror 
was used to split the emission wavelengths. The instrument was calibrated each time with 
Cytometer Setup&Tracking Beads (BD Bioscience) and stabilized for at least 1h before 
laser alignment and data acquisition. The Coefficient of Variation of the instrument (%CV) 
was routinely examined before each experiment. Routinely, a 100µm nozzle and window 
extension (WE) 3 were used for data acquisition and sorting. Imaging flow cytometry was 
performed with an ImageStream imaging cytometer (Amnis) fitted with a 375 UV laser, a 
488 blue laser, a 561 yellow-green laser, a 642 red laser and a 785nm infrared laser. 
Acquisition was performed with the INSPIRE® software and analysis was performed using 
IDEAS® image analysis software. Pictures were taken at 60x magnification at low speed 
high sensitivity mode. 
 
Multicolor cell membrane phenotyping  
Cell cultures were dissociated using Accutase® (Sigma-Aldrich) to obtain a single cell 
suspension. Xenografts were dissociated with MACS Neural Tissue Dissociation Kit (P) 
(Miltenyi) following the manufacturers’ instructions. Single cells were resuspended in HBSS, 
2% FBS, 10mM HEPES buffer (100 µl/test). Cells were incubated with the IR-LIVE/DEAD® 
Fixable Dead Cell Stains (Invitrogen; 1µg/ml) and appropriate preconjugated antibodies for 
30 min at 4°C in the dark (Table S7). For cell cycle analysis in viable cells, cells were 
prestained with Hoechst 33342 (5µg/ml, Bisbenzimide, Ho342; Sigma) at 37°C as described 
before (Stieber et al., 2014). Data acquisition was performed on a FACS AriaTM SORP 
cytometer (BD Biosciences) and ImageStream imaging cytometer (Amnis). Data acquisition 
and analysis were done for FACSAria with DIVA software (BD Bioscience); and INSPIRE 
and IDEAS® for ImageStream. Histograms were prepared with the FlowJo software.  
 
Intracellular marker phenotyping  
Cell cultures were dissociated using Accutase® (Sigma-Aldrich) to obtain a single cell 
suspension. Xenografts were dissociated with MACS Neural Tissue Dissociation Kit (P) 
(Miltenyi) following the manufacturers’ instructions. Single cells were resuspended in HBSS, 
2% FBS, 10mM HEPES buffer (100 µl/test). Cells were incubated with the IR-LIVE/DEAD® 
Fixable Dead Cell Stains (Invitrogen; 1µg/ml) and appropriate preconjugated antibodies for 
30 min at 4°C in the dark (Table S7). Cells were fixed with the BD  
CytofixTM solution for 20 min and permeabilised in the BD Perm/WashTM for 10min at RT. 
Cells were incubated with appropriate preconjugated antibodies for 30 min at 4°C in the 
dark (Table S7). Data acquisition was performed on a FACS AriaTM SORP cytometer (BD 
Biosciences). 
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Selfrenewal test 
Single cells from 16 subpopulations were FACS-sorted to a 96 well plate (1 cell/well; one 
96 well plate per subpopulation) and cultured for 4 weeks in normoxia or 0.5% O2 hypoxia. 
Spheres derived from each subpopulation were collected (passage 1) and single viable 
cells were resorted and plated as single cells (one 96 well plate/subpopulation, 1 cell/well). 
Replating was done 3 times to reach 4 passages in total. Only spheres >40µm were 
considered as a positive result for sphere forming capacity. Total sphere number and 
average sphere size (n=20 per subpopulation if available) were recorded at each passage 
before cell harvesting. Each subpopulation at each passage was phenotyped as described 
above. FACS-sorted viable single cells from the bulk cells were used as control. The 
experiment was repeated independently four times. Significant differences in sphere 
number across populations and passages were evaluated with the Kruskal-Wallis test. 
Significant differences in sphere size were tested with mixed linear models with either 
subpopulation or passage as fixed-effects and considering batch effect as random.  
 
Proliferation and mulitpotency test 
300 cells of each NCH644 subpopulation were FACS-sorted to a 48 well plate and cultured 
for 20, 30 and 70 days in normoxia or 0.5% O2 hypoxia. At each time point, cells derived 
from each subpopulation were phenotyped as described above. Total cell number was 
recorded with the Countess® cell counter (Invitrogen) after 20 and 30 days of culture to 
determine the proliferation rate. Doubling time was calculated as follows: 
 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 =
𝑡2−𝑡1
𝑙𝑜𝑔2 
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟2
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟1
 , where 𝑡1 and 𝑡2
 represented time points. FACS-sorted 
single viable cells from bulk were used as control. The experiment was repeated 
independently four times (nB=4) with three technical replicates per subpopulation (nT=3).  
Significant differences of doubling times were tested with mixed linear models with 
subpopulation as fixed-effects and considering plate effects as random. The proportion of 
each subpopulation was calculated as the percentage of viable single cells. The column 
chart graphs show mean percentage of technical and biological replicates. Error bars were 
omitted for visualization purposes. Alluvial plots have been generated under R using the 
package alluvial available at https://github.com/mbojan/alluvial (R, 2016). Significant 
differences between phenotypic states were calculated with the Student’s t-test with 
Bonferroni’s multiple comparison test/correction. 
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Mathematical Modeling 
Markov model principles 
In order to quantify the transitions between the 16 phenotypes we applied Markov chain 
modeling implemented in the freely available R package CellTrans 
(http://github.com/tbuder/CellTrans) (Buder et al., 2017). The model is based on the 
assumptions that cell state alterations occur due to stochastic cell state transitions only 
depending on the current state of the cell and possibly the experimental environment (e.g. 
hypoxia) and that proliferation rates of the involved phenotypes are approximately equal. 
This led to the estimation of a Markov chain with a transition matrix containing the 
probabilities of state transitions allowing to discriminate frequent and non-frequent state 
transitions and identify hierarchical or non-hierarchical transition behavior. If the underlying 
network is irreducible, each state can transit directly or via intermediate steps into any other 
state. This behavior implies that stochastic state transitions are non-hierarchical and 
therefore reversible in a biological sense. In contrast, if the transition network has a tree 
structure, it corresponds to a perfect hierarchy. Intermediate network structures are possible 
as well, which imply some degree of hierarchy between transient states at the top of the 
hierarchy and recurrent states at the bottom of the hierarchy. Moreover, on the basis of the 
estimated transition matrix, it is possible to predict the composition of the population in 
equilibrium by calculating the Markov chain stationary state. In addition, the time from a 
specific initial composition until an approximate equilibrium is reached can be estimated.  
Construction of data matrices. Let 𝑤𝑖,𝑗
(𝑡)
 denote the experimentally observed mean 
proportion of phenotype 𝑗, 𝑗 = 1,… ,16, in the experiment starting with pure subpopulations 
of phenotype 𝑖, 𝑖 = 1,… ,16, at time 𝑡. Then, one can construct a phenotype proportion 
matrix at time 𝑡 as follows. 
𝑊(𝑡) = (
𝑤1,1
(𝑡)
⋯ 𝑤1,16
(𝑡)
⋮ ⋱ ⋮
𝑤16,1
(𝑡)
⋯ 𝑤16,16
(𝑡)
) 
Note that the phenotype proportion matrix describing the initial proportions is the 
16𝑥16 identity matrix, i.e. 
𝑊(0) =
(
 
 
1 0 ⋯ ⋯ 0
0 1 0 ⋯ 0
⋮ ⋱ ⋱ ⋱ ⋮
⋮ ⋱ ⋱ ⋱ 0
0 0 ⋯ 0 1)
 
 
. 
The transitions between the phenotypes were estimated as probabilities of state transition 
per time-step of the underlying Markov chain. Importantly, the implications of the model with 
respect to hierarchical structure, equilibrium composition and relaxation time are highly 
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independent of the choice of the time-step length. Here, we choose a time-step length of 
one day. We obtained three phenotype matrices from the experimental data in normoxia: 
𝑊(20) after 20 days, 𝑊(30) after 30 days and 𝑊(70) after 70 days. In hypoxia we 
constructed only one matrix, namely 𝑊(60) for the measurement after 60 days. 
Estimation of the transition probabilities. Markov chain theory allows to connect the 
initial phenotype proportion matrix with the phenotype matrix after 𝑛 time-steps with the 
equation 𝑊(0)𝑃𝑛 = 𝑊(𝑛). This equation can be solved for the underlying transition 
matrix 𝑃, i.e. 
?̂?(𝑛) = ((𝑊
(0))
−1
𝑊(𝑛))
1
𝑛
 . 
Hence, we obtained the three transition matrices ?̂?(20),  ?̂?(30) and ?̂?(70) in normoxia which 
needed to be regularized in order to obtain stochastic matrices, see (Buder et al., 2017) for 
details. These matrices were averaged to obtain a final estimate for the transition matrix 𝑃, 
i.e. ?̂? =
?̂?(7)+ ?̂?(10)+ ?̂?(23)
3
. In hypoxia, 𝑃 = ?̂?(60) was used since there was only one time point 
of measurement. 
Krackhardt Hierarchy. In order to estimate the degree of hierarchy of the estimated 
transition matrixes from data obtained under different environmental conditions, graph 
hierarchy introduced by Krackhardt was calculated (Krackhardt, 1994). The degree of 
deviation from pure hierarchy, i.e. tree structure, is assessed by counting the number of 
pairs that have reciprocated ties relative to the number of pairs where there isn’t? any tie, 
i.e. the proportion p of all tied pairs having reciprocated ties. Krackhardt hierarchy is then 
defined as 1-p. A perfect hierarchy is characterized by no reciprocated ties and exhibits a 
Krackhardt hierarchy of one. Calculations were performed in R using “hierarchy” function 
with “Krackhardt” measure. 
Marker dependency calculation. We investigated whether the cell state transitions 
between positive and low/negative expression of one marker in normoxia and hypoxia were 
dependent on the level of expression of the other markers. For each marker, we 
distinguished two phenotypic states with respect to positive and low/negative expression of 
this marker. In detail, we added the percentage of all CSC-associated subpopulations with 
positive or low/negative expression of that marker in the measured plasticity data for each 
time-point of measurement. This resulted in 2x2 cell state proportion matrixes per time point. 
This coarse-grained data could be utilized to derive corresponding 2x2 cell state transition 
matrixes and corresponding steady states by applying CellTrans (Buder et al., 2017).  
The steady states of these 2x2 cell state transition matrices could then be compared to the 
fractions of the corresponding phenotype when considering all 4 markers in the analysis. 
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Therefore, percentage of subpopulations with the same expression of a single marker were 
added to obtain the steady state proportion for each individual marker. Nearly equal 
equilibrium proportions indicate independent transitions whereas large differences indicate 
a dependency. Calculations were performed for normoxic and hypoxic datasets. 
 
Cell line-derived xenografts and in vivo tumor formation test 
GBM patient-derived cultures were implanted intracranially to NOD/Scid mice (50,000 per 
mouse for NCH644 and NCH421k, 300’000 cells for NCH660h and NCH601, n=3) into the 
right frontal cortex using a stereotactic device. Animals were sacrificed at the appearance 
of neurological symptoms and weight loss. To test tumorigenicity in vivo, 5000 cells of P2, 
P6, P11 and P15 subpopulations and original NCH644 cells were engrafted into nude mice 
directly after sort (n=7 per group). Animals were monitored daily and the following criteria 
were evaluated: (1) loss of more than 10% of body weight, (2) exhibition of strong 
neurological signs (difficulty ambulating or abnormal movement), (3) increased lordosis or 
(4) swollen belly. The criteria were scored as follows: 0 = none, 1 = early, 2 = established, 
3 = severe signs and animals were sacrificed when 3 criteria with grade 2 or 1 criterion with 
grade 3 were reached. Tumor developed in xenografted mice were FACS phenotyped as 
described above. The handling of the animals and the surgical procedures were performed 
in accordance with the European Directive on animal experimentation (2010/63/EU) and 
the local ethical committees approved the protocol.  
 
Single cell RNAseq using Drop-seq 
Cell preparation 
To obtain a pure population of single viable cells all GBM cultures were FACS-sorted 
(NCH644, NCH421k bulk cultures and NCH644 subpopulations P2 and P6). For GBM PDXs 
we have pre-selected hCD90-positive tumor cells. FACS-sorted populations were collected 
in HBSS, 0.5% BSA and stored on ice until the start of the Drop-seq experiment. Prior to 
cell loading on the Drop-seq chips, the viability of cells was verified and concentration was 
adjusted to ~150 cells/l as optimal concentration to achieve single cell encapsulation within 
each droplet of ~1 nl . All samples analysed had a cell viability > 95%. 
Mircrofluidics Fabrication 
Microfluidics devices were fabricated using a previously published design (Macosko et al., 
2015). Softlithography was performed using SU-8 2050 photoresist (MicroChem) on 4” 
silicon substrate to obtain a feature aspect depth of 100m. After overnight silanization 
(using Chlorotrimethylsilane, Sigma), the wafer masks were used for microfluidics 
fabrication. Drop-seq chips were fabricated using silicon based polymerization chemistry, 
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with the previously published protocol (Mazutis et al., 2013). Briefly, Polydimethylsiloxane 
(PDMS) base and crosslinker (Dow Corning), were mixed at a 10:1 ratio, mixed and 
degassed before pouring onto the Drop-seq master template. PDMS was cured on the 
master template, at 80°C for 2h. After incubation and cooling, PDMS slabs were cut and 
the inlet/outlet ports were punched with 1.25 mm biopsy punchers (World Precision 
Instruments). The PDMS monolith was plasma-bonded to a clean microscopic glass slide 
using a Harrick plasma cleaner. Immediately after pairing the plasma-treated surfaces of 
the PDMS monolith and the glass slide, flow channels of the Drop-seq chip were subjected 
to a hydrophobicity treatment using 1H,1H,2H,2H-Perfluorodecyltrichlorosilane (in 2% v/v 
in FC-40 oil; Alfa Aeser/Sigma). After 5 min of treatment, excessive silane was blown 
through the inlet/outlet ports. Chips were further incubated at 80°C for 15 minutes. 
Single cell droplet suspension  
Experiments followed the original Drop-seq protocol (Macosko et al., 2015) with minor 
changes described below. Synthesized barcoded beads (Chemgenes corp., USA) were co-
encapsulated with cells inside the droplets containing lysis reagents using an optimal bead 
concentration of 200 beads/l in Drop-seq Lysis buffer medium. Cellular mRNA was 
captured on the beads via barcoded oligo (dT) handles synthesised on the surface. 
For cell encapsulation, 2 ml of cell and bead suspensions were loaded into 3 ml syringes 
(BD), respectively. To keep beads in homogenous suspension a micro-stirrer was used (VP 
scientific). The QX 200 carrier oil (Bio-rad) used as continuous phase in the droplet 
generation was loaded into a 20 ml syringe (BD). For droplet generation, 3.6 ml/hr and 
13 ml/hr were used in KD scientific Legato syringe pumps for the dispersed and continuous 
phase flows, respectively. After stabilization of droplet formation, the droplet suspension 
was collected into a 50 ml Falcon tube. Collection of the emulsion was carried out until 1µl 
of the single cell suspension was dispensed. Droplet consistency and stability were 
evaluated by bright-field microscopy using INCYTO C-Chip Disposable Hemacytometer 
(Fisher Scientific). Bead occupancy within droplets was carefully monitored to avoid multiple 
bead occupancy. 
The subsequent steps of droplet breakage, bead harvesting, reverse transcription and 
exonuclease treatment were carried out in accordance to (Macosko et al., 2015). RT buffer 
contained 1x Maxima RT buffer, 4% Ficoll PM-400 (Sigma), 1 μM dNTPs 
(ThermoScientific), 1 U/ml Rnase Inhibitor (Lucigen), 2.5 μM Template Switch Oligo, and 
10 U/ml Maxima H-RT (ThermoScientific). Post Exo-I treatment, the bead counts were 
estimated using INCYTO C-Chip Disposable Hemacytometer, and 10,000 beads were 
aliquoted in 0.2 ml Eppendorf PCR tubes. PCR mix was dispensed in a volume of 50l 
using 1x Hifi HotStart Readymix (Kapa Biosystems) and 0.8 mM Template-Switch-PCR 
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primer. The thermocycling program for the PCR amplification was modified for the final PCR 
cycles by 95°C (3 min), four cycles of 98°C (20s), 65°C (45s), 72°C (3 min), 10 cycles of 
98°C (20s), 67°C (20s), 72°C (3 min) and followed by a final extension step of 72°C for 5 
min. Post PCR amplification, libraries were purified with 0.6x Agencourt AMPure XP beads 
(Beckman Coulter), in accordance with the manufacturer’s protocol. Finally, the purified 
libraries were eluted in 20 μl RNAase/DNAase-free molecular grade water. Quality and 
concentration of the sequencing libraries were assessed using BioAnalyzer High Sensitivity 
Chip (Agilent Technologies). 
NGS preparation for Drop-seq libraries 
The 3’ end enriched cDNA libraries were prepared by tagmentation reaction of 600 pg cDNA 
library using the standard Nextera XT tagmentation kit (Illumina). Reactions were performed 
according to the manufacturer’s instructions, except for the 400nM primer sets replaced by 
Primer 1 (AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGG 
AAGCAGTGGTA TCAACGCAGAG T*A*C) and Primer 2 (N703: 
CAAGCAGAAGACGGCATACGAGA TTTCTGCCTGTCTCGTGGGCTCGG for the 
NCH644 subpopulation 6 and N709: 
CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG for NCH644 
subpopulation 2, NCH644 and NCH421k). The PCR amplification cycling program used 
was: 95°C 30s; fourteen cycles of: 95°C (10s), 55°C (30s), 720C (30s) followed by a final 
extension step of 72°C (5 min). Libraries were purified twice to reduce primers and short 
DNA fragments with 0.6x and 1x Agencourt AMPure XP beads (Beckman Coulter), 
respectively, in accordance with the manufacturer’s protocol. Finally, purified libraries were 
eluted in 15 μl molecular grade water. Quality and quantity of the tagmented cDNA library 
was evaluated using BioAnalyzer High Sensitivity DNA Chip. The average size of the 
tagmented libraries prior to sequencing was between 400-700 bps. 
Purified Drop-seq cDNA libraries were sequenced using Illumina NextSeq 500 with the 
recommended sequencing protocol except for 6pM of custom primer 
(GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC) applied for priming of read 1. 
Paired end sequencing was performed with the read 1 of 20 bases (covering the random 
cell barcode 1-12 bases and the rest 13-20 bases of random unique molecular identifier 
(UMI) and for read 2 the 50 bases of the genes. 
Bioinformatics processing and data analysis 
The FASTQ files were assembled from the raw BCL files using Illumina’s bcl2fastq 
converter and ran through the FASTQC codes [Babraham bioinformatics; 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/] to check for consistency in 
library qualities. The monitored quality assessment parameters were a) quality per base 
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sequence (especially for the read 2 of the gene), b) per base N content, c) per base 
sequence content and d) overrepresented sequences. Libraries that showed significant 
deviation were re-sequenced. The FASTQ files were then merged and converted to binaries 
using PICARD’s fastqtosam algorithm. 
The sequencing reads were converted to a digital gene expression matrix (DGE) using the 
Drop-seq bioinformatics pipeline (Macosko et al., 2015). To normalize for the transcript 
loading between the beads, the averaged normalized expression levels (log2(TPM+1)) were 
calculated. Beads without cellular mRNAs were identified by using a cumulative function of 
the total number of transcripts per barcode and empirical thresholding on the resulting “knee 
plot”. To filter poor quality reads and cells with low transcript content, only cells with at least 
1500 expressed genes and genes at least expressed in 20 cells were considered for further 
analysis. The average number of UMI-collapsed transcripts per cell was 5970 
corresponding to the 2430 genes detected per cell on average.  
To remove batch effect, we used independent component analysis ICA (R fastICA package) 
decomposing the original expression matrix into a product of statistically independent 
signals and weight matrices: Xnm = Snk x Mkm , where Xnm is the log-transformed count matrix 
for n genes and m cells, Snk is a matrix of k independent components and Mkm is the weight 
matrix for each component over m cells. Stability of the ICA decomposing was tested by 
100 runs of ICA. The log-transformed count matrix was decomposed using 8 independent 
components. The optimal number of components was selected by minimizing the 
correlation between rows of weight matrix. We observed that the weight of component #7 
was strongly linked to the experimental batch. In accordance with (Biton et al., 2014), this 
component was suppressed by setting its weight (M7,i, where i = 1..m) to 0, and the 
normalized data were recovered by matrix multiplication of the components by their weights. 
Estimation of the highly variable genes and principal component reduction and tSNE 
dimensionality reduction was implemented using SEURAT R package 
(http://satijalab.org/seurat/) or the R package Rtsne with an initial PCA, a perplexity 
of 40 and a learning rate of 200 (5000 iterations) (https://github.com/jkrijthe/Rtsne). For 
reproducibility with the original algorithm, the theta value was set to zero. 
The correlation coefficient was calculated between each cell after filtering using the 
Pearson method; the mean value is represented for each group/subpopulation/fraction. 
Differential expression analysis was performed using DESeq2 package of R (Love et al., 
2014). Here the raw integer counts were used for consistency with the algorithm 
requirements. Centering of the gene expression value was performed by obtaining the 
relative expression levels, by subtracting the average expression value (log2(TPM+1)) of 
each gene from all the cells of the gene expression matrix. For cell cycle analysis we have 
 239 
 
 
7 
 
applied two prominent gene expression programs of the G1/S (100 genes) and G2/M 
phases (133 genes) (Whitfield et al., 2002), shown to overlap in the two programs (Macosko 
et al., 2015).  
Due to the sparsity of the single cell RNAseq data, the expression data for each cell cycle 
phase was refined by evaluating the correlation data between each of the genes in the 
scRNAseq data with the average gene expression values of all the genes involved in the 
respective cell cycle program (G1/S & G2/M), and including all the genes with high 
correlation value (R2 > 0.3; Pval < 0.05). Hierarchical clustering of the data demonstrated 
that some cells are cycling with high relative expression of most of the genes included in 
either of the cell cycle program or both of the programs, while other cells show basal 
expression for most of these genes (data not shown). The biaxial plot of G1/S and G2/M 
programs illustrated in the Figure 5C is the average score of all the genes involved in the 
respective cell cycle programs. Figure 5C, further represents the expression value of 
different genes of interest by mapping the expression value onto the respective cells.  
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Figure 1. CSC-associated heterogeneity in GBM. A. Inter-patient heterogeneity at the 
gene expression level for a panel of CSC-associated markers and selected GBM drivers. 
See further analysis in Fig. S1 and Table S1; B. Pearson gene expression correlation 
between CSC-associated markers and main GBM drivers. No significant correlation was 
observed. C. Flow cytometric analysis of tumor cells for CD133, CD44, A285 and CD15 in 
3 GBM PDXs (P3, P8, P13). Percentage of positive cells (‘black’ gate) is indicated vs. 
negative control and vs. high expressing cells (‘red’ gate). See Fig. S2 for gating strategy 
and Fig. S3 for more examples. D. Marker expression profiles in the genetically 
heterogeneous T16 PDX (all tumor (‘black’), pseudodiploid (‘blue’) and aneuploid (‘red’) 
clones). Separately implanted pseudodiploid (blue) and aneuploid clones (red) adapted the 
CSC-associated profiles in the xenograft  (right). E. Multicolor phenotyping. Representative 
ImageStream images are shown for NCH644 subpopulations. Right pannel presents color 
code for 16 subpopulations applied in consecutive figures. F. Distribution of the 
subpopulations in 7 stem-like cultures (mean percentage, error bars were ommitted for 
visualization purposes) as determined by flow cytometry. For color code see E. G. 
Distribution of CSC-associated markers and Ki67 proliferating cells  in 3D NCH644 spheres 
(bar = 100µm).  
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Figure 2. GBM subpopulations undergo state transitions in a non-hierarchical 
manner. A. Experimental setup of FACS sorting and functional analysis performed on 16 
subpopulations. See Fig. 2E for gating strategy. Data is shown for the 16 subpopulations 
of NCH644 cells. B. Self-renewal test, including sphere formation and sphere diameter 
(mean +/- SEM). Bulk cells were used as control (CTR). No statistical difference was 
observed, except for P11 passages 1 vs. 2 and 1 vs. 3 (p*≤0.05). C. Proliferation test (mean 
doubling time +/- SEM). No statistical differences were observed. D. Multipotency test. 
Marker expression over time: FACS-sorting day 0 (D0) and re-phenotyping after 20 (D20), 
30 (D30) and 70 (D70) days in culture. The order of subpopulations in alluvial plots is based 
on highest to lowest percentage at each time point. See Fig. S5 for column chart and Table 
S3A for statistics. For color code see Fig.1E E. Markov modeling of state transitions 
between 16 subpopulations. Arrows represent predicted direct state transitions between 
subpopulations, thickness of lines corresponds to transition probabilities. See Fig. S5C for 
transition matrix. F. Proportions of subpopulations predicted in equilibrium state is similar to 
initial culture. G. Validation of Markov modeling. FACS-sorted admixtures (time 0) were re-
phenotyped at the predicted equilibrium time (39 days) showing the accuracy of the 
mathematical model. See Table S2A for statistics. H. Predicted time to reach equilibrium 
for each subpopulation.  
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Figure 3. Adaptation of GBM subpopulations to hypoxia. A. Distribution of 
subpopulations in hypoxia (H). Normoxia (N) is shown as control (CTR) and hypoxia (H) at 
16h, 48h, 7 and 60 days. Data is shown for NCH644, additional cultures are shown in Fig. 
S4C. See Table S2B for statistics. For color code see Fig.1E. Self-renewal test of 16 
subpopulations in hypoxia (mean +/- SEM).  Bulk cells were used as control (CTR). 
Statistical differences within the same subpopulations are shown (*pvalue≤0.05). See Table 
S6 for statistical differences at different passages. C. Proliferation test in hypoxia (mean 
doubling time +/- SEM). Bulk cells were used as control (CTR). Statistical difference was 
only found between P7 and P13. D. Distribution of 16 subpopulations after 60 days in 
hypoxia. For each FACS-sorted subpopulation day 0 (left) and 60 (right) are presented. See 
Table S3B for statistics. E. Markov modeling of state transitions in hypoxia. Arrows 
represent direct state transitions between subpopulations, thickness of lines corresponds 
to transition probabilities. See Fig. S5E for transition matrix. F. Predicted time needed to 
reach equilibrium for each subpopulation in hypoxia.  
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Figure 4. Reversible adaptation after in vitro differentiation and in vivo growth. 
A. Examples of NCH644 grown as adherent cultures in stem cell (Undiff_N) or differentiation 
(Diff_N) conditions in normoxia. B. Flow cytometric analysis of intracellular markers in 
control 3D sphere cultures (CTR), differentiation (Diff) conditions. N= normoxia, H= hypoxia. 
Black lines discriminate between negative and positive cells. Dotted line indicate mode 
expression in control cells. C. Distribution of subpopulations under different environmental 
conditions compared to 3D spheres in normoxia (CTR). For each condition phenotyping 
was performed after 14 days of environmental change (left) and 14 days after subsequently 
reverting to original 3D sphere culture (right). See Table S2D for statistics. D. Distribution 
of subpopulations in xenografted NCH644 tumors in vivo (X) and after regrowth in vitro (De-
X). NCH644 cultured in normoxia are shown as control (CTR). See Table S2F for statistics. 
E. Flow cytometric analysis of intracellular markers. Black lines discriminate between 
negative and positive cells. Dotted line indicate mode expression in control cells. F. Kaplan-
Meier survival curves of xenotransplanted mice. Subpopulations P2, P6, P11 and P15 were 
implanted directly after FACS. FACS-sorted bulk cells were used as control (CTR) 
(*pvalue≤0.05; **pvalue≤0.01). G. Distribution of subpopulations in xenografted tumors. For 
each subpopulation, day of implant and day of mouse sacrifice are presented. See Table 
S2H for statistics.  
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Figure 5. Distinct phenotypic states carry similar transcriptome. A. Overall gene 
expression relationship between single cells of 3 GBM PDXs and 2 stem-like cultures. 
Patient-derived cells are color coded. B. Expression of marker genes in NCH644. The 
expression gradient is color coded. C. Estimation of cell cycle state of individual NCH644 
cells on the basis of relative expression of G1/S and G2/M gene sets. The expression 
gradient of marker genes is color coded. D. Gene expression relationship between FACS-
sorted subpopulations P2 and P6 and the original heterogeneous NCH644 (CTR). Each 
sample is color coded.  
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Figure S1. Genetic aberrations and mutations in GBM patient samples.  Analysis of 
genetic alterations in main cancer and selected stem cell markers in GBM. A. Heatmap 
showing an integrated value dimension for genomic alterations (mutation and/or copy 
number alteration) in the different GBM expression subgroups (Proneural, Neural, 
Mesenchymal and Classical) B. Heatmap showing promoter methylation of some genes in 
clinical samples. C. Heatmap of Pearson correlation significance calculated from promoter 
methylation data. Only the FUT4 promoter displayed altered DNA methylation, which was 
not correlated to the MGMT promoter methylation (p=0.086). 
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Figure S2. Gating strategy for multicolor phenotypic analysis and sorting. A. The 
step-by-step gating strategy for FACS analysis is shown for the intracranial NCH644 
xenograft. The same strategy was used for all subsequent experiments using single viable 
cells. (1) Cells were distinguished from debris on the flow cytometric profile based on the 
Forward Scatter (FSC) and Side Scatter (SSC). (2) Cell doublets and aggregates were 
gated out based on their properties displayed on the FSC area (FSC-A) versus height (FSC-
H) dot plot. (3) Dead cells were recognized by their strong positivity for the dead cell 
discrimination marker. B. In xenografts, human tumor cells were selected as the eGFP 
negative population (eGFP+ Nod/SCID mice) or hCD90 positive cells (nude mice and non-
eGFP Nod/SCID mice). C. Multicolor phenotyping was performed by simultaneous staining 
for four CSC-associated markers: CD133, CD44, CD15, and A2B5. D. 16 subpopulations 
were distinguished based on the presence/absence of the expression of the four cell 
membrane markers. E. For multicolor sorting more stringent gates were applied to ensure 
no overlap between the 16 subpopulations. FACS-sorting gates were applied near the 
brightest and dimmest ends of the spectrum. 
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Figure S3. CSC-associated marker expression profiles in GBM PDXs and stem-like 
cultures. A. Flow cytometric analysis of tumor cells showing inter-patient heterogeneity for 
a panel of CSC-associated epitopes in GBM PDXs.  Expression was considered negative 
(-) when positive staining was equal to negative control, low when mean fluorescence 
intensity (MFI) of positive staining was less than 10x negative control (low), positive with 
10-100x difference in MFI (+) and high when MFI was >100x higher compared to negative 
control (++).  B. Flow cytometric analysis of tumor cells showing inter-patient heterogeneity 
for the CD133, CD44, CD15 and A2B5 epitopes in GBM PDXs (left panels) and stem-like 
cultures (right panels). Percentage of positive cells is indicated for all markers vs. negative 
control (‘black’ gating, positive vs. negative cells). For intratumoral heterogeneity 
discriminating negative, low and high expressing cells additional gating was applied (‘red’ 
gating). For defining 16 distinct subpopulations heterogeneity based on low vs. high 
expression levels (‘red’ gating) had priority over negative vs. positive discrimination (‘black’ 
gating) if applicable.  See Fig. S2 for gating strategy.  
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Figure S4. Characterization of intratumoral CSC-associated heterogeneity. A. Cell 
cycle analysis of 16 subpopulations of NCH644 cells. Cells in S/G2/M cell cycle phase were 
distinguished from the G1 phase based on the Hoechst flow cytometric profile combined 
with multicolor phenotyping in viable cells (n=3, mean +/- SEM, ttest, *pvalue≤0.05; 
**pvalue≤0.01; ***pvalue≤0.001). B. Multipotency of NCH421k cells. NCH421k cells were 
stained with one epitope at a time (CD133, CD44, A2B5 and CD15). 500 positive and 
negative cells were FACS-sorted, cultured (n=4) and re-phenotyped after 25 days for the 
presence of the same markers. All populations were able to recreate initial heterogeneity. 
C. Distribution of NCH644 subpopulations upon hypoxia. NCH421k cells were cultured in 
normoxia (N) and hypoxia (H) for 16h, 48h, and 7 days. Distribution of subpopulations is 
presented as a mean percentage of each subpopulation in viable single cells (nB=3; nT=3). 
See Table S2C for statistics. 
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Figure S5. GBM state transitions in normoxia and hypoxia. A. Distribution of 16 FACS-
sorted NCH644 subpopulations over time. Re-phenotyping was performed 20 (D20), 30 
(D30) and 70 (D70) days after FACS (D0) for each subpopulation (nB=4; nT=3). The 
distribution of subpopulations is presented as a mean percentage of each subpopulation in 
viable single cells. Distribution of 16 subpopulations is presented for control NCH644 
cultures (CTR).  See Table S3A for statistics. B. Distribution of 16 subpopulations after 
single cell sorting (self-renewal test). Re-phenotyping was performed at each self-renewal 
passage for each subpopulation (all single spheres gathered together in one pool, n=4). 
Distribution of subpopulations is presented as a mean percentage of each subpopulation in 
viable single cells. NCH644 viable single cells were sorted as a control (CTR_EXP). See 
Table S4A for statistics.  C. Markov modeling of state transitions in normoxia. Probabilities 
of state transitions within one time-step (1 day) are presented for each subpopulation. Y 
axis displays subpopulations in the present state. X axis displays the probabilities of each 
subpopulation to change to respective phenotypes. D. Graphs represent distribution of 16 
subpopulations after single cell sorting (self-renewal test) cultivated in hypoxia. Re-
phenotyping was performed at each self-renewal passage for each subpopulation (n=4). 
Distribution of subpopulations is presented as a mean percentage of each subpopulation in 
viable single cells. NCH644 viable single cells were sorted as a control (CTR_EXP). See 
Table S4B for statistics. Distribution of 16 subpopulations of control NCH644 cultures after 
60 days in hypoxia is presented as an environmental control (CTR_H). E. Markov modeling 
of state transitions in hypoxia. Probabilities of state transitions within one time-step (1 day) 
are presented for each subpopulation. Y axis displays subpopulations in the present state. 
X axis displays probabilities of each subpopulation to change to respective phenotypes.  
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Figure S6. Reversible adaptation upon differentiation and in vivo microenvironment. 
A. Examples of ICC after 14d of adherent NCH644 cultures in stem cell (Undiff_H) or 
differentiation (Diff_H) conditions in hypoxia. B. Flow cytometric analysis of internal stem 
cell (Nestin, Vimentin) and differentiation markers (β-III-tubulin, GFAP) in control 3D 
NCH421k cultures (CTR), and differentiation (Diff) conditions after 14 days. N= normoxia, 
H= hypoxia (n=3). Negative control for antibody staining is shown for each type of cells 
(Isotype). Black lines discriminate between negative and positive cells. Dotted line indicate 
mode expression in control cells. C. Flow cytometric analysis of internal stem cell (Nestin, 
Vimentin) and differentiation markers (β-III-tubulin, GFAP) in control 3D NCH644 and 
NCH421k cultures (CTR), and 14 day 3D cultures that were previously subjected to 
differentiation (De-Diff) conditions. N= normoxia, H= hypoxia (nB=3; nT=3). Negative control 
for antibody staining is shown for each marker (Isotype). Black lines discriminate between 
negative and positive cells. Dotted line indicate mode expression in control cells. D. 
Distribution of NCH421k subpopulations upon differentiation (Diff) conditions, N= normoxia, 
H= hypoxia (n=3). For each condition equilibrium is presented after 14 days of 
environmental change (left) and 14 days after consecutive change to original 3D stem cell 
conditions (right). NCH421k cultured as 3D spheres in normoxia are shown as control 
(CTR).  See Table S2E for statistics.  E. Graphs represent distribution of 16 subpopulations 
in xenografted NCH601 and NCH660h tumor cells (X). Normoxic cultures are shown as a 
control (CTR). (n=3).  F. Distribution of 16 subpopulations in xenografted NCH421k tumor 
cells (X) and 56 days after regrowth in vitro as 3D cultures (De-X) (nB=2; nT=3).  NCH421k 
cultured in normoxia are shown as a control (CTR).  See Table S2G for statistics.  G. Flow 
cytometric analysis of internal stem cell (Nestin, Vimentin) and differentiation markers (β-
III-tubulin, GFAP) in control NCH421k cultures (CTR), tumor cells in tumor mass developed 
upon xenografting (X) and xenografted cells recultured in vitro for 56 days (De-X). Negative 
control for antibody staining is shown for each marker (Isotype). Black lines discriminate 
between negative and positive cells. Dotted line indicate mode expression in control cells 
(nB=2; nT=3). 
 261 
 
 
7 
 
 
  
262 
 
Figure S7. Single cell Drop-seq analysis. A-B.  tSNE plots showing the expression of 
marker genes in FACS-sorted tumor cells of 3 GBM PDXs (P3, P8, P13) and 2 patient 
derived stem-like cultures (NCH644, NCH421k). The expression gradient is color coded.  
See top-left graph for tSNE plot showing the overall gene expression relationship between 
single cells of different patient-derived cells. Plots in (A) show the expression of stem cell-
associate markers highlighting inter-patient and intratumoral heterogeneity. Plots in (B) 
show the expression of cell membrane markers (CD90, CD29) with high levels in most 
tumors and relatively uniform expression profile as detected by flow cytometry. EGFR is 
presented as a control expected to be highly expressed by P8 cells. C. Differential gene 
expression analysis between single cells of subpopulation P2 versus P6. Threshold for 
differential expression was set at FDR<0.01 and |logFC|>0.5. Only 6 genes were found to 
be differentially expressed between the 2 subpopulations (FDR<0.01, |logFC|>1). D. tSNE 
plots showing the expression of marker genes in FACS-sorted subpopulations P2 and P6.  
The expression gradient is color coded. For visualization purposes cells with no reads were 
displayed as transparent. MIF and CD44 were expressed at higher levels in FACS-sorted 
P6 subpopulation.  PROM1 and ST8SIA1 were detected in a similar proportion of cells.  P6 
showed upregulation of Macrophage migration inhibitory factor (MIF), a known ligand of the 
CD74/CD44-receptor complex (Shi et al., 2006). CD44 mRNA, the phenotypic discriminator 
between two subpopulations, was also detected at higher, though not significant, level in 
the CD44+ P6 subpopulation. 
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SUPPLEMENTAL TABLE LEGENDS (submitted as a separate excel file) 
Table S1. Group comparison for CSC-associated gene expression in GBM patient 
subgroups. Related to Fig. 1A. 
Group comparison was performed in Gitools using mannWhitneyWilcoxon and Benjamini 
Hochberg multiple test correction was applied. The GBM expression subgroup were 
considered as: Neural Group (n=28, Mesenchymal (n=51),Proneural (n=39),Classical 
(n=40).  
A. Group comparison for CSC-associated gene expression in the different GBM subgroups 
(column headers). P value log summary is depicted in left panel as follows: yellow-to-red is 
represented if values in Group 1 are significantly shifted 
B. Statistical analysis of group comparisons. 
Several markers were correlated with previously defined transcriptional subgroups e.g. 
CCR5 (CD195), ITGB1 (CD29), CD44 and FAS (CD95) are more expressed in the 
mesenchymal subtype, whereas PROM1 (CD133), NCAM (CD56) and CD24 are enriched 
in the proneural subtype. 
 265 
 
 
7 
 
 
 
  
266 
 
Table S2. Statistical analysis of phenotypic states distribution upon treatment and 
adaptation to changing environment. Statistical analysis was performed with the  Student t-
test with  a Bonferroni multiple-significance-test correction for 16 phenotypic states. 
Statistical differences between proportion of phenotypic states are presented for each 
subpopulation if pvalue < 0.05. Each line represents statistical comparison between 
proportions of each phenotypic state present in defined environmental conditions. *<0.05; 
**<0.01; ***<0.001 
 
A. Markov model validation in pre-designed NCH644 equilibria. Related to Fig. 2G. 
MixA and MixB subpopulation combinations were cultured for 39 days after FACS. 
B. Phenotypic analysis of NCH644 cultures upon hypoxic cultures. Related to Fig. 3A 
Hypoxia (H) was applied for  16h, 48h, 7 and 60 days. 
C. Phenotypic analysis of NCH421k cultures upon hypoxic cultures. Related to Fig. S4C 
Hypoxia (H) was applied for  16h, 2 and 7 days. 
D. Phenotypic analysis of NCH644 cultures upon differentiation (Diff) and de-differentiation 
(De-Diff) in normoxic (N) and hypoxic (H) conditions. Related to Fig. 4C 
E. Phenotypic analysis of NCH421k cultures upon differentiation (Diff) and de-differentiation 
(De-Diff) in normoxic (N) and hypoxic (H) conditions. Related to Fig. S6D 
F. Phenotypic analysis of NCH644 cultures (CTR) upon xenografting (X) and reculture of 
xenografted cells in 3D normoxic conditions (De-X). Related to Fig. 4D 
G. Phenotypic analysis of NCH421k cultures (CTR) upon xenografting (X) and reculture of 
xenografted cells in 3D normoxic conditions (De-X). Related to Fig. S6F 
H. Phenotypic analysis of NCH644 subpopulations upon xenografting (X). Phenotypic 
equilibrium of FACS-sorted subpopulations (P2, P6, P11, P15) was compared to control 
cultures in normoxia in vitro (CTR) and bulk NCH644 xenografted in vivo (X). Related to 
Fig. 4G 
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Table S3. Statistical analysis of phenotypic state transitions of FACS-sorted subpopulation 
upon time in normoxia (A.) and in hypoxia (B.). Related to Fig. 2D and Fig. 3D respectively. 
Statistical analysis was performed with the  Student t-test with  a Bonferroni multiple-
significance-test correction  for 16 phenotypic states . Each line represents statistical 
comparison between proportions of each phenotypic state present in FACS-sorted 
subpopulations at  a defined self-renewal passage. No statistical differences were detected 
between the same subpopulations at different passages. Statistical differences between 
proportion of phenotypic states (PSs) in different subpopulations and control cells (CTR = 
control cells cultures in normoxia; CTR_H = control cells cultured 60 days in hypoxia) at the 
same passage is presented if pvalue < 0.05 NCH644 exp corresponds to FACS-sorted bulk 
NCH644 cells w/o discrimination of 16 subpopulations 
*<0.05; **<0.01; ***<0.001 
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a. Multipotency in normoxia 
 
  
20d Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs P1 *** ** *** ***
CTR vs P2 *** * ***
CTR vs P3 *** ** ***
CTR vs P4 * *** ** *** ***
CTR vs P5 *** ***
CTR vs P6 *** *** ***
CTR vs P7 ** ***
CTR vs P8 *** *** *** *** ***
CTR vs P9 ** *** ** ***
CTR vs P10 * ** * *
CTR vs P11 *** * *** ** ***
CTR vs P12 **
CTR vs P13 *** *** * ** * *
CTR vs P14 *** *** ** ** ***
CTR vs P15 *** *** *** *
CTR vs P16 ** * *
30d Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs P1 * ** *** ** *
CTR vs P2 *
CTR vs P3 ** ** ** **
CTR vs P4 *
CTR vs P5 ** *** *** ** ** ** **
CTR vs P6 *** *** * *
CTR vs P7 * *** ** *** ** *
CTR vs P8 *** *** ** * *** *** ** *** *
CTR vs P9 *** ***
CTR vs P10
CTR vs P11 *** *** ** *** ** ** * ***
CTR vs P12 *
CTR vs P13 *** *** *** *** *** *** * * ***
CTR vs P14 *** *** *** *** ***
CTR vs P15 *** *** *** ***
CTR vs P16 * ***
70d Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs P1 * *** *** *** *** *** *
CTR vs P2 *** *** *** **
CTR vs P3 *** *** ** *** *** *** **
CTR vs P4 *** *** *** *** * **
CTR vs P5 *** ** *** * *** *** ***
CTR vs P6 *** *** *** *** *** ***
CTR vs P7 *** *** **
CTR vs P8 * *** *** *** *** *** ** ***
CTR vs P9 ** *** *** *** *** **
CTR vs P10 ***
CTR vs P11 * *** *** *** ** *** * **
CTR vs P12 ** ***
CTR vs P13 *** *** ***
CTR vs P14 ***
CTR vs P15 * *** **
CTR vs P16
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b. Multipotency in hypoxia 
 
Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs CTR_H *** *** * ** ** *** ** *** *** **
CTR vs P1 *** *** * *** *** *** *** *** *** ** ***
CTR vs P2 *** ** *** *** *** *** *** *** * **
CTR vs P3 *** *** *** ** *** *** *** *** *** *** * **
CTR vs P4 *** *** ** *** *** *** *** *** *** **
CTR vs P5 *** ** *** *** *** *** *** *** ***
CTR vs P6 *** *** ** *** *** *** *** *** *** *
CTR vs P7 ** *** ** *** *** *** *** *** *** *** **
CTR vs P8 *** *** *** *** *** *** *** *** *** **
CTR vs P9 *** *** *** *** *** *** *** *** ** **
CTR vs P10 ** *** ** ** *** ** ** *** ** *** *
CTR vs P11 * *** *** *** *** *** *** *** **
CTR vs P12 *** ** * *** ** *** *** * *** *
CTR vs P13 *** ** *** *** * *** *** *** *** ** *
CTR vs P14 *** *** * *** * * *** *** ***
CTR vs P15 * *** ** *** ** * *** ** *** *** **
CTR vs P16 *** *** *** *** * * *** *** *** ***
CTR_H vs P1
CTR_H vs P2
CTR_H vs P3 ** * **
CTR_H vs P4 *
CTR_H vs P5 *
CTR_H vs P6 **
CTR_H vs P7 * *
CTR_H vs P8 ** *
CTR_H vs P9
CTR_H vs P10 **
CTR_H vs P11 *
CTR_H vs P12
CTR_H vs P13
CTR_H vs P14
CTR_H vs P15
CTR_H vs P16 *
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Table S4. Statistical analysis of phenotypical state transitions upon 4 consecutive self-
renewal passages in normoxia (A.) and in hypoxia (B.). Related to Fig. S5B and Fig. S5D 
respectively. 
a. Self-renewal in normoxia 
 
b. Self-renewal in hypoxia 
Passage 1 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp
CTR vs P1 * *** ** **
CTR vs P2 * ** ** **
CTR vs P3 * *** ** **
CTR vs P4 * *** *
CTR vs P5 *
CTR vs P6 *** *
CTR vs P7 ** * * *
CTR vs P8 ** *** **
CTR vs P9 ** *** ** ** * *
CTR vs P10 * * *
CTR vs P11 ** ** **
CTR vs P12
CTR vs P13 * *** ** ** ** * **
CTR vs P14 *** *** * *
CTR vs P15
CTR vs P16 ** *** ***
Passage 2 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp
CTR vs P1 ** *** **
CTR vs P2
CTR vs P3 ***
CTR vs P4 ** *** *
CTR vs P5 ** * ** *
CTR vs P6 *** *
CTR vs P7 ** ** *** * **
CTR vs P8 ** ** * *** * *
CTR vs P9 ** * *** ** *** *
CTR vs P10 **
CTR vs P11 * * * *** ** *** **
CTR vs P12
CTR vs P13 ** ** * ** ** * *
CTR vs P14 *** * * **
CTR vs P15 ** ** * ** * **
Passage 3 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp *
CTR vs P1 ** ** *
CTR vs P2 *
CTR vs P3 * *
CTR vs P4 *** *
CTR vs P5
CTR vs P6 *** *
CTR vs P7
CTR vs P8 * *** * *
CTR vs P9 ** *** * * *
CTR vs P10 * ** *
CTR vs P11 **
CTR vs P12
CTR vs P13 **
CTR vs P14 *** ** * * **
CTR vs P15 **
CTR vs P16 ** *
Passage 4 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp
CTR vs P1 *** ** * **
CTR vs P2 * ** ** *** * * ** **
CTR vs P3 * * *** * ** **
CTR vs P4 *** **
CTR vs P5 * * *
CTR vs P6 **
CTR vs P7 *** * * *
CTR vs P8 ** ** *** * ** *
CTR vs P9 ** *** *
CTR vs P10 *
CTR vs P11 * *** *
CTR vs P12 ***
CTR vs P13 * * * ** **
CTR vs P14 *** * ** **
CTR vs P15 * * *
CTR vs P16 **
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Passage 1 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp ** * *
CTR vs CTR_H *** *** * ** ** *** ** *** *** **
CTR vs P1 * ** *** ** ** * ** **
CTR vs P2 * *** ** **
CTR vs P3 *** * *** * ** **
CTR vs P4 *** * * ** **
CTR vs P5 ** *** * * *
CTR vs P6 *** * ** ** *
CTR vs P7 *** * ** **
CTR vs P8 * ** *** * ** * ** *
CTR vs P9 ** * *** ** **
CTR vs P10 * *
CTR vs P11 * ** ** ** **
CTR vs P12 *
CTR vs P13 ** * ***
CTR vs P14 ** *** * * *** * ** ** *
CTR vs P15
CTR vs P16 ** *** *
CTR_H vs NCH644 exp * ** *
CTR_H vs P1 * ** **
CTR_H vs P2 * *** * * *
CTR_H vs P3
CTR_H vs P4 ***
CTR_H vs P5
CTR_H vs P6 *
CTR_H vs P7 *
CTR_H vs P8 *
CTR_H vs P9 ** **
CTR_H vs P10 *
CTR_H vs P11 * * * *
CTR_H vs P12 **
CTR_H vs P13 * *** *
CTR_H vs P14 * * *
CTR_H vs P15
CTR_H vs P16 *
Passage 2 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp *** * * * * **
CTR vs P1 ** *** * *** * * ** **
CTR vs P2 *** * * ** ** **
CTR vs P3 * *** * * **
CTR vs P4 * * *
CTR vs P5 * * *** * ** * **
CTR vs P6 * ** * *** * ** ** **
CTR vs P7 *** * * ** **
CTR vs P8 ** *** * *** * ** ** **
CTR vs P9 ** ** ** *
CTR vs P10 ** * *
CTR vs P11 * ** ** ** * * * **
CTR vs P12 ** *
CTR vs P13 * *** * * **
CTR vs P14 *** ** *** * * * **
CTR vs P15 ** * *** ** * **
CTR vs P16 * ** *** ** **
CTR_H vs NCH644 exp *
CTR_H vs P1 ** * *
CTR_H vs P2 *
CTR_H vs P3
CTR_H vs P4 *** *
CTR_H vs P5
CTR_H vs P6
CTR_H vs P7
CTR_H vs P8
CTR_H vs P9 *
CTR_H vs P10 *
CTR_H vs P11 *
CTR_H vs P12
CTR_H vs P13 *
CTR_H vs P14 *
CTR_H vs P15
CTR_H vs P16
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Passage 3 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp ** * * * **
CTR vs P1 ** *** *** ** *** * **
CTR vs P2 * *** * * * **
CTR vs P3 ** * *** * * **
CTR vs P4 ** *** * * * **
CTR vs P5 * *** ** * * **
CTR vs P6 ** * * *** *** * ** **
CTR vs P7 ** * ** ** * * ** **
CTR vs P8 ** * * * *** * ** **
CTR vs P9 ** *
CTR vs P10 ** *
CTR vs P11 * *** ** ** * **
CTR vs P12 **
CTR vs P13 ** ** * *
CTR vs P14 *** ** *** * * **
CTR vs P15 * ** ** * *
CTR vs P16
CTR_H vs NCH644 exp *
CTR_H vs P1 ** ** *
CTR_H vs P2 ** **
CTR_H vs P3
CTR_H vs P4
CTR_H vs P5
CTR_H vs P6
CTR_H vs P7
CTR_H vs P8
CTR_H vs P9
CTR_H vs P10
CTR_H vs P11
CTR_H vs P12
CTR_H vs P13
CTR_H vs P14 *
CTR_H vs P15 * **
CTR_H vs P16
Passage 4 Conditions/Phenotypic states P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16
CTR vs NCH644 exp ** * ** * *
CTR vs P1 * * *** * ** * * *
CTR vs P2 *** * * *
CTR vs P3 * ** *** * *** * * * *
CTR vs P4 ** * ** *** *** *** * * *
CTR vs P5 * *** * * *
CTR vs P6 * ** * *** * * * *
CTR vs P7 * * *** * * *
CTR vs P8 * ** *** * ** *** * *
CTR vs P9 **
CTR vs P10 **
CTR vs P11 ** * * ** * *** * * * *
CTR vs P12 * * ** * * *
CTR vs P13 * ** * ** * *
CTR vs P14 * ** *
CTR vs P15 * ** * * * ***
CTR vs P16 * *
CTR_H vs NCH644 exp
CTR_H vs P1 * *
CTR_H vs P2
CTR_H vs P3 *
CTR_H vs P4
CTR_H vs P5
CTR_H vs P6
CTR_H vs P7
CTR_H vs P8 *
CTR_H vs P9
CTR_H vs P10
CTR_H vs P11
CTR_H vs P12
CTR_H vs P13
CTR_H vs P14
CTR_H vs P15 **
CTR_H vs P16
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Table S5. Independence analysis of 4 markers in state transitions in normoxia (A.) and in 
hypoxia (B.). Related to Fig. 2E and Fig. 3E respectively. Table presents transition 
probabilities considering only a single marker. 
 
 
  
A. Marker dependency in normoxia B. Marker dependency in hypoxia
Equilibrium 
calculated from 
sinlge marker 
state transitions
Equilibrium 
calculated from 
four markers 
state transitions
Equilibrium 
calculated from 
sinlge marker 
state transitions
Equilibrium 
calculated from 
four markers 
state transitions
CD133+ CD133- CD133+ CD133-
CD133+ 97.48 2.52 77.18 79 CD133+ 99.7 0.3 97.63 96.19
CD133- 8.52 91.48 22.82 21 CD133- 12.4 87.6 2.37 3.81
CD44+ CD44- CD44+ CD44-
CD44+ 95.96 4.04 46.17 41 CD44+ 98.87 1.13 73.2 55.79
CD44- 3.46 96.54 53.83 59 CD44- 3.09 96.91 26.79 44.21
A2B5+ A2B5- A2B5+ A2B5-
A2B5+ 79.69 20.31 42.91 41.6 A2B5+ 94.05 5.95 40.68 33.92
A2B5- 15.27 84.73 57.09 58.4 A2B5- 4.08 95.92 59.32 66.08
CD15+ CD15- CD15+ CD15-
CD15+ 93.11 6.89 36.43 39.5 CD15+ 92.45 7.55 16.27 18.29
CD15- 3.95 96.05 6.35 60.5 CD15- 1.47 98.53 83.73 81.71
A. Marker dependency in normoxia B. Marker dependency in hypoxia
Equilibrium 
calculated from 
sinlge marker 
state transitions
Equilibrium 
calculated from 
four markers 
state transitions
Equilibrium 
calculated from 
sinlge marker 
state transitions
Equilibrium 
calculated from 
four markers 
state transitions
CD133+ CD133- CD133+ CD133-
CD133+ 97.48 2.52 77.18 79 CD133+ 99.7 0.3 97.63 96.19
CD133- 8.52 91.48 22.82 21 CD133- 12.4 87.6 2.37 3.81
CD44+ CD44- CD44+ CD44-
CD44+ 95.96 4.04 46.17 41 CD44+ 98.87 1.13 73.2 55.79
CD44- 3.46 96.54 53.83 59 CD44- 3.09 96.91 26.79 44.21
A2B5+ A2B5- A2B5+ A2B5-
A2B5+ 79.69 20.31 42.91 41.6 A2B5+ 94.05 5.95 40.68 33.92
A2B5- 15.27 84.73 57.09 58.4 A2B5- 4.08 95.92 59.32 66.08
CD15+ CD15- CD15+ CD15-
CD15+ 93.11 6.89 36.43 39.5 CD15+ 92.45 7.55 16.27 18.29
CD15- 3.95 96.05 6.35 60.5 CD15- 1.47 98.53 83.73 81.71
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Table S6. Statistical analysis of self-renewal potential of 16 FACS-sorted subpopulation in 
hypoxia. Related to Fig. 3B. 
Matrix represents statistical changes by the Kruskal-Wallis test observed for sphere number 
in self-renewal test between subpopulations across 4 passages in hypoxia (*pvalue≤0.05). 
Note that statistical differences were present only upon two first passages. 
 
  
Passage 1
Subpopulation P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 NCH644
P1 * * * * * * *
P2 * * *
P3 * * * * *
P4 * * *
P5 * * *
P6 * * * *
P7 * * * *
P8 * * * * * *
P9 * * * * * *
P10 * * * * * *
P11 * * * * * * *
P12 * * * * * *
P13 * * *
P14 * * *
P15 * * * * * *
P16 * *
Passage 2
Passage 3
Subpopulation P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 NCH644
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
P13
P14
P15
P16
Passage 4
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Table S7. Antibodies used in the study. 
 
FC = Flow cytometry (test 106 cells/100µl); ICC = Immunocytochemistry
Epitope Conjugate Clone Supplier Concentration
A2B5 APC/PE 105-HB29 Miltenyi FC:10µl/test
A2B5 AF488 MAB312RX Chemicon ICC:1:20
FC:5µl/test
ICC:1:50
CD15/SSEA-1 PE MEM-158 Immunotools FC:10µl/test
CD15/SSEA-1 PerCP-Cy5.5 W6D3 Biolegend FC:5µl/test
CD24 PE SN3 Immunotools FC:10µl/test
CD29 APC MEM-101A Immunotools FC:10µl/test
CD44 FITC MEM-85 Immunotools FC: 10µl/test
FC:1.2µl/test
ICC:1:50
CD56 PE-Cy7 N-CAM BD Bioscience FC:5µl/test
CD90 PE-Cy7/APC 5E 10 BD Bioscience FC:5µl/test
CD95 APC Fas/APO1 BD Bioscience FC:20µl/test
FC:10µl/test
ICC:1:50
CD195 PE 2D7/CCR5 BD Bioscience FC:20µl/test
EGFR PE EGFR.1 BD Bioscience FC:20µl/test
GFAP AF647 1B4 BD Bioscience FC:5µl/test
Isotype control IgG1 FITC PPV-06 Immunotools FC:5µl/test
Isotype control IgG1κ PerCP-Cy5.5 MOPC-21 BD Bioscience FC:5µl/test
Isotype control IgG2a AF647 eBR2a eBioscience FC:5µl/test
Isotype control IgG2b AF647 eB1491/10H5 eBioscience FC:5µl/test
NG2 PE LHM-2 R&D FC:10µl/test
Nestin PerCP-Cy5.5 25/NESTIN BD Bioscience FC:5µl/test
Nestin 10C2 Millipore ICC: 1:200
Vimentin FITC V9 Thermo Fischer FC:5µl/test
Vimentin V10 Millipore ICC: 1:200
B-III-tubulin AF647 TUJ1 BD Bioscience FC:5µl/test
B-III-tubulin Tu-20 Millipore ICC: 1:200
Goat anti-mouse IgG Alexa488 AF488 policlonal Thermo Fischer ICC: 1:500
Goat anti-rabbit IgG Alexa488 AF488 policlonal Thermo Fischer ICC: 1:500
CD133-1 PE /APC 293C3/AC133 Miltenyi
CD15/SSEA-1 AF647 MC-480 Biolegend
CD44 PE-Cy7 IM7 eBioscience
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